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Abstract 
Idiopathic Pulmonary Fibrosis (IPF) involves excess extracellular matrix (ECM) deposition within the 
lung interstitium, caused by non-resolving chronic inflammation and dysregulated repair. Alveolar 
macrophage (AMφ) may contribute to IPF through releasing various mediators by different subsets, 
investigated here in vitro, and ex vivo using a mouse model of bleomycin (BLM)-induced pulmonary 
fibrosis. The role of foamy AMφ in the reported increased susceptibility of Hermansky Pudlak 
Syndrome (HPS) 1 mice to BLM-induced pulmonary fibrosis was also assessed. 
Novel characterisation studies revealed that terminally differentiated AMφ are inducible into M1-
like [nitric oxide synthase 2 (NOS2)hi interleukin (IL)-1βhi IL-12 p40 (total)hi major histocompatibility 
protein (MHC)-IIhi mannose receptor C, type 1 (MRC1)-] or M2-like [Arginase 1 (Arg1)hi Fibronectinhi 
IGF-1hi MHC-IIlo MRC1-/+] phenotypes following IFN-Υ or IL-13 priming respectively. Lipopolysccharide 
(LPS) altered these AMφ subset phenotypes.  
AMφ heterogeneity in a novel multiple oropharyngeal dose, BLM-induced pulmonary fibrosis was 
evaluated from days 7 to 21. Accumulation of M1-like AMφ at day 7, and M1/M2-hybrid AMφ 
[Arg1hi IL-12 p40 (total)hi fibronectinhi MHC-IIlo MRC1-/+] from days 7 to 21, may promote 
inflammation and fibrosis respectively. Toll-like Receptor (TLR) 9 messenger ribonucleic acid (mRNA) 
and TLR2 surface protein, and both TLRs2 and 9 ex vivo activities were increased in BLM-challenged 
mice from days 7 to 21, suggesting their roles in inflammation and fibrosis. 
Foamy AMφ accumulated in BLM-induced pulmonary fibrosis, and their potential role in the 
reported increased susceptibility to BLM-induced pulmonary fibrosis of HPS1 mice was evaluated. 
BLM-challenged HPS1 mice (days 7-21) had increased weight loss indicating reduced BLM tolerance 
from days 7 to 11, but little/no difference in collagen accumulation, suggesting that reduced BLM 
tolerance is not correlated with increased pulmonary fibrosis. 
In conclusion AMφ alter their phenotype in response to their environment that contributes to 
different stages of BLM-induced pulmonary fibrosis. Reduced BLM tolerance in HPS1 mice is not 
correlated with increased pulmonary fibrosis. 
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Chapter 1| General introduction 
1.1 Idiopathic Pulmonary Fibrosis (IPF) 
1.1.1 Epidemiology of IPF patients 
IPF is a chronic fibrosing interstitial lung disease of unknown etiology that is characterised by a 
histological pattern of usual interstitial pneumonia (UIP)1. IPF has a prevalence of 50 per 100,000 
population, and mostly occurs in adults over 50 years old2–4. It is more common in men than women 
(1.5:1)5,6, and 1-4% of patients have a family history of the disease7–10. 
1.1.2 Prognosis of IPF patients 
IPF has a high incidence of morbidity and mortality, with a median survival of 3 years following 
diagnosis11. A worse prognosis is associated with old age (>70 years old), smoking history, low body-
mass index (BMI), severe physiological impairment, large radiological extent of disease and 
pulmonary hypertension. Several variants of IPF pathology have been identified, including a stable or 
progressive course, an accelerated form of IPF, and acute exacerbation of stable IPF12.  
Many IPF patients have a stable or slowly progressive course that can last for decades. They present 
with decreased lung volumes and capacities, and hypoxemia at rest that worsens with exercise. A 
subgroup of IPF patients that are in general male cigarette smokers have a shortened survival, 
termed accelerated IPF. Accelerated IPF patients have a different clinical course and transcriptional 
profile compared to the slowly progressive counterparts, despite showing similar signs of lung 
function, chest imaging and histological findings13. Altered transcriptional profiles are present mostly 
in the alveolar epithelial and mesenchymal domains. An example of upregulated genes in the 
accelerated variant are members of the Mitogen-Activated Protein Kinase (MAPK)-Early Growth 
Response protein 1 (EGR1) -Heat Shock Protein 70 (HSP70) pathway, which regulate cigarette smoke 
induced inflammation14. Acute exacerbation is defined as the rapid deterioration of the disease in 
the absence of infection, heart failure, or pulmonary embolism15,16. The cause of 50% of acute 
exacerbations in IPF is unknown17, perhaps triggered by an occult stressor such as viral infection, 
microaspiration or ambient pollution18,19. Acute exacerbations affect 5-20% IPF patients, and have 
>60% mortality during administration to hospital and >90% mortality rate within 6 months of
discharge for those who survive15,17,20 (Figure 1.1). 
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Figure 1.1 The prognosis of Idiopathic Pulmonary Fibrosis (IPF) patients. IPF has a long (months to years) 
asymptomatic period. Patients consult when the severity of lung lesions reaches a threshold that is 
sufficient to provoke symptoms. Most patients follow a relatively slow clinical and functional decline 
(slowly progressive course) after diagnosis. About 10% of these patients present with acute episodes of 
clinical deterioration (acute exacerbations) that precede or possibly initiate the terminal phase of their 
disease. A few patients have a short duration of illness with a rapidly progressive course. Smokers may 
develop emphysema, and have shorter survival when compared to IPF patients alone. Figure adapted 
from King JE Jr, 201012. 
1.1.3 Diagnosis of IPF patients 
Definitive diagnosis of IPF patients consists of four criteria based on pulmonary physiology analyses, 
surgical lung biopsies, and High-Resolution Computer Tomography (HRCT) scanning21. 
x IPF patients have abnormal pulmonary physiology with evidence of restriction and/or
impaired gas exchange.
x Surgical lung biopsies of IPF patients show a pattern of UIP. There is spatial heterogeneity,
where normal lung architecture alternates with patchy areas of histologically apparent
pulmonary parenchymal fibrosis. The most affected part of the lung is replaced by dense
collagen and occasional cystic structures known as microscopic honeycombs. At the leading
edge of fibrosis specialised structures known as fibrotic foci can be found, which comprise of
pale staining whirls of extracellular matrix (ECM) interspersed with numerous cells of the
fibroblast type. Hyperplastic type II alveolar epithelial cells (AEC2s) can be observed
overlying the fibrotic foci22. Inflammation is absent except in occasional lymphoid follicles
found in end stage fibrosis. IPF: UIP also does not contain hyaline membranes, granulomas
or organised alveolar exudates.
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x HRCT demonstrates a pattern of ‘confident’ or ‘patchy’ IPF, which consists of patchy,
predominantly peripheral and subpleural, bibasilar reticular opacification with little to no
ground glass opacity, thickened interlobular septae, traction bronchiectasis and subpleural
honeycombing.
x All other known causes of interstitial lung disease have been excluded.
1.1.4 Molecular Mechanisms of IPF 
1.1.4.1 IPF may arise from a dysregulated wound healing process 
IPF is believed to arise as a result of dysregulated wound healing process following alveolar epithelial 
injury caused by a persistent irritant. It is proposed that initial and repetitive injury occurs to the 
alveolar epithelium, and most likely causes damage to the type I alveolar epithelial cells (AEC1s) that 
line the alveolar surface23. Under homeostatic conditions, these cells play a role in regulating 
structural mesenchymal cells through cell-cell contact and mediator secretion. When AEC1s are 
injured or lost, it is thought that the underlying AEC2s undergo hyperplastic proliferation to cover 
the exposed basement membranes. If this process is inefficient, alveoli can collapse and consolidate. 
In normal conditions, AEC2 undergo steady state turnover (apoptosis), and the remainder of the 
cells will spread and differentiate into AEC1s. Under pathological conditions and in the presence of 
profibrotic mediators, including Transforming Growth Factor (TGF)-β however, fibroblasts 
accumulate at the site of injury and differentiate into α-Smooth Muscle Actin (α-SMA) expressing 
myofibroblasts that have increased expression of ECM components, including collagen to form 
specialised structures called fibrotic foci21,22. AEC2 surrounding the fibrotic foci are hyperplastic and 
abnormal rather than undergoing normal repair24, and may relate to cellular stress and failure to 
regenerate AEC1s lost by injury25. 
Several lines of evidence support the hypothesis that insults to the alveolar epithelium can serve as a 
trigger of IPF. Early ultrastructural studies by electron microscopy have demonstrated alveolar 
epithelial injury in lung biopsies from IPF patients26. Immunohistochemical studies have shown the 
upregulation of various mediators indicative of alveolar cell apoptosis, including pro-apoptotic Fas, 
p53 and p21, B-cell lymphoma (Bcl)-2 associated X protein (Bax) and Caspase-3, whereas anti-
apoptotic Bcl-2 is downregulated27–30.BAL from IPF patients also show soluble mediators indicative of 
increased apoptosis31. Inhibiting epithelial cell apoptosis with various approaches, including blocking 
the Fas-Fas ligand pathway and blocking caspase activation, abrogates bleomycin (BLM)-induced 
pulmonary fibrosis32–35. On the other hand, direct stimulation of Fas via anti-Fas antibody or injury to 
type II pneumocytes via a diphtheria toxin (DTR) approach also leads to pulmonary fibrosis36,37. The 
various factors that may lead to AEC damage is summarised in figure 1.2. 
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Epithelial injury may occur through insults from environmental factors, viral infections or genetic 
mutations in AECs. Enviromental factors such as cigarette smoking and microaspiration 
(asymptomatic aspiration of oropharyngeal secretions or gastric fluids into the lung)1,38,39 may lead 
to repeated injury to the lung. Other environmental factors, such as asbestos or silica, may persist in 
the lungs due to their large size and failure of antigen presenting cells (APCs) to effectively 
phagocytose and remove them, resulting in prolonged lung injury. Both of these events may lead to 
that pathological chronic inflammation and subsequent dysregulated wound-healing that may 
ultimately result in pulmonary fibrosis. 
Chronic viral infections, mainly herpes virus infections, may contribute to the pathogenesis of 
IPF38,40–43. There is correlation between certain latent viral infections, such as Epstein-Barr Virus 
(EBV), Cytomegalovirus (CMV), Human Herpesvirus (HHV)-7 and HHV-8 and human IPF25,40–42,44–47. 
Such viruses are known to infect and remain latent in pulmonary epithelial cells48, thereby rendering 
them less able to repair subsequent injury. Infection may also potentially change the transcriptional 
program of these cells such that they secrete profibrotic factors and recruit inflammatory cells and 
fibrocytes (bone marrow derived cells that express both hematopoietic and stromal markers) to the 
lung12. 
Genetic predisposition may also contribute to some forms of familial pulmonary fibrosis as identified 
in early studies49–52. Pulmonary fibrosis developed in a subset of patients with defined clinical 
syndromes, such as Hermansky-Pudlak Syndrome (HPS) and dyskeratosis congenita (DKC)49,53–55. HPS 
patients carry autosomal recessive mutations that lead to defective trafficking of intracellular 
Figure 1.2 IPF may arise from persistent injury of the alveolar epithelium, leading to alveolar epithelial cell 
(AEC)1 apoptosis and AEC2 hyperplasia.  Persistent injury may be caused by endogenous genetic mutations 
in familial IPF, environmental factors such as cigarette smoke, microaspiration, asbestos or silica, or viruses 
including Epstein Barr Virus (EBV), Cytomegalovirus (CMV) and Human Herpes Virus (HHV)-7 and -8. 
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organelles. HPS associated pulmonary fibrosis (HPSPF) is thought to be caused by defective secretion 
of pulmonary surfactant by AEC2s that leads to tissue injury, or lysosomal accumulation that leads to 
aberrent activation of pulmonary macrophages, and will be discussed in greater detail in section 1.4. 
DKC involves a group of mutations that directly or indirectly affects the functionality of telomerase 
RNA component (TERC) that extends telomeres. Shortened telomeres may lead to cellular apoptosis 
or permanent cell cycle damage due to the deoxyribonuclease nucleic acid (DNA) damage response. 
In the context of IPF, AECs may not be able to self-renew and differentiate effectively following 
tissue injury56 and thereby fail to efficiently repair and cover the denuded basement membrane, 
thus perpetuating the release of pro-fibrotic mediators and promoting fibrosis56. 
Genetic analysis of IPF patients have since identified mutations in several genes that may be 
involved in pathogenesis of the disease. A common theme to all mutations identified to date is that 
they affect genes that are expressed in lung epithelial cells [e.g. Surfactant Protein A (SPA)57, 
Surfactant Protein C (SPC)12,49,58–62, and Mucin 5B (MUC5B)63,64] or lead to molecular changes in AECs 
[e.g. Telomerase Reverse Transcriptase (TERT)56,65]. Pulmonary surfactants are released by AEC2s to 
reduce surface tension within the lung. Missense or short deletion mutations in the SPC gene gives 
rise to the variant misfolded protein that acts as a persistent irritant through accumulation or 
complex formation and causes alveolar epithelial injury12,49,58–62. SPC mutations account for ~1% of 
sporadic IPF61,62. Missense mutations in the SPA gene give rise to protein instability and retention in 
the endoplasmic reticulum (ER)57. Reduced SPA secretion may affect lung homeostasis and lead to 
tissue injury. MUC5B is essential for the production of mucus, which is a pulmonary lubricant that 
serves as a chemical barrier. A common single nucleotide polymorphism (SNP) in the MUC5B 
promoter region is associated with familial interstitial fibrosis and also sporadic IPF63,64. The SNP is 
present in 34-38% of sporadic IPF patients compared with 9-11% of healthy controls64. The exact 
mechanism the variant MUC5B in promoting pulmonary fibrosis is unclear, although two hypotheses 
have been proposed. First, the variant protein that may alter the local cell environment, perhaps by 
altering the mucosal host defence and/or local cytokine production, such that these changes affect 
the capability of bronchiolar or alveolar epithelial cells to self-renew or differentiate in response to 
injury. Second, the variant MUC5B may also lead to excessive mucus production that may provide a 
physical barrier that compromises normal epithelial repair of denuded basal lamina63. Mutations in 
essential telomerase genes, including human telomerase transcriptase (hTERT), telomerase RNA 
(hTR), and the associated machinery [e.g. dyskerin gene in DKC] lead to accelerated telomere 
shortening65–69, and as aforementioned affects the ability of AEC2 to repair efficiently following 
tissue injury56. 8-15% of patients with FPF56,70 and 1-3% of patients with sporadic IPF71,72 have one or 
more telomere-related mutations. 
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There are two non-exclusive hypotheses on the inducers for such dysregulated wound healing, 
including pathological chronic inflammation, and also an aberrantly activated epithelial cell 
mediated process. Pathological chronic inflammation may lead to prolonged tissue injury that results 
in a dysregulated wound healing process. Immune cells that are recruited to the site of tissue injury, 
such as monocytes, macrophages, and lymphocytes, accumulate and may drive fibrosis through the 
extended release of of pro-fibrotic mediators that induce the migration, proliferation and activation 
of fibroblasts. In the aberrantly activated epithelial cell model, it was proposed that injury to the 
alveolar epithelium directly activated AECs to promote fibrosis through the release of pro-fibrotic 
mediators and also epithelial-to-mesenchymal (EMT) transition. The mechanisms for chronic 
inflammation and aberrantly activated epithelial cells in the initiation and progression of IPF will be 
discussed in greater detail in sections 1.1.4.2 and 1.1.4.3 respectively. 
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1.1.4.2 The potential role of chronic inflammation in IPF 
1.1.4.2.1 Physiological inflammation in wound healing 
The wound healing process takes place over three phases; these include (i) the anti-fibrinolytic 
coagulation cascade to temporarily plug the affected tissue to prevent it from further damage and 
facilitate the recruitment of inflammatory cells; (ii) physiological inflammation where phagocytes 
such as macrophages and neutrophils clear cellular debris and invading pathogens by phagocytosis, 
and leukocytes release pro-inflammatory and pro-fibrotic mediators to promote epithelial and 
endothelial cell proliferation, and the recruitment and proliferation fibroblasts; and (iii) the repair 
and resolution phase, where wound closure occurs and tissue injury-induced inflammationis 
resolved to complete the wound healing process. The various stages of the wound-healing process 
will be described in greater detail below.  
Following tissue injury, damaged endothelial and epithelial cells release pro-inflammatory mediators 
that initiate the coagulation phase, which triggers blood clot formation and formation of the 
provisional ECM. Platelets are exposed to ECM components, triggering aggregation, clot formation 
and haemostasis. The coagulation cascade also provide access to inflammatory cells for tissue entry 
through basement membrane disruption and neoangiogenesis Platelet degranulation also promotes 
vasodilation and increased blood vessel permeability, while myofibroblasts and epithelial and 
endothelial cells secrete matrix metalloproteinases (MMPs), which disrupt the basement membrane 
allowing the recruitment of inflammatory cells to be recruited to the site of injury. Growth factors, 
cytokines and chemokines are also produced, which stimulates the recruitment and proliferation of 
macrophages and neutrophils73. Tissue resident macrophages are also activated through binding 
alarmins with their pathogen recognition receptors (PRRs) and secrete a number of pro-
inflammatory mediators [e.g. Tumour Necrosis Factor (TNF)-α, Interleukin (IL)-6]. Tissue-resident 
mast cells can also be activated through binding endogenous alarmins through their PRRs, or via 
cross-linking of their cell surface FcεRI, by multivalent antigens or complement peptides C3a or C5a, 
Activated mast cells can release secretory granules containing preformed mediators, including 
histamine, eosinophil chemotactic factor (ECF) and neutrophilic chemotactic factor (NCF), acid 
hydrolases (e.g. acid hydrolases, β-glucuronidase, phosphatase) and neutral proteases (e.g. tryptase, 
chymase) that promote smooth muscle contraction and increased vascular permeability, granulocyte 
activation and chemotaxis, and cytotoxicity. Mast cells also release heparin sulfate, an 
anticoagulation and anti-complementary factor that may play a role in the diffusion of mast cell 
mediators despite the activation of the coagulation pathway. Mast cells can also synthesise 
secondary mediators in a delayed response, which include leukotrienes, prostaglandins, platelet 
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activating factor (PAF), and other pro-inflammatory mediators that promotes further vasodilation, 
chemotaxis of neutrophils, macrophages and lymphocytes74.  
In the inflammatory phase, immune cells are recruited to the site of injury and are involved in the 
clearance of cellular debris, recruitment and activation of fibroblasts and further angiogenesis. Some 
of the early responders to inflammation are the phagocytes, including macrophages and neutrophils, 
which eliminate cellular debris, dead cells and invading organisms by phagocytosis. They can release 
cytokines and chemokines, which are mitogenic for endothelial cells that begin to surround the 
injured site. They also help form new blood vessels through the release of pro-angiogenic mediators 
as endothelial and epithelial cells migrate towards the centre of the wound. In addition, neutrophils 
are able to release high levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
to eliminate invading pathogens. Macrophages also release growth factors for fibroblast activation 
(e.g. TGF-β) and also MMPs for further disruption of the basement membrane for macrophage entry 
into the site of injury. Neutrophils are the predominant leukocyte involved in the early inflammatory 
response. However, as these cells release cytotoxic mediators (e.g. ROS and RNS) that may induce 
collateral damage to the surrounding tissue they have to be eliminated quickly. To this end 
neutrophils are rapidly negatively regulated by apoptosis and subsequent efferocytosed by 
macrophages75,76.. Efferocytosis of apoptotic neutrophils by macrophages increases TGF-β and CC 
chemokine ligand (CCL)2 secretion and decreases CXC chemokine ligand (CXCL)8 production, leading 
to a chemokine shift that favours monocyte recruitment77. As neutrophils are depleted from the 
inflammatory site, blood monocytes continue to accumulate and differentiate into inflammatory 
macrophages, which complete phagocytosis and destruction of the pathogens and/or irritants78–80. 
The monocytes and macrophages then emigrate after several days into the local lymph node81. 
During this migratory process, monocytes differentiate into dendritic cells, upregulating human 
leukocyte antigen (HLA) class II antigen membrane expression, and acquiring costimulatory 
molecules such as cluster of differentiation (CD)80 and CD8682. These cells may then present 
antigenic peptides to lymphocytes, contributing to the generation of an adaptive immune response. 
Lymphocytes are then recruited to the site of injury and become activated and begin secreting pro-
fibrotic cytokines and growth factors [e.g. TGF-β, IL-13 and platelet derived growth factor (PDGF)], 
which further activates macrophages and fibroblasts83–85. 
In the repair and resolution phase, fibroblasts are activated and differentiate into α-SMA+, collagen-
secreting myofibroblasts. Myofibroblasts are able to contract and draw the edges of the wound 
towards the centre. Epithelial and/or endothelial cells then divide and migrate over the basal layers 
to regenerate the damaged tissue, which completes the wound healing process. The remainder 
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myofibroblasts and inflammatory cells then undergo apoptosis to inhibit excessive ECM deposition, 
and apoptotic cells are then subsequently phagocytosed by macrophages.  
Physiological inflammation therefore plays an important role in the wound-healing process, 
including the elimination of invading pathogens through the release of ROS/RNS, clearance of 
cellular debris, invading pathogens and/or apoptotic cells by phagocytosis, release of cytokines 
and/or growth factors, to promote inflammation and wound-healing, tissue remodelling proteases 
(e.g. MMPs/TIMPs) and pro-angiogenic factors (e.g. ELR+ CXC chemokines) to promote tissue 
remodelling and angiogenesis respectively to allow tissue access by haematopoetic cells, which are 
recruited by chemokines that are secreted at the site of tissue injury. The role of physiological 
inflammation in wound healing is summarised in Figure 1.3.  
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Figure 1.3 The role of physiological inflammation in wound healing. Upon infection and/or tissue injury, 
pathogens and/alarmins may trigger an inflammatory response. Tissue-resident macrophages may release a 
number of pro-inflammatory mediators: chemokines recruit other immune cells, including granulocytes, 
monocytes, macrophages, and lymphocytes to the site of injury to amplify the inflammatory response. In 
addition, chemokines may also recruit fibroblasts to promote wound repair. ELR+ chemokines are 
angiogenic factors that promote neovascularisation and allows the recruitment of hematopoietic cells, 
including immune cells and fibrocytes (hematopoietic precursor of fibroblasts), to the site of tissue injury. 
Tissue remodelling proteases, including MMPs and TIMPs, facilitate the access of hematopoietic cells into 
the site of injury. Cytokines facilitates the inflammatory response and tissue repair through the activation of 
several hematopoietic and mesenchymal cells. Phagocytes, such as macrophages or neutrophils, may also 
be able to remove pathogens or alarmins through phagocytosis. In addition, phagocytes may produce 
reactive oxygen species (ROS) or reactive nitrogen species (RNS) to digest phagocytosed material. 
Physiological inflammation aids wound healing through the coordinated process in removal of the source of 
tissue injury, wound repair and return to homeostasis. Persistent irritation may lead to chronic 
inflammation and dysregulated wound repair that may lead to further tissue injury and fibrosis. 
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1.1.4.2.2 Pathological inflammation in pulmonary fibrosis 
Although physiological inflammation is essential for efficient wound healing, chronic inflammation 
that arises as a result of persistent irritation, as in the case of pulmonary fibrosis is pathological. In 
chronic inflammation, the inflammatory repertoire is dominated by macrophages and lymphocytes 
with little granulocytic presence. The transition from acute to chronic inflammation involves the 
replacement of short-lived neutrophils with long-lived macrophages and lymphocytes in an IL-6-
dependent process. Levels of IL-6 are elevated in several chronic inflammatory diseases, including 
rheumatoid arthritis, systemic juvenile idiopathic arthritis, ankylosing spondylitis, psoriasis and 
Crohn’s disease, and elevated levels are correlated with disease activity86. IL-6 is also elevated in 
different types of tissue fibrosis, including IPF 87, liver fibrosis88 and systemic sclerosis89. IL-6 
promotes the transition from acute to chronic inflammation through selectively recruiting 
monocytes and macrophages, but not neutrophils to the site of injury90, through promoting the 
release of CCL2 but not CXCL8. Transignalling by IL-6, through the formation of complexes with 
soluble IL-6 receptors, and subsequent binding to cell surface IL-6 co-receptor gp130 activates 
endothelial cells and promotes their release of CCL2 and IL-6 but not CXCL891,92. IL-6 also promotes 
the apoptosis of neutrophils, and the subsequent efferocytosis of these cells by macrophages also 
favours the secretion of CCL2 and TGF-β and decreases CXCL8 release as mentioned above77. 
The accumulation and persistent activation of macrophages and lymphocytes lead to the prolonged 
release of pro-inflammatory and pro-fibrotic mediators, and also tissue remodelling enzymes that 
results in dysregulated wound healing and ultimately fibrosis. As aforementioned wound healing is 
negatively regulated following myofibroblast contraction and wound closure, epithelial and/or 
endothelial cell proliferation and migration to cover the basal layer, followed by myofibroblast 
apoptosis and subsequent efferocytosis by macrophages. Excessive pro-inflammatory mediators 
(e.g. TNF-α, IL-1β) may lead to further tissue injury that affects effective wound repair; increased 
levels of TNF-α may also induce hyperproliferation of epithelial cells that may further propagate the 
dysregulated wound healing process through promoting fibroblast recruitment, proliferation and 
activation, fibrocyte recruitment and EMT. The excessive release of pro-fibrotic mediators may result 
in the disproportionate increase in the recruitment, proliferation and/or activation of fibroblasts, 
thereby leading to the excessive accumulation of ECM components (e.g. collagen) that results in a 
fibrotic scar. Excessive release of tissue remodelling enzymes such as MMPs may lead to extensive 
disruption to the basement membrane and tissue architecture that may affect tissue functionality. 
MMPs may also cleave and activate other pro-fibrotic zymogens (e.g. TGF-β), thereby further 
propagating the pro-fibrotic response. 
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Chronic inflammation has a pivotal role in pathology for most forms of interstitial lung diseases, and 
may lead to alveolar capillary wall and basement membrane disruption, which may in turn lead to 
loss of alveoli, dysregulated wound healing and fibrosis93. Chronic inflammation may also play a role 
in IPF, and inflammatory mediators have been found to be elevated in Bronchoalveolar lavage (BAL) 
and lung biopsies of IPF patients and also murine models of pulmonary fibrosis. TNF-D was found at 
elevated levels in surgical lung biopsies and serum of IPF94 and systemic sclerosis associated 
pulmonary fibrosis95 patients. IL-1β was found present in chronic inflamed tissues and tissues 
undergoing fibrogenesis, with accumulation of myofibroblasts and matrix deposition96–99. IL-12 p40 
was elevated in silica-100, BLM-101,102 or anti-Fas antibody32 induced models of pulmonary fibrosis, 
and are found to be largely produced by alveolar macrophage (AMφ)100. There are also increased 
levels of tissue remodelling proteases such as MMPs in IPF patients, including MMP-7 and MMP-9 
that are secreted by macrophages.  
MMP-7, also known as matrilysin, is among the most highly expressed103,104 and have increased gene 
transcript levels104,105 in fibrotic lungs. The levels of MMP-7 in BAL fluid (BALF) are also related to the 
severity of lung function impairment in IPF106. Immunoblot and immunohistochemistry revealed that 
both pro-and active forms of MMP-7 were increased in levels within the BALF and lung respectively. 
Immunohistochemistry showed that pro-MMP-7 localised to bronchial epithelial cells and AMφ, 
whereas active MMP-7 was found in hyperplastic epithelial cells and AMφ respectively. In a 
subsequent cross-linked carboxymethylated transferrin-(CCm-Tf) bioassay, BALF from IPF patients 
had greater CCm-Tf degrading activity than healthy controls107. This has been accredited to increased 
MMP bioactivity in IPF patients, as a mixture of serine protease (aprotinin and elastinal) and MMP 
inhibitors (1, 10-phenathroline), but not serine proteinase inhibitors alone, inhibited CCm-Tf 
degradation. From these studies however it is not clear which MMP(s) is/are contributing to 
increased CCm-Tf-degrading bioactivity107. Further inhibition studies with specific MMP neutralising 
antibodies will have to be carried out to deduce the particular MMPs that have increased bioactivity 
in IPF patients. 
MMP-9/gelatinase B is upregulated in both human and experimental lung fibrosis108,109, and an 
increased gene and protein expression was observed in AMφ and fibroblasts isolated from IPF 
patients compared to normal controls109,110. Levels of an elastin fragment that is generated 
exclusively by MMP-9 and/or MMP-12 cleavage of elastin was found to be increased in BALF of IPF 
patients, suggesting the increased bioactivities of these proteases111. The increased levels of the 
active form of MMP-9 in BALF were reported to be greatest in patients with rapidly progressive 
IPF106,112. Further animal studies have identified the importance of these mediators in the initiation 
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and/or progression of experimental pulmonary fibrosis, which will be discussed in greater detail later 
(Section 1.2.3.1). 
1.1.4.2.3 Debate on the contributions of pathological inflammation on pulmonary fibrosis 
Despite the apparent role of inflammation in the initiation and progression of murine models of 
pulmonary fibrosis, its participation in the human disease has been challenged over the recent years, 
primarily because treatment of IPF with anti-inflammatory drugs, including corticoids and 
glucocorticoids, have been largely ineffective113. In addition, there is no histological difference 
between early and late stage IPF with respect to inflammation114. Furthermore, long term 
overexpression of the anti-inflammatory cytokine IL-10 in bitransgenic mice that carry a doxyclcline 
inducible IL-10 transgene was also able to induce pulmonary fibrosis in the absence of inflammation. 
Lung specificity of IL-10 overexpression was achieved by the introduction of the IL-10 transgene into 
the in the clara cell secretory protein promoter, a protein that is uniquely expressed by alveolar 
epithelial cells115. These observations have led to the proposal of an epithelial injury-driven fibrosis 
model that is inflammation-independent. In this model, AECs, rather than immune cells, are 
proposed to be central to the fibrotic response. AECs that become activated following tissue injury 
by alarmins can facilitate the initiation and progression of fibrosis through the release of pro-fibrotic 
mediators, EMT or recruitment of fibrocytes in the absence of inflammation. This will be discussed in 
greater detail in Section 1.1.4.3.  
Inflammation may be required for the initiation but not the progression of fibrosis. In a study of 
idiopathic interstitial pneumonia (IIP), of which the most common form is IPF116, surgical lung 
biopsies present with intralobar and interlobar heterogeneity of Non-Specific Interstitial Pneumonia 
(NSIP) that is associated with chronic inflammation, and also UIP that is associated with fibrosis117. 
Interestingly, a gradual increase in mean age from NSIP only (mean age, 53.1 years), to NSIP and UIP 
(mean age, 57 years), to UIP only (mean age, 63.3 years) in patients was observed117, indicating that 
UIP may be a result of unresolved NSIP. Inflammation may be required for the recruitment of 
inflammatory cells, such as macrophages, into the lungs where they accumulate. These cells display 
plasticity and are able to adapt their phenotype to their surrounding environment. Within a 
dysregulated wound healing environment, these may contribute to pulmonary fibrosis through the 
release of pro-fibrotic mediators such as TGF-β118, fibronectin119 and PDGF120. Interestingly these 
cells are also responsive to glucocorticoid induction to display a wound-healing/ pro-fibrotic 
phenotype, with increased production of mediators such as IL-10 and TGF-β121. Glucocorticoid 
treatment may therefore worsen rather than protect from pulmonary fibrosis.  
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Finally, ongoing inflammation may be required for the progression of fibrosis. As aforementioned 
above, animal studies have revealed that inflammatory mediators, such as IL-1β122 and IL-12 
p40100,123–125, are required for the progression of pulmonary fibrosis. The lack of beneficial effects of 
anti-inflammatory glucocorticoid and corticosteroid therapies in IPF patients113 may be due to their 
reduced response to these mediators, rather than inflammation being non-essential. IPF patients 
were reported to have lower glucocorticoid receptor (GR) content than normal controls126 and the 
messenger Ribonucleic Acid (mRNA) levels of GR-α, the predominant isoform of the receptor that 
binds steroids and is able to mediate the transactivation or transrepression of target genes, is 
decreased in IPF patients as compared to other steroid sensitive interstitial lung diseases, such as 
sarcoidosis and crytogenic organising pneumonia (COP)127. 
1.1.4.3 The potential role of aberrantly activated AECs in IPF 
Following the lack of efficacy of IPF patients to anti-inflammatory therapy, an inflammation-
independent pathway resulting in pulmonary fibrosis was proposed instead. In the epithelial injury 
model, it was hypothesised that aberrantly activated AECs, rather than inflammatory cells, were 
responsible for the recruitment and activation of fibroblasts that are involved in dysregulated wound 
healing that ultimately drives the initiation and progression of pulmonary fibrosis. There is strong 
evidence that indicates that AECs are the primary source of mediators that function as chemokines 
or mitogens for mesenchymal cells, including PDGF, TGF-β, and TNF-α and Endothelin-1103.  
AECs in IPF patients also strongly express CXC chemokine receptor (CXCR) 4 ligand, CXCL12128, which 
may be responsible for the observed recruitment of fibrocytes into the lungs of IPF patients128  
through their CXCR4 receptor. Fibrocytes are a unique subpopulation of leukocyte characterised by 
their expression of both hematopoietic [Cluster of Differentiation (CD)45, CD34] and mesenchymal 
cell markers (collagen 1, fibronectin)129 that may contribute to the fibroblast pool.  
In addition, there may be abnormal alveolar epithelial and mesenchymal cross talk, which may lead 
to EMT. In EMT, epithelial cells acquire mesenchymal properties through which they increase their 
capability to move and to synthesize interstitial matrix103,130. Several evidence have supported the 
role of EMT as a source of IPF myofibroblasts. There is co-localisation of epithelial cells (pro-
surfactant proteins) and mesenchymal (α-SMA, N-Cadherin) markers in AECs from IPF lungs11,131. 
There is also an upregulation of typical epithelial proteins (Keratin-18) in IPF fibroblasts132. AEC2 
from IPF patients also have an increased gene expression of mesenchymal proteins and potential 
regulators of EMT133. Moreover, there is an increase in EMT drivers in hyperplastic AECs from lungs 
of IPF patients, including Snail family zinc finger 1 (SNA1) and TWIST134–136. SNA1 is a transcription 
factor that facilitates TGF-β induced EMT134,135; high levels of TWIST in IPF patients is often 
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associated with the presence of the herpesvirus, EBV, and may therefore facilitate EBV induced EMT 
and fibrosis136. The potential role of aberrantly activated AECs in the intitation and progression of 
pulmonary fibrosis, through the recruitment and activation of fibroblasts, is summarised in figure 
1.4. 
 
 
 
1.1.4.4 Dysregulation of tissue repair and the Nicotinamide Adenine Dinucleotide Phosphate (NADPH) 
Oxidase (NOX)4 pathways in IPF 
The activation of embryological pathways are essential for the tissue repair process. There is 
increasing evidence that persistent irritation to the lung leads to dysregulation of some 
embryological pathways, including Wnt/Wingless137, phosphatase and tensin homologue (PTEN)138, 
Sonic hedgehog (Shh)139 and bone morphogenetic proteins (BMPs)140, which may play a role in the 
abnormal behaviour of AECs and perhaps fibroblasts in IPF141. The dysregulation of the NOX4 redox 
signalling pathway has also been reported to participate in the pathogenesis of IPF142. 
1.1.4.4.1 Wnt/Wingless pathway 
The Wnt ligands comprise a large family of proteins that are essential to the morphogenetic 
processes. Results from several studies have indicated an overexpression of members of the 
Wnt/wingless pathway in the lungs of IPF patients103,143–145. In addition, there is an accumulation of 
Figure 1.4 Aberrantly activated AEC2s may facilitate fibroblast recruitment and activation in IPF. AEC2s may 
recruit and activate local fibroblasts to generate α-SMA+ myofibroblasts by secretion of PDGF. AEC2s may 
also recruit fibrocytes via CXCR4 from the bloodstream by their secretion of CXCL12. Fibrocytes express both 
hematopoietic (CD45, CD34) and mesenchymal (collagen 1, fibronectin) markers. Furthermore, AECs can 
undergo epithelial to mesenchymal transition (EMT) to give rise to fibroblasts. Fibroblasts arising from EMT 
express both epithelial (pro-surfactants) and also mesenchymal (α-SMA, N-cadherin) proteins. 
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β-catenin, a signal transducer of the Wnt signalling pathway, in AECs and fibroblasts, suggesting that 
the Wnt–β-catenin pathway is switched on in both cell types146. 
1.1.4.4.2 PTEN 
PTEN is crucial for development. In adults, PTEN participates in the regulation of physiological 
processes such as cell polarity, proliferation and apoptosis147. In IPF patients, myofibroblasts within 
the fibrotic foci downregulate PTEN expression, which may protect them from apoptosis148. The 
interaction between β1-intergrin, a transmembrane receptor required for cell-cell or cell-ECM 
interactions, and collagen in normal fibroblasts activates PTEN, which is also a negative growth 
regulator; this negative feedback is however defective in fibroblasts in IPF patients149. 
1.1.4.4.3 Shh 
Shh is an essential morphogen for patterning during embryogenesis. This developmental ligand 
allows the evasion of apoptosis and cell cycle arrest and promotes proliferation in cells. In the lungs 
of IPF patients an elevated level of Shh expression was observed, particularly in epithelial cells lining 
the honeycomb cysts150,151. Shh overexpression may contribute to AEC2 hyperplasia observed in the 
lungs of IPF patients. 
1.1.4.4.4 BMPs 
BMPs belong to the TGF-β superfamily and have an essential role in embryonic and postnatal 
development152. In adults, reactivating the expression of BMP antagonists can contribute to the 
progression of some chronic degenerative diseases, such as IPF153, liver154 and renal155 fibrosis and 
cervical cancer156,157. BMP-4 is one of the key morphogens during embryonic lung development158. 
BMP-4 inhibits the proliferation of human pulmonary fibroblasts and during embryogenesis induces 
the proliferation and differentiation of pulmonary epithelial cells159. Gremlin is a strong BMP 
antagonist that can associate with BMP-2, -4 and -7 and inhibit their binding to cell surface 
receptors160. Increased expression of gremlin-1 has been reported in fibroblasts in lungs affected by 
IPF42. Increased concentrations of gremlin-1 could attenuate the mothers against decapentaplegic 
homolog (Smad)1/5/8 phosphorylation mediated by BMP-4 signalling in the lungs, leading to 
increased TGF-β1 induced EMT and reduced myofibroblast apoptosis161–163. 
In conclusion, some of embryological pathways are activated during normal tissue repair, but this 
process must be tissue specific and temporarily modulated.  On the other hand, sustained activation 
of these programmes as a result of dysregulated wound healing may contribute to the pathology of 
IPF.  
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1.1.4.4.5 NOX4 
NOX4 is a member of the NADPH oxidases, a group of transmembrane multiprotein complexes 
found in the plasma membrane and phagosomes, which generates superoxide anions by transferring 
electrons from NADPH across the membrane to molecular oxygen164.  Accumulating evidence 
highlights the involvement of NOX-dependent redox signalling, in particular NOX4165–171, in the 
profibrotic responses mediated by TGF-β signalling165. TGF-β1 induced the increased gene expression 
of NOX4, but not other NOX family members, in human fetal lung mesenchymal cells (hFLMCs). 
Hydrogen peroxide (H2O2) generated by NOX4 induction is found to promote TGF-β1 induced 
differentiation of hFLMC into α-SMA+ myofibroblasts. Knockdown of NOX4 expression by small 
interfering RNA (siRNA) inhibited TGF-β1-induced H2O2 production and hFLMC differentiation into 
myofibroblasts. Removal of H2O2 by exogenous catalase activity also mimicked such TGF-β1 
inhibitory activity168. H2O2  may promote the conversion of latent TGF-β into its active form, 
enhancing the phosphorylation and activation of the TGF-β receptor (TGF-βR) TGF-βR1/ ALK5 and/or 
the downstream signalling molecule Smad2/3, and increasing the activation of the transcription 
factors c-Jun N-terminal kinase (Jnk) and p38172. 
NOX4 has been shown to play a role in pulmonary fibrosis. There is evidence showing increased 
NOX4 mRNA and protein levels in pulmonary fibroblasts isolated from IPF patients, and the NOX4 
expression level correlates with expressions of procollagen I and α-SMA142. NOX4 was observed in 
immunohistochemistry staining to be highly expressed in the fibrotic foci of IPF patients168. NOX4 
was also found to mediate TGF-β1 signalling in human mesenchymal cells isolated from IPF patients 
that lead to fibronectin and α-SMA gene and protein expression, collagen secretion, and 
proliferation. These processes were inhibited by NOX4 siRNA168. In BLM-induced pulmonary fibrosis 
in mice, NOX4 was induced between days 7 to 21 post-challenge, and was found to accumulate 
around remodelled alveolar structure at day 14168. Knockdown of NOX4 by siRNA at day 0 post BLM 
challenge reduced fibrosis that is observed by reduced staining for collagen, α-SMA and decreased 
acid soluble collagen in whole lung homogenate at days 14 and 21168. Therapeutic treatment of BLM 
challenged mice at day 8 with diphenyleneiodonium (DPI), a NOX/flavoenzyme inhibitor, protected 
mice from pulmonary fibrosis at day 21168. NOX4 knockout mice were also protected from BLM-
induced pulmonary fibrosis, which was attributable to reduced TGF-β induced epithelial cell 
apoptosis173. Oral treatment with a NOX4 inhibitor attenuated BLM-induced pulmonary fibrosis in 
rats and TGF-β-induced induction of procollagen and α-SMA expression in human pulmonary 
fibroblasts174. Knockdown of NOX4 by siRNA similarly attenuated fluorescein isothiocyanate (FITC)-
induced pulmonary fibrosis in mice168. 
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1.1.4.5 The role of immune cells in IPF 
The pathogenesis of IPF, including potential pathological chronic inflammation-induced injury, 
fibrosis, and tissue remodelling, may be mediated by cells of the immune system that accumulate in 
the lungs of IPF patients, including macrophages, mast cells, T lymphocytes and B lymphocytes, 
through their release of various mediators. 
1.1.4.5.1 Macrophages 
AMφ accumulate in the BAL and lung tissue of IPF patients and contribute to pulmonary fibrosis 
through the release of various pro-inflammatory and pro-fibrotic mediators. AMφ have been found 
to be essential for the progression and/or resolution of BLM-induced pulmonary fibrosis in mice 
challenged intratracheally, as depletion of pulmonary macrophages by liposomal chondrate or DTR 
in CD11c-DTR mice at the active or established fibrotic phases (day 14 or 21), or resolution phase 
(days 42-46) reduced or prolonged fibrosis at days 32 or 56 respectively175. These distinct roles may 
be contributed by various subpopulations of AMφ, which will be described in greater detail later 
(section 1.2.3͘Ϯ). AMφ can be replenished by proliferation within the lung176,177 or recruitment of 
circulating monocytes176,178. However, it is unclear which source is responsible for the increased 
AMφ population in pulmonary fibrosis. Ly6chi monocytes generated from bone marrow in vitro were 
found to exacerbate BLM-induced pulmonary fibrosis and promote the generation of Ym1+ M2-like 
macrophages in mice when injected intravenously during the progressive fibrotic phase (day 21). On 
the other hand, adoptive transfer experiments of Ly6Chi pro-inflammatory circulating monocyte 
precursors isolated from donor CD45.1 mice intravenously injected into recipient CD45.2 mice 
during the established fibrotic phase (day 21) of BLM-induced pulmonary fibrosis did not lead to an 
accumulation of CD45.1+ cells in the recipient lung, suggesting that Ly6chi cells do not directly 
contribute to the M2-like AMφ population during pulmonary fibrosis at day 28175. It may be possible 
that these Ly6chi monocytes indirectly induce M2-like AMφ in the lung during pulmonary fibrosis 
through the release of a number of M2-inducing mediators, such as IL-4, IL-13, IL-10, and TGF-β. 
Ly6c- monocytes may also participate in pulmonary fibrosis through their release of the pro-
angiogenic mediator vascular endothelial growth factor (VEGF) to promote fibroblast differentiation 
into myofibroblast and promote collagen deposition179. The human equivalent of both murine Ly6chi 
and Ly6clo monocytes, CD14hiCD16lo CC chemokine receptor (CCR)2+ and CD14hiCD16hiCCR2+ 
monocytes respectively, were found to be elevated in IPF patients and correlated with disease 
progression, although their exact role in pathology remains to be determined180. It is possible that 
these monocyte subsets play a similar role to their mouse counterparts in biasing towards M2 
polarisation and angiogenesis respectively. 
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1.1.4.5.2 Mast cells 
Mast cells are tissue resident innate immune cells that exerts its effects through acute degranulation 
of preformed mediators (e.g. histamine, tryptase, chymase) and also the release of synthesised 
cytokines and chemokines (e.g. IL-13, CCL2, CCL5) in a delayed response. Two different type of mast 
cells have been identified in mice based on their production of the serine proteases, chymase and 
tryptase, and their anatomical positions. In mice mast cells secreting both tryptase and chymase are 
found in connective tissue of intestinal submucosa, peritoneal cavity and surrounding blood vessels 
and skin, and are known as connective tissue mast cells (CTMCs); mast cells secreting chymase only 
are found in the mucosal tissue of lungs and intestine, and are named mucosal tissue mast cells 
(MMCs)181. In humans mast cells are classified into two groups based on their secretion of chymases 
or tryptases, including MCTC that secretes both chymases and tryptases, and MCT that secretes 
tryptase only. MCTC and MCT in humans correspond to CTMC and MMC in mice respectively182,183. 
There are several evidence suggesting the role of mast cells in pulmonary fibrosis. There is an 
accumulation of mast cell specific products in the BAL of IPF patients, including histamine184 and 
basic fibroblast growth factor (FGF)185. The level of tryptase in BAL also predicted a poorer outcome 
in IPF patients186. An accumulation of mast cells was also observed in the BAL and lung tissue of IPF 
patients. MCT are most frequently found in the healthy lung187, but in IPF patients there was an 
increase in the ratio of MTC as compared to MT in BAL188, suggesting that MTC may have a more 
significant role in pathology. There was also a 10-fold increase in the number of interstitial mast cells 
in IPF patients as compared to control subjects189. Immunohistological analysis revealed that mast 
cells accumulated in the connective tissue directly adjacent to the lumen of small airways and 
fibrotic foci in IPF patients and appeared to be degranulating190,191. Elevated c-kit+ mast cells positive 
for both chymase and trypase (i.e. MTC) were also observed in the lungs of IPF patients192. In 
addition, an increased TGF-β expression in mast cells found in the alveolar parenchyma, and the 
density and percentage of MTC correlated positively with the degree of fibrosis and negatively with 
patient lung function188. 
Rodent models have also provided clues about the potential role of mast cells in pulmonary fibrosis. 
WBBF1-W/Wv mice, which are deficient in mast cells through a mutation in the mast cell survival 
and proliferation factor [stem cell factor (SCF)] receptor c-kit, were protected from BLM-induced 
pulmonary fibrosis193. However, this protection was lost when mast cells were restored193, indicating 
a role for mast cells in the initiation of pulmonary fibrosis. SCF was reported to be elevated on 
fibroblast membranes in IPF patients, and the co-culture of fibroblasts from IPF patients prolonged 
mast cell proliferation and survival194. On the contrary, the genetic or pharmacological inhibition of 
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SCF abolished BLM-induced pulmonary fibrosis in mice, again indicating a role for mast cells in the 
pathology of pulmonary fibrosis195. 
1.1.4.5.3 T lymphocytes  
T lymphocytes accumulate within the BAL196,197 and lung tissue198–201 of IPF patients, and are 
activated following antigen presentation by APCs201,202. Both CD4+ and CD8+ T-cells are present in the 
lung tissue of IPF patients, although CD8+ cells represent the majority. In the BAL the CD4/CD8 ratio 
is more variable where some patients present with greater numbers of CD4+ T-cells, whereas others 
present with more CD8+ T-cells 196. IPF patients with CD4/CD8 greater than one is correlated with a 
higher percentage of lymphocytes, a lower percentage of neutrophils in BALF and a better response 
to steroid treatment with respect to transfer factor for carbon monoxide (TLCO)196. However, the role 
of T lymphocytes in pulmonary fibrosis remains unclear due to the discrepancies observed in animal 
models of pulmonary fibrosis. Genetic depletion of T lymphocytes in athymic nude mice, or all 
lymphocytes in severe combined immunodeficiency (SCID) mice and recombination activation gene 
(RAG) mice, or systemic depletion of T lymphocytes with neutralising antibodies either had no effect 
on203–206, protected from207,208 or amplified209 pulmonary fibrosis. However, the presence of diverse 
T-lymphocyte subsets in pulmonary fibrosis would suggest that these are not the primary cause for
the initiation of pathology, but recruited to the lung by a chemokine gradient and and activated by 
autoantigens (e.g. annexin-1, periplakin, HSP70210–212) at the site of tissue injury, resulting in 
secondary complications and facilitating disease progression. Indeed mice expressing a transgenic T-
cell receptor (TCR)-β gene, which prevents effective recognition of antigens (other than a single 
epitope of hen-egg lysozyme), when instilled with BLM presented no difference in the inflammatory 
or fibrotic response compared with control mice, suggesting that the initiation of fibrogenesis 
involves an antigen-independent mechanism213. Various CD4+ T-lymphocyte subsets may release 
different mediators that contribute to different aspects of the disease. TH1 and TH2 cells may 
contribute to tissue injury and fibrosis through the release of pro-inflammatory mediators [e.g. 
Interferon (IFN)-Υ and TNF-α], or pro-fibrotic mediators (e.g. IL-4, IL-13 and TGF-β) respectively214. 
TH17 cells also appear to be critical to BLM or IL-1β induced pulmonary fibrosis through their 
production of IL-17215–217. Furthermore another subset of cells, namely CD4+ CD25+ Forkhead box 
Protein 3 (FOXP3)+ regulatory T cells (Treg), have been found to have different roles at different 
stages of pulmonary fibrosis218. Treg cells may promote fibrosis through their direct or indirect release 
of the pro-fibrotic mediator TGF-β214. Indeed co-culture studies have identified the induction of TGF-
β expression in epithelial cells by Treg cells218. Treg cells has also been shown to inhibit fibrocyte 
recruitment via suppression of fibroblast growth factor (FGF)-9 expression in a lung-specific, 
doxycycline-inducible TGF-β overexpression model of pulmonary fibrosis in mice219.  
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1.1.4.5.4 B lymphocytes 
B lymphocytes may also play a role in IPF: highly abnormal intrapulmonary B-cell aggregates201,220 
and an overexpression of immunoglobulin genes104 were found in IPF patients. Potentially 
pathogenic immune complexes have been detected in the sera, BAL and pulmonary parenchyma of 
IPF patients212,221,222. Diverse circulating immunoglobulin (Ig) G antibodies are present in more than 
80% of IPF patients210–212,222–227 that has been linked to disease severity and/or poor prognosis210–
212,224. The role of B lymphocytes in pulmonary fibrosis was controversial due to the lack of effect of 
lymphocyte depletion in SCID or RAG mice in animal models of pulmonary fibrosis described 
earlier204,205. However, plasma B-lymphocyte stimulating factor (BLyS), an obligate factor for B cell 
survival and differentiation was significantly greater in IPF patients than normal controls, and the 
concentration of circulating BLyS is inversely correlated with patient outcome228. BLyS was also 
found to be central to BLM- and IL-17-induced pulmonary fibrosis229.  
B lymphocytes may contribute to pulmonary fibrosis by the expression of tissue bound or circulating 
antibodies. Tissue bound antibodies can cause cytotoxicities through antibody-dependent cellular 
cytotoxicity (ADCC), where natural killer (NK) cells are recruited and/ or activated by the Fc portion 
of IgG1 and IgG3 through their FcΥIII receptor (FcΥRIII) 230–233. Tissue-bound antibodies can also direct 
release of pro-inflammatory, pro-fibrotic or vasoactive mediators by complement activation233, 
and/or act as APCs to T lymphocytes to promote phagocytosis233,234.  
B lymphocytes also produce autoantibodies that promote a pro-inflammatory response in target 
cells through neutralisation of anti-inflammatory proteins, or formation of pro-inflammatory auto-
antigens. Autoantibodies that recognise endogenous Annexin-1, periplakin and HSP70 are elevated 
in IPF patients, and the levels of these have been linked to more severe disease and poor 
prognosis210–212. Annexin-1 is a calcium and phospholipid binding protein produced by AECs and 
AMφ, and has anti-inflammatory properties through its inhibition of phospholipase A2, the first 
enzyme in the metabolism of the pro-inflammatory eicosinoids235. Neutralisation of Annexin-1 leads 
to increased inflammation in pulmonary fibrosis that may increase tissue injury. Moreover, inhibition 
of Annexin-1 abrogates the inhibitory glucocorticoid effects on neutrophil extravasation and may 
again lead to an exacerbation of the pro-inflammatory response236. Periplakin is a small protein of 
the plakin family that is produced by brochial and alveolar epithelial cells211, and is localised to 
demosomes and intermediate filaments237; inhibition of periplakin with autoantibodies inhibits 
alveolar epithelial repair in vitro211. Extracellular HSP70 is an alarmin that acts as an intracellular 
messenger by binding to specific cell surface receptors hat transduce signals and modulate 
inflammatory responses238,239. HSP autoantibodies can augment production of pro-inflammatory 
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mediators238,240,241 by cross-linking the cell surface receptor complexes or after gaining access to 
intracellular auto-antigens via lipid rafts. 
1.1.4.6 Hypoxia in IPF 
In IPF the continuous proliferation and activation of fibroblasts and excessive deposition of collagen 
within the alveolar airspaces results in scarred non-functional airspaces and subsequent hypoxia5,242–
247. Progressive fibrosis clinically correlates with worsening hypoxia, and increasing desaturation
during exercise has been found to be a significant predictor of subsequent mortality248. This will 
eventually lead to death by asphyxiation. Experimental evidence suggests that tissue hypoxia may 
play a role in the progression of IPF249–254, and hypoxic lung tissue is associated with pulmonary 
fibrosis255. Another study has found that lactic acid levels, a mediator generated by cells in response 
to hypoxia, are high in IPF lung tissue256. Hypoxia exerts its effects via the transcription factors 
hypoxia-inducible factor (HIF)-1α and HIF-2α257,258. Hypoxia may contribute to fibrosis through 
promoting cell proliferation, such as fibroblasts found in IPF patients259 via expression of the 
microRNA (miR)-210 that represses the c-myc (a transcription factor with a role in cellular 
proliferation) inhibitor, MNT. Indeed MNT levels are reduced in IPF fibroblasts, and knockdown of 
miR-210 increased MNT levels. Overexpression of MNT also inhibited hypoxia-induced IPF fibroblast 
proliferation. Hypoxia-mediated increase in miR-210 and fibroblast proliferation are downstream of 
HIF-2α, as silencing of HIF-2α attenuates both of these processes259. Hypoxia also induced a pro-
fibrotic macrophage phenotype in MH-S cells (a mouse alveolar macrophage cell line260) in vitro261. 
Treatment of MH-S cells increased the production of activated PAI-1 that is attenuated through 
siRNA silencing of HIF-1α expression261. PAI-1 is a pro-fibrotic mediator that is found at elevated 
levels in the lung tissue of mice with BLM-induced pulmonary fibrosis262. Overexpression of PAI-1 
augmented BLM-induced pulmonary fibrosis263, whereas PAI-1 deficient mice had increased 
fibrinolysis, reduced collagen accumulation and prolonged survival264. Activated PAI-1 is an indirect 
inhibitor of plasminogen activation into plasmin, which mediates the cleavage of a multitude of 
substrates, such as cytokines, MMPs, and fibrin. PAI-1 inhibition of fibrinolysis may promote fibrosis 
through cellular recruitment through sustaining the fibrin clot265. HIF-1α also mediates the TGF-β1 
induced production of the pro-fibrotic mediator PDGF-AA in MH-S cells. As HIF-1α is a downstream 
effector of hypoxia, it is possible that this process is also inducible by hypoxia alone261.  
1.2 Macrophages  
Macrophages are innate immune cells that are derived from bone marrow precursors. Mature 
macrophages localise in tissues and constitute to the mononuclear-phagocyte or reticuloendothelial 
system. In general, macrophages are characterised morphologically by an enlarged horse-shoe 
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shaped nucleus, significant rough surfaced ER, and large number of mitochondria or ER. They are 
motile cells, and appear at sites of inflammation within 24-48 hours. They are relatively long-lived, 
and exhibit continuous secretory activity during inflammatory processes, allowing them to destroy a 
range of cells, antigens and pathogens266,267. Macrophages are also highly phagocytic to a number of 
substances, including viruses, bacteria, effete red blood cells (RBCs), tissue and debris and some 
tumour cells268. Macrophages play a variety of roles in an organism’s biology, including development, 
homeostasis, tissue repair and immune defence against pathogens268. Resident macrophages 
regulate tissue homeostasis by acting as sentinels and responding to changes in tissue physiology 
and also environmental challenges. In the event of tissue injury or infection, macrophages are 
recruited from the monocyte reservoirs of blood, spleen and bone marrow269, and perhaps from 
tissue progenitors or local proliferation270–272.   
Within the alveolar space, tissue resident AMφ act as the first line of defence against invading 
pathogens. AMφ are lung-specific long-lived cells, with a turnover rate of around 40% per year273,274. 
These cells have adapted to deal with factors unique to the lung environment that is reflected by 
their ability to respond to airborne irritants and microbes through increased chemotaxis, 
phagocytosis, cytotoxicity and release of reactive oxygen and nitrogen intermediates, Prostaglandin 
E (PGE), TNF-α and IFN275. Critically, AMφ have adapted to default to a relatively quiescent state so 
as to minimize damage to the lung tissue in response to external stimuli. AMφ secrete latent TGF-β 
that is activated by αvβ6 integrin expressed on adjacent injured epithelial cells to limit inflammation 
and protect from alveolar epithelial damage276. At the same time, AMφ may also suppress 
inflammation by efferocytosis of apoptotic cells277. In chronic lung diseases such as IPF, AMφ are 
defective in their ability to resolve inflammation and homeostasis and therefore allowing tissue 
injury to persist. This will be discussed in greater detail in section 1.2.3. 
Macrophages are able to carry out these diverse roles through altering their phenotype in response 
to signals in their immediate environment to generate heterogeneous specialised subpopulations278. 
Several signals have been identified through in vitro experiments, which will be described below. 
1.2.1 Heterogeneity of macrophages to environmental signals 
Macrophages have phenotypic heterogeneity and are engaged in a diverse range of activities279,280  
including pro- and anti-inflammatory activities281, immunogenic and tolerogenic activities279 and 
tissue destruction and tissue repair280 activities. This plastic expression profile of macrophage is 
influenced by the nature, concentration and length of exposure to the inducing signals in their 
immediate environment. Two types of signals have been reported to alter macrophage phenotype, 
including priming signals (e.g. cytokines, growth factors, immune complexes, hypoxia) that influence 
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the inflammatory potential and the wound-healing response in macrophages, and also stimulatory 
signals (e.g. PRR ligands) that have strong inflammatory effects282.  
Several macrophage subsets have been characterised in vitro through the distinct priming and/or 
stimulation of bone marrow derived macrophages (BMMφ)283 in mice and monocyte derived 
macrophages (MDM) in humans that can broadly be classified into two groups dependent on their 
inflammatory potential. ‘Classical activation’ of macrophages, also known as M1 macrophages, are 
characterised as those that have an elevated inflammatory potential, with enhanced microbicidal 
capacity and increased secretion of pro-inflammatory mediators284,285, and includes macrophages 
that have been primed with the TH1 cytokine IFN-Υ alone or in combination with stimulation from 
PRR ligands, and the growth and survival factor macrophage colony stimulatory factor (M-CSF). 
‘Alternative activation’ of macrophages, also known as M2 macrophages, have a reduced 
inflammatory potential and were proposed to play an important role in the immune response to 
parasites, allergy, wound healing and tissue remodelling281,282. M2 macrophages are characterised as 
those primed with the TH2 cytokines IL-4 or IL-13, the growth and survival factor granulocyte 
macrophage colony stimulatory factor (GM-CSF), immune complexes in the presence of PRR 
stimulation, or the resolution mediators IL-10 or TGF-β. These macrophages are also known as M2a, 
M2b, or M2c macrophages respectively283; M2b and M2c macrophages were also referred to as M2-
like macrophages owing to their functional similarities to the prototypical M2a macrophages. 
Priming with the macrophage growth and survival factor GM-CSF were also reported to promote a 
M2-like phenotype. The different nomenclature, priming and/or stimulatory signals, associated 
mediators and function for distinct macrophage subsets pre-defined ex vivo is summarised in table 
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The priming or stimulatory signals have only a temporary effect on macrophage phenotype. In other 
words, macrophages will eventually revert to their original, functional status after the cytokine 
signalling ceases. For example, the in vitro or in vivo treatment of macrophages with cytokines alter 
their functional response pattern to lipopolysaccharide (LPS). However, if the cytokines are washed 
away after incubation and macrophages are then maintained in the absence of cytokines for 1-2 
days before LPS stimulation, the functional response is usually identical to macrophages that have 
not been pre-stimulated with cytokines286. This reversibility of macrophage phenotype thereby 
allowing them the flexibility to adapt their phenotype to the ever changing microenvironment. 
Macrophages also display a high level of plasticity in their phenotype, and demonstrate reversibility 
in their polarisation state. Macrophages display distinct functions when primed with IFN-Υ, IL-12, IL-
4, or IL-10 in vitro, and additional functional patterns are displayed depending on whether or not the 
cytokine is present alone or with other cytokines, and whether or not the cytokine is added before 
or together with the activating stimulus LPS. For example, IL-10 is able to promote IL-4 –induced 
Arginase protein expression in mouse BMMφ. Sequential treatment of macrophages with different 
cytokines results in a progression through multiple functional phenotypes. For example, treatment 
of mouse BMMφ and peritoneal macrophages with IL-10 following IFN-Υ polarisation reduced IL-12 
protein levels upon LPS stimulation287.  
Furthermore, macrophage polarisation in tumour associated macrophages (TAM) have been shown 
both in vitro and in vivo to be reversible. TAM adopt a M2-like phenotype (Arg-1hi IL-10hi) that is 
dependent on NFκB activation via the IL-1R and MYD88 signalling pathways. Co-culture of 
macrophages with ID8 cells, a mouse ovarian cancer cell line, was able to generate M2-like TAM in 
vitro. However, inhibition of NFκB activation through impairment of IKKβ production, an upstream 
signalling mediator of NFκB, in IKKβ-/- mice, biases BMDM co-cultured with ID8 cells away from M2-
like polarisation (Arg-1hi IL-10hi) towards M1-like polarisation (IFN-Υhi IL-12 p70hi NOS2hi)288.  
IL-12 p70 secretion was found to be defective in M2-like TAMs isolated from human and mice 
tumours, which was attributed towards increased production of IL-10. Inhibition of IL-10 with 
neutralisaing antibodies restored the defective capacity of TAMs to produce IL-12 p70289. These 
results indicate that macrophages display a high level of plasticity, and are able to adapt their 
phenotype to their changing microenvironment. 
In light of the temporal effects of signals and plasticity of macrophages, the M1-M2 classification of 
macrophage subsets in vitro is therefore, likely to be an oversimplification of the actual in vivo 
phenotype, where a multitude of inducing signals, including both M1 and M2 stimuli, are present. 
Macrophages are subject to at least four levels of recognition/ response, including one where the 
monocyte survives and acquires mature phenotypes, a level where macrophage interacts with 
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immune cells (NK and TH cells, eosinophils and basophils), a level where macrophages deals with the 
pathogen and a resolution phase, each of which are capable of shaping macrophage phenotype290. 
The different signals that may influence macrophages at various stages of development and immune 
response is summarised in table 1.2. These signals may have agonistic or antagonistic effects to one 
another such that a spectrum, rather than mutually exclusive, distinct M1 or M2 macrophage 
phenotypes are thought to be present in vivo. For example in smoking and non-smoking COPD 
patients, AMφ expressed a mixture of some M1 [pro-inflammatory mediators (TNF-α, IL-1β, and IL-
12 p70), complement receptor (CR)-3] and M2 [CD209/dendritic cell- specific intercellular adhesion 
molecule-grabbing nonintegrin (DC-SIGN)] macrophage-associated markers291, although it is unclear 
whether or not these represent distinct subpopulations or hybrid phenotypes.  
Growth and 
survival factors 
Lineage determining cytokines 
(Conventional maturation) 
Survival, 
recruitment and 
retention 
Other 
M-CSF, GM-CSF
Adhesion 
molecules, 
chemokines 
VitD3, Retinoic acid, 
PPR gamma ligands 
Lymphoid and 
myeloid 
cytokines 
Classical and alternative 
activation 
Pro-inflammatory 
cytokines 
Anti-inflammatory 
cytokines 
IFN-Υ, IL-4, IL-13 TNF, IL-6, IL-1β IL-10, TGF-β 
Interaction with 
pathogens 
Direct interaction Humoural 
PRRs IgG, IgE, IgA Complement, Lectins, Ficolins 
Resolution 
Systemic mechanisms Local mechanisms 
IL-10, TGF-β ECM Proteoglycans, ATP and sugar nucleoCdes, Resolvins, Maresins 
Table 1.2 Different mediators at various stages of macrophage development and immune response may 
influence macrophage phenotype. Growth and survival factors released during monocyte maturation into 
macrophages, lymphoid and myeloid cytokines released during an immune response, direct or indirect 
activation of macrophages through PRR stimulation or the release of humoural mediators as a result of 
pathogen interaction, and resolution phase mediators may act together to alter macrophage phenotype. 
ATP, adenosine triphosphate; ECM, extracellular matrix; GM-CSF, granulocyte macrophage-colony 
stimulatory factor; IFN-γ, interferon gamma; Ig, immunoglobin; IL, interleukin; M-CSF, macrophage 
stimulatory factor; PRR, pathogen recognition receptor; TGF-β, transforming growth factor-beta; TNF-α, 
tumor necrosis factor-alpha; vitamin D3 (VitD3). This table is adapted from Martinez FO and Gordon S, 
2014290. 
For the sake of simplicity however, macrophages subsets derived in vitro will be referred to as M1, 
M2 and M2-like, and their phenotype will be discussed below. Macrophages also play various roles 
in tissue fibrosis, including IPF that may be mediated by different subpopulations. The role of 
macrophages in various diseases, including fibrosis, and the participation of various subsets in IPF 
specifically will be discussed further in sections 1.2.2 and 1.2.3 respectively. 
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1.2.1.1 M1 ‘classically activated’ macrophages 
M1 ‘classically-activated’ macrophages develop following exposure to IFN-ϒ and/or TNF-α or LPS, 
which induces TNF- α production. M1 macrophages increase the production of pro-inflammatory 
cytokines, including IL-1β, TNF-α, IL-12 p70 and IL-6, and chemokines, including CCL15/ Macrophage 
Inflammatory Protein (MIP)-5, CCL20/MIP-3α and CXCL13/ B-Cell Attracting chemokine (BCA)285. M1 
macrophages also increase the surface expression of antigen presenting proteins, including MHC-II 
and the co-stimulatory proteins CD80 and CD86, and have increased antigen presenting capabilities 
to T-cells292. M1 macrophages also facilitate a type I immune response through the release of 
CXCL11/ Interferon-inducible T-cell alpha Chemoattractant (I-TAC), which recruit NK cells and TH1 
cells through CXCR3278,292–297. M1 macrophages also show increased phagocytosis of 
microorganisms292,298,299, and enhanced production and secretion of MMPs, such as MMP-7 and 
MMP-9300,301. MMPs enable macrophage to gain access to the injured tissue during inflammation 
through basement membrane disruption, but excessive release or unregulated production results in 
tissue damage121,301. In addition, M1 macrophages have increased microbicidal activity by restriction 
of iron and other nutrients for microorganisms, acidification of phagosomes, synthesis of reactive 
oxygen intermediates (ROI)302,303and also Nitric Oxide (NO) through the increased expression of 
Nitric Oxide Synthase (NOS) 2/inducible NOS (iNOS)304.  
1.2.1.2 M2 or M2-like macrophages 
M2 ‘alternatively activated’ macrophages were originally identified in BMMφ exposed to IL-4/ IL-
13282,305, and are so-called to distinguish them from the ‘classically-activated’ M1 macrophages. 
Other related subsets, closely resembling each other but distinct in function, have since been 
identified121,306, and are referred to as M2-like macrophages121.  These M2-like macrophages include 
those primed with anti-inflammatory mediators, such as immune complexes, glucocorticoids, 
prostaglandin (PG) E2, IL-10, and TGF-β that are subsequently stimulated by a TLR ligand, and are 
characterized by their high expression of IL-10 and low expression of IL-12 p70121. 
1.2.1.2.1 M2 macrophages 
M2 macrophages generated by IL-4 or IL-13 primimg increase the expression of scavenger receptors, 
such as mannose receptor C, type 1 (MRC1)/ Macrophage Mannose Receptor (MMR)/ CD206 in 
humans and mice305,307,308. They are considered wound-healing macrophages, and can play a role in 
physiological and pathological tissue remodelling121,308. M2 macrophages increase fibrogenic 
mediators, such as fibronectin 1 and matrix associated protein beta Ig-H3119. They also release 
mediators required for tissue repair and proliferation, including coagulation factor XIII309, insulin-like 
growth factor (IGF)-1310. In addition, M2 macrophages increase the expression of arginase-1 (Arg-
1)311–313, an enzyme that converts arginine into L-proline, the precursor for collagen synthesis.
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M2 macrophages also facilitate a type II immune response and are responsible for defence against 
parasites121. M2 macrophages produce the chemokines CCL13/ Macrophage Chemoattractant 
Protein (MCP)-4, CCL8/ MCP-2 and CCL26/ eotaxin-3, which recruit eosinophils, basophils and some 
polarized TH2 cells through the activity of CCR3292. However, M2 macrophages have poor antigen-
presentation skills and exhibit increased release of iron314 and clearance of apoptotic cells and ECM 
components306,315. 
1.2.1.2.2 M2-like macrophages 
M2-like macrophages are a group of macrophage subpopulations that are characterised by their high 
levels of IL-10 production, and the requirement for two stimuli, an anti-inflammatory priming signal 
followed by a TLR stimulatory signal, to induce their anti-inflammatory activity. The primary signals 
include antibody immune complexes, glucocorticoids, PGE2, TGF-β and IL-10, adenosine and 
apoptotic cells121, which has little or no stimulatory function of its own. However, when combined 
with a second stimulus, such as TLR ligand (e.g. LPS), the two signals reprogramme macrophages to 
produce IL-10121. In addition, M2-like macrophages reduced levels of IL-12 p35 and p40 
production316. IL-10 may suppress an inflammatory response through the ligation of the IL-10 
receptor (IL-10R) complex, which is a heterotetramer composed of two ligand-binding α-subunits (IL-
10Rα) and two signal transducing β-subunits (IL-10Rβ), and activation of a signalling cascade 
involving janus kinase (JAK)1, tyrosine kinase (TYK)2, and signal transducers and activator of 
transcription (STAT)3317.  IL-10 induces the inactivation of macrophages and dendritic cells (DC), with 
a resulting inhibition of inflammatory cytokine secretion and inhibition of the expression of MHC-II 
and co-stimulatory molecules318–323. IL-10 also inhibits the maturation of DCs from monocyte 
precursors324,325 and limits the ability of macrophages to kill intracellular organisms, partly by 
inhibiting their production of TNF318,326. IL-10 also suppresses a TH1 response by inhibiting the 
production of its primary inducer IL-12 p70 by macrophages and DCs318,327. In addition, IL-10 induced 
IL-10 producing CD4+ Treg, which may amplify its immunosuppressive response328. 
As a result of their high IL-10 production, M2-like macrophages are considered to be anti-
inflammatory and may play an immunoregulatory role to limit inflammation at the later stages of 
immune response121. M2-like macrophages may be the subpopulation that produces TGF-β in 
addition to IL-10, although this has not been shown rigorously due to the overlap in markers 
between M2 and M2-like macrophages329–332. 
There are subtle differences in M2-like macrophages induced by different priming signals. M2-like 
macrophages generated by priming with immune complexes and TLR stimulation resemble M1 
macrophages more than M2 macrophages, and have increased expression of NOS2 but low levels of 
Arg-1, and increased expression of the antigen presenting co-stimulatory molecules CD80 and 
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CD86292. While these M2-like macrophages produce high levels of anti-inflammatory IL-10, they are 
not anti-inflammatory per se as they also produce pro-inflammatory cytokines, including TNF-α, IL-6 
and IL-1β121. M2-like macrophages generated from immune complex and TLR stimulation have been 
reported to favour the development of a type II adaptive immune response333. These macrophages 
may also play a role in immunoregulation through the recruitment of Treg through the release of 
CCL1/I-309284,292,334.  
On the other hand, M2-like macrophages generated from priming with anti-inflammatory mediators, 
including IL-10, TGF-β and glucocorticoids have inhibited secretion of pro-inflammatory mediators, 
including TNF-α, IL-6, IL-12 p70 and IL-18335,336. There is also a decreased antigen presenting 
capabilities by these cells, with a reduced expression of MHC-II, CD80 and CD86336. Similar to M2 
macrophages, M2-like macrophages induced by IL-10 also have increased surface and intracellular 
expression of MRC1307.  
1.2.2 The role of macrophages in disease 
Following tissue damage resulting from injury or infection, inflammatory monocytes (Ly6c+ in mice) 
are recruited from the circulation and differentiate into macrophages that migrate into the affected 
tissues269. These recruited macrophages are usually pro-inflammatory and M1-like in the early stages 
of a wound-healing process, secreting a variety of inflammatory mediators including TNF-α, IL-1 and 
NO, which activate antimicrobial defence mechanisms, including oxidative processes that contribute 
to the killing of invading organisms337. These macrophages also secrete IL-12 and IL-23, which direct 
the differentiation and expansion of TH1 and TH17 cells that help drive inflammatory responses 
forward306. Although these inflammatory macrophages are beneficial in that they facilitate the 
clearance of invading organisms, they also trigger collateral tissue damage arising from the toxic 
activities of ROS and RNS and of TH1 and TH17 cells338. If the inflammatory response is not quickly 
controlled, it can become pathogenic and contribute to disease progression, as is seen in many 
chronic inflammatory and autoimmune diseases339,340, including atherosclerosis, asthma, 
inflammatory bowel disease, rheumatoid arthritis, and fibrosis337,341–343. To counteract the tissue 
damaging potential of the inflammatory macrophage response, macrophages undergo apoptosis or 
switch to an anti-inflammatory M2 and/or M2-like phenotype that dampens the pro-inflammatory 
response, while facilitating wound healing337. These regulatory macrophages usually produce ligands 
that are associated with development such as WNT ligands that are essential for tissue repair344.  
There may be several contributors to the switch in macrophage phenotype. Anti-inflammatory 
mediators, such as IL-10 and TGF-β may be produced to negatively regulate the inflammatory 
response in tissue injury and promote a M2-like phenotype. Efferocytosis of apoptotic neutrophils 
induce macrophages to produce IL-4 and IL-13 that acts in an autocrine manner to promote the M2 
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phenotype in a mouse peritonitis model345. Prolonged LPS stimulation in vitro may also induce 
tolerance in peritoneal macrophages to dampen the pro-inflammatory M1-like phenotype and 
promote the expression of M2-like associated proteins346. These factors have a major impact on 
many chronic diseases. In the presence of persistent irritation, these homeostatic and reparative 
functions can be subverted, resulting in casual association of macrophages with various disease 
states, including fibrosis, obesity and cancer268.  
Macrophages have pleiotropic roles in tissue fibrosis, including the initiation, progression and 
resolution of fibrosis. In a carbon tetrachloride (CCl4)-induced model of liver injury, repeated injury 
(3 month in mice) leads to extensive scarring that is induced by the transdifferentation of hepatic 
stellate cells (HSCs) into myofibroblasts347. Following cessation of CCl4 injections, the scarring 
resolves completely347. Selective depletion of CD11b+ scar-associated macrophages (SAM) using DTR 
in CD11b-DTR mice during peak fibrosis at 12 weeks reduced the accumulation of ECM components 
and loss of myofibroblasts in the liver following CCl4-induced injury, indicating that SAM may play a 
role in the progression of liver fibrosis. On the other hand, depletion of SAM in the recovery phase 
attenuated matrix degradation, particularly perisinusoidal fibrosis348. In a single intratracheal dose 
model of BLM-induced pulmonary fibrosis, depletion of CD11c+ AMφ with liposomal chondrate, or 
with DTR in CD11c-DTR mice during active (day 21) or established (day 28) fibrogenesis reduced 
collagen deposition observed at day 32. On the other hand, depletion of pulmonary macrophages 
with liposomal chrondrate during the recovery phase (days 42-46) slows down the removal of 
collagen and the resolution of fibrosis observed at day 56349.   
Macrophages may contribute to the initiation and progression of fibrosis through the release of a 
number of mediators that promote inflammation, and fibrosis and tissue remodelling respectively 
(discussed further in section 1.2.3.1). Macrophages may also regulate fibrosis through the 
phagocytosis of apoptotic or necrotic cells, which inhibits or promotes inflammation 
respectively350,351. Efferocytosis of apoptotic cells may be either pro- or anti-fibrotic. In liver fibrosis, 
ingestion of apoptotic hepatocytes increase TGF-β secretion in macrophages, which may promote 
fibrosis302,350–352. On the other hand, clearance of apoptotic myofibroblasts, hepatocytes, and cellular 
debris removes the stimuli inducing TGF-β347,353. Efferocytosis of necrotic cells may also be pro- or 
anti-fibrotic. Efferocytosis of erythrocytes by macrophages or Kupffer cells promotes oxidative 
stress, inflammation and fibrosis by depositing iron derived from haemoglobin in the liver354. 
Conversely, efferocytosis of apoptotic hepatocytes by macrophages or Kupffer cells reduced the 
inflammatory response and shortened the course of tissue injury, thereby preventing fibrosis in a 
CCl4-induced liver injury model355. Macrophage-mediated efferocytosis of apoptotic cholangiocytes 
has also been shown to promote the reversal of biliary fibrosis356. AMφ from IPF patients have lower 
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rates of efferocytosis as compared to controls from other forms of interstitial lung disease in a yet 
unknown mechanism. This may reduce the clearance rate of apoptotic and/or necrotic cells and 
prolong cellular activation357, thereby promoting dysregulated wound healing and fibrosis. 
Macrophages may also aid in the resolution of fibrosis through the secretion of collagen degrading 
mediators, such as milk fat globule epidermal growth factor 8 (mfge8)358.  
1.2.3 The role of macrophages in IPF 
Macrophages may play a role in IPF. The study of clinical lung biopsies has shown an accumulation of 
macrophages around fibrotic lesions in IPF patients359. Gene and protein expression analyses showed 
elevated levels of pro-inflammatory (e.g. TNF-α, IL-1β, IL-12 p40, IL-6, CCL2, CCL3, CCL4, CCL5, CXC1, 
CXCL2, CXCL4, CXCL8), pro-fibrotic (e.g. fibronectin, TGF-β) and tissue remodelling mediators (e.g. 
MMPs) in AMɸ from IPF patients, which may lead to tissue injury and fibrosis respectively. The 
function of these macrophage derived mediators in IPF is described in greater detail below in section 
1.2.3.1. Depletion of macrophages at the active fibrotic phase (day 14) with liposomal chlondrate in 
C57BL/6 mice, or diphtheria toxin in CD11c-DTR mice, attenuated collagen accumulation in a mouse 
model of BLM-induced pulmonary fibrosis, suggesting a causatative rather than bystander role of 
macrophages in pulmonary fibrosis349. 
As aforementioned in section 1.2.1, macrophages have been shown to differentiate into heterogenous 
phenotypes in response to various priming and stimulatory signals in vitro. It is possible that these 
different macrophage subsets may contribute to various aspects of pulmonary fibrosis: M1 
macrophages may promote tissue injury through the release of various pro-inflammatoy mediators, 
ROS, and RNS. M2 and M2-like macrophages may promote tissue fibrosis through the release of pro-
fibrotic mediators. These will be discussed in greater detail in section 1.2.3.2.  
1.2.3.1 Macrophage-derived mediators in pulmonary fibrosis 
Macrophages have been shown to release a number of mediators, including cytokines, chemokines, 
matrix remodelling proteins and also ECM components that may contribute to the pathogenesis of 
pulmonary fibrosis, several of which that are assessed in this thesis will be described in detail below. 
TNF-α 
TNF-α is a pleiotropic inflammatory cytokine that is predominantly produced by activated 
macrophages360. TNF-α is produced in its 27 kDa transmembrane precursor form, but can be cleaved 
by the metalloprotease TNF-α Converting Enzyme (TACE)/ A Disintegrin And Melloproteinase 
(ADAM)17 into a soluble 17 kDa form361. Both transmembrane and soluble forms can bind as 
homotrimers to TNF receptors (TNFR), including a ubiquitously expressed TNFR1 (55kDa) and a 
hematopoietic cell restricted TNFR2 (75kDa), which activate the Nuclear Factor κ B (NFκB), MAPK 
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and/or apoptotic signalling pathways362,363. Soluble forms of TNFRI and TNFRII can be released to 
neutralise TNF-α activity364. TNF-α has been associated with a number of responses, including 
regulation of cell proliferation, and mediation of the local inflammatory response365. The pleiotropic 
effects of TNF-α may be mediated through extensive cross-talk between different signalling 
pathways, the type of cell they stimulate, and/or concurrent stimulation with other cytokines362,363.  
Lung specific overexpression in mice by introduction of the TNF-α transgene into the SPC promoter, 
a pulmonary surfactant expressed exclusively by AEC2, induced pulmonary fibrosis366. TNF-α may 
contribute to pulmonary fibrosis through inducing promoting tissue injury, fibroblast proliferation 
and/or propagating chronic inflammation. 
However, TNF-α may also protect from pulmonary fibrosis. TNF-α have been shown to inhibit 
collagen synthesis367 in myofibroblasts, and have a role in aiding epithelial cell recovery368. 
Intratracheal instillation of TNF-α at the 3rd and 4th week following BLM-challenge induced resolution 
of pulmonary fibrosis that included reduction of collagen accumulation, improved lung function and 
lung architecture.On the other hand, fibrosis was prolonged in TNF-α-/- knockout mice369. The 
contrasting effects of TNF-α to pulmonary fibrosis may be due to its different contibutions to various 
stages of pulmonary fibrosis, where it acts to promote the initiation but prevent the progression of 
pulmonary fibrosis. 
IL-1β  
IL-1β is a member of the IL-1 gene family that is an important group of cytokines involved in acute 
and chronic inflammation96. IL-1β is produced by a wide variety of cells, including macrophages, in 
response to inflammatory agents, infections, or microbial endotoxins. IL-1β is produced as an 
inactive zymogen370, and the 17kDa bioactive form is released after proteolytic cleavage by IL-1β 
converting enzyme (ICE)371 or the Nucleotide-binding Oligomerization Domain (NOD)-Like Receptors 
(NLR) family, Pyrin domain containing 3 (NLRP)3 inflammasome 372. IL-1β exerts its effects through 
binding to IL-1 receptor (IL-1R)1, which then associates with IL-1R accessory protein (IL-1R3/ IL-1R 
AcP) to form a high affinity receptor complex that is competent for signal transduction. IL-1R2 has 
high affinity for IL-1β but function as a decoy receptor and negatively regulates IL-1β activity373. IL-1 
receptor antagonist (IL-1ra) also functions as a competitive antagonist by preventing IL-1β from 
interacting with IL-1RI374.  
IL-1β may contribute to pulmonary fibrosis through its promotion of inflammation and fibrosis. 
Transient overexpression of IL-1E within rat lungs by adenoviral gene transfer after intranasal 
administration induced pulmonary fibrosis375. This was accompanied by an increase in TNF-α and IL-6 
protein levels and evidence of increased acute lung injury (ALI), suggesting that IL-1β may contribute 
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to elevated fibrotic response by inducing more severe tissue injury375. In addition, IL-1E promotes 
the production of the angiogenic chemokines, including CXCL1 (also known as keratinocyte-derived 
chemokine, KC) and CXCL2 (also known as MIP-2), which are murine homologues of CXCL8/IL-
8/melanoma growth stimulating activity (GRO)-α376. On the other hand, lung-specific IL-1β 
overexpression also induced an increase in the pro-fibrotic mediators TGF-β and PDGF, suggesting 
that IL-1β may also participate in progressive fibrotic changes375.  
Histological analyses revealed that continual inhibition of IL-1β, by administration of with IL-1ra 
through an interperitoneal osmotic minipump at day 2, prevented hydroxyproline accumulation in 
the lung and pulmonary damage in BLM- or silica-challenged mice at day 15 (active fibrosis), but had 
no effect on cellular composition within BAL, suggesting a causative role between IL-1β induced 
inflammation and subsequent fibrosis122. Furthermore, treatment of BLM- or silica-challenged mice 
with IL-1ra at day 25 (established fibrosis) also reduced hydroxyproline content within the lung, 
indicating a role for IL-1β in established fibrosis122.   
IL-12 p40 
IL-12 (IL-12p70)/cytotoxic lymphocyte maturation factor (CLMF)/ NK cell stimulatory factor (NKSF) is 
a heterodimer composed of two disulphide-linked subunits of 35 (p35) and 40 kDa (p40) that are 
encoded by two separate genes. These two subunits combine to form the bioactive heterodimer of 
70-75 kDa (IL-12 p70)377,378. IL-12 p70 is highly expressed by activated APCs, and is a key cytokine for 
induction of a TH1 immune response, primarily acting on T lymphocytes and NK cells379. IL-12p70 
exerts its effects through binding to the IL-12 receptor complex that is a heterodimer composed of 
the IL-12R-β1 and IL-12R-β2 subunits. In addition to the dimerization with IL-12 p35 to form the 
bioactive IL-12 p70, IL-12 p40 can also form homodimers that act as antagonists to IL-12 p70 through 
its ability to compete binding to IL-12 receptor IL-12R-β1. In addition, IL-12 p40 can also 
heterodimerise with a 19kDa polypeptide (IL-23 p19) to form IL-23, which is reported to have similar 
functions to IL-12 p70380.  
IL-12 p40 has been reported to be elevated in the serum of IPF patients125. IL-12 p40 play a critical role 
in murine models of pulmonary fibrosis: Neutralisation of IL-12 p40 with antibodies (day 0) attenuated 
BLM-induced pulmonary fibrosis102,124 and IL-1β-induced pulmonary fibrosis124. On the other hand, the 
administration of recombinant IL-12 p70 attenuated BLM-induced pulmonary fibrosis381. In a silica-
induced model of pulmonary fibrosis, IL-12 p40-/- mice exhibited limited inflammation and fibrosis, 
whereas administration of recombinant IL-12 p40 restored pulmonary fibrosis in IL-12 p40-/- mice and 
exacerbated pulmonary fibrosis in wild type (WT) mice. On the other hand, IL-12 p35-/- mice had well-
developed inflammation and fibrosis following silica challenge. These results indicate that IL-12 p40, 
Chapter 1 | General Introduction 
62 
but not IL-12 p35 or IL-12 p70, was responsible for the initiation of silica-induced pulmonary fibrosis123. 
It was observed that IL-12 p35-/- mice had significantly higher IL-12 p40 levels in mouse lungs following 
silica challenge than WT controls, and was correlated with an increased pulmonary macrophage 
infiltration123. Administration of recombinant IL-12 p40 into IL-12 p40-/- mice restored macrophage 
accumulation following silica challenge, whereas in WT controls there was an increased macrophage 
influx123. IL-12 p40 is chemotactic for macrophages in vitro and in vivo382,383, and was proposed to 
promote the initiation of silica-induced pulmonary fibrosis through the macrophage recruitment123.  
IL-12 p40 may also complex with IL-23 p19 to play a significant role in the initiation of BLM-induced 
pulmonary fibrosis, and IL-23 p19-/- mice have reduced collagen accumulation following BLM 
challenge384. IL-23 may promote the differentiation of IL-17 producing TH17 cells385–387, and IL-17A can 
mediate BLM124,384 or IL-1β induced pulmonary fibrosis124. The pro-fibrotic roles of IL-12 p40 
mentioned here are deduced from animal models of pulmonary fibrosis; further studies will have to 
be carried out to deduce their involvement in IPF.  
IL-6 
IL-6 is a pleiotropic 22-28 kDa cytokine that plays important roles in the acute phase reaction, 
inflammation, hematopoiesis, bone metabolism, and cancer progression388–392. IL-6 signals through a 
cell surface heterodimeric receptor complex composed of a ligand binding subunit, IL-6 Receptor (IL-
6R) α (IL-6Rα) and a signal transducing subunit (gp130). IL-6 binds to IL-6Rα, which then triggers the 
association with gp130, and gp130 dimerization393. Soluble forms of IL-6Rα are generated by both 
alternative splicing and proteolytic cleavage392.In a mechanism known as trans-signalling, complexes 
of soluble IL-6 and IL-6Rα can elicit responses from cells expressing gp130 but not IL-6Rα on their cell 
surface392. Trans-signalling allows a wider range of cell types to respond to IL-6, as the expression of 
gp130 is ubiquitous, whereas that of IL-6Rα is predominantly restricted to hepatocytes, monocytes 
and resting lymphocytes389,392. Soluble splice forms of gp130 block trans-signalling from IL-6/IL-6Rα 
but not from other cytokines using gp130 as a co-receptor392. IL-6, along with TNF-α and IL-1, drives 
the acute inflammatory response and the transition from acute inflammation to either acquired 
immunity under normal conditions, or chronic inflammatory disease when dysregulated388–392, 
including that observed in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis 
and atherosclerosis388,389,392. IL-6 can also act as an anti-inflammatory molecule, as in skeletal muscle 
where it is secreted in response to exercise389. In addition, IL-6 enhances hematopoietic stem cell 
proliferation and the differentiation of TH17 cells, memory B cells and plasma cells388,394. IL-6 and 
soluble IL-6Rα are elevated in systemic sclerosis395,396 and liver cirrhosis397, correlating with disease 
severity. In the kidneys, heart and skin, IL-6 also promotes collagen production398–400. In the lungs, IL-
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6 is important in airway remodelling in asthma401 and induces the conversion of fibroblasts to 
myofibroblasts402, and it promotes pancreatitis-associated lung injury403.   
IL-6 may also play a role in interstitial pulmonary fibrosis: IL-6 levels were increased in the BALF of 
IPF, sarcoidosis and systemic sclerosis with interstitial lung disease patients87. IL-6 levels in BALF is 
correlated with worse prognosis in sarcoidosis patients, and is increased in patients requiring steroid 
therapy or having progressive disease87. Serum IL-6 levels is predictive of early functional decline and 
mortality in interstitial lung disease associated with systemic sclerosis404. Adenosine is a purine-
signalling nucleoside that is generated in excess during cellular stress and damage and has been 
implicated in pulmonary fibrosis, where transgenic mice deficient in the enzyme responsible for 
adenosine catabolism, adenosine deaminase (ada), spontaneously develop pulmonary fibrosis405. In 
a model of adenosine-induced pulmonary fibrosis in ada-/- mice, genetic or pharmacological ablation 
of IL-6, in ada-/- IL-6-/- mice or by anti-IL-6 antibodies respectively, resulted in the attenuation of 
inflammation and fibrosis406. Genetic mutant mice of the IL-6 signal-transducing subunit gp130 with 
deregulated STAT1/3-signalling (gp130ΔSTAT) attenuated, whereas those with deregulated 
extracellular regulated kinase (ERK)1/2 signalling (gp130757F) amplified BLM-induced pulmonary 
fibrosis in mice407, indicating that IL-6 promotes pulmonary fibrosis in a STAT-3 dependent manner. 
Immunhistochemistry also showed excessive STAT3 phosphorylation in the lungs of IPF patients407. 
IL-6 may mediate the progression of pulmonary fibrosis through trans-signalling: blockade of IL-6 
trans-signalling by sequestration of soluble IL-6Rα by addition of soluble gp130 (day 19 to day 32 
daily) attenuated BLM-induced pulmonary fibrosis in vivo, whereas activation of IL-6 trans-signalling 
with a combination of IL-6 and soluble IL-6Rα induced proliferation and ECM (collagen and 
fibronectin) production in normal and IPF fibroblasts in vitro408. 
In summary, there are increased levels of a number of pro-inflammatory mediators in human 
patients with interstitial lung diseases, and also rodent models of pulmonary fibrosis. In murine 
models of pulmonary fibrosis, pro-inflammatory mediators may play a role in initiating ALI-induced 
fibrosis, especially when overexpressed within the lung at non-physiological levels in transgenic 
mice. This may contribute to the lack of resolution of tissue injury, leading to progressive cycles of 
tissue injury and dysregulated wound healing, and ultimately fibrosis. The receptors for regulation 
and function of macrophage-derived proinflammatory cytokines that are elevated in pulmonary 
fibrosis are summarised in table 1.2. It should be noted however that therapeutic treatment 
targeting some of these pro-inflammatory cytokines (e.g. TNF-α neutralising antibody etanercept409) 
did not reverse pathology in IPF patients, such that they are unlikely to be key mediators in the 
established active fibrotic response.  On the other hand, therapeutic treatment of others (e.g. IL-1β 
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and IL-6) attenuated pathology in rodent models of pulmonary fibrosis, and may therefore play a 
role in the progression as well as initiation of fibrosis.
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CC chemokines 
The CC chemokines are a family of chemoattractant that have two conserved adjacent cysteines 
near their amino terminus. This family of chemokines may attract a variety of immune cells in 
response to tissue injury and inflammation. Several CC chemokines that are produced by AMφ have 
been implicated in pulmonary fibrosis, including CCL2, CCL3, CCL4, CCL5, and CCL20, which will be 
described in detail below. 
CCL2 
CCL2, also known as MCP-1, is best known as a chemotactic agent for mononuclear cells410,411. CCL2 
is predominantly produced by monocytes and macrophages, but can also be produced by 
fibroblasts, glioma cells, smooth muscle cells, endothelial cells, lymphocytes and mononuclear 
phagocytes either constitutively or upon mitogenic stimulation410,411. In addition to its chemotactic 
role, CCL2 also induces enzyme and cytokine release by monocytes, NK cells and lymphocytes, and 
histamine release by basophils that express its receptor CCR2411. In addition, CCL2 promotes TH2 
polarization in CD4+ T cells412. CCL2-mediated recruitment of monocytes to the site of inflammation 
is proposed to play a role in atherosclerosis, multiple sclerosis and allergic asthma413,414. CCL2 is 
upregulated in breast cancer and promotes tumour progression by recruiting pro-inflammatory 
TAM, promoting angiogenesis, and increasing the migratory and invasion-related properties of 
tumour cells415. 
CCL2 has been implicated in pulmonary fibrosis, and CCL2 mRNA and protein were strongly 
expressed in the lungs of IPF patients416. CCL2 levels in serum and BALF were also elevated in IPF 
patients417. CCR2-/- mice were protected from BLM- and FITC-induced pulmonary fibrosis418 and CCL2 
gene therapy attenuated BLM-induced pulmonary fibrosis419. CCL2 may play a role in pulmonary 
fibrosis through the recruitment and activation of mononuclear cells416,420. CCL2 may also promote 
fibrosis through the direct and indirect activation of fibroblasts through the induction of TGF-β, 
leading to ECM generation421. In addition, CCL2 may recruit and activate a subset of circulatory bone 
marrow-derived CD45+ CD13+ collagen1+ CCR2+ CD34- fibrocytes to the lungs through their surface 
CCR2 expression in pulmonary fibrosis422. Indeed the recruitment of fibrocytes by CCL2 via their cell 
surface CCR2 expression has been demonstrated in a mouse model of FITC-induced pulmonary 
fibrosis. CCR2-/- mice had attenuated FITC-induced pulmonary fibrosis and fewer number of lung 
fibrocytes isolated, whereas these were restored in recipient CCR2-/- mice following bone marrow 
transplantation from donor CCR2+/+ mice, indicating that CCR2 is required for the initiation of FITC-
mediated tissue injury and fibrocyte recruitment respectively. Furthermore, fluorescent-labelled 
CCR2+ fibrocytes generated ex vivo, administered via an intravenous route were found to migrate to 
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FITC-injured lung air spaces in CCR2-/- mice in vivo. Isolated lung fibrocytes also expressed CCR2 and 
migrated towards CCL2 in vitro, and CCL2 is able to induce collagen production in fibrocytes422.  
CCL3 
CCL3, also known as MIP1α, is closely related to CCL4/ MIP1β. CCL3 is expressed by a variety of 
hematopoietic cells, fibroblasts, smooth muscle cells and epithelial cells423. CCL3 exerts its effects 
through interactions with CCR1, CCR3 and CCR5423. CCR3 promotes the chemoattraction, adhesion to 
activated vascular endothelium, and cellular activation of many hematopoietic cell types including 
activated T cells, NK cells, neutrophils, monocytes, immature dendritic cells and eosinophils423–426. 
CCL3 can also act as a stem cell inhibitor (SCI) that inhibits the proliferation of hematopoietic 
progenitor cells427. CCL3 also contributes to tumour metastasis and the pro-inflammatory 
component of viral infection, rheumatoid arthritis, and hepatitis428–431, although it can also suppress 
the replication of Human Immunodeficiency Virus (HIV)432. CCL3 can also promote hyperalgesia 
(increased sensitivity to pain) by sensitizing sensory neurons to transient receptor potential cation 
channel subfamily V member 1 (TRPV-1) mediated noxious stimulation433. 
CCL3 is elevated in the BALF of IPF434,435, sarcoidosis434, and mustard-gas induced pulmonary fibrosis 
patients436. Immunohistochemitry has revealed that CCL3 is predominantly produced by lung 
macrophages, including AMφ and interstitial macrophages (IMφ), and also by interstitial 
fibroblasts434. Interestingly, there is an increased CCL3 production by BAL immune cells from IPF and 
sarcoidosis patients with progressive but not stable disease, indicating that CCL3 may be involved in 
active fibrosis437. Indeed elevated levels of CCL3 in BAL is also predictive of a poor outcome in IPF438. 
BALF from IPF or sarcoidosis patients has been found to be chemotactic for monocytes but not 
neutrophils, but this was reduced when pre-incubated with monoclonal rabbit anti-human CCL3 
antibodies434. CCL3 may therefore participate in active fibrosis through the recruitment of 
monocytes. In a mouse model of BLM-induced pulmonary fibrosis, CCL3 gene and protein expression 
were elevated from day 1 to at least day 21 post-challenge, and was detected in infiltrating 
macrophages and granulocytes as determined by immunofluorescent staining at day 7. CCL3-/-mice 
had reduced collagen accumulation and fewer infiltrating macrophage and fibrocytes, indicating that 
CCL3 plays a role in the initiation of pulmonary fibrosis and macrophage and fibrocyte recruitment 
respectively439. 
CCL4 
CCL4, also known as MIP-1β, is secreted at sites of inflammation by activated leukocytes, 
lymphocytes, vascular endothelial cells, and pulmonary smooth muscle cells423,440. CCL4 is also 
secreted from activated monocytes as a heterodimer with CCL3441–443. The first two N-terminal 
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amino acids can be cleaved from human CCL4 by CD26/ Dipeptidyl peptidase-IV (DPPIV)442,443. Both 
the full length and truncated forms of CCL4 can exert their biological activity through CCR5, and the 
truncated form additionally interacts with CCR1 and CCR2. CCL4 attracts a number of immune cells, 
including monocytes, macrophages, NK cells and T lymphocytes to sites of microbial infection as well 
as pathological inflammation, including allergic asthma and ischemic myocardium444,445. CCL4 is 
elevated in the BALF of IPF435 and mustard-gas induced pulmonary fibrosis patients436. CCL4 may 
recruit immune cells to the site of fibrosis, however this hypothesis remains to be confirmed. 
CCL5 
CCL5, also known as Regulated upon Activation, Normal T cell Expressed and Secreted (RANTES), 
plays a primary role in the inflammatory immune response by its recruitment and activation of 
leukocytes446–448. CCL5 is secreted by a number of cell types at the site of inflammation, including T 
cells, macrophages449 and also AEC450, and exerts its effects through binding to CCR1, CCR3, CCR4 
and CCR5451,452. Sequestration of CCL5 by the cytomegalovirus protein US28 can impair the 
inflammatory response453. In humans, the first two N-terminal amino acids can be cleaved from CCL4 
by CD26/ DPPIV, generating a protein that acts as a chemotaxis inhibitor and blocks M-tropic HIV-1 
infection of monocytes454. Oligomerisation of CCL5 on glycosaminoglycans is required for CCR1-
mediated leukocyte adhesion and activation and also interaction with the chemokine CXCL4/ 
Platelet Factor (PF)4455–459. The deposition of CCL5 on vascular endothelial cells is crucial for 
monocyte adhesion to the damaged vasculature, but CCL5 oligomerisation is not required for the 
extravasation of adherent leukocytes457–459. CCL5 is upregulated in breast cancer and promotes 
tumour progression by recruiting pro-inflammatory TAM, promoting angiogenesis, and increasing 
the migratory and invasion-related properties of tumour cells415. 
CCL5 may play a role in pulmonary fibrosis: CCL5 mRNA and protein levels were elevated in BALF of 
sarcoidosis460,461, interstitial pneumonia with collagen vascular disease (CVD-IP)461 and IPF 
patients461. In sarcoidosis patients, CCL5 was localised to CD68+ pulmonary macrophages, and there 
was significant correlation between CCL5 mRNA and protein expression and CD45RO+ memory T-
lymphocyte and total lymphocyte numbers, indicating that CCL5 may mediate T-lymphocyte influx in 
pathology460. In addition, CCL5 is a chemokine for mast cells that may promote pulmonary fibrosis 
through the release of a number of pro-fibrotic mediators  
In summary, CCL chemokines may promote the initiation and progression of pulmonary fibrosis 
through the recruitment of various hematopoetic cells that are involved in pathogenesis, such as 
circulating monocytes, fibrocytes and macrophages. It should be noted however that there is 
considerable redundancy in chemokine expression, in that multiple chemokine ligands bind to the 
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same receptor, and most chemokines bind multiple receptors, which may pose a challenge when 
trying to establish the relative importance in disease pathology and designing potential therapeutic 
approaches for targeting chemokine signalling pathways. The alternative nomenclature, receptors 
for, and function of macrophage-derived CC-chemokines that are elevated in pulmonary fibrosis are 
summarised in table 1.3. 
CC 
Chemokines 
Other 
names 
Receptor Function 
CCL2 MCP-1 CCR2 
Chemoattraction of monocytes, macrophages 
and fibrocytes. 
CCL3 MIP-1α CCR1, CCR3, CCR5 
Chemoattraction, adhesion to activated vascular 
endothelium, and cellular activation of many 
hematopoietic cell types including fibrocytes, 
monocytes, activated T lymphocytes, NK cells, 
neutrophils, immature dendritic cells and 
eosinophils 
CCL4 MIP-1β CCR1, CCR2, CCR5 
Chemoattraction of monocytes, macrophages, 
NK cells and T-lymphocytes. 
CCL5 RANTES 
CCR1, CCR3, CCR4, 
CCR5 
Recruitment and activation of leukocytes. 
Table 1.4 Macrophage-derived CC chemokines elevated in pulmonary fibrosis. CCL, CC chemokine Ligand; 
CCR, CC chemokine Receptor; LARC, Liver and Activation-regulated Chemokine; MCP-1, Monocyte 
Chemoattractant Protein-1; MIP, Macrophage Inflammatory Protein; NK cells, Natural Killer cells.   
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CXC chemokines 
The CXC chemokines are a family of chemoattractant that have two conserved cysteines separated 
by one amino acid (X) near their amino terminus. In mammals, CXC chemokines can be separated 
into two functional subgroups, those with a conserved glutamine-leucine-arginine (ELR) immediately 
preceding the first cysteine of the CXC motif (ELR+) and those without (ELR-). ELR+ CXC chemokines 
are chemoattractive to neutrophils, and have an angiogenic role; ELR- CXC chemokines on the other 
hand are chemoattractive to lymphocytes and have an angiostatic role462. 
While the role of granulocytes in pulmonary fibrosis is unclear, aberrant angiogenesis has been 
associated with chronic inflammation and chronic fibroproliferative disease. The metabolic demands 
of tissue undergoing proliferative, reparative and hyperplastic changes are extremely high and 
require a proportionally greater capillary blood supply as compared to normal tissue, which is 
provided by aberrant angiogenesis462. The existence of aberrant angiogenesis was originally 
identified by Turner-Warwick, who examined the lungs of patients with widespread interstitial 
fibrosis and demonstrated aberrant angiogenesis linking systemic and pulmonary microvasculatures 
and evidence of vascular remodelling in areas of fibrosis463. Aberrant angiogenesis (neoangiogenesis) 
is also observed within fibrotic tissue and surrounding the fibrotic foci in BLM-induced pulmonary 
fibrosis in mice464. In IPF patients, there is also an imbalance of ELR+ and angiostatic ELR- CXC 
chemokines, with elevated levels of angiogenic CXCL8 and reduced expression of the angiostatic 
CXCL10465. The ELR+ CXC chemokines induce angiogenesis through promoting endothelial cell 
survival and proliferation. These effects are exerted through the binding of CXC chemokines to their 
respective CXC receptors: CXCR1 is bound by CXCL6 and CXCL8 only, whereas CXCR2 is bound by all 
ELR+ CXC chemokines466. Endothelial cells express both CXCR1 and CXCR2 on their cell surface466–468. 
However, ELR+ chemokine mediated angiogenesis is through binding and activation of CXCR2 but not 
CXCR1462,466,467,469. NIH3T3 (a mouse fibroblast cell line) transfected with CXCR2, but not CXCR1, was 
migratory towards CXCL8469. Human microvascular endothelial cells respond to CXCL8 with rapid 
stress fiber assembly, chemotaxis, enhanced proliferation, and phosphorylation of ERK1/2 related to 
CXCR2 activation. Blocking the function of CXCR2 by specific neutralizing antibodies or inhibiting 
downstream signalling using specific inhibitors of ERK1/2 and PI3K impaired CXCL8-induced stress 
fibre assembly, chemotaxis and endothelial tube formation in endothelial cells470. In a rat corneal 
micropocket assay for detecting angiogenesis, ELR+ chemokine mediated angiogenesis was abolished 
in CXCR2-/- mice, and also CXCR2+ mice in the presence of CXCR2-neutralizing antibodies466. CXC 
chemokines may play a pro-fibrotic role in BLM-induced pulmonary fibrosis through promoting 
angiogenesis via CXCR2. Blockade of CXCR2 with a CXCR2 antagonist, DF1262, dosed twice daily from 
days 0 to 16, reduced collagen deposition following BLM challenge and von Willebrand Factor (vWF), 
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a marker for angiogenesis levels at day 16471. Several angiogenic ELR+ chemokines, including CXCL1, 
CXCL2 and CXCL8, which are produced by macrophages, which will be discussed in greater detail 
below. The role of CXCL12, an ELR- CXC chemokine that plays an important role in the recruitment of 
fibrocytes in pulmonary fibrosis will also be discussed. 
CXCL1 
CXCL1 is expressed in monocytes472, macrophages473, neutrophils, fibroblasts474,475, epithelial473 and 
endothelial cells476,477. CXCL1 exerts its bioactivities through the ligation of CXCR2, and is a potent 
neutrophil attractant and activator478,479. CXCL1 has important roles in inflammation, and was found 
to be involved in monocyte arrest on atherosclerotic endothelium480,481 and may also pay a 
pathophysiological role in Alzheimer’s disease403. CXCL1 also promotes angiogenesis482, which have 
important roles in wound healing483, and tumourigenesis482,484.  
CXCL1 was elevated in ada-/- mice485 that spontaneously develop pulmonary fibrosis405, and gene 
expression analysis and immunohistochemistry revealed that CXCL1 was predominantly produced by 
AMφ485. Lung extracts from ada-/- mice showed increased angiogenic activity in corneal micropocket 
angiogenesis assay as compared to ada+/+ controls, but this was abrogated by inhibition of CXCL1 or 
its receptor CXCR2 with neutralising antibodies485, suggesting that CXCL1 is responsible for 
angiogenesis in a mouse model of pulmonary fibrosis. Further studies will have to be carried out to 
study the effects of CXCL1 inhibition on angiogenesis and also pulmonary fibrosis in ada-/- mice in 
vivo.  
CXCL2 
CXCL2 is expressed in monocytes and macrophages. CXCL2 exerts its effects through binding to 
CXCR2, and is chemotactic for neutrophils472,486 and hematopoietic stem cells487, and may also play a 
role in angiogenesis462.  
In a BLM-induced pulmonary fibrosis in mice, CXCL2 was directly correlated with total lung 
hydroxyproline levels, a measure of collagen deposition488. Depletion of CXCL2 in BLM-challenged 
mice attenuated pulmonary fibrosis that was entirely attributed to a reduction in angiogenesis in the 
lung488. 
CXCL8 
CXCL8, also known as IL-8, Granulocyte Chemotactic Protein (GCP) 1 and Neutrophil Activating 
Peptide (NAP) 1, is produced by macrophages, epithelial cells, airway smooth muscle cells489, 
endothelial cells490,491 and fibroblasts. CXCL8 can associate into a homodimer or a heterodimer with 
CXCL4/ PF4492, and can also interact with matrix and cell surface glycosaminoglycans493. The 
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bioactivity of CXCL8 is regulated by truncations by multiple proteases at the N-terminal, by CXCL8 
citrullination by Arg 5 (N-terminal to the ELR motif)494, and by the decoy receptor Duffy Antigen 
Receptor for Chemokines (DARC)495. CXCL8 effects are mediated by CXCR1/ IL-8RA, which is also 
used by CXCL6, and through CXCR2/ IL-8RB, which is used by multiple ELR+ chemokines496. CXCR1 
and CXCR2 associate into functional homodimers and heterodimers with each other497. CXCL8 
promotes neutrophil adhesion to the vascular endothelium, and migration to sites of 
inflammation498, and triggers antimicrobial activation of neutrophils through CXCR1499. CXCL8 also 
binds to Serpin A1/ α1 Antitrypsin, which prevents CXCL8 interaction with CXCR1500. CXCL8 is 
upregulated in atherosclerotic lesions and other cardiac pathologies where it exacerbates 
inflammatory tissue damage501. In addition, it induces VEGF expression502, vascular endothelial cell 
proliferation503, angiogenesis and tumour cell invasiveness504,505. 
CXCL12 
CXCL12/stromal cell derived factor (SDF)-1/Pre-B cell growth Stimulatory Factor is an ELR- CXC 
chemokine that acts via its receptor CXCR4/leukocyte-derived seven transmembrane receptor 
(LESTR)/ fusin506 and serves as a chemoattractant for fibrocytes, monocytes, T-lymphocytes, pro and 
pre B-lymphocytes but not neutrophils507.  
In IPF patients, CXCL12 levels are increased in the BAL, lung tissue and plasma. 
Immunohistochemistry revealed that this chemokine was primarily expressed by hyperplastic AECs 
lining the fibrotic foci, but were also found in AMφ and endothelial cells128.  Increased CXCL12 was 
also correlated with poorer lung function in IPF patients. CXCL12 is thought to contribute to IPF 
through their recruitment of circulating fibrocytes via CXCR4, which may then further differentiate 
into collagen-secreting fibroblasts128. Indeed immunofluorescence revealed that CXCR4+ procollagen-
I+ fibrocytes were found to accumulate in the lungs of IPF patients128. Human peripheral blood CD45+ 
collagen I+ CXCR4+ fibrocytes undergo chemotaxis in response to CXCL12 in vitro. These cells, when 
injected into the tail vein of BLM-challenge SCID mice at day 4 is found to migrate to the injured lung 
by day 8, presumably mediated by CXCL12. Mouse CD45+ collagen I+ CXCR4+ fibrocytes were also 
found to accumulate from day 2, at maximal levels at day 8, to at least day 20 post BLM-challenge in 
C57BL/6 mice. In addition, daily administration of CXCL12 neutralizing antibody from day 0 blocked 
CD45+ collagen I+ CXCR4+ fibrocyte recruitment (but not other CXCR4-expressing cells, e.g. 
monocytes, lymphocytes) and attenuates fibrosis in BLM-challenged mice at day 16. This indicates 
that CXCL12 mediated recruitment of fibrocytes is crucial for the initiation of BLM-induced 
pulmonary fibrosis508. The alternative nomenclature, receptors for, and function of macrophage-
derived CC-chemokines that are elevated in pulmonary fibrosis are summarised in table 1.4. 
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CXC chemokines ELR Receptor Function 
CXCL1 + CXCR2 Neutrophil recruitment, angiogenesis. 
CXCL2 + CXCR2 Neutrophil recruitment, angiogenesis. 
CXCL8 + CXCR1, CXCR2 Neutrophil recruitment, angiogenesis. 
CXCL12 - CXCR4 Fibrocyte, monocyte, lymphocyte recruitment. 
MMPs 
MMPs belong to the metzincin superfamily of metalloproteinases, and they play key roles in ECM 
catabolism, activation and inactivation of cytokines, chemokines, growth factors, and other 
proteinases at the cell surface and within the ECM509. MMPs are involved in many physiological 
processes including embryonic development, morphogenesis, tissue remodelling, cell growth, 
migration and apoptosis509,510 and pathological conditions such as inflammation, rheumatoid arthritis, 
osteoarthritis, cardiovascular diseases, nephritis, chronic wounds, pulmonary diseases, cancer and 
fibrosis509,511. MMPs are produced and released in their inactive zymogen form, and has to be 
subsequently cleaved by other proteinases, including other MMPs, into its bioactive state.  
MMP-7 null mice are protected from BLM-induced pulmonary fibrosis, suggesting the importance of 
this protease in initiating pathology104. It can promote pulmonary fibrosis through actions on its 
various bioactive substrates, including TGF-β512, osteopontin513 and MMPs512. MMP-7 is able to release 
latent TGF-β and thereby promote fibroblast growth, survival and collagen synthesis512. MMP-7 may 
also cleave and activate osteopontin513 to induce fibroblast migration and 
proliferation514.Furthermore, MMP-7 may promote epithelial cell migration by reducing the affinity of 
α2β1 integrin514. In addition, MMP-7 may activate other pro-fibrotic proteases, including itself, pro-
MMP1, -2 and -9512. MMP-9 is implicated in basement membrane disruption515. 
Fibronectin 
Fibronectin is a large modular glycoprotein that is found as a polymeric fibrilliar network in the ECM, 
as a soluble disulphide-linked dimeric protomers in plasma and other types of body fluid. The 
protein subunits is made up of three types of homologous structural repeats termed fibronectin type 
1, type II and type III repeats. Fibronectin is a ligand for fibrin, heparin, chondroitin sulfate, collagen/ 
gelatin, and many integrin receptors. It is involved in multiple cellular processes including cell 
adhesion/ migration, blood clotting, morphogenesis, tissue repair and cell signalling516,517.  
There was increased fibronectin levels detected in the BALF of IPF patients518. AMφ isolated from IPF 
patients also had increased production of fibronectin ex vivo as compared to normal controls519. IPF 
AMφ supernatant was found to recruit human lung fibroblasts ex vivo, but depletion of fibronectin 
Table 1.5 Macrophage-derived CXC chemokines elevated in pulmonary fibrosis.ELR, Glutamine-Leucine-
Arginine; CXCL, CXC chemokine Ligand; CXCR, CXC chemokine Receptor. 
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with gelatin-bound Sepharose beads from AMφ supernatant abolished this observation, suggesting 
that fibronectin is chemoattractive to fibroblasts519. Indeed fibronectin is a major component of the 
fibrotic clot, and may also act as a scaffold for fibroblast migration520,521. 
TGF-β 
The TGF-β family consists of three isoforms, including TGF-β1, TGF-β2 and TGF-β3522–524, which are 
highly pleiotropic cytokines that are secreted by all cells525,526. TGF-β acts as a cellular switche to 
regulate processes such as immune function, proliferation and EMT527,528. Targeted deletions of 
these genes in mice show that each TGF-β isoform has some non-redundant functions529. TGF-β1 is 
involved in homeostasis and endothelial differentiation; TGF-β2 affects the development of cardiac, 
lung, craniofacial, limb, eye ear and urogenital systems; TGF-β3 influences palatogenesis and 
pulmonary development529. 
TGF-β is initially synthesised as a 390 amino acid inactive zymogen (pre-pro-TGF-β) consisting of an 
N-terminal signal peptide (29 amino acids), a central pro-region called the latency associated peptide
(LAP) (249 amino acids) and a C-terminal consisting of the active form of TGF-β (112 amino 
acids)530,531. The N-terminal signal peptide is first removed by proteolysis, and the resulting pro-TGF-
β then homodimerises through the formation of three disulphide bonds532. The covalent bonds 
between the LAP and mature TGF-β in the pro-TGF-β homodimer are then cleaved by furin/paired 
basic amino acid cleaving enzyme (PACE) to form the small latent complex (SLC). In the SLC, the 
connection between LAP and mature TGF-β are still maintained by non-covalent interactions533,534. 
LAP acts as a chaperone to TGF-β to maintain its latency through conformational changes and also 
non-covalent interactions that prevents TGF-β from binding its receptor535. The SLC may interact 
with latent TGF-β binding protein (LTBP) via disulphide bonds to form the large latent complex 
(LLC).The LLC can then be secreted into the extracellular space, where they anchor via the LTBP onto 
ECM components, such as fibronectin. Active TGF-β can be released through the proteolytic cleavage 
by proteases (e.g. MMP2, MMP9, plasmin), ROS and FGF-2, or by conformational change in the LLC 
through the binding to integrins536–538. Active TGF-β can then exert its effects through binding the 
TGF=βR heterotetrameric complex consisting of two TGF-βR1 and TGF-βR2528,539,540 either via Smad-
dependent541–543 or Smad-independent [e.g. MAPK, small Guanosine TriPhosphate (GTP)-binding 
proteins, protein tyrosine kinase (PTK), NK-κB and Wnt/β-catenin] pathways544–553. 
The TGF-β1 isoform are found at elevated levels in the lung tissue of IPF patients around the fibrotic 
foci118,554, indicating that TGF-β1 may play an important role in pulmonary fibrosis555. 
Immunohistochemistry has identified AECs and AMφ as the predominant source for TGF-β1 in IPF 
patients118,554. TGF-β1 is elevated in the BALF and lung tissue of mice with BLM-induced pulmonary 
fibrosis, and treatment with daily intratracheal administration of a peptide inhibitor to TGF-β from 
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day2 of the early inflammatory phase, or from day 10 of the early fibrotic phase, reduced collagen 
accumulation556. A protective effect towards BLM-induced pulmonary fibrosis was also observed in 
other rodent models when treated with TGF-β inhibitors, including anti-TGF-β neutralising 
antibodies, decorin and soluble TGF-βR receptors557–560. On the other hand, adenovector-mediated 
gene transfer of active TGF-β1 induced prolonged pulmonary fibrosis in rat lung that is characterised 
by extensive deposition of ECM proteins, including collagen, fibronectin and elastin, and an 
accumulation of myofibroblasts 561.  
TGF-β may play a role in dampening the immune response that may cause tissue damage and loss of 
homeostasis following tissue injury. However following persistent injury, prolonged TGF-β elevation 
may contribute to pulmonary fibrosis via several mechanisms, including the promotion of EMT131, 
fibroblast migration561, proliferation561, differentiation into myofibroblasts562, ECM (procollagen and 
fibronectin) expression in myofibroblasts563, and AEC apoptosis564.  
1.2.3.2 The potential role of macrophage subsets in IPF 
Macrophages may play a role in tissue injury and fibrosis through the release of a number of 
mediators, as described in the above section (section 1.2.3.1) in IPF patients. These different roles 
may be contributed by different macrophage subsets in response to signals from their immediate 
environment (Figure 1.5). Previous studies have suggested that M1 macrophages may participate in 
inflammation-induced tissue injury through its release of various ROS, RNS, pro-inflammatory 
cytokines, chemokines and tissue remodelling proteases. M2 and M2-like macrophages may 
contribute to the wound healing process, and if dysregulated the progression of pulmonary fibrosis 
through their release of pro-fibrotic mediators (Figure 1.5). On the other hand, M1, M2 and/or M2-
like macrophages may also contribute to tissue repair and the resolution of fibrosis through the 
release of anti-fibrotic mediators278. However, as forementioned in section 1.2.1, tissue 
macrophages interact with a number of priming or stimulatory signals, such that the phenotype of 
macrophage found in vivo are unlikely to be strictly associated with a distinct in vitro defined subset, 
but rather exist within the M1-M2 polarisation spectrum. It is therefore more likely than not that 
pro-inflammatory and pro-fibrotic macrophages observed in pulmonary fibrosis are M1- and M2-
biased, rather than strictly adhering to a distinct subset. 
Despite the shortfall on describing the complexity of macrophage heterogeneity in vivo, the M1-M2 
paradigm provides a simple starting point for the assessment of complex macrophage polarisation in 
vivo. Previous studies of macrophage heterogeneity in IPF have based their classification along the 
M1-M2 paradigm, presumably due to the lack of technology to identify complexities in macrophage 
phenotypes. These include single-cell analysis to identify macrophage heterogeneity within a patient 
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sample, or genomic and proteomic analysis to identify subtle differences between in vivo and in vitro 
derived macrophage subsets.  
In the following section, these previous studies on macrophage heterogeneity will be summarised in 
the context of the M1-M2 paradigm, with respect to the pro-inflammatory M1 macrophages, and 
pro-fibrotic M2 and M2-like macrophages as described in section 1.2.1. It should be noted that the 
macrophage-subsets described below are unlikely to be mutually exclusive and may coexist in the 
form of hybrid macrophages.  
 
 
 
1.2.3.2.1 The potential role of M1 macrophages in IPF 
There has been one study indicating the presence of M1 macrophages in pulmonary fibrosis: 
immunostaining analyses with anti-human or anti-mouse folate-receptor-beta (FR-β) monoclonal 
antibody revealed that FR-β positive macrophages were present in the fibrotic areas of IPF patients 
and mice with BLM-induced pulmonary fibrosis respectively565. These macrophages are likely to be 
M1 macrophages, as they have a pro-inflammatory phenotype and produce TNF-α and oxygen 
radicals566. Treatment by ablation of FR-β expressing macrophages by intranasal administration of a 
recombinant immunotoxin, consisting of Ig heavy and light chain Fv portions of an anti-mouse FR-β 
Figure 1.5 The potential contributions of various macrophage subsets to pulmonary fibrosis. M1 
macrophages may promote inflammation-induced tissue injury and the initiation of pulmonary fibrosis 
through the release of various reactive oxygen species (ROS), reactive nitrogen species (RNS), pro-
inflammatory cytokines, chemokines and tissue remodelling proteases. M2 and M2-like macrophages may 
contribute to the wound healing process, but may promote the progression of fibrosis when this process 
becomes dysregulated when the irritation is persistent. Conversely, M1, M2 and M2-like macrophages also 
have the potential to resolve fibrosis through their release of anti-fibrotic mediators and phagocytosis of 
ECM components. Figure adapted from Boorsma CE, 2013278. 
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monoclonal antibody and truncated Pseudomonas exotoxin A, dosed from day 3 every other day, 
increased survival and reduced hydroxyproline (collagen precursor) and fibrosis in BLM-challenged 
mice at day 21565. Immunohistochemical analysis also revealed decreased numbers of TNF-α, CCL2 
and CCL12 producing cells in the immunotoxin-treated group565. The authors concluded that FR-β-
positive macrophages have a critical role in the initiation of pulmonary fibrosis, possibly through 
their release of pro-inflammatory mediators565. However, the pro-inflammatory role of FR-β positive 
macrophages in BLM-induced pulmonary fibrosis has to be confirmed by further flow cytometric 
analysis of pulmonary macrophages co-stained for FR-β and the aforementioned pro-inflammatory 
mediators. FR-β positive pulmonary macrophages can also be isolated by fluorescence activated cell 
sorting (FACS) and the levels of their protein products analysed by enzyme linked immunosorbent 
assay (ELISA) or meso scale discovery (MSD). M1 macrophages may contribute to inflammation 
induced tissue injury through the production of various pro-inflammatory mediators, including TNF-
α, IL-1β and IL-12 p40, ROS and NO, and MMPs (MMP-7 and MMP-9), leading to fibrosis 
development. TNF-α may contribute to pulmonary fibrosis through inducing promoting fibroblast 
proliferation, AEC1 apoptosis and/or propagating chronic inflammation. IL-1β may induce the 
release of other pro-inflammatory mediators (e.g. TNF-α and IL-6) to amplify inflammation567, pro-
angiogenic mediators (e.g. CXCL1, CXCL2, CXCL8) to promote neovascularisation376 and also pro-
fibrotic mediators (e.g. TGF-β and PDGF) to promote fibrosis567. IL-12 p40 may act as a 
chemoattractant for macrophages as observed in vitro and in vivo382,383. MMP-7 may promote 
epithelial cell migration by reducing the affinity of α2β1 integrin514 and activate other pro-fibrotic 
proteases, including itself, pro-MMP1, -2 and -9512. MMP-9 is implicated in basement membrane 
disruption515. 
However, other evidence challenges the role of M1 macrophages in established fibrosis. TNF-α is also 
shown to inhibit collagen synthesis367 in myofibroblasts, and have a role in aiding epithelial cell 
recovery368 and treatment of TNF-α in established fibrosis contributes to resolution of BLM-induced 
pulmonary fibrosis in mice369. The pleiotropic effects of TNF-α observed in pulmonary fibrosis may 
result from different types of cells present at various stages of pulmonary fibrosis. TNF-α promotes 
inflammation-induced tissue injury, fibroblast proliferation and subsequent fibrosis in the 
inflammatory phase; on the other hand, fibroblast are activated into myofibroblasts in the fibrotic 
phases and their collagen-secreting activities are inhibited by TNF-α in a negative feedback loop. 
Depletion of tissue macrophages and/or circulating inflammatory monocytes during the inflammatory 
phase of in vivo models does not affect the onset or degree of fibrosis developing later on349. On the 
other hand, it is equally possible that pro-inflammatory mediators that are associated with M1 
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macrophages in the inflammatory phase are also released at a low level by M1/M2 hybrid 
macrophages in the fibrotic phases.  
1.2.3.2.2 The potential role of M2 macrophages in IPF 
There is a body of evidence demonstrating that M2 macrophages accumulate in the lungs of IPF 
patients and also mouse models of pulmonary fibrosis. Markers found on or produced by M2 
macrophages have been found to be increased in IPF patients, including Galectin-3 (Gal-3)568,569, 
CCL18570, Chitinase 3 like 3 (Chi3l3)/ Tyrosine-Lysine-Leucine, 40 kDa (YKL-40)571, CD163572, IGF-I and 
PDGF573–575. M2 markers are also increased in murine models of pulmonary fibrosis, including Arg-1576, 
Found In Inflammatory Zone (FIZZ1)/ Resistin-Like Molecule alpha (RELM-α)577,578, and MRC1337,579. 
There is also an increase in the M2-inducing cytokine IL-13 in IPF patients compared to controls, and 
AMɸ isolated from IPF patients produce more IL-13 than that from control lungs580. IL-13 may 
therefore participate in promoting the M2 macrophage phenotype in IPF patients. M2 macrophages 
may play a pro-fibrotic role through the release of their various associated mediators. For example, 
Arg-1 promotes the conversion of arginine into orthinine581, the precursor of proline that is required 
for collagen synthesis could support fibrosis582. FIZZ1 induces the differentiation and survival of 
myofibroblasts583, as well as increase ECM production in fibroblasts that would favour the 
development of fibrosis577. IGF-I and PDGF drive the proliferation of fibroblasts and their 
transformation to ECM-producing myofibroblasts120. M2 macrophages are able to secrete the ECM 
component fibronectin119; Fibronectin is a major component of the fibrotic clot, and may also act as a 
scaffold for fibroblast migration520,521. 
Alternatively other studies have suggested that M2 macrophages have an anti-fibrotic role. For 
example, mannose receptors and the glycoprotein mfge8 are responsible for the uptake of ECM 
components, and both can attenuate fibrosis in different mouse models358,584. Mannose receptors are 
associated with M2 macrophages, which may suggest that this subset may play a role in the resolution 
of fibrosis. These mechanisms for the clearance of ECM components may serve as a negative feedback 
mechanism for M2 macrophages to prevent excessive ECM accumulation. In the presence of a 
persistent irritant however, it is possible that the pro-wound healing activities of M2 macrophages 
may become dysregulated in a frustrated effort to repair damaged tissue, which is able to overcome 
negative feedback activities and lead to excessive ECM accumulation and fibrosis. 
1.2.3.2.3 The potential role of M2-like macrophages in IPF 
M2-like macrophages share many M2-associated proteins (e.g. Arg-1, FIZZ1, MRC1), but are 
distinguished by their high levels of IL-10 production. M2-like macrophages contribute to 
immunoregulation, matrix deposition, and tissue remodelling, and may be important during the 
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transition from inflammation towards wound healing following lung injury. Elevated levels of IL-10 
have been observed in several fibrotic diseases, including IPF125,585,586 and systemic sclerosis patients 
with interstitial lung disease572. The role of IL-10 in pulmonary fibrosis remains elusive. Some studies 
suggest that it has a protective role: IL-10 is an anti-inflammatory cytokine, and can suppress T-cell 
activation587, inhibit T cell activity320, and also suppress TNF-α and ROS production in macrophages 
following LPS stimulation588. IL-10 is essential for the regulation of acute and chronic inflammation: in 
IL-10-deficient mice infected with rapidly replicating pathogens, such as Trypanosoma cruzi and 
Toxoplasma gondii, the mice typically die rapidly but not from excessive growth of the pathogens, but 
of a massive inflammatory response589,590. In the context of pulmonary fibrosis, IL-10 may prevent 
further tissue injury and fibrosis591. However, this hypothesis is challenged by another study, where 
IL-10 knockout mice showed increased BLM-induced inflammation but not fibrosis592. On the other 
hand, prophylactic and therapeutic gene delivery of IL-10 attenuated BLM-induced pulmonary fibrosis 
in mice through inhibiting the production of TGF-E in the lung, suggesting an anti-fibrotic role for IL-
10593. IL-10 can have a pro-fibrotic role: long term lung-specific overexpression of IL-10 in mice induced 
pulmonary fibrosis through fibrocyte recruitment and M2-like macrophage activation through a CCR2/ 
CCL2 axis594. M2-like macrophages may also be producers of the pro-fibrotic cytokine TGF-E, which 
may promote fibrocyte recruitment, and fibroblast activation/differentiation into the ECM-producing 
myofibroblasts554.  
In conclusion, there is evidence for both the contribution and inhibition by different macrophage 
subsets, including M1-, M2-, or M2-like macrophages, of pulmonary fibrosis. These pleiotropic effects 
of these macrophage subsets to promote or inhibit pulmonary fibrosis are more likely than not to 
represent the complexity in macrophage activation in vivo, with respect to the plasticity of 
macrophages to respond to multiple signals to give rise to hybrid macrophages, and the adaption of 
macrophages phenotype to the changing environment during disease progresson in IPF (i.e. temporal 
heterogeneity of IPF). 
1.2.4 The role of PRRs in IPF 
Macrophages express a variety of PRRs to detect endogenous alarmins released by apoptotic or 
necrotic cells, or exogenous pathogens entering the lung. Several PRRs that can be found on 
macrophages are increased in BAL cells (including macrophages, T and B lymphocytes) from IPF 
patients, including TLR2595, TLR3 596, TLR7, TLR9595,596 and NLRP3 inflammasome230,597. TLR2 is 
upregulated in immune cells (macrophages, lymphocytes) and AECs in BLM-induced pulmonary 
fibrosis in mice598. NLRP3 has also been implicated in various mouse models of pulmonary 
fibrosis230,597. 
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1.2.4.1 TLRs 
TLRs are type I transmembrane glycoproteins which are structurally characterized by extracellular 
leucine-rich repeats (LRRs) and Toll/IL-1 receptor (TIR) signalling domains and includes 10 members in 
humans and 12 members in mice599,600. TLRs can be activated by highly conserved pathogen associated 
molecular patterns (PAMPs) of bacteria, viruses, fungi, and parasites, and also by danger associated 
molecular patterns (DAMPs) of endogenous ligands or alarmins, such as chromatin-IgG complexes601, 
hyaluronan fragments (HA)602–605 or High Mobility Group Box 1 (HMGB1)606–611. 
TLR ligation following the binding of their respective ligands is signalled through a number of TIR-
domain containing adaptors, such as Myeloid Differentiation primary response 88 (MyD88), TIR 
domain containing Adaptor Protein (TIRAP), TIR-domain containing adaptor-inducing interferon-β 
(TRIF), and TRIF Related Adaptor Molecule (TRAM), and can be categorised into MYD88-dependent 
and MYD88-independent pathways. All TLRs, with the exception of TLR3, signal through the MY88- 
dependent pathway, whereas TLR3 and TLR4 signal through the MYD88-independent, TRIF-dependent 
pathway. TLR1, TLR2, TLR4, and TLR6 recruit TIRAP, which serves as an adaptor between the TIR 
domain of TLRs and MyD88, while TLR5, TLR7, TLR9, TLR10, TLR11 and TLR12 can recruit MyD88 
directly. TLR3 recruits TRIF directly, but TLR4 recruits TRIF indirectly through TRAM. The recruitment 
of these adaptor proteins trigger a signal cascade of signalling molecules that ultimately activate 
transcription factors, including NFκB and IRFs. These transcription factors induce the expression of 
various inflammatory cytokines, type I IFNs, and chemokines. NF-κB is a central regulator of immune 
responses involved in cell proliferation and survival and induces the expression of many cytokine and 
chemokine genes including IL-2, IL-6, IL-12, MCP-1, and TNF-α612. 
In the MYD88-dependent pathway, MYD88 recruits the Interleukin-1 Receptor Associated Kinase 
(IRAK) family of protein kinases that phosphorylates and activates the E3 ubiquitin protein ligase TNF 
Receptor Associated Factor 6 (TRAF)6. TRAF6 induces the activation of TGF-β Activated Kinase 1 (TAK1) 
through K63-linked polyubiquitination. NF-κB, Activator Protein (AP)-1 and cyclic Adenosine 
Monophosphate (cAMP) Response Element Binding protein (CREB) is then activated by the IκB Kinase 
(IKK) complex and MAPK, respectively. 
In the TRIF-dependent pathway induced by TLR3 ligation, the N-terminal domain of TRIF interacts with 
TRAF6 while the C-terminal domain of TRIF interacts with Receptor Interacting Protein (RIP)-1 and 
activates TAK1, both of which can activate NF-κB, resulting in the expression of inflammatory 
cytokines613. TLR3 ligation also induces the expression of type I interferons via IRF3614. TRIF recruits 
TRAF3 and the IKK-related kinase TRAF family member-associated NFκB activator (TANK) Binding 
Kinase 1 (TBK1), which then phosphorylates and activates the transcription factor IRF3615. 
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TLR7 and TLR9 engagement induces the secretion of inflammatory cytokines through the activation of 
NF-κB via MyD88. However, TLR7 and TLR9 can also induce the expression of type I IFNs through the 
activation of IRF7, which is phosphorylated by IRAK1, IRAK4, or IKKα, and then translocated to the 
nucleus where it induces the transcription of IFN-α616. 
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Binding Kinase 1 (TBK1), which then phosphorylates and activates the transcription factor IRF3 to induce 
the expression of type I IFNs. 
Figure 1.6 Toll Like Receptor (TLR) 2, TLR3, TLR4, TLR7, TLR8 and TLR9 signalling pathways.TLR2 binds to 
di- or tri-acetylated lipoproteins when complexed with TLR1 or TLR6 respectively. TLR2 heterodimers are
also able to bind alarmins, including High Mobility Group Box protein 1 (HMGB1) and low molecular
weight (LMW) Hyaluronan (HA) fragments. TLR3 binds to double stranded Ribonucleic Acid (dsRNA)
expressed by viruses. TLR4 binds to Lipopolysaccharide (LPS), and also to HMGB1 and LMW HA fragments. 
TLR7 and 8 bind to single stranded RNA (ssRNA) and TLR9 bind to CpG-oligodinucleotide (CpG-ODN) from
viruses. TLR9 also binds to alarmins such as histones. The alarmin HMGB1 is also able to act as a
molecular chaperone to TLR2, TLR4 and TLR9 ligands, thereby enhancing their responses. TLR2, 4, 7, 8 and
9 are able to signal through the Myeloid Differentiation 88 (MYD88) pathway. Activation of the MYD88
pathway results in the increased gene expression of pro-inflammatory genes. TLR2 recruits MYD88
indirectly through TIR domain containing Adaptor Protein (TIRAP), whereas TLR7, 8 and 9 are able to
recruit MYD88 directly. MYD88 is then able to recruit the interleukin-1 receptor associated kinase (IRAK)
family of protein kinases, including IRAK1, IRAK2, and IRAK3 that recruits and activates the E3 ubiquitin
protein ligase Tumour Necrosis Factor Receptor Associated Factor 6 (TRAF6). TRAF6 modulates the
activation of TGF-β Activated Kinase 1 (TAK1) through K63-linked polyubiquitination. TAK1 can then
initiate a phosphorylation cascade via the IκB Kinase (IKK) complex to activate NFκB, or via the Mitogen
Activated Protein Kinase (MAPK) pathway to activate cyclic Adenosine Monophosphate Response
Element Binding protein (CREB) or Adaptor Protein 1 (AP1). The phosphorylation and activation of MAPK
kinase (MKK) 3 or 6 leads to the activation of CREB via p38, whereas that of MKK 4 or 7 leads to the
activation of AP1 via c-Jun N-terminal Kinase (JNK). TLR7 and TLR9 can also induce the expression of type I 
IFNs through the activation of Interferon Regulatory Factor (IRF)7, which is phosphorylated by IRAK1,
IRAK4, or IKKα, and then translocated to the nucleus where it induces the transcription of IFN-α. TLR3 and
endocytosed TLR4 are also able to signal through a MYD88-independent pathway via the adaptor protein
TIR-domain containing adaptor inducing IFN-β (TRIF) instead. TLR3 recruits TRIF directly, but TLR4 recruits
TRIF indirectly through TRAM. TRIF recruits Receptor Interacting Protein-1 (RIP-1), which in turn activates
TAK1, thereby integrating with the MYD88-dependent pathway to activate pro-inflammatory genes. TRIF
also recruits TRAF3 and the IKK-related kinase TRAF family member-associated NFκB activator (TANK) 82 
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TLR2 
TLR2 is an extracellular membrane protein involved in the recognition of a wide range of PAMPs 
originating from bacteria, parasites and viruses617. These include lipoproteins from bacteria, 
peptitoglycan and lipoteichoic acid from Gram-positive bacteria, lipoarabinomannan from 
mycobacteria, zymosan from fungi, Glycosylphosphatidylinositol-anchored mucin-like glycoprotein 
(tGPI-mucin) from Trypanosoma cruzi and the haemagglutinin protein from measles viruses. TLR2 
usually forms heterodimers with TLR1 or TLR6. TLR1-TLR6 heterodimers recognise triacetylated 
lipopeptides from Gram-negative bacteria and mycoplasma, whereas TLR2-TLR6 heterodimers 
recognise diacetylated lipopeptides from Grampositive bacteria and mycoplasma618. TLR2 is thought 
to induce mainly the production of inflammatory cytokines but not type I IFN by macrophages and 
DCs. On the other hand, it can trigger type I IFN production by inflammatory monocytes in response 
to infection with vaccinia virus619, which suggests a cell specific role in TLR2 in antiviral responses. This 
process requires the internalization of TLR2, as blockade of endocytosis with the actin-depolymerizing 
drug cytochalasin D or blockade of endosomal maturation with chloroquine abrogates IFN-β 
production. However, nucleic acids that usually trigger the production of type I IFN do not participate 
in TLR2 activation619. 
TLR2 is involved in the pathogenesis in a mouse model of BLM-induced pulmonary fibrosis. TLR2-/- 
mice were protected from BLM-induced inflammation and subsequent pulmonary fibrosis. This was 
confirmed by prophylactic administration of an anti-TLR2 neutralizing antibody in BLM-challenged WT 
mice, suggesting a role for TLR2 in the inflammatory response that precedes onset of fibrosis620. 
Therapeutic treatment of BLM-challenged WT mice at the late inflammatory (day 7) or early fibrotic 
phases attenuates pulmonary fibrosis, suggesting a role for TLR2 beyond inflammation and in active 
fibrosis620. TLR2 is also elevated in immune cells, including AMɸ, granulocytes, lymphocytes, and AECs 
in BLM-induced pulmonary fibrosis598.  
TLR2 is able to recognize various alarmins, including low molecular weight (LMW) HA fragments and 
HMGB1. High molecular weight (HMW) (>500 kDa) HA is a nonsulfated glycosaminoglycan composed 
of repeating polymeric disaccharides D-glucuronic acid and N-acetyl-D-glucosamine linked by a 
glucuronidic β (1-3) bond621,622. HA is a major ECM component that is conserved from simple 
organisms such as bacteria623,624 to complex eukaryotes625. HA has multiple functions, such as space 
filling hydration, lubrication of joints, and provision of a matrix through which cells can migrate626. 
HA is actively produced during tissue injury, tissue repair, and wound healing603,627.  
During tissue injury, HA may be broken down into LMW fragments (10-500 kDa) that may function as 
alarmins to elicit an immune response by promoting angiogenesis602,603 and inflammation604,605,628. 
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For example, LMW HA induces pro-inflammatory chemokine production, including CCL2, CCL3 and 
CCL4 in MH-S cells628 and also CCL2 in renal tubular epithelial cells629, whereas LMW HA fragments 
accumulates during tissue injury in IPF patients and in the BLM-induced pulmonary fibrosis630–632, 
and may contribute to chronic inflammation in IPF.  
HMGB1 is an abundant and highly conserved non-histone chromosomal protein that is present in 
almost all eukaryotic cells that acts as a transcription factor-like protein to regulate the expression of 
several proteins633–635, such as the GR636. HMGB1 binds without sequence specificity to the minor 
groove of DNA, causing local distortions in the DNA structure. In addition, HMGB1 associates with 
high affinity to DNA with highly bent structures, such as four-way junctions and cisplatin-modified 
DNA637. HMGB1 is thought to be associated with active chromatin, and have crucial roles in nuclear 
events including transcription, DNA replication and recombination, either by remodelling chromatin 
and nucleosome structure, or through direct interactions with transcription factors, including 
Homeobox (Hox), steroid hormone receptors638–640, p53-p73 transcriptional complexes635,641,642, NFκB 
and TATA-Binding Protein (TBP)643, and recombination factors such as V (D) J recombinase644.  
Upon tissue injury or infection, extracellular HMGB1 acts as a delayed mediator of inflammation606. 
HMGB1 release occurs considerably later (12-18 hours) than secretion of the classical pro-
inflammatory mediators TNF (2 hours) and IL-1 (4-6 hours) following LPS administration to generate 
endotoxemia in mice645,646. Administration of HMGB1-specific antibodies protects against the lethal 
effects from LPS, even when administration is delayed after the peak levels of TNF and IL-1.  
HMGB1 is passively released by necrotic cells647 and actively released by activated macrophages, 
neutrophils and mature DCs in response to the presence of elevated level of pro-inflammatory 
mediator and oxidative stress648–652. Extracellular HMGB1 can activate immune cells, including 
macrophages, through the ligation of TLR2, TLR4607–610 and Receptor for Advanced Glycation End-
products (RAGE). HMGB1 can also act as a molecular chaperone to the ligands of TLRs 2, 4 and 9611 
and augment the stimulatory responses of their respective TLRs by promoting ligation of these 
receptors653.  HMGB1 may bind and accumulate multiple TLR ligands, thereby simultaneously 
activating multiple TLRs and amplifying the pro-inflammatory response. Alternatively, the 
presentation of TLR ligands on the surface of HMGB1 may also make them more accessible to 
receptors on target cells and thereby promote binding653. 
In IPF, HMGB1 is upregulated in BALF654. During acute exacerbation, macrophages and injured 
epithelial cells also have an increased expression of HMGB1651. HMGB1 contributes to BLM-induced 
pulmonary fibrosis, and treatment by intraperitoneal injection of an anti-HMGB1 neutralising 
antibody at day 5 attenuated inflammation and fibrosis at day 21654. 
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TLR7 and TLR9 
TLR7 and TLR9 are intracellular nucleotide-activated PRRs important for detecting viral infection. 
TLR7 is located in the cytoplasm and recognizes single stranded Ribonucleic Acid (ssRNA) derived 
from RNA viruses such as vesicular stomatitis virus, influenza A virus and human immunodeficiency 
virus617,655. TLR7 also recognizes synthetic poly (U) RNA and certain siRNA656. TLR9 are found on the 
endosomal membrane recognizes unmethylated 2’-deoxyribo (cytidine-phosphate guanosine) (CpG) 
DNA motifs that are frequently present in bacteria and viruses but rare in mammalian cells. 
Synthetic CpG oligodinucleotides (ODN) function as TLR9 ligands and drive strong TH1 responses617. 
Recently it has been reported that TLR9 can recognize endogenous histones released by necrotic 
cells, which act as alarmins during sterile inflammation in liver injury657. In addition, TLR9 can 
interact with HMGB1, and thereby promote TLR9-mediated pro-inflammatory responses by acting as 
a molecular chaperone to its ligand CpG-ODN611. Stimulation of TLR7 and/or TLR9 results in the 
release of pro-inflammatory cytokines, and also of type I IFNs (IFN-D and IFN-E), both of which are 
important in the anti-viral response618. 
Chronic viral infections, mainly herpes virus infections, may contribute to the pathogenesis of 
IPF38,40–43. There is correlation between certain latent viral infections, such as EBV, CMV, HHV-7 and 
HHV-8 and human IPF25,40–42,44–47 (section 1.1.4.1). Such viruses can infect and remain latent in 
pulmonary epithelial cells48, thereby rendering them less able to repair subsequent injury. Infection 
may also potentially change the transcriptional programme of these cells such that they secrete 
profibrotic factors and recruit inflammatory cells and fibrocytes (bone marrow derived cells that 
express both hematopoietic and stromal markers) to the lung. TLR7 and TLR9 may therefore 
promote chronic inflammation and induce tissue injury in pulmonary fibrosis through their anti-viral 
responses. 
TLR9 appears to play a pathogenic role in IPF. Rapidly progressing IPF patients have elevated TLR9 
expression compared to slowly progressing IPF patients and normal controls. In a xenograft mouse 
model of IPF, fibroblasts from rapid progressors induced more severe fibrosis than slow progressors 
in response to TLR9 activation. CpG-ODN also induced EMT in a human epithelial cell line658.  
However, in another study, TLR9 stimulation was protective of pulmonary fibrosis in mice. TLR9-/- 
BALB/c mice had increased collagen deposition in gamma herpes virus-induced exacerbation of BLM-
induced pulmonary fibrosis, and CpG-ODN abrogated BLM-induced pulmonary fibrosis in C57BL/6 
mice. This may occur through the induction of IFN-E production by fibroblasts659,660, which inhibit their 
proliferation661. 
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1.2.4.2 NLRP3 inflammasome 
NLRP3 is a cytosolic PRR consisting of 3 domains, including a LRR responsible for ligand binding at its 
C terminus, a central oligomerization domain [domain present in Neuronal Apoptosis Inhibitor 
Protein (NAIP), MHCII Transcriptor Activator (CIITA), HET-E (incompatibility locus protein from 
Posospora anserine) and Telomerase associated Protein 1 (TP1)] (NACHT domain), and an effector 
domain at the N-terminus662. In humans, common effector proteins include the Pyrin Domain (PYD), 
Caspase Recruitment Domain (CARD) and Baculovirius Inhibitor of apoptosis protein Repeat (BIR)663. 
Under healthy cellular conditions, NLRP3 is auto-repressed by internal interactions between the 
NACHT domain and LRRs. In the presence of exogenous pathogens or endogenous alarmins binding 
to the LRRs, this auto-repression is removed and the NACHT domain is exposed. This allows NLRP3 
monomers to oligomerise through their NACHT domains, and recruit the adaptor molecule, 
Apoptosis-associated Speck-like protein containing a CARD (ASC) through PYD-PYD interactions. ASC 
in turn recruits pro-caspase 1 through CARD-CARD interactions. Pro-caspase 1 clustering on 
oligomerised NLRP3 results in caspase 1 auto-activation and caspase 1-dependent processing of 
cytoplasmic targets, including the zymogens of several pro-inflammatory cytokines, including pro-IL-
1β and pro-IL-18372. 
NLRP3 inflammasomes may contribute to BLM-induced lung injury and fibrosis. As mentioned above, 
ASC is the adaptor molecule for the recruitment of the NLRP3 inflammasome substrate pro-caspase 
1 and knockout of ASC in ASC-/- mice may effect NLRP3 inflammasome activation of pro-caspase 1, 
and subsequent downstream activation of pro-IL-1β and pro-IL-18. ASC-/- mice have reduced IL-1β 
and IL-6 levels in BALF in the early inflammatory phase (day 1) compared to wild type controls when 
challenged with BLM664. There was a reduction in lymphocyte accumulation, collagen deposition and 
matrix turnover proteases (pro-MMP-2, pro-MMP-9, MMP-9, TIMP-1) in the lung of NLRP3-/- mice at 
the early fibrotic phase (day 14) following BLM challenge compared to wild type controls230. The 
NLRP3 inflammasome contribute to silicosis and asbestosis, and NLRP3-/- mice have decreased 
inflammation and fibrosis as compared to wild type controls665.  The NLRP3 inflammasome may 
promote fibrosis through the uptake of uric acid crystals released from BLM-induced DNA 
damage230. This PRR may also be activated by ROS generated by macrophages and neutrophils665,666 
and extracellular Adenosine Tri-Phosphate (ATP)667 and drive IL-1β activation668,669 through a 
caspase-1 dependent mechanism372. The activation of the pro-inflammatory IL-1E may contribute to 
tissue injury through the induction of the release of other pro-inflammatory cytokines such as TNF-α 
and IL-6567. IL-1β may also promote neovascularization through the release of –CXC- chemokines, 
including CXCL1, CXCL2 and CXCL8376. Moreover, IL-1β may promote fibrosis through the release of 
pro-fibrotic mediators such as TGF-β and PDGF567. 
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Figure 1.7 The Nucleotide-binding Oligomerization Domain (NOD)-Like Receptors (NLR) family, Pyrin domain 
containing 3 (NLRP3) inflammasome pathway. Under healthy cellular conditions, NLRP3 is auto-repressed 
by internal interactions between the domain present in Neuronal Apoptosis Inhibitor Protein (NAIP), MHCII 
Transcriptor Activator (CIITA), HET-E (incompatibility locus protein from Posospora anserine) and 
Telomerase associated Protein 1 (TP1)] (NACHT domain) and Leucine Rich Regions (LRRs). In the presence of 
exogenous pathogens, such as bacteria or viruses, or endogenous alarmins, such as reactive oxygen species 
(ROS), Adenosine TriPhosphate (ATP) and uric acid, binding to the LRRs, this auto-repression is removed and 
the NACHT domain is exposed. This allows NLRP3 monomers to oligomerise through their NACHT domains, 
and recruit the adaptor molecule, Apoptosis-associated Speck-like protein containing a Caspase 
Recruitment Domain (CARD) (ASC) through PYD-PYD interactions. ASC in turn recruits pro-caspase 1 through 
CARD-CARD interactions. Pro-caspase 1 clustering on oligomerised NLRP3 results in caspase 1 auto-
activation and caspase 1-dependent processing of cytoplasmic targets, including the zymogens of several 
pro-inflammatory cytokines, including pro-IL-1β and pro-IL-18.  
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1.3 BLM-induced pulmonary fibrosis in mice 
BLM is the most frequently applied method and therefore the best characterised experimentally-
induced pulmonary fibrosis670,671. Originally used as a chemotherapeutic agent, BLM was discovered 
to cause pulmonary fibrosis in some cancer patients as a side effect. The incidence of interstitial 
pulmonary fibrosis is directly linked to the dose of BLM administered and the length of treatment. 
This indicates that there is a multiple injury threshold effect directly linked to BLM, and pulmonary 
fibrosis is not caused by cancer per se. The lung is thought to be particularly susceptible to BLM due 
to the lack of the BLM inactivating enzyme, BLM hydrolase, that converts BLM into the less active 
deamidoBLM (dBLM), which has only 1% efficiency as the parent compound in producing oxygen 
radicals, DNA strand scissions, tumour cytotoxicity or pulmonary fibrosis in animal models672. Indeed, 
lung extracts from C57BL/6 mice was revealed to be less efficient than that from BALB/c mice in the 
catabolism of BLM into dBLM, signifying a lower BLM hydrolase activity in the lungs of these mice673.  
Since then BLM-induced pulmonary fibrosis has been used in multiple animal models, including 
mice, rats, guinea pigs, hamsters, rabbits, dogs and primates; mice however remains the most 
common670,671. Several delivery routes are employed, including intratracheal, intraperitoneal, 
subcutaneous, intravenous, and inhalational310,670. Regardless of the delivery route, BLM induces cell 
injury through the induction of DNA breaks, the generation of free radicals and the induction of 
oxidative stress671. This is followed by cell necrosis and apoptosis, with subsequent inflammation and 
development of fibrosis670. 
When delivered systematically (intravenously, intraperitoneally or subcutaneously) the initial site of 
injury is the pulmonary vascular endothelium, which is thought to reflect similar occurring in humans 
affected by BLM-induced pneumonitis674. With this delivery route BLM first causes endothelial cell 
damage, before gaining access to the alveolar epithelium to induce damage. In contrast, with lung-
specific delivery, BLM directly induces damage to AECs670,671,675. The delivery of BLM directly to the 
airways can take place via several administration methods, including oropharyngeal route, 
intratracheal injections with or without surgical neck cutdown422,675, injections of dry powder676, or 
endotracheal intubation677.  
BLM can induce fibrosis in a relatively short time period, from 2-4 weeks in an intratracheal model to 
4-12 weeks in a systemic delivery model. The histopathology is not fully consistent with UIP (e.g. lack
of fibrotic foci hyperplastic epithelium, and temporal heterogeneity), and pulmonary fibrosis arising 
from the single-dose BLM model has widely been reported to resolve spontaneously over time, 
although there has been conflicting reports420,675,678–681. The response to BLM-induced pulmonary 
fibrosis is strain-dependent, with C57BL/6 being more susceptible than BALB/c mice, possibly due to 
their difference in expression of BLM hydrolase. BLM can be delivered as a single-dose or multiple-
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doses. Multiple dosing is thought to mimic the repetitive or chronic injury that induces pulmonary 
fibrosis and provide a more representative model than single dosing. In an endotracheal intubation 
model, single dosing with 0.04 U BLM increased collagen accumulation indicating fibrosis from the 
second week following dosing. Similar to that observed in a single dose intratracheal model, UIP was 
not observed and there was a lack of AEC2 hyperplasia, fibrotic foci, and also the presence of 
neutrophilic inflammation. However, in multiple dosing (0.04 U BLM every other week for eight 
doses), analysed two weeks after the last dose, neutrophilic inflammation is reduced as compared to 
a single dose671,677. AEC hyperplasia is also prominent at the sites of fibrosis, and fibrosis and AEC 
hyperplasia remains conspicuous by 20-30 weeks after the final dose of BLM671,677. Histopathological 
changes are also more similar to UIP that is observed in human IPF677, and features including AEC2 
hyperplasia, formation of fibrotic foci and reduced neutrophilic inflammation were present. Active 
fibrotic remodelling also persisted 10 weeks after the last BLM dose671,677.  
There has been much debate over the translatable nature of the BLM model to clinical IPF due to 
several reasons. In the single-dose models of BLM-induced pulmonary fibrosis, fibrosis does not fully 
recreate UIP, in that there is a lack of AEC2 hyperplasia, formation of fibrotic foci and sustained 
neutrophilic inflammation. Fibrosis is also self-limiting after 28 days following the last dose, and may 
spontaneously resolve after 5-6 weeks. Moreover, the mechanism and kinetics of BLM-induced 
pulmonary fibrosis appears to differ from IPF. BLM-induced pulmonary fibrosis is dependent on tissue 
injury from an initial inflammatory phase, and pathogenesis represents acute lung injury (ALI), 
whereas in IPF only low levels of inflammation is found682. On the other hand, IPF may be the result of 
pathological inflammation caused by the presence of a persistent irritant that have since subsided 
(section 1.1.4.2). There is also a rapid (2-3 weeks) onset of pulmonary fibrosis in mice as compared to 
a chronic (decades) onset in humans. Finally, there is a strain-dependent difference in response to 
BLM-induced fibrosis, primarily due to difference in expression of the inactivating enzyme BLM 
hydroxylase across strains671,683,684 . To date there has been only one study investigating the potential 
variation in pulmonary toxicity of BLM chemotherapy on germ cell cancer patients with BLM 
hydroxylase genetic variation, the deletion of a 1450A→G polymorphic site that should decrease BLM 
hydrolase activity. However, results did not show a difference in pulmonary toxicity between patients 
with the different genotypes. It is possible that this particular polymorphism has only subtle effects 
that is masked by normal renal clearance of BLM685. Further studies looking into the variation of 
susceptibility to BLM-induced pulmonary toxicity in other forms of BLM hydrolase polymorphisms will 
have to be carried out.  
Despite these differences in the histopathology and initiation of pulmonary fibrosis, it should be 
highlighted that a recent study using gene set enrichment analyses (GSEA) have revealed that murine 
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BLM-induced pulmonary fibrosis at the progressive and established fibrotic phases (days 14 and 21) 
shared a number of commonly altered signatures with IPF patients, including cell-cycle related genes 
[e.g. cell cycle division proteins (CDCs), cyclin-dependent kinases (CDKs)], fibrosis-related pathways 
gene sets (PDGF-, integrin, and syndecan) and other pro-fibrotic mediators (MMPs, collagen, and TGF-
β)686. These results suggest that for the purpose of investigating the mechanism of pathogenesis for 
IPF, the murine BLM-model is somewhat translatable.  
In addition, BLM-induced pulmonary fibrosis has the advantage over other models of pulmonary 
fibrosis in that BLM produces relatively uniform pathology and experiments are repeatable, BLM can 
be delivered via the nasal cavity through a number of different routes (intranasal, intraperitoneal, 
oropharyngeal) such that it is more clinically relevant, and pulmonary fibrosis develops quickly (2-4 
weeks). Indeed, BLM-induced pulmonary fibrosis has been widely used and accepted in literature to 
identify and study the involvement of a large number of mediators in IPF and is the best characterised 
model for pulmonary fibrosis670,683,687.  
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1.4 Hermansky Pudlak Syndrome Pulmonary Fibrosis (HPSPF) 
HPS is a collection of autosomal recessive genetic disorders that is characterized by abnormal 
biogenesis and/or function of lysosome related organelles (LROs) found in specialised secretory cells, 
including melanosomes, platelets, epithelial cells and macrophages690–692. Several forms of HPS, 
including HPS1, HPS2 and HPS4 are associated with interstitial pulmonary fibrosis that, similar to IPF 
patients, present with UIP1,693. It is therefore possible that HPSPF and IPF share common pathways in 
pathogenesis leading to the development of pulmonary fibrosis1,693. Notably in HPSPF patients there 
is an accumulation of giant lamellar bodies in AEC2 and also foamy macrophages that are engorged 
with cholesterol crystals. The altered appearances of AEC2 and macrophages may be the result of 
defective lysosomal transport in HPS patients, which affects the release of pulmonary surfactants 
and cholesterol efflux respectively. It is possible that such defects result in persient irritation that 
ultimately leads to pulmonary fibrosis. Pulmonary surfactants reduce surface tension within the lung 
and are exclusively released by AEC2; defective pulmonary surfactant release may therefore lead to 
prolonged tissue injury. Excessive cholesterol crystal accumulation in foamy macrophages may 
induce a pro-inflammatory phenotype that result in chronic inflammation and subsequent tissue 
fibrosis. Spontaneous mutations in HPS1 and HPS2 have arisen in C3HeB/FeJ mice694, but have since 
been backcrossed onto the more well-studied C57BL/6 strain. Similar to their human counterparts, 
naïve HPS1 and HPS2 single mutants have increased numbers of foamy AEC2 and AMφ695. However, 
they do not spontaneously develop pulmonary fibrosis, but are reported to have an increased 
susceptibility to BLM-induced pulmonary fibrosis696. It would be interesting to investigate whether or 
not the accumulation of foamy macrophages and/or in naïve HPS1 and HPS2 mice contributes to 
their increased pathology compared to their WT counterparts. On the other hand, HPS1/HPS2 
double mutant mice are reported to spontaneously develop pulmonary fibrosis from 9 months of 
age697. These mice may therefore be a useful model for the study of naturally occurring interstitial 
pulmonary fibrosis. The background of HPS mutations, HPSPF, and also mouse models of HPS will be 
discussed further below.  
1.4.1 HPS 
HPS is primarily found in Northwest Puerto Ricans in the form of a HPS-1 mutation, with a prevalence 
of one in 1,800698, and accounts for ~50% cases in non-Puerto Rican cases699. Occurrence in other 
nationalities is extremely rare, affecting 1: 500,000 to 1,000,000. 
HPS patients may experience a variety of symptoms, including oculocutaneous albinism, a bleeding 
diathesis secondary to platelet storage disease, lysosomal accumulation of ceroid lipofuscin, and 
pulmonary fibrosis. These are thought to result from defective organelle transport in melanosomes, 
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platelet dense granules and lysosomes respectively. The occurrences of these different symptoms is 
variable between patients, but are generally dependent upon HPS subtype caused by the mutation of 
different HPS genes690,700.  
There are eight known HPS human genes, which code for proteins that mostly function in membrane 
and protein trafficking in LROs. Many of these HPS proteins associate with one another to form 
multiple protein complexes, namely the AP-3 complex, or the Biogenesis of Lysosome-Related 
Organelles Complex (BLOC)-1, BLOC-2 and BLOC-3. Mutations of HPS genes results in a defect in 
these complexes that leads to dysfunctional LRO biogenesis and/or transport692. 
1.4.2 HPSPF 
Pulmonary fibrosis is associated with several subtypes of HPS, including HPS1, HPS2, and HPS4. HPS1 
and HPS4 encode for components of the BLOC-3 complex, which has recently been reported to be a 
Guanine Exchange Factor (GEF), and may play a role in activation and membrane localization of Ras 
GTP hydrolases (GTPases) (Ras-32 and Ras-38) that is required for organelle biogenesis and enzyme 
trafficking701. Dysfunction of the BLOC-3 complex leads to defects in organelle cargo trafficking and 
production, and is associated with pulmonary fibrosis in adults702–704. HPS-2 encodes for the β3A 
subunit of the AP-3 complex, which regulates biogenesis of lysosome related organelles and 
modulates intracellular trafficking of proteins to late endosomes, lysosomes, and lysosome-related 
organelles. Dysfunction of the AP-3 complex leads to defects in lysosome biogenesis and intracellular 
protein trafficking, and may result in pulmonary fibrosis in children and young adults705.  
Although the exact link between defective organelle transport and pulmonary fibrosis of HPSPF is 
unclear, several hypotheses have been proposed705. Increased number and size of lysosomes may 
lead to their increased fragility followed by more severe lung abnormalities including lung cell 
necrosis. Reduced secretion of lysosome contents may also disrupt normal lung physiology706. For 
example, pulmonary surfactant, in lysosomes or lamellar bodies, is regularly secreted from type II 
cells to the air-liquid interface to reduce surface tension707,708. In macrophages, the accumulation of 
cholesterol crystals, either by increased uptake of modified low density lipoprotein (LDL) through 
their scavenger receptors, or reduced/ defective cholesterol efflux, may also lead to the formation of 
foamy macrophages.  
Foamy macrophages have been characterised to have a pro-inflammatory phenotype in 
atherosclerosis and HPS1 patients709. Human macrophages that were stimulated in vitro with 
minimally oxidised LDL induced the release of pro-inflammatory cytokines, including TNF, IL1 and IL-
6 in a CD14-TLR4-MD2-dependent manner710. Stimulation of human macrophages with moderately 
oxidised LDL promoted the release of pro-inflammatory chemokines, including CCL2, CCL5, CXCL1 in 
Chapter 1 | General Introduction 
94 
a CD36 dependent manner711. Cholesterol crystals in foamy macrophages may also directly activate 
the NLRP3 inflammasome, resulting in IL-1β and IL-18 activation712. Human foamy macrophages 
generated by oxLDL challenge has also been reported to secrete tissue remodelling mediators such 
as MMP-9713. Therefore, foamy macrophages can promote both inflammation and tissue 
remodelling, perhaps as a frustrated effort to remove excess lipids from tissue. Pro-inflammatory 
foamy macrophages may function in tissue injury associated with chronic inflammation. On the 
other hand, there has been one report of in vitro generated foamy macrophages that had a pro-
fibrotic M2-like phenotype, with increased protein expression of IL-10 and TGF-β, which may play a 
role in tissue fibrosis714. Indeed, foamy macrophages accumulate in IPF patients715, and also HPS1 
patients709.  
HPSPF resembles IPF in terms of disease progression1,693, and its UIP histopathology1; however, 
HPSPF is characterized by giant lamellar body formation in AEC2s, resulting in AEC2 swelling702,703. 
1.4.3 Mouse models of HPSPF 
There are fifteen mouse HPS genes, eight of which are human orthologues. Mutations of such mouse 
orthologues have been reported as models to represent the corresponding human condition. Three 
HPS mouse models have been used extensively to study HPSPF, including pale ear (ep; HPS1) mice 
carrying a double recessive mutation in the HPS1 gene, pearl (pe; HPS2) mice carrying a double 
recessive mutation in the HPS2 gene, and the  HPS1 and HPS2 crossed, double recessive, double 
mutant (HPS1/2). 
1.4.3.1 Pale ear (HPS1) mice 
The HPS1 mutations originally arose spontaneously in the C3HeB/FeJ strain694, but have since been 
maintained in the more well-studied C57BL/6 strain. Two different types of HPS1 mutation have 
been observed, including the insertion of an intracisternal A particle (IAP) at the end of exon 19 of 
the HPS1 gene in HPS1 mice716,717, or a 23bp insertion, 3 bp deletion on exon 17 in the HPS1 (6J) 
mice716. The nomenclature of mouse models for various types of HPS mutations, the identity of the 
affected protein, the intracellular transport complex they form, and their corresponding function is 
summarised in table 1.6. The phenotypes of different HPS mutations in humans and mice are 
summarised in table 1.7. 
Adult HPS1 mice present with ears, paws and tails that are pale in colour, although the pigmentation 
of the coat and eyes are almost normal. HPS1 mice exhibit an abnormal respiratory phenotype: 
There are progressive cytoplasmic foamy changes in AEC2 from P0 to 24 months, increasing in both 
affected cell number and degree of severity as mice age. There is also marked swelling and 
degenerative changes of AEC2s in so called Giant Lamellar Body Degeneration’ (GLBD) in aged mice. 
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Alveolar lamellar bodies are also found to be increased in size, and often fused to each other in aged 
mice. There is an enlargement of air spaces, and also mild lymphocytic infiltration of the alveolar 
septa in some aged mice697,718. HPS1 mice also display basal inflammatory dysregulation with 
elevated IL-12 p40 levels in BAL and constitutive AMφ activation that parallels abnormalities that 
have been reported in HPS patients695,709. However in HPS1 mice, unlike human HPS1 patients 
pulmonary fibrosis does not spontaneously occur697,718,719. However, HPS1 mice have increased 
susceptibility to BLM-induced pulmonary fibrosis, including reduced survival, increased collagen 
accumulation as determined by Masson’s trichrome staining and Sircol assay at day 7 post BLM-
challenge, and elevated levels of TGF-β and also IL-12 p40 in the lungs of HPS2 mice from day 3 to 
day 7696. 
1.4.3.2 Pearl (HPS2) mice 
The HPS2 mutation originally occurred spontaneously in the C3H/HeJ strain720, but are now 
maintained as a congenic mutant onto C57BL/6 mice. Three different types of mutations have been 
observed, including HPS2, with a 793 bp tandem duplication of exons 17 to 23721, HPS2 (8J), a 107 bp 
deletion in exon 20722; and HPS2 (9J), an 867 bp deletion in exons 8-14722 of the HPS2 gene in HPS2 
mice. 
Adult HPS2 mice present with a hypopigmented phenotype as compared to wild type controls, with 
a brown-grey coat colour, and also lighter ears, tails and paws720. HPS2 mice also exhibit premature 
death, with less than 40% (as compared to 100% of WT C57BL/6 control mice) surviving for more 
than 2 years723. HPS2 mice also have an abnormal respiratory phenotype723. They have basal 
inflammatory dysregulation with elevated IL-12 p40 and MIP-1Υ levels in BAL and constitutive AMφ 
activation that parallels abnormalities that have been reported in HPS patients695,709. There is a 
moderately honeycombed structure within the lung, and moderate air space enlargement. In three 
out of eight aged mice surviving beyond 2 years, lung haemorrhage was also observed723. Similar to 
HPS1 mice, HPS2 mice do not spontaneously develop pulmonary fibrosis697,719, but display increased 
susceptibility to BLM-induced pulmonary fibrosis696, including reduced survival, increased collagen 
accumulation as determined by Masson’s trichrome staining and Sircol assay at day 7 post BLM-
challenge, elevated levels of TGF-β and also IL-12 p40 in the lungs of HPS2 mice from day 3 to day 7, 
a rise in the release of TGF-β and IL-12 p40 by AMφ at day 1, and also increased AEC2 apoptosis as 
determined by TUNEL assay from as early as five hours post BLM-challenge696. 
There are some explanations for this discrepancy in spontaneous pulmonary fibrosis between mice 
and humans. There are fifteen HPS genes in mice compared to eight in humans, and some of these 
genes may carry some redundancy to HPS1. HPS1 and HPS2 mice also carries different types of 
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mutations compared to their respective human orthologues, which may have less negative effects 
on functional activity than its human counterparts. Although HPS1 and HPS2 single mutant mice do 
not spontaneously develop pulmonary fibrosis, they have increased susceptibility to single 
intratracheal dose BLM-induced pulmonary fibrosis (at day 7)696, and are therefore invaluable 
models to study the contributing factors that may augment pathology. 
1.4.3.3 HPS1 and HPS2 double mutant mice 
Double mutant HPS mice may be useful because epistatic effects between different mutant genes 
may amplify mutant physiological abnormalities, although it may be difficult to dissect the 
contributions to each gene mutation to the phenotype. The fact that each mouse model is 
maintained as a congenic mutant on the C57BL/6J background enables genetically controlled in vivo 
tests for interaction of these 2 important genes706.  
Mutants homozygous for both HPS1 and HPS2 genes displayed a lighter coat colour than either 
single parental single mutant and light red eye colour in both new-born and adult animals. HPS1/2 
double mutants also have more severe respiratory defects than each of the single mutants697,719. 
Unlike other HPS single mutants, levels of lung lysosomes were also elevated in the HPS1/2 double 
mutant, suggesting abnormalities in LROs, such as lamellar bodies in AEC2s706. AEC2s and the 
lamellar bodies are engorged with surfactant697,719. Extensive surfactant abnormalities observed in 
these mice were correlated with early lysosomal stress, ER stress and marked AEC2 apoptosis719. 
Mutant lung also accumulate excessive autofluorescent pigment, and air spaces of mutant lungs 
contain age-related elevations of inflammatory cells and foamy macrophages. Spontaneous and 
slowly progressive pulmonary fibrosis was observed in HPS1/2 double mutant mice, with subpleural 
onset at 3 months and extensive fibrosis by 9 months719. HPS1/2 mutants are therefore a suitable 
genetic model for interstitial pulmonary fibrosis. 
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1.5 Hypothesis of thesis 
The main hypothesis of this thesis is that AMφ are able to respond to signals in their immediate 
environment, including priming and stimulatory signals, to differentiate into different functional 
subpopulations that may play dissimilar roles. The specific chapter hypotheses are listed below. 
The hypothesis of Chapter 3 is that AMφ are able to respond to various priming and/or stimulation 
signals to form distinct subsets, in a similar fashion to that observed in BMMφ. Stimulatory signals 
on PRRs may have a modulatory effect on gene and protein expression of AMφ that have been 
polarised by a priming signal. 
The hypothesis of Chapter 4 is that AMφ may alter their gene and protein expression in response to 
external priming and stimulatory signals and contribute differently to different stages of pulmonary 
fibrosis. Foamy macrophages are formed following the accumulation of cholesterol crystals , either 
by excessive uptake of modified LDL or by reduced cholesterol efflux, and may promote a pro-
inflammatory and/or a pro-fibrotic phenotype in macrophages. Foamy macrophages accumulate in 
HPS1 patients and also naïve HPS1 mice, and it is hypothesesed that these cells contribute to the 
increased susceptibility to BLM-induced pulmonary fibrosis observed in HPS1 mice696. 
The hypothesis of Chapter 5 is that PRRs expressed on AMφ may be stimulated by endogenous 
alarmins that are released following tissue injury, and may alter AMφ gene and/or protein 
expression to promote fibrosis. 
1.6 Aim of the thesis 
The main aim of the thesis is to assess the heterogeneity of AMφ and investigate the contributions 
of heterogeneous macrophage populations on pathophysiology in murine models of pulmonary 
fibrosis. The chapter aims are listed below. 
The aim of Chapter 3 is to investigate the heterogeneity of AMφ in vitro in response to various 
priming and stimulatory signals. 
The aim of Chapter 4 is to evaluate AMφ heterogeneity ex vivo isolated from a mouse model of 
BLM-induced pulmonary fibrosis. The potential role of foamy macrophages in increased 
susceptibility to BLM-induced pulmonary fibrosis will also be evaluated in HPS1 mice. HPS1 mice, but 
not HPS1/2 mice were used as the latter cannot be successfully bred despite several attempts. 
The aim of Chapter 5 is to identify the contributions of PRRs on AMφ heterogeneity in BLM-induced 
pulmonary fibrosis in mice. 
The specific background and detailed aims are described in the separate results chapters. 
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Chapter 2| Materials and Methods 
2.1 Materials  
Table 2.1 Cell culture reagents used in thesis. 
Product Company Catalogue number 
RPMI-1640 (Glutamax) Gibco 72400-021 
Fetal Bovine Serum (Heat Inactivated) Gibco 10500 
Sodium Pyruvate Gibco 11360 
β-mercaptoethanol Gibco 315350-010 
Geneticin Gibco 10131 
DPBS Gibco 14190-094 
Penicillin/Streptomycin Gibco 15140-122 
Polymyxin B sulfate salt Sigma-Aldrich P-4932-1MU 
Cell Dissociation Buffer Sigma-Aldrich 5914-100ML 
0.25% Trypsin (1X), Phenol Red Gibco 15050-065 
Ammonium chloride (NH4Cl) Sigma-Aldrich A9434-500G 
Potassium bicarbonate (KHCO3) Sigma-Aldrich 237205-100G 
Ethylenediaminetetraacetic acid disodium 
salt dihydrate Sigma-Aldrich E4884-100G 
BD-Falcon Cell strainer (70 μm) VWR 21008-952 
0.4% Trypan Blue solution Sigma-Aldrich T8154-20ML 
Corning® CoStar® culture plates (48-well, flat 
bottom) Sigma-Aldrich CL S3548-100EA 
Corning® CoStar® culture plates (96-well, flat 
bottom) Sigma-Aldrich CL S3997-50EA 
Recombinant mouse IFN-γ R&D Systems 485-MI-100 
Recombinant mouse IL-4 R&D Systems 404-ML-050 
Recombinant mouse IL-13 R&D Systems 413-ML-025 
Recombinant mouse TGF-β R&D Systems 7666-MB-005 
Recombinant M-CSF R&D Systems 416-ML 
LPS-EB Ultrapure Invivogen tlrl3-pelps 
Pam2CSK4 Invivogen tlrl-pm2s-1 
ODN1585 Invivogen tlrl-1585-1 
 
Table 2.2 Reagents used for RNA extraction and reverse transcription. 
Product Company Catalogue number 
Rneasy Micro Kit Qiagen 74004 
Trizol ® Life Technologies 15596 
Chloroform Sigma-Aldrichs C2432 
Taqman® Reverse Transcription Reagents Life Technologies N8080234 
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Table 2.3 Primers used for qRT-PCR analysis. 
Product Company Catalogue number 
Arg-1 Life Technologies Mm00475988_m1 
Hprt-1 Life Technologies Mm00446968_m1 
IL-1β Life Technologies Mm00434228_m1 
IL-6 Life Technologies Mm00446190_m1 
NLRP3 Life Technologies Mm00840904_m1 
NOS2 Life Technologies Mm00440502_m1 
TLR2 Life Technologies Mm00442346_m1 
TLR4 Life Technologies Mm00445273_m1 
TLR7 Life Technologies Mm00446590_m1 
TLR9 Life Technologies Mm00446193_m1 
TNF Life Technologies Mm00443260_g1 
 
Table 2.4 Reagents used for protein level analysis. 
Product Company Catalogue number 
Mouse Fibronectin ELISA Kit AbCam ab108849 
Mouse TH1/TH2 9-plex ultra sensitive kit MSD K15013C-2 
V-Plex proinflammatory panel 1 (mouse)  kit MSD K15048D-2 
 
Table 2.5 Reagents used for flow cytometr analysis. 
Product Company Catalogue number 
Mouse Serum Sigma M5905-5ML 
BD CellFix™ BD BioSciences 340181 
BD™ CompBeads BD BioSciences 552845 
BD Cytofix/ Cytoperm Cell Fixation/ 
Permeabilisation Kit BD BioSciences 554714 
FcR blocking reagent, mouse Miltenyi Biotec 130-092-575 
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Table 2.7 Reagents used for histology analysis, 
Product Company Catalogue number 
Wright-Giemsa Stain Set for Hema-Tek® 1-, 1000 
and 2000 Sigma-Aldrich WGHT-1SET 
Hemotoxylin solution, Harris modified Sigma-Aldrich HHS128-4L 
Aqueous Eosin (1%) Leica 3801590BBE 
Sirius Red F3B BDH laboratory supplies 341492F 
Cell Conditioning 2 (CC2) Roche 950123 
Rat anti-mouse CD68 antibody [FA11] AbCam Ab53444 
Polyclonal Rabbit anti-Rat Immunoglobulin Dako E0468 
Discovery DAB Map Detection Kit (RUO) Roche 760-124 
Ethanol Sigma-Aldrich 458600-25L 
Oil Red O Sigma-Aldrich O0625-100G 
Mayer's hematoxylin AbCam ab128990 
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2.2 Methods 
2.2.1 Animals 
All procedures were carried out in accordance with Home Office guidelines (Animal Scientific 
Procedures of 1986) [Home office project license number: 70/7336; Home Office personal license 
number: 70/24209]. Male C57BL/6 mice were 8-10 weeks old, weight-matched (23-27 g), purchased 
from Charles River.  
The breeding pair of HPS1 mice were purchased from Jackson Laboratory (Maine) and the colony was 
bred and maintained in-house. HPS1 mice were genotyped by Transnetyx (Tennessee, United States). 
8-12 week old male and female HPS1 mice were used for studies.
2.2.2 Multiple oropharyngeal dose BLM challenge of mice 
WT C57BL/6 male mice or male or female HPS1 mice were challenged three times by oropharyngeal 
instillations of 50μl of 0.13U BLM sulfate (Kyowa Nippon, Kayakin Co Ltd.) or saline controls at 72 hour 
intervals on Days -7, -4 and -1. Mice were culled on days 7, 14 and 21 post-challenge, which include 
time points in the ALI phase, early fibrotic phase and the progressive fibrotic stage respectively (Figure 
2.1).  
Figure 2.1 Diagram illustrating time course of pathogenesis in multiple oropharyngeal dose BLM-induced 
pulmonary fibrosis. Mice were dosed via an oropharyngeal route at 72 hour intervals at days -7, -4 and -1. 
Mice were culled at days 7, 14 and 21 for analysis at the late inflammatory, active fibrotic and established 
fibrotic phases respectively. O.p., oropharyngeal; U, international units.  
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2.2.3 Histology 
For histology analysis of C57BL/6 mice challenged with multiple oropharyngeal dose of saline or BLM 
(chapter 4), the right lobe of C57BL/6 mouse lungs was tied off for RNA analysis, and the left lobe was 
inflated by 0.5 ml 10% formalin, and then removed for histology analysis. The formalin inflated left 
lobe was then immersed in 10% formalin overnight for further fixation. The fixed left lobe was then 
dissected longitudinally into four pieces and embedded into paraffin. Embedded tissues were then cut 
into 3μm slides sections for immunohistological staining. Stained slides were viewed and analyzed on 
ImagePro (Mediacy). 
For histological comparison of saline or BLM-challenged HPS1 and WT C57BL/6 mice, both left and 
right lungs were inflated with 1 ml (total) Optimal Cutting Temperature (OCT) and snap frozen in liquid 
nitrogen; 10μm sections were cut for histology analysis.  
2.2.3.1 Haematoxylin and Eosin (H&E) Staining 
H&E staining was automated by the Leica Discovery XT multistainer. Tissue slides were first 
deparaffinized at 60oC by heating for 10 minutes, and then washed three times with xylene for 5 
minutes each. Tissue slides were then hydrated by three washes in 100% Industrial Methylated Spirit 
(IMS) for 1 minute each, once in 70% IMS for another minute, and then twice in water for 30 seconds 
each. Tissue slides were then stained with Harris Haematoxylin for 5 minutes, and then washed in 
water for another 5 minutes. Non-specific Haematoxylin staining was then removed from tissue slides 
through differentiation in acid alcohol (99% of 70% ethanol, 1% concentrated Hydrochloric Acid (HCl)). 
Tissue slides were then stained for 2 minutes in eosin, and excess stain was washed off with water. 
Tissue slides were then dehydrated by one wash in water for 5 minutes, one wash in 70% IMS for 30 
seconds, and then two washes in 100% IMS for 1 minute each. Slides were then cleared of alcohol by 
three xylene washes, twice for one minute and once for two minutes. A cover slip was then mounted 
onto the H&E stained tissue slide. 
2.2.3.2 Picrosirius Red (PSR) Staining 
PSR staining was automated by the Leica Discovery XT multistainer. Tissue slides were first 
deparaffinized at 60oC by heating for 10 minutes, and then washed three times with xylene for 5 
minutes each. Tissue slides were then hydrated by three washes in 100% IMS for 1 minute each, once 
in 70% IMS for another minute, and then twice in water for 30 seconds each. Tissue slides were then 
stained with PSR stain for 1 hour. Non-specific PSR stain was then removed by three HCl (0.01M) 
washes for 5 seconds each, followed by a 5 second rinse in water. Tissue slides were then stained with 
Harris Haematoxylin for 5 minutes, and then washed in water for another 5 minutes. Non-specific 
Haematoxylin staining was then removed from tissue slides through differentiation in acid alcohol 
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(99% of 70% ethanol, 1% concentrated HCl). Tissue slides were then dehydrated by one wash in water 
for 5 minutes, one wash in 70% IMS for 30 seconds, and then two washes in 100% IMS for 1 minute 
each. Slides were then cleared of alcohol by three xylene washes, twice for one minute and once for 
two minutes. A cover slip was then mounted onto the PSR stained tissue slide. 
2.2.3.3 CD68 Staining 
CD68 staining was automated by Ventana Discovery XT. In brief, tissue slides were deparaffinized and 
pretreated with mild Cell Conditioner 2 (CC2) for renaturation of protein molecules. Tissue slides were 
then stained with 2μg/ml Rat anti-CD68 (AbCam) for 12 hours, followed by Biotinylated Rabbit anti-
Rat antibody (DAKO) and Discovery DAB MAP Detection Kit (RUO) (Roche) for 32 minutes. The amount 
of staining was quantified by positive pixel count of brown stain by ImageScope (Aperio). 
2.2.3.4 ORO staining  
0.25% stock solution of ORO stain was made by dissolving 25 mg of ORO powder (Sigma) into 100 ml 
100% isopropanol. Stock solution was kept at 4oC until further use. For working solution, 6 ml of 
0.25% ORO stock was dissolved in 4 ml dH2O and filtered with 0.2 μm filter paper. 
Prior to ORO staining, cells were fixed in 10% formalin for 10 min, and then permeabilised in 60% 
isopropanol for another 10 min. Fixed and permeabilised cells were then stained with ORO for 15 
min; excess ORO stain was washed off with distilled water. ORO stained cells were subsequently 
stained for cell nuclei with Mayer’s Haematoxylin (AbCam) for 5 min; excess Mayer’s haematoxylin 
stain was then washed off with distilled water. 
BAL cells on microscope slides were scanned using Aperio ScanScope XT (Leica Biosystems) and 
visualised on ImageScope (Leica Biosystems). AMφ in 96-well plates were visualised by scanning with 
Zeiss Axio Observer Z1 inverted microscope (Zeiss). 
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2.2.4 BAL cells isolation 
AMФ were isolated from BAL of C57BL/6 mice. Mice were sacrificed by intraperitoneal (i.p.) 10% 
pentobarbital overdose. Lungs were lavaged twice with 0.5 ml sterile Dulbecco’s Phosphate Buffered 
Saline (DPBS) (Gibco) through an intratracheal catheter. A total of 1.0 ml saline was instilled and ~0.8 
ml was recovered from each mouse. 
2.2.5 Total and Differential Cell Count 
100μl was aliquoted from the 1ml sample in DPBS for total cell count, which was determined by 
manual counting of 0.5% trypan blue stained cells using a hemocytometer. It was noted that around 
3-5 X 104 BAL cells were recoverable per naïve mouse.
Another 100μl was then aliquoted from the 1ml sample in DPBS for differential cell count. BAL cells 
were mounted onto microscope slides by cytospin. Differential cell count was determined by manual 
counting of BAL cells stained with Wright-Giemsa stain (Hematek, Sigma-Aldrich). 300 cells were 
counted per field, and at least 3 fields were counted. AMφ predominated the BAL cell population at 
~90%, with minimal granulocytic or lymphocytic infiltration.  
Flow cytometry was also possible for differential cell count through staining for CD11c+ AMφ, Ly6G+ 
granulocytes, CD3+ T-lymphocytes and B220+ B-lymphocytes, but was not used in these studies due 
to limited amount of BAL cells retrievable from naïve mice.  
2.2.6 AMΦ enrichment 
BALF was pooled together and passed through a 70μm cell strainer (BD FalconTM) to remove cell 
clumps, and then washed in Ammonium Chloride Potassium (ACK) lysis buffer (0.15M NH4Cl, 1.0mM 
KHCO3 and 0.1mM Na2EDTA) (Sigma-Aldrich) for lysis of contaminating RBCs. Cells were then washed 
equal volume of macrophage complete media [RPMI-1640 GlutamaxTM media (Gibco) supplemented 
with 10% Fetal Calf Serum (FCS) (Biosera) for growth factors to promote cell survival, 1mM Sodium 
Pyruvate (Lonza) for additional nutrients for cell culture, 0.05mM of β-Mercaptoethanol (Gibco) as a 
reducing agent to prevent the buildup of toxic oxygen radicals in cell culture, 1mM of 
penicillin/streptomycin (Gibco) as antibiotics, and 50μg/ml Geneticin as an antifungal agent (Gibco) ]. 
10% FCS inhibits the lysis reaction by the ACK lysis buffer. Cells were then centrifuged at 500 g for 10 
minutes at 4oC. The supernatant was discarded, and the cell pellet was resuspended in 2 ml of 
macrophage media. 100μl was aliquoted from the 2 ml sample in macrophage complete media for cell 
count, which was determined by manual counting of 0.5% trypan blue stained cells using a 
hemocytometer. 
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BAL cells were resuspended at 2 x 105 cells/ml, and 1x105 cells (0.5 ml) were then seeded per well on 
a 48 well plate (Corning®) and allowed to enrich for 90 minutes by plastic adherence. Non-adherent 
cells were then removed and fresh macrophage complete media was added. Inspection by light 
microscopy revealed that adherent cells were macrophages.  
Magnetic-activated cell sorting (MACS) is also possible for the immuneseparation of AMφ, either by 
positive enrichment of CD11c+ AMφ or by negative elimination of Ly6G+ granulocytes, CD3+ T-
lymphocytes, and B220+ B-lymphocytes. However, MACS was not used in these studies as adherent 
AMφ apredominate BAL cells in naïve mice (~90%) and there is little contamination of other cell 
populations. Moreover, MACS involves a number of adherence and washing steps that may lead to 
cell loss, and not be an ideal method of enrichment for AMφ where very few BAL cells (¬3-5x104 
cells/mouse) were retrievable to begin with. 
2.2.7 Bone marrow isolation 
Bone marrow was isolated from BAL of C57BL/6 mice. Mice were sacrificed by intraperitoneal (i.p.) 
10% pentobarbital overdose. Bone marrow was isolated from the femur and tibia of mice by flushing 
with DPBS. In brief, the ends of each femur/ tibia were cut, and a 27AG needle was used to flush out 
bone marrow cells (until bones appear white). Cell clumps were then broken up by pipetting with 
syringe, and the cell suspension was then passed through a 10 μm filter to remove contaminants 
(e.g. mouse fur). The cell suspension was then centrifuged for 500 g for 5 minutes; supernatant was 
discarded and the cell suspension was resuspended in ACK lysis buffer (0.15M NH4Cl, 1.0mM KHCO3 
and 0.1mM Na2EDTA) (Sigma-Aldrich) for 10 minutes at room temperature for the lysis of 
contaminating RBCs. Cells were then mixed with an equal volume of macrophage complete media to 
inhibit further lysis from the ACK lysis buffer, and centrifuged at 500g for 10 min. The supernatant was 
discarded, and the cell pellet was then resuspended in 10 ml of macrophage complete media (see 
section 2.Ϯ͘ϲ). 100μl was aliquoted from the 10 ml sample in macrophage complete media for cell 
count, which was determined by manual counting of 0.5% trypan blue stained cells using a 
hemocytometer. 
2.2.8 BMMφ generation 
On day 0, 1.5 x 106 bone marrow cells were seeded at 3 ml per well of a 6-well plate (i.5. 0.5 x 106 
cells/ml). Bone marrow cells were supplement cells with 100 ng/ml M-CSF (R&D Systems) and 
incubated at 37oC, at 5% CO2. On day 4, 3ml of fresh macrophage complete medium supplemented 
with 100 ng/ml M-CSF was added without disturbing the old media. This was to replenish M-CSF within 
the media and allow non-adherent undifferentiated bone marrow cells to mature into BMMφ. On day 
8, macrophage complete media was aspirated to remove non-adherent cells, and adherent BMMφ 
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were harvested for ex vivo priming and/or stimulatory studies. 3 ml 0.5% trypsin was added to 
BMMφ at 3 ml per well and incubated for 15 minutes at 37oC. BMMφ were lifted off the wells by 
gentle scrapping and further trypsin activity was inhibited by the addition of 3 ml of macrophage 
complete media. The cell suspension was centrifuged at 4oC, 500 g for 10 minutes. The supernatant 
was discarded and the cell pellet was resuspended in 2 ml of macrophage media. 100μl was aliquoted 
from the 2 ml sample in macrophage complete media for cell count, which was determined by 
manual counting of 0.5% trypan blue stained cells using a hemocytometer. 
BMMφ were resuspended at 2 x 105 cells/ml, and 1x105 cells (0.5 ml) were seeded per well on a 48 
well plate (Corning®) and allowed to enrich overnight by plastic adherence. Non-adherent cells were 
then removed and fresh macrophage complete media was added. Inspection by light microscopy 
revealed that adherent cells were macrophages.  
2.2.9 Ex vivo  priming and stimulation of BMMφ/AMI for mRNA and protein level analyses 
For the generation of M1- or M2-like macrophage subsets, 1 x 105 BMMφ or AMI/ well of a 48-well 
plate were primed with either media control (macrophage complete media, section 2.2.ϲ), 20ng/ml 
IFN-J (R&D Systems), 10 ng/ml IL-4 (R&D Systems) or 10 ng/ml IL-13 (R&D Systems) for 18 hours, 
and then cultured with or without 10 ng/ml LPS-EB (Invivogen), for another 4 hours for gene 
expression analysis or for 24 hours for measurements of protein levels in the AMφ supernatant. 
For the priming of AMφ with lung-fibrosis associated signals, 1 x 105 AMI/ well a 48-well plate were 
serum-starved for 24 hours, and then primed with either media control (macrophage complete 
media, section 2.2.ϲ), 10 ng/ml TGF-β1 (R&D Systems) or subject to hypoxia (1% O2, 5% CO2) for 18 
hours, and then cultured with or without 10 ng/ml LPS-EB (Invivogen), for another 4 hours for gene 
expression analysis, or for 24 hours for measurements of protein levels in the AMφ supernatant. 
Total RNA extraction, reverse transcription, and quantitative real time polymerase chain 
reaction (qRT-PCR) for gene expression analysis is described in greater detail at sections 2.2.11, 
2.2.12 and 2.2.13 respectively. Measurements of proteins of interest in culture supernatant is 
described in greater detail in sections 2.2.14 (fibronectin enzyme linked immunosorbent assay 
(ELISA) and 2.2.15 [Meso-Scale Discovery (MSD)]. 
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2.2.10 Ex vivo stimulation of AMI from saline or BLM-challenged mice for mRNA and protein  
level analyses 
AMI isolated from saline or BLM-challenged mice were stimulated by media, 10 ng/ml Pam2CSK4 (P2C) 
(Invivogen), 3μM of CpG-ODN (A) (ODN1585, Invivogen) or CpG-ODN (A) Control (ODN1585c, 
Invivogen) for 24 hours, and AMφ supernatant was collected for protein expression analysis. 
Measurements of proteins of interest in culture supernatant is described in greater detail in sections 
2.2.14 (fibronectin enzyme linked immunosorbent assay (ELISA) and 2.2.15 [Meso-Scale Discovery 
(MSD)]. 
2.2.11 Total RNA extraction 
Total RNA was extracted using RNeasy® micro kit (Qiagen). For RNA isolation from cell culture, 1x105 
cells were lysed in 350 μl buffer RLT, which contains the chaotropic agent and protein denaturant 
guanidium thiocyanate. Guanidium thiocyanate can also denature RNase and thereby inhibit RNA 
degradation. Lysed cells in RLT buffer were then mixed with 350 μl 70% isopropanol for RNA 
precipitation. The 700 μl mixture was then added onto an RNeasy MinElute spin column and 
centrifuged for 30 seconds at 10,000 g and room temperature. RNA precipitate was captured onto 
the silica membrane of the MinElute spin column, and the flowthrough was discarded. The RNeasy 
MinElute spin column was then washed by 350 μl buffer RW1, which contains guanidium and 
ethanol, and was able to efficiently remove biomolecules such as carbohydrates, proteins and fatty 
acids, while RNA larger than 200 bases remain bound to the column. The RNeasy MinElute spin 
column was then centrifuged for 30 seconds at 10,000 g and room temperature, and the 
flowthrough was discarded. 10 μl stock DNase1 (reconstituted from adding 550 μl of RNase-free 
water to 1 vial of lyophilized DNase1 powder) was then diluted by 70 μl buffer RDD into 80 μl 
working solution, which was then loaded onto the RNeasy MinElute spin column, mixed by inversion 
and incubated for 15 minutes at room temperature, for the digestion of contaminating DNA. The 
RNeasy MinElute spin column was subsequently washed with 350 μl buffer RW1, and centrifuged for 
30 seconds at 10,000 g and room temperature. The flowthrough and the 2 ml collection tube was 
discarded, and a new collection tube was applied to the RNeasy column. The RNeasy Minelute spin 
column was then washed by 500 μl working buffer RPE (stock RPE + 4 volumes of 100% ethanol) that 
contains ethanol, and centrifuged for 30 seconds at 10,000 g and room temperature. The RNeasy 
Minelute spin column was subsequently washed by 500 μl 80% ethanol, and centrifuged for 5 
minutes at 10,000 g and room temperature. The flowthrough and the 2 ml collection tube were 
discarded, and a new collection tube was applied to the RNeasy MidElute column. The RNeasy 
MidElute spin columns were then centrifuged for 5 minutes at 10,000 g and room temperature, with 
their lids open to dry the columns to remove residual ethanol that may affect downstream 
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applications. The collection tubes were then discarded, and the RNeasy MidElute spin columns were 
placed onto new 1.5 ml Eppendorf tubes. RNA was then eluted by adding 15 μl of RNase-free water 
onto the RNeasy MidElute spin column, and centrifuging for 30 seconds at 10,000 g and room 
temperature. Eluted RNA was subsequently placed on ice and 1 μl sample was used to test for purity 
by evaluating optical density (230nm: organic compounds [e.g. ethanol); 260 nm: nucleic acids; 280 
nm: proteins] using Nanodrop (Thermoscientific). RNA samples had 260/230 and 260/280 ratios of 
around 1.8 and 2.0 respectively indicating that they were free of organic acid or protein 
contaminants.  
For RNA extraction from lung tissue, OCT-inflated lungs (see section 2.Ϯ.3) were homogenised using 
the automated homogeniser PrecellLys at 2 x 3 x 500 reps. RNA was then isolated from lung 
homogenates using phenol-chloroform extraction. In brief, lung homogenates were mixed with 1 ml 
Trizol® (Life Technologies) (contains guanidium thiocyanate and phenol). 200μl of choloroform was 
added to each 1ml Trizol/ lung homogenate mixture and shaken vigorously for 15 seconds. The 
homogenates were then left to stand at room temperature for 2 min, before centrifuged at 4oC at 
10,000 x g for 10 min. The upper aqueous layer containing the RNA was then isolated and further 
purified using RNeasy MinElute spin columns as described above, whereas the lower layer 
containing the organic phase was discarded. 
2.2.12 Reverse transcription 
RNA was then reverse transcribed by reverse transcription-polymerase chain reaction (RT-PCR) using 
the Taqman® reverse transcription kit (Life Technologies). In brief for a 10 μl RT-PCR solution, the 
RT-PCR reaction mix required 10 μl of 10X RT buffer to maintain solution PH, 22 μl of 25 mM MgCl2 
(working concentration: 5.5 mM) to provide Mg2+ cations to aid negatively charged deoxynucleotides 
(dNTPs) into binding RNA and assembling into complementary deoxyribonucleic acid (cDNA), 20 μl of 
2,50 μM dNTPs (working concentration: 50 μM) as substrates for reverse transcriptase to 
synthesise cDNA, 5 μl of 50 μM random hexamers (working concentration: 2.5 μM) as primers for 
reverse transcriptase, 2 μl of 20 U/μl RNase inhibitor (working concentration: 0.4 U/μl) to prevent 
RNA degradation, 2.50 μl of 50 U/μl MultiScribeTM reverse transcriptase [a recombinant moloney 
murine leukemia virus (rMoMuLV) reverse transciptase that has been optimised for TaqMan-based 
assays] (working concentration: 1.25 U/μl) to catalyse reverse transcription, 20 ng/μl RNA sample as 
template for reverse transcription, and DNase and RNase-free water to make up total volume to 100 
μl. To minimizre pipetting errors between samples, a reverse transcriptase master mix containing 
RT-buffer, MgCl2, dNTPs, random hexamers, RNase inhibitor and MultiScribeTM reverse transcriptase 
was used, whereas the volumes of RNA samples and DNase/RNase water used was adjusted per  
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various components of the reverse transcription mix are listed in Table 2.8. 
Per Reaction 
Master 
Mix 
Component 
Stock 
conc. 
Units Final conc. Vol. (ul) 
TaqMan RT buffer 10 X 1 10.00 
MgCl2 25 mM 5.5 22.00 
dNTPs 2500 uM each 500 20.00 
Random hexamers * 50 uM 2.5 5.00 
RNase Inhibitor 20 U/ul 0.4 2.00 
MultiScribeTM Reverse 
Transcriptase 
50 U/ul 1.25 2.50 
SUB TOTAL - - - 61.50 
Sample-
dependent 
DNase/RNase-free water - - - 36.50 
RNA ** 500 ng/ul 20 2.00 
TOTAL 100 
Table 2.8 Reverse Transcription master mix using Taqman® reverse transcription kit. Sample ribonucleic 
acid (RNA) isolated from cells using the RNeasy® kit (Qiagen) is added to the reverse transcription master 
mix in the above concentrations and then subsequently reverse transcribed using polymerase chain 
reaction (PCR). NTP, nucleotide triphosphate. 
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The reverse transcription mix was then loaded onto a thermocycler with the following settings: 
preheat lid to 95oC, 25oC for 10 minutes to allow primer annealing to RNA sample, 48oC for 30 
minutes to allow reverse transcription by MultiScribeTM reverse transcriptase at its optimal 
temperature, 95oC for 5 minutes to denature MultiScribeTM reverse transcriptase to terminate 
reverse transcription, and cooling to 4oC. The thermocycle regimen for RT-PCR is summarised in 
table 2.9. 
 Table 2.9 Thermocycle for reverse transcription (RT)-PCR.
2.2.13 Quantitative real time PCR (qRT-PCR) 
qRT-PCR was performed on cDNA that is generated using Taq fast universal 2x PCR Master Mix 
(Applied Biosystems) and Taqman primer and probes assay (Applied Biosystems). For a 20 μl 
reaction, 1μl of cDNA generated from RT-PCR was mixed with 10 μl of 2x PCR Master Mix (Life 
Technologies), 1 μl of Taqman primer and probes (Life Technologies) and 8 μl of DNase/RNase-free 
water (Gibco). All reactions were performed in triplicate using a 7500 Fast Real-time PCR system 
(Applied Biosystems). The qRT-PCR cycles is listed in table 2.10. The relative units were calculated 
from a standard curve generated from a control sample by plotting the average of triplicate log 
dilutions against the cycle threshold. Expression data for all genes were normalized to the 
housekeeping gene Hypoxanthine phosphoribosyltransferase 1 (Hprt1). qRT-PCR results were 
analyzed on GraphPad Prism (La Jolla, CA). 
Preheat Lid 90oC 
Steps Procedure oC min 
1 Annealing 25 10 
2 Extension 48 30 
3 Reverse Transcriptase 
Denaturation 
95 5 
4 Pause 4 Pause 
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Temperature (oC) Time (min: sec) 
Holding Denaturation 95 00:20 
Cycling Stage (40 
cycles) 
Denaturation 95 00:03 
Cycling Stage (40 
cycles) 
Amplification 60 00:30 
Table 2.10 Thermocycle in ABI7500 FAST (Life Technologies) for qRT-PCR. 
2.2.14 Fibronectin Enzyme Linked Immunosorbent Assay (ELISA) 
Fibronectin ELISA was obtained from AbCam (ab108849) and carried out according to manufacturer’s 
instructions with the following exceptions: Fibronectin Standard range was set at 0.78 to 50.00 ng/ml, 
and chromogen substrate incubation was for 4 minutes only instead of the 10 minutes recommended 
in the protocol due to colour saturation of the standard curve. 
2.2.15 Meso-Scale Discovery (MSD) 
Mouse TH1/TH2 9-Plex Ultra-Sensitive Kit (Part number: 15013C-2) [IFN-Υ, IL-1β, IL-2, IL-4, IL-5, IL-10, 
IL-12 p40 (total), CXCL1, and TNF-α] and custom Mouse 10-plex MSD (IL-13, IL-6, IL-1β, CCL2, CCL3, 
CCL4, CCL5, CCL20, CXCL2, and mMMP-9) was obtained from Meso-Scale Diagnostics LLC. MSD was 
carried out according to manufacturer’s instructions.   
2.2.16 AMI subsets generated ex vivo for flow cytometric analysis 
For flow cytometric analysis in naïve mice, 3 x 104 AMφ were cultured in Corning Costar® 6 Well Clear 
Flat Bottom Ultra Low Attachment Multiple Well Plates to prevent binding and preserve cell surface 
proteins (Corning). For M1-associated MHC-II (IA/IE) analysis, AMɸ were primed with media or 20 
ng/ml of IFN-ϒ for 24 hours. For M2-associated MRC1 analysis, AMɸ were primed with media or 10 
ng/ml of IL-13 for 72 hours. AMɸ were then collected by gentle scraping followed by centrifugation 
of culture media, and stained for CD11c, MHC-II and MRC1 as described later. 
2.2.17 Flow Cytometry 
For each antibody-stained sample analysed, there is an unstained control (without staining) and an 
isotype control (consisting of isotype control antibodies for every different type of detection antibody 
used), which act as negative controls for background signals and non-specific antibody binding 
respectively (i.e. 3 tubes per sample analysed). For each tube, cells were resuspended at 1x104 cells 
per 100 Pl Fluorescence Activated Cell Sorting (FACS) analysis buffer (DPBS + 0.1% FCS), 1% of Fc 
Receptor (FcR) block (Miltenyi Biotech) and 5% mouse serum per 100Pl reaction. FcR block was added 
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to prevent non-specific binding of the Fc (constant) region of detection antibodies/ isotype controls 
to cell surface FcR that may generate a false positive signal. Mouse serum was added to prevent non-
specific binding of the variable region of detection antibodies/ isotype controls. For extracellular 
proteins, cells were stained with the appropriate antibodies for 30 minutes in the dark at 4oC by the 
appropriate antibodies. BAL cells were then washed in 2 ml DPBS and centrifuged at 500 g for 10 
minutes at 4oC. The supernatant was then discarded and BAL cells were fixed and permeabilised with 
300 μl BD Cytofix/CytopermTM (BD Biosciences) for 20 minutes in the dark at 4oC. BAL cells were then 
washed with 2 ml BD Perm/WashTM (BD Biosciences). For extracellular staining only, stained cells are 
then resuspended in 500 μl 1 x Cell Fix (BD Biosciences) (diluted 1:10 from 10x stock solution), and 
kept in the dark at 4oC until further analysis. 
For intraceullar staining, permealised BAL cells were stained with primary or directly conjugated 
antibodies for 30 minutes in the dark at 4oC, and then washed with 2 ml BD Perm/WashTM (BD 
Biosciences). This step was repeated for staining with secondary antibodies. Stained cells were then 
resuspended in 500 μl 1 x Cell Fix (BD Biosciences), and kept at 4oC until further analysis. Details for 
the concentrations of individual antibodies used will be described further in the text.  
Anti-Rat/ anti-Hamster IgK compensation kit (BD Biosciences) was used on the day of flow 
cytometric analysis to compensate for fluorophore spectral overlap in multi-colour staining. The set 
consists of two populations of microparticles, including the BD CompBeads Anti-Rat/Hamster Ig, κ 
particles (positive control), which bind any rat or hamster κ light chain-bearing immunoglobulin, and 
the BD CompBeads Negative Control (FBS) Particles (negative control), which has no binding 
capacity. When mixed together with a flurochrome-conjugated rat or hamster antibody, the BD-
CompBeads provide distinct positive and negative (background fluorescence)-stained populations 
that can be used to set compensation levels manually. Anti-Rat/ anti-Hamster IgK compensation kit 
(BD Biosciences) was prepared according to manufacturer’s instructions. In brief, 60 μl of BD 
CompBeads Anti-Rat/Hamster Ig, κ particles and 60 μl of BD CompBeads Negative Control (FBS) 
particles were added to 100 μl FACS buffer (+0.1 % FBS), and 20 μl of pre-diluted antibody stock 
(where final concentration in 220 μl is equivalent to that used in experiments) was subsequently 
added. This process was carried out separately for every different type of fluorophore that was used 
in multicolour experiments. The BD CompBeads Anti-Rat/Hamster Ig, κ particles/ BD CompBeads 
Negative Control (FBS) particles/ antibody mixture was then incubated in the dark at 4oC for 30 
minutes. The mixture was then washed with 2 ml FACS buffer and centrifuged at 500 g for 10 
minutes. The supernatant containing unbound antibodies was discarded, and the pellet containing 
Compbeads was resuspended in 500 μl FACS buffer.  
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FACS data was read by FACS CANTO II (BD Biosciences). Prior to recording data for samples, 
compensation for spectral overlap was determined from the pre-stained BD CompBeads Anti-
Rat/Hamster Ig, κ particles/ BD CompBeads Negative Control (FBS) particles using the compensation 
setup on the FACS CANTO II software (BD Biosciences). FACS data was analyzed by Flowjo (Tree Star 
Inc). Cell populations were identified using sequential gating strategy (see results) and the 
expression of the protein of interest was presented as median fluorescence intensity (MFI) and % 
positive with respect to isotype controls. 
2.2.18 Statistical analysis 
All statistical analysis was carried out using GraphPad Prism 6.0 software (GraphPad 
software, CA, USA). Normality distribution was evaluated by visual inspection of data. When 
comparing two groups unpaired two-tailed t-tests (followed by 
Welch’s correction test for non-equal standard deviations) and Mann-Whitney tests were 
used for parametric and non-parametric datasets, respectively. When comparing more than 
two groups, One-way ANOVA followed by Tukey’s or Bonferroni’s multiple comparison 
test and Kruskal Wallis test followed by a Dunn’s multiple comparison test were used for 
parametric and non-parametric datasets, respectively. Two-way ANOVA was used to 
compare time-course curves followed by Sidak’s multiple comparison test to 
determine the significance. P values of less than 0.05 were deemed statistically significant with *** p 
< 0.001, ** p <0.01 and * p < 0.05. Error bars represent standard deviation (SD) as indicated 
in the figure legends unless otherwise specified. 
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3.1 Introduction 
Macrophages display plasticity and heterogeneity between different tissues. Within the local 
environment the phenotypes of macrophages can be modified by the requirements of a specific tissue 
during normal and pathological processes to generate subsets that are tailored to carry out specific 
functions. These phenotypes initially defined by in vitro studies can be broadly categorized into 
‘classical’ M1 macrophages that may contribute to antimicrobial response and ‘alternative’ M2 and M2-
like macrophages that may contribute to wound healing and immunoregulation respectively. However, 
this categorization may be an oversimplification of the situation in vivo, where a variety of macrophage 
inducing signals are likely to exist within the tissue environment and to vary over time. Quantitatively 
and qualitatively different types of signals have been identified that contribute to tissue macrophage 
heterogeneity. These include weak priming signals that may influence the inflammatory potential of 
macrophages and their response to other stimuli, or strong inflammatory signals initiated by PRR 
stimulation579.  
There has been some confusion in the comparison between classical and alternative macrophage 
subsets, in that M1 macrophages can be generated by both a priming and/or a stimulatory signal (IFN-Υ 
and/or LPS respectively), whereas M2 macrophages can be generated with a priming signal only (IL-4 or 
IL-13). Given that both priming and stimulatory signals can activate their own gene-regulatory 
programme, this broad definition may likely obscure differences between different priming signals and 
also the stimulatory signal281,282. The substantial differences observed between the two subsets may 
actually be solely dependent on the presence or absence of an antimicrobial stimulus738.  
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The effects of priming and/or stimulatory signals on macrophage phenotype have been investigated in 
in vitro studies738. BMMφ were primed with IFN-Υ, IL-4 or media control, and then cultured with or 
without LPS. Although these two cytokines often induce opposing effects on gene transcription, the 
subsequent activation of BMMφ by LPS produced a strong, priming-dependent pro-inflammatory 
response in both macrophage phenotypes. For example, the gene expression of several key pro-
inflammatory cytokines, including IL-6 and IL-12a (gene encoding the IL-12 p35 subunit) was significantly 
higher in IL-4 compared to IFN-Υ-primed macrophages. On the other hand, in a subset of genes (e.g. IL-
12a), IFN-Υ priming was actually found to suppress LPS-induced gene expression in a STAT-1 dependent 
manner. These data suggested that IL-4 priming is not anti-inflammatory per se, but generates a tissue 
protective ‘hybrid’ macrophage subset phenotype that is also capable of generating a pro-inflammatory 
response following TLR4-stimulation738. In the context of tissue repair and fibrosis, endogenous alarmins 
are often found at sites of tissue injury. These may act as stimulatory signals to various macrophage 
PRRs, in addition to the M2-priming cytokines IL-4 and IL-13, to influence macrophage phenotypes. The 
hybrid subset may therefore better represent the macrophage phenotype in tissue repair in vivo. There 
have been no studies directly addressing the heterogeneity in AMφ; all attempts to subdivide AMφ into 
subsets have been done on the basis of experiments that examined these cells during pulmonary 
diseases using subset-associated markers pre-defined in BMMφ. 
Priming Stimulation Subset Associated markers Function 
M1 
IFN-Υ340 TNF-α, LPS340 NOS2, MHC-II, TNF-α, IL-1β, IL-
6, IL-12739 
Pro-inflammatory 
M2 
IL-4/IL-13282,305 N/A Arg-1, Chi3l3, MRC, 
Fibronectin, PDGF, IGF-1739 
Enhanced endocytosis, 
antigen presentation, 
tissue repair 
M2-like 
IL-10/TGF-
β/PGE306,740 + TLR
ligand306,740 
IL-10, TGF-β740 Tissue repair 
Table 3.1 Summary of macrophage subset inducing priming and stimulation signals, and subset associated 
markers. Arg-1, Arginase-1; Chi3l3, Chitinase 3 like 3; IFN-Υ, interferon-Υ; IGF-1, insulin-like growth factor-1; 
IL, interleukin; LPS, Lipopolysaccharide; MHC, Major Histocompatibility Complex; MRC1, Mannose Receptor 
C, type 1; N/A, not applicable; NOS2, Nitric Oxide Synthase 2; PDGF, platelet derived growth factor; PGE, 
prostaglandin E; TGF-β, transforming growth factor-β; TNF-α, tumour necrosis factor-α. 
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In healthy humans, there is no general consensus about whether AMφ are M1- or M2-like in nature. 
There has been great variation in the number of MRC1-expressing M2 AMφ reported in humans, ranging 
from 8% in one study741, to 50% in another study573. Around 20% of human AMφ have been reported to 
express stabilin-1 (STAB-1), another protein that is associated with M2 in humans741. These conflicting 
reports highlight the fact that AMφ in healthy individuals do not neatly fit into either a strict M1 or M2 
classification, and it may be that a resting lung-resident macrophages cannot necessarily be driven to 
become one of these defined cell subtypes. 
There are many potential signals that may potentially alter macrophage phenotypes within the lung of 
IPF patients. As mentioned above, the M2-inducing signal IL-13 has been reported to be upregulated in 
the lungs of IPF patients580. Similarly the M2-like inducing signal TGF-β1 also is more abundantly 
expressed in the lungs of rodent models of pulmonary fibrosis and IPF patients554,561,742–745. Hypoxic 
conditions are also commonly found in fibrotic lungs due to loss of alveolar architecture as a result of 
prolonged lung injury and dysregulated wound healing. The extreme local hypoxia is a consequence of 
decreased perfusion, which is secondary to microvascular injury, thrombosis or increased interstitial 
pressure, coupled with the metabolic activities of the recruited inflammatory cells746. Hypoxic conditions 
in wounds or necrotic tissue sites have been described as less than 1% oxygen in comparison to 2.5% to 
9% found in healthy tissues747–749.  
It was discovered that hypoxia share the TGF-β1 signalling pathway to promote a pro-fibrotic response 
in MH-S cells (an AMφ derived cell line) by protecting the transcription factor HIF-1α from degradation 
and thereby allowing increased secretion of pro-fibrotic mediators including PAI-1 and PDGF-AA. 
Silencing of HIF-1α by siRNA abolishes TGF-β induction of PAI-1 and PDGF-AA upregulation261.  
3.2 Hypothesis 
To emphasize my comments above although a number of studies have been carried out to characterise 
the functionality of different subsets of BMMφ, few investigations have explored the phenotype of 
primary lung macrophages induced by different signalling pathways. Therefore reports of macrophage 
subsets identified in pulmonary diseases have largely been based on subset-associated markers 
characterised in BMMφ.  
While BMMφ subsets may provide a useful in vitro model, it should be highlighted that these cells are 
artificially generated from bone marrow cells by application of a single inducing mediator [Granulocyte 
Macrophage Colony Stimulating Factor (GM-CSF) in humans; Macrophage Colony Stimulating Factor (M-
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CSF) in mice], and may not truly represent a terminally-differentiated tissue resident lung macrophage 
that are influenced by multiple signals within its immediate environment. It is hypothesised that 
terminally differentiated AMφ display similar plasticity to external stimuli that has been observed in 
BMMφ in vitro, and may be induced into distinct subsets through priming signals ex vivo. Furthermore, 
stimulatory signals, such as LPS, will be able to alter the phenotype of AMφ subsets.  
3.3 Aims  
The overall aim of this chapter was to explore the heterogeneity of AMφ with respect to mRNA and 
protein levels in response to priming (media control, IFN-Υ, IL-4 and/or IL-13, hypoxia, and TGF-β) signals 
to generate distinct subsets that were observed in BMMφ, and whether or not the gene and/or protein 
expression of these subsets could be modified by stimulatory signals (LPS). More specifically, this 
chapter aims to: 
1. Validate macrophage polarisation protocols obtained from literature by priming BMMφ with the 
M1- or M2-inducing cytokines, IFN-Υ or IL-4/ IL-13 respectively.  
2. Investigate the response of AMφ to the M1- or M2-inducing cytokines, IFN-Υ or IL-4/ IL-13 
respectively. IL-13 is a TH2 cytokine with similar properties to IL-4; both cytokines signal through a 
common Type II IL-4R dimer, resulting in the activation of the STAT6 pathway. IL-13 was used 
instead of IL-4 for the priming of AMφ, as it is considered more disease relevant in IPF, as IL-13 has 
been found to be upregulated in IPF patients580. 
3. Investigate the response of AMφ to hypoxic conditions or TGF-β1, which are commonly found in the 
fibrotic lung. 
4. The modulatory effects of LPS on the gene and/or protein expression of these BMMφ or AMφ 
subsets were also reviewed. 
The studies described here are the first of their kind to systematically investigate various signals 
affecting macrophage phenotypes in terminally differentiated AMφ, and provide a useful insight into 
AMφ heterogeneity for future studies in various pulmonary diseases. 
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3.4 Methods 
3.4.1 Generation of BMMφ and AMφ 
BMMφ were generated and AMφ were isolated as described in chapter 2 (sections 2.2.7 and 2.2.8, and 
sections 2.2.4, 2.2.5 and 2.2.6 respectively). BMMφ and AMφ were primed for the polarization of 
macrophages into distinct subsets.  
3.4.2 Priming and stimulation of BMMφ and/or AMφ 
For the generation of M1- or M2-like macrophage subsets, 1 x 105 BMMφ or AMI/ well of a 48-well 
tissue culture plate were primed with either macrophage complete media control (RPMI-1640 + 10% 
fetal bovine serum + 1.5 mM sodium pyruvate + 0.05 mM β-mercaptoethanol + 1 mM penicillin/
streptomycin + 50 μg/ml geneticin), 20ng/ml IFN-J (R&D Systems), 10 ng/ml IL-4 (R&D Systems) or 10 
ng/ml IL-13 (R&D Systems) and incubated for 18 hours at 37oC, 5% CO2, 20% O2. To evaluate the 
alterations of macrophage mRNA and/or protein levels to PRR stimulation, cytokine-primed BMMφ/
AMφ were further cultured with or without 10 ng/ml LPS-EB (Invivogen), for another 4 hours for mRNA 
level analysis, or for 24 hours for measurements of protein levels in the AMφ supernatant. 
For the priming of AMφ with lung-fibrosis associated signals, 1 x 105 AMI/ well a 48-well plate were 
serum-starved for 24 hours, and then primed with either macrophage complete media control 
(RPMI-1640 + 10% fetal bovine serum + 1.5 mM sodium pyruvate + 0.05 mM β-mercaptoethanol + 1 
mM penicillin/streptomycin + 50 μg/ml geneticin), 10 ng/ml TGF-β1 (R&D Systems) or subject to 
hypoxia (1% O2, 5% CO2) for 18 hours. AMφ were serum starved prior to hypoxia or TGF-β1 priming as 
fetal bovine serum (FBS) contains TGF-β that may activate the TGF-β induced HIF-1α pathway that is 
under investigation (section 3.1). To evaluate the alterations of macrophage mRNA and/or protein 
levels to PRR stimulation, hypoxia or TGF-β1-primed AMφ were then cultured with or without 10 ng/ml 
LPS-EB ;Invivogen), for another 4 hours for gene ƚƌĂŶƐĐƌŝƉƚůĞǀĞů analysis, or for 24 hours for 
measurements of protein levels in the AMφ supernatant. 
3.4.3 Assessment of mRNA and protein levels 
Total RNA extraction, reverse transcription, and qRT-PCR for mRNA level analysis were carried out as 
described at sections 2.2.11, 2.2.12 and 2.2.13 respectively. Measurements of proteins of interest in 
culture supernatant was measured as mentioned in sections 2.2.14 (fibronectin enzyme linked 
immunosorbent assay (ELISA) and 2.2.15 [Meso-Scale Discovery (MSD)]. 
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3.4.4 Flow cytometry experiments for differentially primed AMφ 
AMφ were cultured at 3 x 105 cells/ well in a Corning Costar® Ultra-Low attachment culture plate (Sigma-
Aldrich) with macrophage complete media control (RPMI-1640 + 10% fetal bovine serum + 1.5 mM 
sodium pyruvate + 0.05 mM β-mercaptoethanol + 1 mM penicillin/streptomycin + 50 μg/ml geneticin), 
20ng/ml IFN-J (R&D Systems), or 10 ng/ml IL-13 (R&D Systems) for 24 or 72 hours. Corning Costar® 
Ultra-Low attachment culture plate were used to avoid AMφ adherence, as mechanical (gentle scraping) 
or enzymatical (trypsin digestion) of cells may damage cell surface proteins under investigation. There 
was expected to be little contamination from other cell types as AMφ was found to constituted over 
90% of BAL cells in naïve mice from differential cell count (section 2.2.5). 
After 24 or 72 hours of incubation, each sample of 3 x 105 cells/well were separated into 3 tubes (i.e. 1 x 
105 cells/tube), one for positive staining for surface proteins of interest (CD11c, MHC-II and MRC1), one 
for unstained negative control, and one for isotype control of nonspecific antibody binding. For each tube, 
cells were resuspended at 1x105 cells per 100 Pl Fluorescence Activated Cell Sorting (FACS) analysis buffer 
(DPBS + 0.1% FCS), 1% of Fc Receptor (FcR) block (Miltenyi Biotech) and 5% mouse serum per 100Pl 
reaction. FcR block was added to prevent non-specific binding of the Fc (constant) region of detection 
antibodies/ isotype controls to cell surface FcR that may generate a false positive signal. Mouse serum 
was added to prevent non-specific binding of the variable region of detection antibodies/ isotype controls. 
For the positive staining tube, cells were incubated with FACS analysis buffer, 0.25 μg/100 μl CD11c-APC, 
0.25 μg/100 μl MHC-II-FITC and 0.5 μg/100 μl MRC1-PerCP/Cy5.5. For the isotype control tube, cells were 
stained with the isotype controls 0.25 μg/100 μl Armenian hamster IgG-APC, 0.25 μg/100 μl Rat IgG2b-
FITC and 0.5 μg/100 μl Rat IgG2a-PerCP/Cy5.5 for 30 minutes in the dark at 4oC. For the unstained control, 
cells were incubated with FACS analysis buffer only. 
BAL cells were then washed in 2 ml DPBS and centrifuged at 500 g for 10 minutes at 4oC. The supernatant 
was then discarded and BAL cells were fixed and permeabilised with 300 μl BD Cytofix/CytopermTM (BD 
Biosciences) for 20 minutes in the dark at 4oC. BAL cells were then washed with 2 ml BD Perm/WashTM 
(BD Biosciences). Cells were then resuspended in 500 μl 1 x Cell Fix (BD Biosciences) (diluted 1:10 from 
10x stock solution), and kept in the dark at 4oC until further analysis. 
Anti-Rat/ anti-Hamster IgK compensation kit (BD Biosciences) was used on the day of flow cytometric 
analysis to compensate for fluorophore spectral overlap in multi-colour staining. The set consists of two 
populations of microparticles, including the BD CompBeads Anti-Rat/Hamster Ig, κ particles (positive 
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control), which bind any rat or hamster κ light chain-bearing immunoglobulin, and the BD CompBeads 
Negative Control (FBS) Particles (negative control), which has no binding capacity. When mixed together 
with a flurochrome-conjugated rat or hamster antibody, the BD-CompBeads provide distinct positive 
and negative (background fluorescence)-stained populations that can be used to set compensation 
levels manually. Anti-Rat/ anti-Hamster IgK compensation kit (BD Biosciences) was prepared according 
to manufacturer’s instructions. In brief, 60 μl of BD CompBeads Anti-Rat/Hamster Ig, κ particles and 60 
μl of BD CompBeads Negative Control (FBS) particles were added to 100 μl FACS buffer (+0.1 % FBS), and 
20 μl of pre-diluted antibody stock (where final concentration in 220 μl is equivalent to that used in 
experiments) was subsequently added. This process was carried out separately for every different type 
of fluorophore that was used in multicolour experiments. The BD CompBeads Anti-Rat/Hamster Ig, κ 
particles/ BD CompBeads Negative Control (FBS) particles/ antibody mixture was then incubated in the 
dark at 4oC for 30 minutes. The mixture was then washed with 2 ml FACS buffer and centrifuged at 500 g 
for 10 minutes. The supernatant containing unbound antibodies was discarded, and the pellet 
containing Compbeads was resuspended in 500 μl FACS buffer.  
FACS data was read by FACS CANTO II (BD Biosciences). Prior to recording data for samples, 
compensation for spectral overlap was determined from the pre-stained BD CompBeads Anti-
Rat/Hamster Ig, κ particles/ BD CompBeads Negative Control (FBS) particles using the compensation 
setup on the FACS CANTO II software (BD Biosciences). FACS data was analyzed by Flowjo (Tree Star Inc). 
AMφ were defined as SSChi FSChi CD11c+, and the expression of the protein of interest was gated with 
respect to their respective isotype controls. Data was presented as median fluorescence intensity (MFI) 
and % positive with respect to isotype controls. 
3.4.5 Statistical analysis 
All statistical analysis was carried out using GraphPad Prism 6.0 software (GraphPad 
software, CA, USA). Normal distribution was evaluated by visual inspection of data due to insufficient 
numbers for normality tests. Data appeared to be parametric, and one-way ANOVA followed by Tukey’s 
test were used for statistical analysis for comparison of three or more sets of data over one parameter. 
P values of less than 0.05 were deemed statistically significant with *** p < 0.001, ** p <0.01 and * p < 
0.05. Error bars represent standard deviation (SD) as indicated in the figure legends. 
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3.5 Results 
3.5.1 Preliminary experiments 
In the beginning of this PhD, several preliminary experiments (n=1) were carried out to validate 
macrophage priming (media control, IFN-Υ or IL-4) and/or stimulation (LPS) protocols in BMMφ, and 
to explore AMφ heterogeneity in response to these and other pro-fibrotic signals (e.g. IL-13, TGF- 
and hypoxia).  
The change in mRNA and/or protein levels of AMφ in response to macrophage subset-inducing 
cytokines, including M1-inducing IFN-Υ and M2-inducing IL-4/IL-13, and also hypoxic conditions (1% 
O2, 5% CO2) or TGF-β1 that are commonly found in fibrotic tissues, were evaluated. The modulatory 
effect of PRR stimulation (LPS) on primed AMφ mRNA and protein levels were also assessed. The 
change in levels of a number of markers that have been characterised to distinct macrophage 
subsets [M1 (NOS2, IL-1β, MHC-II); M2 (Arg-1, fibronectin 1); TGF-β1 or hypoxia-primed 
macrophages (PAI-1)] mediators were investigated in these studies. The secreted protein levels of 
macrophage-associated mediators that may play a role in fibrosis, including IL-6, CCL2, CCL3, CCL4, 
CCL5, CXCL2, mMMP-9, IL-1β, were also evaluated for differentially primed AMφ to assess whether 
or not they are associated with a particular macrophage subset. Finally, the effect of LPS stimulation 
on differentially primed AMφ mRNA and protein levels were determined. 
Due to the large amount of parameters and mediators that were under preliminary investigation, 
further repeats were carried out only for AMφ primed with IFN-Υ or IL-13 (n=3), but not the BMMφ 
and TGF-β1 or hypoxia-primed macrophage studies. These studies were selected for further 
investigation due to the novelty in investigating AMφ (vs. BMMφ) polarisation, and because IFN-Υ or 
IL-13-primed macrophages (versus TGF-β1 or hypoxia-primed macrophages) generated M1- or M2-
like AMφ respectively that represented opposite ends of the macrophage polarisation spectrum. 
Characterisation of these subsets can therefore provide a greater scope of the various changes in 
mRNA and protein levels in response to diverse signals. 
In the following section, results from preliminary studies (n=1), including BMMφ priming and/or 
stimulatory studies, and also TGF-β1 or hypoxia-primed AMφ are reported first (section 3.5.1). These 
preliminary results (n=1) are not statistically significant without further repeats; but may provide 
clues on how BMMφ/ AMφ may behave in response to the inducing signals under investigation. 
Results from preliminary experiments are then followed by those from repeated studies, including 
mRNA, surface protein, and secreted protein level analyses studies in IFN-Υ or IL-13-primed AMφ 
(section 3.5.2). 
Chapter 3 | The heterogeneity of AMφ in vitro  
127 
3.5.1.1 Differentially primed BMMφ express macrophage subset associated markers 
3.5.1.2 Investigation of the potential modulatory effects of cytokine priming and or LPS stimulation on 
AMφ mRNA and protein levels 
Previous publications282,340,738,739 have reported a change in BMMφ phenotype in response to priming 
in vitro; these changes were correlated with the priming signal used. In the experiments reported 
here similar conditions are used to determine whether or not disease relevant primary cells which 
contribute to the pathophysiological host response in a variety of respiratory diseases, namely AMφ, 
have the potential to be influenced in a comparable manner. Priming conditions for the generation 
of the macrophage subsets are first to be validated in BMMφ, and this would then provide a basis 
for investigating and characterizing the phenotype of AMφ primed under similar conditions. 
3.5.1.2.1 Differentially primed BMMφ express macrophage subset associated markers 
In order to validate the priming conditions for macrophage subsets described in previous 
publications, BMMφ were cultured under the same conditions and analysed for the mRNA levels of 
type I (M1) (NOS2) or type 2 (M2)- (Arg-1, Chi3l3and MRC1) associated mediators following priming 
by the M1-inducing cytokine, IFN-Υ, or M2-inducing cytokine, IL-4 respectively. The increased levels 
of these mediators in response to their corresponding inducing cytokines would serve as a positive 
control for further cytokine-priming experiments in AMφ polarisation, which is the primary objective 
of these experiments. However, it should be noted that the mRNA levels of M2-associated mediators 
were not evaluated in M1, nor M1-associated mediators in M2 BMMφ. In other words, these 
experiments only reveal whether or not priming signals can induce a change in mediator mRNA 
levels in BMMφ, but cannot fully characterise BMMφ polarisation (whether or not M1 or M2 BMMφ 
have been generated).  
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In the BMMφ-priming experiments, IFN-Υ-primed BMMφ displayed increased NOS2 mRNA levels, 
whereas Arg-1, Chi3l3, and MRC1 mRNA levels was elevated in IL-4 primed BMMφ (Figure 3.1). 
These results demonstrate that as reported in the literature282,340,738,739, BMMφ increase different 
gene transcripts in response to different cytokine priming. 
Figure 3.1 Effect of cytokine priming on mRNA levels of macrophage subset markers in Bone Marrow 
Derived Macrophages (BMMφ).1 x 105 BMMΦ were seeded per well of a 48-well culture plates, and primed 
with macrophage complete media control (RPMI-1640 + 10% fetal bovine serum + 1.5 mM sodium pyruvate 
+ 0.05 mM β-mercaptoethanol + 1 mM penicillin/streptomycin + 50 μg/ml geneticin) alone or together with
20 ng/ml Interferon-Υ (IFN-Υ) or 10 ng/ml Interluekin-4 (IL-4) for 22 hours. Nitric Oxide Synthase (NOS) 2,
Arginase-1 (Arg-1), Mannose Receptor C, type 1 (MRC1), and Chitinase 3 like 3 (Chi3l3) mRNA levels were
measured by Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR). Data are from one
pilot study collected from pooled samples run in triplicates and the average was presented as relative % to
the housekeeping gene Hypoxanthine Phosphoribosyltransferase 1 (HPRT-1). ND: Not detected.
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3.5.1.2.2 Differentially primed BMMφ have distinct responses to LPS stimulation 
TLR activation is generally ascribed to modifying macrophages to promote a pro-inflammatory 
phenotype. However this phenotype may be differentially regulated in various macrophage subsets. 
M1 macrophages have been described to promote inflammation through the release of pro-
inflammatory mediators, ROS, and RNS, and augment the pro-inflammatory response following TLR 
stimulation. M2 macrophages have a wound healing phenotype that is characterised by Arg-1 
expression581,582 and expression of various wound healing mediators (e.g. PDGF and 
fibronectin)120,520, but have also been reported to have increased expression of pro-inflammatory 
mediators in response to LPS stimulation738.  
In order to validate these observations, a pilot study was carried out. M1 and M2 macrophages were 
generated as before by priming BMMφ with IFN-Υ or IL-4; these were then further stimulated with 
LPS for TLR4 activation.  
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3.5.1.2.2.1 IFN-Υ primed macrophages have an exaggerated pro-inflammatory response to LPS 
stimulation 
As has been reported by others282,340,738,739, LPS stimulation promoted a pro-inflammatory response 
and increased both NOS2 and IL-1β gene transcript levels. IFN-Υ-primed macrophages have an 
exaggerated response to LPS stimulation, which strongly augmented increased transcript levels of 
NOS2 by around 4-fold and to a lesser extent IL-1β. On the other hand, IL-4-primed macrophages 
have a dampened pro-inflammatory response to LPS stimulation and reduced LPS-induced increase 
in IL-1β mRNA levels (Figure 3.2). 
As has been reported by others283,341,738,739, LPS stimulation promoted a pro-inflammatory response 
and increased both NOS2 and IL-1β gene transcript levels. IFN-Υ-primed macrophages have an 
exaggerated response to LPS stimulation, which strongly augmented increased transcript levels of 
NOS2 by around 4-fold and to a lesser extent IL-1β. On the other hand, IL-4-primed macrophages 
have a dampened pro-inflammatory response to LPS stimulation and reduced IL-1β upregulation 
(Figure 3.2). 
Figure 3.2 The effects of Lipopolysaccharide (LPS) stimulation on mRNA levels of M1-associated markers in 
differentially primed BMMφ.1 x 105 BMMΦ were seeded per well of a 48-well culture plates, and primed 
with macrophage complete media control (RPMI-1640 + 10% fetal bovine serum + 1.5 mM sodium pyruvate 
+ 0.05 mM β-mercaptoethanol + 1 mM penicillin/streptomycin + 50 μg/ml geneticin) alone or together with
20 ng/ml Interferon-Υ (IFN-Υ) or 10 ng/ml Interluekin-4 (IL-4) for 18 hours. Primed BMMΦ were then further
cultured with macrophage complete media control or 10 ng/ml LPS from E. coli 0111:B4 for 4 hours. NOS2
and IL-1β mRNA levels were measured by qRT-PCR. Data are from one pilot study collected from pooled
samples run in triplicates and the average was presented as relative % to the housekeeping gene HPRT-1.
ND: Not detected.
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3.5.1.2.2.2 LPS stimulation shifts macrophage subset bias away from M2 phenotype 
LPS stimulation promoted a pro-inflammatory phenotype, and was synergistic to increased levels of 
NOS2 and IL-1β gene transcripts in BMMφ induced by IFN-Υ priming (Figure 3.2). In contrast, LPS 
stimulation shifts the macrophage subset bias away from an IL-4 primed phenotype, as observed by 
the decline in Arg-1 and Chi3l3 transcript levels in IL-4-induced BMMφ by approximately 25% and 
50% respectively (Figure 3.3). These results demonstrate that LPS stimulation of TLR4 may alter 
macrophage phenotype driven by cytokine priming.  
 
 
 
Figure 3.3 The effects of Lipopolysaccharide (LPS) stimulation on mRNA levels of M2-associated markers in 
differentially primed BMMφ.1 x 105 BMMΦ were seeded per well of a 48-well culture plates, and primed 
with macrophage complete media control (RPMI-1640 + 10% fetal bovine serum + 1.5 mM sodium pyruvate 
+ 0.05 mM β-mercaptoethanol + 1 mM penicillin/streptomycin + 50 μg/ml geneticin) alone or together with
20 ng/ml IFN-Υ or 10 ng/ml IL-4 for 18 hours. Primed BMMΦ were then further cultured with macrophage
complete media control or 10 ng/ml LPS from E. coli 0111:B4 for 4 hours. Arg-1 and Chi3l3 mRNA levels
were measured by qRT-PCR. Data are from one pilot study collected from pooled samples run in triplicates
and the average was presented as relative % to the housekeeping gene HPRT-1.
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3.5.1.3 Investigation of the potential modulatory effects of pro-fibrotic conditions on AMφ phenotypes 
Having shown that the mRNA levels of various macrophage subset associated genes can be 
differentially altered by different cytokine priming in BMMφ, I then investigated whether or not the 
cytokines IFN-Υ or IL-13, or fibrotic conditions including TGF-β or hypoxic conditions can also alter 
macrophage mRNA and protein levels. Studies regarding IFN-Υ and IL-13 were repeated and will be 
further discussed in section 3.5.2; in this section I will focus on the preliminary results from TGF-β or 
hypoxia-induced AMφ. 
TGF-β is elevated in the BALF and lung tissue of IPF patients118, and is able to induce fibrosis in 
vivo750,751. TGF-β priming of BMMφ has been reported to promote a M2-like phenotype that is anti-
inflammatory. It may also promote fibrosis through increased fibrin deposition by stabilisation of the 
transcription factor HIF-1α. Furthermore, it has been documented that TGF-β can reduce expression 
of the HIF-1α inhibitor Propyl Hydroxylase Domain (PHD)-2 in MH-S cells (a murine AMφ derived cell 
line260), thereby promoting the downstream transcription of PAI-1, leading to inhibition of the 
fibrinolytic enzyme plasminogen activation261.  
Hypoxic conditions arise in lungs of IPF patients due to an injury to alveolar capillary membrane and 
impaired gaseous exchange, which cause cell stress and an increase in HIF-1α that can regulate 
expression of a number of genes that drive remodelling and fibrosis. Hypoxia can promote fibrosis 
through reducing PHD-2 in MH-S cells, thereby promoting HIF-1α activation, PAI-1 transcription and 
plasminogen inhibition, resulting in the activation of plasmin and accumulation of fibrin261. Plasmin 
can promote fibrosis through the proteolysis and activation of its pro-fibrotic substrates (e.g. MMPs) 
and also promote cellular infiltration via the fibrin clot265. 
AMφ cultured with TGF-β1 or hypoxic conditions were analysed for changes in mRNA levels for two 
L-Arginine catalytic enzymes, NOS2 and Arg-1, which are associated with M1- or M2-BMMφ (and
AMφ – see section 3.5.2.1) respectively, and pro-fibrotic mediators, including PAI-1, TGF-β and 
PDGF-β.  
3.5.1.3.1 Differentially primed AMφ express macrophage subset associated markers 
The results of TGF-β1 priming and hypoxia induction suggested that there was a trend in the 
increase of PAI-1 mRNA levels in AMφ by 5-fold and 7-fold respectively (Figure 3.4). In TGF-β1 
primed AMφ there appeared to be an increase in the pro-fibrotic mediators TGF-β1 and PDGF-β, but 
no such elevation was observed for hypoxia induced AMφ (Figure 3.5). There was an enhancement 
in both M1 associated NOS2 and M2 associated Arg-1 gene transcript levels in hypoxia-induced 
AMφ, although no change was observed for TGF-β1 primed AMφ (Figure 3.6).  
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These results suggested that hypoxia and TGF-β1 are both potent signals to alter macrophage 
phenotypes. Hypoxia appears to promote a mixed M1-like and M2-like phenotype, increasing the 
transcript levels of both the M1-associated gene NOS2 and the M2-associated gene Arg-1. Hypoxia 
induction also triggered an increase in PAI-1 transcript levels that may promote fibrin accumulation 
and fibrosis. On the other hand, TGF-β favoured a pro-fibrotic phenotype, inducing elevated 
transcript levels for the pro-fibrotic mediators PAI-1, TGF-β and PDGF-β. Hypoxia and TGF-β  have 
been reported to share a common HIF-1α signalling pathway to upregulate pro-fibrotic mediators 
such as PAI-1261. However, other hypoxia induced HIF-1α independent pathways (e.g. Hif-2α) may 
also contribute to the fibrotic process, as the results presented here reveal a difference in induction 
of various pro-fibrotic mediators and macrophage-subset associated proteins by these two signals. 
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Figure 3.6 Effect of TGF-β priming or hypoxia induction on mRNA levels of macrophage subset associated 
markers in AMφ.1 x 105 AMΦ were seeded per well of 48-well culture plates, and primed with 
macrophage complete media control (RPMI-1640 + 10% fetal bovine serum + 1.5 mM sodium pyruvate + 
0.05 mM β-mercaptoethanol + 1 mM penicillin/streptomycin + 50 μg/ml geneticin), 5 ng/ml TGF-β1 or 
hypoxia (<1% O2, 5% CO2) for 22 hours. NOS2 and Arg-1 mRNA levels were determined by qRT-PCR. Data 
are from one pilot study collected from pooled samples run in triplicates and the average was presented 
as relative % to the housekeeping gene HPRT-1. ND: Not detected. 
Figure 3.4 Effect of TGF-β priming or hypoxia induction on mRNA levels of Plasminogen Activator Inhibitor 
(PAI-1) in AMφ. 1 x 105 AMΦ were seeded per well of 48-well culture plates, and primed with macrophage 
complete media control (RPMI-1640 + 10% fetal bovine serum + 1.5 mM sodium pyruvate + 0.05 mM β-
mercaptoethanol + 1 mM penicillin/streptomycin + 50 μg/ml geneticin), 5 ng/ml TGF-β1 or hypoxia (<1% O2, 
5% CO2) for 22 hours. PAI-1 mRNA levels was measured by qRT-PCR. Data are from one pilot study collected 
from pooled samples run in triplicates and the average was presented as relative % to the housekeeping 
gene HPRT-1. 
Figure 3.5 Effect of TGF-β priming or hypoxia induction on mRNA levels of pro-fibrotic mediators in AMφ.1 x 
105 AMΦ were seeded per well of 48-well culture plates, and primed with macrophage complete media 
control (RPMI-1640 + 10% fetal bovine serum + 1.5 mM sodium pyruvate + 0.05 mM β-mercaptoethanol + 1 
mM penicillin/streptomycin + 50 μg/ml geneticin), 5 ng/ml TGF-β1 or hypoxia (<1% O2, 5% CO2) for 22 hours. 
TGFβ1 and Platelet Derived Growth Factor (PDGF)-β mRNA levels were measured by qRT-PCR. Data are from 
one pilot study collected from pooled samples run in triplicates and the average was presented as relative % 
to the housekeeping gene HPRT-1. 
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Figure 3.8 The effects of LPS stimulation on pro-fibrotic mediator mRNA levels in differentially primed 
AMΦ. 1 x 105 AMφ were seeded per well on 48-well culture plates, and primed with macrophage 
complete media control (RPMI-1640 + 10% fetal bovine serum + 1.5 mM sodium pyruvate + 0.05 mM β-
mercaptoethanol + 1 mM penicillin/streptomycin + 50 μg/ml geneticin), alone or with 5 ng/ml TGF-β1 or 
hypoxia (<1% O2, 5% CO2) for 18 hours. Primed AMΦ were then further cultured with media control or 10 
ng LPS-EB for 4 hours. TGF-β and PDGF-β mRNA levels were determined by qRT-PCR. Data are from one 
pilot study collected from pooled samples run in triplicates and the average was presented as relative % to 
the housekeeping gene HPRT-1.  
C
o n
tr
o l
T G
F -
E
H
y p
o x
ia
C
o n
tr
o l
T G
F -
E
H
y p
o x
ia
0
1 0
2 0
3 0
4 0
5 0
1 5 0
2 0 0
2 5 0
3 0 0
P A I-1
H
P
R
T
-1
m
R
N
A
(r
e
la
ti
v
e
%
)
C o n t r o l + L P S
C
o n
tr
o l
T G
F -
E
H
y p
o x
ia
C
o n
tr
o l
T G
F -
E
H
y p
o x
ia
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
T G F -E 1
H
P
R
T
-1
m
R
N
A
(r
e
la
ti
v
e
%
)
C o n t r o l + L P S
C
o n
tr
o l
T G
F -
E
H
y p
o x
ia
C
o n
tr
o l
T G
F -
E
H
y p
o x
ia
0
2 0
4 0
6 0
8 0
P D G F -E
H
P
R
T
-1
m
R
N
A
(r
el
a
ti
v
e
%
)
C o n t r o l + L P S
3.5.1.3.2 Differentially primed AMφ have distinct responses to LPS stimulation 
Having identified that TGF-β1 or hypoxia that promote fibrotic responses can alter mRNA levels in 
AMφ, it was next investigated whether or not such priming conditions will have affect AMφ 
responses to TLR stimulation. The analysis of mRNA levels revealed that LPS stimulation induced a 
trend implying that PAI-1 is increased in hypoxia but not TGF-β1 primed AMφ (Figure 3.7). It was also 
observed that LPS stimulation increased mRNA levels of the profibrotic mediators TGF-β and PDGF-β 
(Figures 3.8). This trend was accumulative for PDGF-β that had been increased following TGF-β 
priming (Figure 3.8). In addition, LPS stimulation was synergistic to the increased NOS2 gene 
transcript levels by 9-fold observed for hypoxia primed AMφ (Figure 3.9), but on the other hand 
suppressed Arg-1 by about 30% (Figure 3.9). 
 
 
 
 
 
 
 
Figure 3.7 The effects of LPS stimulation on PAI-1 mRNA levels in differentially primed AMΦ.1 x 105 AMφ 
were seeded per well on 48-well culture plates, and primed with macrophage complete media control 
(RPMI-1640 + 10% fetal bovine serum + 1.5 mM sodium pyruvate + 0.05 mM β-mercaptoethanol + 1 mM 
penicillin/streptomycin + 50 μg/ml geneticin) or with 5 ng/ml TGF-β1 or hypoxia (<1% O2, 5% CO2) for 18 
hours. Primed AMΦ were then further cultured with media control or 10 ng LPS-EB for 4 hours. PAI-1 mRNA 
level was determined by qRT-PCR. Data are from one pilot study collected from pooled samples run in 
triplicates and the average was presented as relative % to the housekeeping gene HPRT-1.   
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Figure 3.9 The effects of LPS stimulation on mRNA levels of macrophage subset associated markers in 
various differentially primed AMΦ.1 x 105 AMΦ were seeded per well onto 48-well culture plates, and 
primed with macrophage complete media control (RPMI-1640 + 10% fetal bovine serum + 1.5 mM sodium 
pyruvate + 0.05 mM β-mercaptoethanol + 1 mM penicillin/streptomycin + 50 μg/ml geneticin), with 5 ng/ml 
TGF-β1 or hypoxia (<1% O2, 5% CO2) for 18 hours. Primed AMΦ were then further cultured control with 
media or 10 ng/ml LPS for 4 hours. NOS2 and Arg-1 mRNA levels were determined by qRT-PCR. Data are 
from one pilot study collected from pooled samples run in triplicates and the average was presented as 
relative % to the housekeeping gene HPRT-1. ND: Not detected. 
3.5.1.3.3 Analysis of fibrosis-associated protein levels of differentially primed AMφ subsets 
Next the effect of AMφ priming on protein levels of selected mediators was investigated. AMφ 
primed with either IFN-Υ, IL-4, hypoxia or cultured in media alone (control cultures) were analysed 
for the production of various cytokines and chemokines that have been reported to play a role in 
IPF, including the pro-inflammatory cytokine IL-6408, and the chemokines CCL2 325,438,752–755, CCL3435–
437,439, CCL4435, CCL5461, CXCL2381,756 and MMP-9298–301. The levels of another chemoattractant, CCL20 
was also assessed.  
CCL20 is predominantly expressed in lymph nodes, appendix, peripheral blood lymphocytes (PBL), 
liver, lung, AMφ in the lungs of sarcoidosis patients757 and epithelial cells of the intestinal tissues758. 
CCL20 exerts its chemotactic effects through binding to CCR6 that is expressed in DCs759 and 
lymphocytes760. Synthetic or recombinant CCL20 is chemotactic for lymphocytes and DCs, and 
inhibits proliferation of myeloid progenitors in colony formation assays761. The pro-inflammatory 
cytokine IL-6 may play a role in tissue injury while these chemokines listed above may contribute to 
the recruitment of pro-inflammatory myeloid cells including circulating monocytes (progenitors of 
terminally differentiated alveolar macrophages), to the lung in response to injury or infection. ELR+ 
CXC chemokines may also contribute to the pathogenesis of fibrosis through promoting angiogenesis 
(Section 1.2.3.1). 
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Results showed that CCL20 and MMP-9 protein levels were not detectable under various priming 
signals or LPS stimulation, suggesting that these mediators are not secreted by AMφ (data not 
shown). In the absence of TLR stimulation, IFN-Υ increased CCL2 protein levels; however, all the 
other mediators of interest were undetectable (data not shown). LPS stimulation alone increased 
CCL5 protein levels in AMφ culture supernatant, but had no effect on other mediators (data not 
shown). On the other hand, LPS stimulation of IFN-Υ primed AMφ increased IL-6 and CCL5 protein 
levels, which was not observed in IFN-Υ primed cells alone. CCL2 was also enhanced in IFN-Υ primed 
AMφ stimulated with LPS, although this increment appeared to be of no difference to that of AMφ 
primed with IFN-Υ alone. IL-4 primed AMφ also promoted the increased levels of CCL5 and IL-6 
following LPS stimulation. However, hypoxia-primed AMφ strongly exaggerated the levels of various 
chemokines, including CCL2, CCL3, CCL4, CCL5, and CXCL2. These results indicate that hypoxia may 
be an important signal for induction of chemoattraction in AMφ (Figure 3.10). 
Chapter 3 | The heterogeneity of AMφ in vitro  
138 
C
o n
tr
o l
IF
N
- J
IL
-4
H
y p
o x
ia
C
o n
tr
o l
IF
N
- J
IL
-4
H
y p
o x
ia
0
2 0 0
4 0 0
6 0 0
8 0 0
C C L 3
C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
C o n t r o l + L P S
N D N D
C
o n
tr
o l
IF
N
- J
IL
-4
H
y p
o x
ia
C
o n
tr
o l
IF
N
- J
IL
-4
H
y p
o x
ia
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
C C L 4
C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
C o n t r o l + L P S
C
o n
tr
o l
IF
N
-J
IL
-4
H
y p
o x
ia
C
o n
tr
o l
IF
N
-J
IL
-4
H
y p
o x
ia
0
50
100
150
IL -6
C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
C o n t r o l + L P S
N DN D
C
o n
tr
o l
IF
N
-J
IL
-4
H
y p
o x
ia
C
o n
tr
o l
IF
N
-J
IL
-4
H
y p
o x
ia
0
5
10
15
20
25
C C L 2
C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
C o n t r o l + L P S
C
o n
tr
o l
IF
N
- J
IL
-4
H
y p
o x
ia
C
o n
tr
o l
IF
N
- J
IL
-4
H
y p
o x
ia
0
1 0 0 0
2 0 0 0
3 0 0 0
C C L 5
C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
C o n t r o l + L P S
C
o n
tr
o l
IF
N
- J
IL
-4
H
y p
o x
ia
C
o n
tr
o l
IF
N
- J
IL
-4
H
y p
o x
ia
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
C X C L 2
C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
C o n t r o l + L P S
B .D .
 
 
 
 
Figure 3.10 The effects of differential cytokine priming and/or LPS stimulation on macrophage-associated 
protein levels in AMφ culture supernatant. 1 x 105 AMΦ were seeded per well of a 48-well culture plate, 
and primed with macrophage complete media control (RPMI-1640 + 10% fetal bovine serum + 1.5 mM 
sodium pyruvate + 0.05 mM β-mercaptoethanol + 1 mM penicillin/streptomycin + 50 μg/ml geneticin), 20 
ng/ml IFN-Υ, 10 ng/ml IL-4, or hypoxia (<1% O2, 5% CO2) for 18 hours. Culture media was changed (in the 
presence of priming cytokines) and AMφ were further cultured, with macrophage complete media control 
or with 10 ng/ml LPS-EB (Invivogen) for 24 hours. AMφ supernatant was collected and stored at -80o prior to 
analysis. IL-6, CCL2, CCL3, CCL4, CCL5, and CXCL2 protein levels were detected by MSD. Data from pooled 
samples were ran in duplicates and presented as mean values. Data is from one pilot study. Dotted line 
refers to lower limit of detection. ND: Not detected. Standard curves for the MSDs are attached to Appendix 
1.
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3.5.2 Alveolar Macrophages (AMφ) 
3.5.2.1 Differentially primed AMφ express macrophage subset associated markers  
Having demonstrated that in vitro generated BMMφ differentiate into various subsets following 
differential cytokine priming earlier (section 3.5.1.1), the effect of priming tissue specific AMφ under 
conditions known to promote an M1 or M2 ‘like’ phenotype in BMMφ, were investigated next. AMφ 
are resident in the alveolar space and may facilitate the immune response to respiratory pathogens 
including bacteria and viruses, or endogenous alarmins that are released in response to tissue 
injury617–619,628,655,656. There is evidence for increases in alarmins such as HA fragments and HMGB1 in 
the lungs or BALF or patients with pulmonary fibrosis630–632,651.  
In contrast to BMMφ, AMφ are considered terminally differentiated, and may be less responsive to 
exogenous priming signals. In order to investigate whether or not AMφ can also be induced to 
differentiate into M1-like or M2-like macrophages, primary AMφ isolated from mice were primed for 
18 hours with either IFN-Υ or IL-13 respectively. Primed AMφ were then further cultured for 4 and 
24 hours for mRNA and protein level analysis. 
The analyses of mRNA levels of various macrophage subset associated mediators revealed that 
similar to BMMφ, AMφ can be induced to differentiate into distinct subsets. As with BMMφ, the 
level of transcript for the M1-associated gene NOS2 was elevated following IFN-Υ priming (p<0.05) 
whereas the level of transcript for the M2-associated gene Arg-1 was increased following IL-13 
priming (p<0.01). Further mRNA level analysis showed that in IL-13 primed AMφ the gene transcript 
levels of the profibrotic mediators, including IGF-1 and fibronectin are enhanced by 10-fold (p<0.05) 
and 6-fold (p<0.01) respectively, suggesting a potential pro-fibrotic role for M2 macrophages (Figure 
3.11). 
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Figure 3.11 Effect of cytokine priming on macrophage-subset associated mRNA levels of macrophage subset 
markers in AMφ.1 x 105 AMΦ were seeded per well of 48-well culture plates, and primed with macrophage 
complete media control (RPMI-1640 + 10% fetal bovine serum + 1.5 mM sodium pyruvate + 0.05 mM β-
mercaptoethanol + 1 mM penicillin/streptomycin + 50 μg/ml geneticin) alone or together with 20 ng/ml 
IFN-Υ or 10 ng/ml IL-13 for 18 hours. Primed AMΦ were then further cultured for 4 hours. NOS2, Arg-1, IGF-
1, and fibronectin mRNA levels were measured by qRT-PCR. Pooled samples (per condition) were run in 
triplicates and the average was presented as relative % to the housekeeping gene HPRT-1. Three separate 
studies were carried out (n=3) and data are represented as mean ± SD. One way ANOVA with Tukey post-
test was carried out; *: p<0.05, **: p< 0.01, ***: p<0.005. ND, Not Detected. 
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Using ELISA and MSD analyses it was observed that differentially primed AMφ have distinct changes 
in protein levels. IFN-Υ primed AMφ produced significantly higher levels of pro-inflammatory 
cytokines, including IL-1β (p<0.05) and IL-12 p40 (total) (3.10-fold; p<0.05) than the untreated 
controls, whereas IL-13 primed AMφ produced higher levels of the ECM component fibronectin (2-
fold; p<0.05) (Figure 3.12).  
 
 
 
 
 
Figure 3.12 Effect of cytokine priming on protein levels of macrophage subset markers in AMφ. AMΦ were 
seeded onto culture plates, and primed with macrophage complete media control (RPMI-1640 + 10% fetal 
bovine serum + 1.5 mM sodium pyruvate + 0.05 mM β-mercaptoethanol + 1 mM penicillin/streptomycin + 
50 μg/ml geneticin) alone or together with 20 ng/ml IFN-Υ or 10 ng/ml IL-13 for 18 hours. Primed AMΦ 
were then further cultured for 24 hours. IL-1β, IL-12, and fibronectin protein expression by Meso Scale 
Discovery (MSD) or Enzyme Linked Immunosorbent Assay (ELISA) respectively. Data are represented as 
mean ± SD; n=3 from three separate studies. One way ANOVA with Tukey post-test was carried out; *: 
p<0.05, **: p< 0.01, ***: p<0.005, ****: p<0.001. NS: Not Significant. IL-12 p40 (total) incudes free IL-12 p40, 
IL-12 p40 homodimers and IL-12 p40 heterodimers (IL-12 p70 and IL-23). See Appendix 2 for standard curves 
of individual ELISA/ MSD. 
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Flow cytometric analyses demonstrated that differentially primed AMφ have distinct cell surface 
marker expression. IFN-Υ priming strongly promoted the surface expression of MHC-II at 24 hours 
but suppressed that of MRC1, and therefore can be classified as MHC-IIhi MRC1- (Figure 3.13). Three 
peaks were observed in MHC-II staining for IFN-Υ-primed AMφ, including a MHC-II-, MHC-IImid and a 
MHC-IIhi subsets at 24 hours (Figure 3.13). These three peaks may represent heterogeneous AMφ 
populations within the lung that have different levels of responses to IFN-γ, perhaps due to inherent 
immunosuppression by endogenous anti-inflammatory mediators in vivo that act as a homeostasis 
mechanism against frequently encountered airborne pathogens within the lung. 
IL-13 priming also weakly increased the number of AMφ expressing surface MHC-II at 72 hours, but 
has no effect on MRC1 levels, and as such can be described as MHC-II-/loMRC1-/lo (Figure 3.14). 
These results indicate that similar to BMMφ, AMφ can be driven into distinct macrophage subsets 
with different gene, secreted protein and cell surface protein expression. IFN-γ priming of AMφ 
generated M1-like macrophages that had a pro-inflammatory phenotype; IL-13-priming generated a 
wound healing phenotype that resembles M2 macrophages with the exception of increased surface 
expression of MRC1. 
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Figure 3.13 Effect of cytokine priming on cell surface protein expression of macrophage subset markers AMφ 
at 24 hours.3 x 105 BAL cells were cultured in suspension in a 6-well Corning Costar® Ultra-Low attachment 
culture plate (Sigma-Aldrich) and primed with macrophage complete media control (RPMI-1640 + 10% fetal 
bovine serum + 1.5 mM sodium pyruvate + 0.05 mM β-mercaptoethanol + 1 mM penicillin/streptomycin + 50 
μg/ml geneticin) alone or together with 20 ng/ml IFN-Υ or 10 ng/ml IL-13 for 24 hours. BAL cells were then 
harvested and stained with cluster of differentiation (CD) 11c-APC/Cy7 (2 μg/ml) , Major Histocompatibility 
(MHC)-II (IA/IE)-Pacific Blue (5 μg/ml) and Mannose Receptor C Type 1 (MRC1)-PerCP/Cy5.5 (2 μg/ml)
antibodies. AMΦ were identified as SSChi FSChi CD11c+ and autofluorescent in the FL1 (Green) channel, and 
analysed for changes in surface protein expression in MHC-II and MRC1 by flow cytometry as shown above. 
Difference in cell surface protein expression was evaluated by changes in % Population Positive and Median
Fluorescence Intensity (MFI) of MHC-II (IA/IE) or MRC1 staining in the AMΦ population following cytokine 
priming. Data is represented as mean ± SD; n=3 from three separate studies. A one way ANOVA with Tukey 
post-test was carried out; *: p<0.05, **: p< 0.01, ***: p<0.005, ****: p<0.001. NS, Not significant. % positive 
population expressed as an average of n=3 studies. Dotted lines represent MFI for isotype controls; MFI = 289 
for Pacific BlueTM Rat IgG2b, κ isotype control antibody (isotype control for anti-MHC-II (IA/IE)-Pacific BlueTM) 
and MFI = 155 for Rat IgG2a κ-PerCP/Cy5.5 (isotype control for anti- MRC1-PerCP/Cy5.5). See Appendix 3 for 
histograms of individual repeats. 
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Figure 3.14 Effect of cytokine priming on cell surface protein expression of macrophage subset markers in 
AMφ at 72 hours.3 x 105 BAL cells were cultured in suspension in a 6-well Corning Costar® Ultra-Low 
attachment culture plate (Sigma-Aldrich) and primed with macrophage complete media control (RPMI-1640 
+ 10% fetal bovine serum + 1.5 mM sodium pyruvate + 0.05 mM β-mercaptoethanol + 1 mM
penicillin/streptomycin + 50 μg/ml geneticin) alone or together with 20 ng/ml IFN-Υ or 10 ng/ml IL-13 for 72
hours. BAL cells were then harvested and stained with CD11c-APC/Cy7 (2 μg/ml) , MHC-II (IA/IE)-Pacific Blue
(5 μg/ml) and MRC1-PerCP/Cy5.5 (2 μg/ml) antibodies. AMΦ were identified as SSChi FSChi CD11c+ and
autofluorescent in the FL1 (Green) channel, and analysed for changes in surface protein expression in MHC-
II and MRC1 by flow cytometry by flow cytometry as shown above. Difference in cell surface protein levels
was evaluated by changes in % Population Positive and MFI of MHC-II (IA/IE) or MRC1 staining in the AMΦ
population following cytokine priming. Data is represented as mean ± SD; n=3 from three separate studies.
A one way ANOVA with Tukey post-test was carried out; *: p<0.05, **: p< 0.01, ***: p<0.005, ****: p<0.001. 
NS, Not significant. % positive population expressed as an average of n=3 studies. Dotted lines represent
MFI for isotype controls; MFI = 319 for Pacific BlueTM Rat IgG2b, κ isotype control antibody (isotype control
for anti-MHC-II (IA/IE)-Pacific BlueTM) and MFI = 151 for Rat IgG2a κ-PerCP/Cy5.5 (isotype control for anti-
MRC1-PerCP/Cy5.5). See Appendix 3 for histograms of individual repeats.
Average % positive 
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IFN-Υ: 2.71% 
IL-13: 5.36% 
Average % positive 
Unprimed: 10.0% 
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3.5.2.2 Differentially primed AMφ have distinct responses to LPS stimulation 
Many receptors act synergistically generating cross-talk between different signalling pathways 
within the cell. There have been reports that TLR signalling can act in synergy with cytokine 
receptors, resulting in enhanced pro-inflammatory responses. TLRs on AMφ may have a particularly 
important role, as the respiratory tract in which they are located is not a sterile environment and 
constantly exposed to environmental pathogens and irritants.  Therefore AMφ responses to cytokine 
priming in conjunction with TLR activation may result in the differentiation of functionally distinct 
subsets. 
In the following studies, M1-like and M2-like AMφ were generated as before by priming AMφ with 
IFN-Υ or IL-13; these were then further stimulated with LPS for TLR4 activation.  
3.5.2.2.1 M1 macrophages do not exhibit an exaggerated pro-inflammatory response upon LPS 
stimulation 
In contrast to BMMφ, M1-like AMφ did not appear to have an exaggerated pro-inflammatory 
response upon LPS stimulation. LPS alone did not increase NOS2 mRNA levels, and also failed to 
augment the IFN-Υ induced increase in NOS2 transcripts. LPS alone enhanced TNF-α gene transcript 
levels (p<0.01), but this increase was not amplified in IFN-Υ primed cells (p<0.01). IFN-Υ priming 
significantly enhanced IL-1β protein levels (p<0.01) and also a trend towards increased IL-12 p40 
(total) protein levels, but LPS stimulation failed to amplify the IFN-Υ induced increase in IL-1β and IL-
12 p40 (total) protein levels (Figure 3.15). 
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3.5.2.2.2 LPS stimulation has mixed effects on M2 phenotype 
LPS stimulation had mixed effects on different M2 associated genes. Similar to BMMφ, LPS 
stimulation reduced transcript levels of Arg-1 that had been increased following treatment with IL-
13 by 5-fold in IL-13 induced AMφ (p<0.01). However, there was no effect on either the pro-fibrotic 
mediator IGF-1 or the protein levels of fibronectin (Figure 3.16). 
These results suggest that LPS stimulation of TLR4 appear to influence the AMφ phenotypes 
generated by cytokine priming. These effects however appear to differ to that observed in BMMφ in 
that LPS stimulation had no augmenting effects on M1-associated gene expression, and had mixed 
effects on M2-associated genes, increasing the transcript levels of Arg-1 while having no effects on 
others (IGF-1 and fibronectin). Further experiments using alternate TLR ligands (e.g. Pam2CSK4) will 
have to be carried out to investigate the effects of TLR stimulation on mRNA and protein levels of 
AMφ. 
&ŝŐƵƌĞϯ͘ϭϲdŚĞĞĨĨĞĐƚƐŽĨ>ŝƉŽƉŽůǇƐĂĐĐŚĂƌŝĚĞ;>W^ͿƐƚŝŵƵůĂƚŝŽŶŽŶŵZEĂŶĚƉƌŽƚĞŝŶůĞǀĞůƐŽĨDϮͲĂƐƐŽĐŝĂƚĞĚ
ŵĂƌŬĞƌƐŝŶĚŝĨĨĞƌĞŶƚŝĂůůǇƉƌŝŵĞĚDʔ͘ϭǆϭϬϱDɌǁĞƌĞƐĞĞĚĞĚƉĞƌǁĞůůŽĨϰϴͲǁĞůůĐƵůƚƵƌĞƉůĂƚĞƐ͕ĂŶĚ
ƉƌŝŵĞĚǁŝƚŚŵĞĚŝĂĐŽŶƚƌŽůĂůŽŶĞŽƌƚŽŐĞƚŚĞƌǁŝƚŚϮϬŶŐͬŵů/&EͲɉŽƌϭϬŶŐͬŵů/>ͲϭϯĨŽƌϭϴŚŽƵƌƐ͘WƌŝŵĞĚ
DɌǁĞƌĞƚŚĞŶĨƵƌƚŚĞƌĐƵůƚƵƌĞĚǁŝƚŚŵĞĚŝĂĐŽŶƚƌŽůŽƌϭϬŶŐͬŵů>W^ĨƌŽŵ͘ĐŽůŝϬϭϭϭ͗ϰ͕ϰŚŽƵƌƐĨŽƌŵZE
ůĞǀĞůĂŶĂůǇƐŝƐĂŶĚϮϰŚŽƵƌƐĨŽƌƉƌŽƚĞŝŶůĞǀĞůĂŶĂůǇƐŝƐƌĞƐƉĞĐƚŝǀĞůǇ͘ƌŐͲϭĂŶĚ/'&ͲϭŵZEůĞǀĞůƐǁĞƌĞ
ĚĞƚĞƌŵŝŶĞĚďǇƋZdͲWZ͘WŽŽůĞĚƐĂŵƉůĞƐ;ƉĞƌĐŽŶĚŝƚŝŽŶͿǁĞƌĞƌƵŶŝŶƚƌŝƉůŝĐĂƚĞƐĂŶĚƚŚĞĂǀĞƌĂŐĞǁĂƐ
ƉƌĞƐĞŶƚĞĚĂƐƌĞůĂƚŝǀĞйƚŽƚŚĞŚŽƵƐĞŬĞĞƉŝŶŐŐĞŶĞ,WZdͲϭ͘&ŝďƌŽŶĞĐƚŝŶƉƌŽƚĞŝŶůĞǀĞůƐŝŶƚŚĞĐƵůƚƵƌĞ
ƐƵƉĞƌŶĂƚĂŶƚǁĞƌĞĚĞƚĞƌŵŝŶĞĚďǇD^͘dŚƌĞĞƐĞƉĂƌĂƚĞƐƚƵĚŝĞƐǁĞƌĞĐĂƌƌŝĞĚŽƵƚ;ŶсϯͿĂŶĚĚĂƚĂĂƌĞ
ƌĞƉƌĞƐĞŶƚĞĚĂƐŵĞĂŶц^͘KŶĞǁĂǇEKsǁŝƚŚdƵŬĞǇƉŽƐƚͲƚĞƐƚǁĂƐĐĂƌƌŝĞĚŽƵƚ͖Ύ͗ƉфϬ͘Ϭϱ͕ΎΎ͗ƉфϬ͘Ϭϭ͕
ΎΎΎ͗ƉфϬ͘ϬϬϱ͕ΎΎΎΎ͗ƉфϬ͘ϬϬϭ͘E͕EŽƚĞƚĞĐƚĞĚ͖E^͕EŽƚƐŝŐŶŝĨŝĐĂŶƚ͘^ĞĞƉƉĞŶĚŝǆϰĨŽƌƐƚĂŶĚĂƌĚĐƵƌǀĞƐĨŽƌ
ĨŝďƌŽŶĞĐƚŝŶ>/^͘
Chapter 3 | The heterogeneity of AMφ in vitro  
148 
In conclusion, AMφ displayed heterogeneity in phenotype similar to that observed in BMMφ, and 
can be induced into distinct subsets by external priming signals. IFN-Υ induced M1 macrophages 
have a pro-inflammatory phenotype, whereas IL-13-induced M2 macrophages have a pro-wound 
healing phenotype. Hypoxia and TGF-β, two conditions that have been reported to be prevalent in 
pulmonary fibrosis, are also potent priming signals to drive a wound healing macrophage phenotype. 
LPS stimulation may also alter macrophage phenotype to generate a pro-inflammatory response, 
although this appears to be independent of the IFN-Υ-induced M1-like phenotype as distinctly 
different pro-inflammatory mediators were upregulated. LPS stimulation also altered macrophage 
subset phenotypes induced by different priming signals. In AMφ, LPS stimulation resulted in mixed 
response in subset associated changes in gene and protein levels, and did not bias towards or away 
from a particular subset associated phenotype. This highlights the fact that stimulatory signals 
possess their own gene expression programme, and should not be associated solely with a particular 
macrophage subset.  
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3.6 Discussion 
In this chapter the focus was to investigate the effects of various mediators, hypoxia, and PRR 
stimulation on the phenotypes of BMMφ and/or AMφ ex vivo. In brief the results demonstrated that 
BMMφ and AMφ can be induced by different cytokines to differentiate into distinct phenotypes. TGF-β 
and hypoxic conditions, which are commonly found in the lungs of IPF patients, were also potent signals 
in altering AMφ phenotypes. LPS stimulation can modulate the mRNA and protein levels of BMMφ and 
AMφ that have been primed by various mediators (cytokines, growth factors or hypoxia). In the 
following section, I will first discuss the experimental limitations to these studies and their implications 
to results analyses (section 3.6.1). The implications of the experimental results will then be evaluated 
(sections 3.6.2-3.6.ϯ), future directions will be discussed in section 3.ϳĂŶĚĐŚĂƉƚĞƌĐŽŶĐůƵĚĞĚĂƚƐĞĐƚŝŽŶ
ϯ͘ϴ͘ 
3.6.1 Experimental limitations  
There are several limitations to the above studied here that have been identified and requires to be 
rectified. Preliminary studies (n=1) were carried out for the BMMφ studies, the TGF- β and hypoxia-
induced AMφ studies, and also the protein level analysis of fibrosis-associated mediators in AMφ 
primed with IFN-γ, IL-4, or hypoxia. These studies provide an indication of how BMMφ and/or AMφ 
might behave under these different priming and/or stimulatory conditions, although further repeats will 
have to be carried out to verify these observations.  
Macrophage subset mediators relating to M1- (NOS2) or M2- (Arg-1) were assessed in IFN-γ or IL-4-
induced BMMφ respectively. While these studies were sufficient to indicate whether or not BMMφ 
were responding to the said cytokines, and thereby serve as a positive control for the use of these 
cytokines and priming procedure for later AMφ priming studies, it was unable to fully demonstrate 
whether or not M1 or M2 BMMφ (rather than a hybrid phenotype per se) has been generated. Further 
experiments assessing the mRNA levels for M2- or M1-associated proteins for IFN-γ or IL-4-primed 
BMMφ is therefore required to complete the BMMφ polarisation assessment. 
There were also no controls put in place to verify the efficiency of generating M1- or M2- like BMMφ by 
IFN-γ or IL-4 priming respectively, M1- or M2-like AMφ by IFN- or IL-13 respectively, and pro-fibrotic 
macrophages by TGF-β or hypoxia. The results for changes in mRNA and protein levels in BMMφ and/or 
AMφ may therefore be a net effect of the responders and potential non-responders to such priming 
signals. Further studies involving flow cytometry and/or mass cytometry that assesses the protein levels 
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of M1-(NOS2, MHC-II) or M2-(Arg-1, fibronectin) associated mediators at a cellular level will have to be 
carried out to achieve this. 
Moreover, preliminary experiments (n=1) have been carried out for BMMφ experiments and also TGF-β 
and hypoxia-induced AMφ experiments discussed below (sections 3.ϲ.2); as no repeats were carried out 
the results from these studies should be treated as initial observations rather than conclusive results. 
The repeated experiments (n=3) in IFN-Υ or IL>ͲϭϯƉrimed AMφ (sections 3.ϲ.3) may provide an indication 
of the overall trend in gene transcript and protein levels of various mediators in AMφ subsets, although 
these are more likely than not to be an underestimate, as a result of the lack of control for the efficiency 
for macrophage priming by various mediators. 
Despite the experimental limitations, these studies are able to provide an initial overview of AMφ 
heterogeneity in response to various priming and stimulatory signals, which will be discussed further 
below. Observations from preliminary experiments of mRNA and protein level analyses of TGF-β and 
hypoxia-primed AMφ will first be evaluated, followed by conclusions drawn from the repeated studies 
of IFN-Υ or IL-13 primed AMφ. 
3.6.2 Preliminary experiments 
3.6.2.1 Hypoxia and TGF-β priming promotes a pro-fibrotic response 
Hypoxia and TGF-β are two common conditions found in the fibrotic lung, and previous literature has 
reported that both of these conditions altered the phenotype of MH-S cells260 and promoted a pro-
fibrotic response261. The hypoxic response is predominantly controlled by HIF, a heterodimeric 
transcription factor that in turn is regulated by both oxygen and iron746. The HIF DNA-binding complex is 
comprised of the constitutively expressed HIF-1β subunit, and one of two α- subunit isoforms (HIF-1α or 
HIF-1β)762. Under hypoxic conditions, HIF α-subunits accumulate and translocate to the nucleus where 
they bind HIF-1β, and the heterodimeric HIF complex binds to hypoxia-response elements (HREs) in the 
promoter of target genes. The TGF-β responses are mediated by either the HIF-1α signalling pathway 
that is shared by hypoxia induction, or the mothers against decapentaplegic homolog (Smad) signalling 
pathway763. In the studies presented here it was evaluated whether or not primary AMφ were prone to 
alter their phenotype in response to signalling via hypoxia and TGF-β as well. Several parameters were 
assessed, including the serine protease PAI-1 (Figure 3.4), the macrophage subset-associated mediators 
NOS2 (M1) and Arg-1 (M2) (Figure 3.6), and the pro-fibrotic mediators TGF-β and PDGF-β (Figure 3.5).  
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The findings revealed that both hypoxia and TGF-β priming resulted in enhanced PAI-1 gene transcript 
levels; however hypoxia was the more potent inducer (Figure 3.4). PAI-1 is the primary inhibitor of 
plasminogen activators tissue plasminogen activator (tPA) and urokinase (uPA), which are serine 
proteases that catalyse the activation of plasminogen into plasmin. Plasmin in turn acts to cleave the 
ECM component fibrin. By the increased expression of PAI-1, fibrin is able to accumulate and form the 
fibrin clot that aids the normal wound healing process. On the other hand, PAI-1 may play a role in 
fibrosis upon persistent tissue injury and dysregulated wound healing. PAI-1 is consistently and 
markedly upregulated in pulmonary fibrosis262, and plays a key role in BLM-induced pulmonary 
fibrosis263,264. This fibrosis was more severe in transgenic mice overexpressing PAI-1 gene than WT 
mice264, whereas PAI-1 knockout mice were protected from fibrosis263,264. Several hypotheses have been 
proposed to explain how PAI-1 deficiency protects from fibrosis; it was thought that the lack of PAI-1 
may result in increased plasmin-mediated proteolysis of fibrin, and/or enhanced proteolysis of growth 
factors or MMPs that degrade matrix glycoproteins265.  
The gene transcript levels for two different L-Arginine metabolizing enzymes, namely the M1-associated 
NOS2 and also the M2-associated Arg-1 were elevated in hypoxia-primed AMφ but not TGF-β-primed 
AMφ (Figure 3.6). The transcription of the genes for these two enzymes of divergent roles is reported to 
be catalysed by different HIF α-subunits of the HIF transcription factor. NOS2 is induced by HIF-1α, 
whereas Arg-1 is induced by HIF-2α containing HIF heterodimer764. Interestingly, it was also reported 
that IFN-Υ induced BMMφ (M1) and IL-4 or IL-13 induced BMMφ (M2) increased the transcript levels of 
HIF-1α or HIF-2α respectively764, suggesting that hypoxia priming is synergistic with both macrophage 
subset responses. This allows macrophages to launch an effective and targeted response against 
different types of pathogens/ stimuli at sites of tissue injury where extreme local hypoxia is prominent. 
Further studies will have to be carried out for AMφ isolated from mice challenged with either TH1-or 
TH2-inducing pathogens (e.g. viruses vs. parasites), cultured under hypoxic conditions ex vivo, to 
investigate whether or not hypoxia amplifies NOS2 and Arg-1 mRNA levels respectively as compared to 
normoxic controls (The TH1 or TH2 cytokines, IFN-Υ or IL-13, induced M1 or M2 respectively). In addition, 
the effect of hypoxia on the mRNA and protein levels of other M1- or M2-like mediators on differentially 
primed AMφ can also be analysed. 
The gene transcript levels of the pro-fibrotic mediators TGF-β and PDGF-β were increased in primary 
AMφ induced with TGF-β (Figure 3.5), suggesting a positive feedback loop in the wound healing 
response. In the context of pulmonary fibrosis, the elevation of TGF-β levels within the lung as a result of 
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dysregulated wound healing may therefore further propagate and amplify the fibrotic response by the 
induction of AMφ. TGF-E promotes multiple features associated with fibrosis, including fibroblast 
migration561, proliferation561, myofibroblast differentiation562, EMT131, excessive production of ECM 
components in myofibroblasts563 and AEC apoptosis564. PDGF may contribute to the proliferation of 
fibroblasts and their transformation to ECM-producing myofibroblasts120. 
3.6.2.2 LPS stimulation biases towards M1-like phenotype in hypoxia-primed AMφ 
LPS stimulation altered the transcript level of genes that were increased by hypoxia or TGF-β priming in 
AMφ (Figures 3.7 – 3.9). In hypoxia-primed AMφ, LPS stimulation amplified the increased transcript 
levels of the HIF-1α mediated genes, NOS2 (Figure 3.9) and PAI-1 (Figure 3.7), but suppressed that of 
the HIF-2α mediated gene Arg-1 (Figure 3.9). The synergy between the HIF-1α mediated genes and LPS 
stimulation is consistent with previous reports in the literature, which has demonstrated that NFκB, the 
main transcription factor facilitating TLR responses, mediated increase of HIF-1α mRNA expression765,766. 
However there have been no reported studies investigating the role of the HIF-2α subunit in the HIF-
NFκB pathway746, although in the context of Arg-1 from these studies a modulatory role is expected. 
Indeed, it has been reported that HIF-1α, but not HIF-2α, was responsible for the synergistic induction 
of NOS2 expression and other transcriptional activities in macrophages following exposure to LPS and 
hypoxia767. 
3.6.2.3 LPS stimulation promotes the increase in mRNA levels of pro-wound healing mediators in TGF-β 
primed AMφ 
Along with a pro-inflammatory response as observed before (Figure 3.Ϯ), the results showed that LPS 
stimulation alone in unprimed AMφ increased the transcript levels of several anti-inflammatory or pro-
wound healing mediators, including TGF-β and PDGF-β (Figure 3.8). These results may reflect the 
presence of a negative feedback loop for the regulation of inflammation following LPS stimulation768. In 
TGF-β induced AMφ, LPS stimulation amplified the increased transcript levels of PDGF-β (Figure 3.8). 
Collectively these results suggest that TGF-β biases the LPS stimulatory response towards a wound 
healing phenotype in AMφ.  
It was observed that LPS stimulation did not affect PAI-1 transcript levels in TGF-β induced AMφ (Figure 
3.7) as was the case in hypoxia-induced AMφ. Although TGF-β and hypoxia induction share a common 
downstream HIF-1α pathway that regulates PAI-1 transcription261, other pathways, such as the SMAD 
pathway is also used downstream of TGF-β signalling261. Perhaps PAI-1 transcription in TGF-β induced 
AMφ is more dependent on SMAD as opposed to HIF-1α signalling. It is possible to assess SMAD signalling 
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pathway activation through measuring the change in levels of activated signalling intermediates (e.g. 
phosphorylated SMAD) by western blot or MSD in BLM- versus saline-challenged mice, or by inhibiting 
the signalling intermediates and assessing the change in pathology in BLM-induced pulmonary fibrosis. 
3.6.2.4 IFN-Υ and IL-4 amplified LPS-induced IL-6 and CCL5 expression 
Finally the levels of several other proteins that play a role in pulmonary fibrosis were assessed for AMφ 
that had been primed with various cytokines, in the presence or absence of TLR stimulation (Figure 
3.10). It was proposed that differential cytokine priming and PRR stimulation might also contribute to 
the increased expression of these proteins. CCL2 appeared to be a M1-associated mediator, as its 
protein levels are increased in IFN-Υ induced AMφ (Figure 3.10). LPS stimulation promoted a pro-
inflammatory response, increasing protein levels of various pro-inflammatory cytokines and 
chemokines. Similar to that observed in BMMφ738, AMφ induced with IFN-Υ or IL-4 amplified LPS 
stimulation in terms of IL-6 and CCL5 levels (Figure 3.10). 
3.6.2.5 Hypoxia priming amplified LPS-induced increased expression of pro-inflammatory mediators 
Perhaps the most notable results in these studies is that hypoxia-induced AMφ have highly elevated 
levels of pro-inflammatory chemokines, including CCL2, CCL3, CCL4, CCL5 and CXCL2 following LPS 
stimulation (Figure 3.10). As mentioned above LPS stimulation can promote hypoxic responses through 
the NFκB mediated increase of HIF-1α mRNA expression765,766. Conversely, hypoxia can also amplify pro-
inflammatory responses by stimulating NFκB activation by inhibiting prolyl hydroxylases that negatively 
modulate inhibitor of IKKβ catalytic activities769. These results reinforce the hypothesis that extreme 
local hypoxia may serve as an amplification signal to maximise the immune response at the site of tissue 
injury. 
3.6.3 Repeated experiments on AMφ heterogeneity 
3.6.3.1 AMφ can be induced into distinct subsets following cytokine priming 
Studies exploring the role of lung macrophage subsets in IPF in humans and murine models of 
pulmonary fibrosis have depended on macrophage subset associated markers derived largely from the 
in vitro analysis of BMMφ in mice738 and blood monocyte derived macrophages (BMDM) in 
humans573,770. However, there may be differences in macrophage subset phenotypes between those 
generated in vitro by the stimulation of BMMφ under selected conditions compared to terminally 
differentiated pulmonary macrophages exposed to the environment of the lungs that may behave 
differently. With this in mind experiments were carried out to characterise macrophage subsets derived 
from freshly isolated AMφ by systematically stimulating these cells with various mediators that have 
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been reported to generate functionally distinct BMMφ subsets in vitro. The ability of TLR stimulation to 
modulate AMφ mRNA and protein levels following cytokine priming was also assessed and discussed 
further in section 3.ϲ.ϯ͘ϯ. 
Here it is demonstrated that AMφ, under the same cytokine priming signals as BMMφ, can be induced 
to differentiate into distinct subsets in vitro. AMφ primed by IFN-Υ displayed a M1-like phenotype, and is 
characterised by increased transcript levels of NOS2 (Figure 3.11), and protein levels of IL-1β, IL-12 p40 
(total) (Figure 3.12). Furthermore flow cytometric analysis revealed that the surface phenotype of these 
cells was MHC-IImid/hi MRC1-/lo (Figure 3.13). The increased production of RNS and pro-inflammatory 
mediators would promote microbial killing and the high expression of MHC-II would facilitate efficient 
antigen-presentation, suggesting an antimicrobial response for M1-like AMφ278.  
IL-12 p40 (total) measures free, homodimeric and heterodimeric forms of IL-12 p40, including IL-12 p70 
(p40 + p35) and IL-23 (p40 + p19). Therefore it is unclear from these experiments which specific forms of 
IL-12 p40 are found in IFN-Υ primed AMφ. IFN-Υ has been reported to increase the protein expression of 
both IL-12 p70 and IL-23 in BMMφ. IL-12 p70 was produced in murine BMMφ following IFN-Υ priming 
with or without Mycobacterium bovis Bacillus Calmette-Guérin (BCG) or LPS stimulation, but production 
was attenuated in mutant mice lacking the IFN-Υ receptor771. In Sendai virus stimulated monocyte 
derived macrophages, IFN-Υ priming further amplified the production of IL-12 p40, IL-12 p35 and IL-23 
p19 gene expression 772. Further protein analyses experiments that specifically detect IL-12 p40, IL-12 
p70, and IL-23 will have to be carried out to verify whether or not IFN-Υ induces IL-12 p40, IL-12 p70 
and/or IL-23 production in AMφ.  
The phenotype of AMφ primed by IL-13 is M2-like, with elevated transcripts for Arg-1,IGF-1 E
ĨŝďƌŽŶĞĐƚŝŶ(Figure 3.11), and higher levels of fibronectin protein (Figure 3.ϭϮ). These cells also weakly 
increased the number of AMφ with surface expression of MHC-II proteins (Figure 3.14). These results 
suggest that M2-like AMφ may play a role in wound healing, but in the presence of persistent 
stimulation may drive fibrosis278. Together these results demonstrate that AMφ can adjust their 
phenotype to their environment and polarise into distinct subsets. 
3.6.3.2 There is no increased surface protein levels of MRC1 on M2-like AMφ 
The use of MRC1 as a M2 marker originates from a study in which an increase of both intracellular and 
extracellular MRC1 in mouse peritoneal macrophages was observed following induction by IL-4 or IL-10, 
which are cytokines associated with alternative activation of macrophages307. Surface expression of 
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MRC1 has since been widely used as a marker for M2-like macrophages in flow cytometry analyses in 
various diseases, including adipose tissue macrophages in diabetes773, splenic macrophages in 
experimental autoimmune encephalomyelitis774 and TAMs in breast cancer775. However in this report an 
increase of MRC1 surface expression was not observed on M2-like AMφ generated by IL-13 priming at 
24 and 72 hours (Figures 3.13 and 3.14). Several factors may give rise to this difference. IL-13 has lower 
potency compared to IL-4 in inducing MRC1 expression and activity as reported in mouse peritoneal 
macrophages776. Conversely, there may be different response between peritoneal macrophages and 
AMφ to IL-13 priming such that MRC1 is induced in the former but not the latter. Another possibility is 
that MRC1 protein expression is induced in IL-13 primed AMφ, but remains in an intracellular location. 
Regardless these results propose reconsidering using cell surface MRC1 as a M2-asociated marker and 
particularly for AMφ. On the other hand there was a non-significant trend suggesting decrease in MRC1 
surface expression in IFN-Υ-induced AMφ (Figure 3.13) compared to media control, suggesting that 
these cells are MRC1-. 
Together these results demonstrate that terminally differentiated AMφ are able to adjust their 
phenotypes, in a similar manner to that reported for BMMφ, in response to cytokine priming. Similar to 
BMMφ, IFN-Υ induces a M1-like antimicrobial response in AMφ, whereas IL-13 induces a M2-like wound-
healing phenotype. Several commonly used BMMφ subset associated markers have been shown here to 
also be increased in corresponding AMφ subsets: IFN-Υ primed M1-like AMφ can be described as NOS2hi 
TNFhi IL-1βhi IL-12 p40 (total)hi MHC-IIhi MRC1-, and M2-like AMφ can be characterised as Arg-1hi IGF-1hi 
fibronectinhi MRC1-/lo, for IL-13 generated. These results have validated the use of several BMMφ-
derived macrophage subset markers in characterising AMφ populations with different functional profiles 
and provide a useful guide for future studies of AMφ heterogeneity in other murine pulmonary studies. 
Further gene microarray studies can expand these studies to detect differential expression of MMPs, 
chemokines, and cytokines, between the two different AMφ subsets to better understand their role in 
host defence, inflammation, repair, tissue remodelling and/or fibrosis within the lung. 
3.6.3.3 LPS stimulation alters AMφ phenotype induced by cytokine priming 
LPS stimulation induces a pro-inflammatory response in macrophages, and differential cytokine priming 
can promote or repress these responses. The M1-inducing cytokine IFN-Υ can synergize with or have 
additive effects to LPS stimulation, which may be due to the coexistence of binding sites for their main 
signalling mediators, IRF and NFκB respectively, in proximal promoters of regulated genes777. The M2-
inducing cytokine IL-4 can also synergistically upregulate some pro-inflammatory mediators upon LPS 
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stimulation of BMMφ738. This prompted an investigation as to whether or not LPS stimulation would 
have an effect on the phenotype of AMφ subsets. 
The results showed that LPS stimulation alone increases TNF-α gene transcript levels, but neither IFN-Υ 
nor IL-13-priming elicited any additive effects to LPS stimulation of TNF-α. LPS stimulation also had no 
effect on NOS2 transcript, or IL-1β protein levels (Figure 3.15). On the other hand, IL-12 p40 (total) levels 
were amplified in IFN-Υ induced mice following LPS stimulation (Figure 3.15). IL-12 p40 can form the 
bioactive IL-12 p70 following LPS stimulation of IFN-Υ primed monocytes778–780.  
LPS stimulation may also suppress IL-4/ IL-13 signalling through the inhibition of STAT6 by upregulating 
its inhibitor SOCS1781,782, and also through the PI3K pathway by SOCS3783. In these studies the effect of 
LPS stimulation on the levels of IL-13-induced, M2-associated mediators was evaluated. The results 
presented here revealed that LPS stimulation reduced IL-13-induced increase in Arg-1 gene transcript 
levels, but had no effect on IGF-1 gene transcript levels, or fibronectin protein levels (Figure 3.16). These 
results indicate that an alternative IL-13 signalling pathway independent of STAT6 or PI3K signalling 
responsible for the elevated levels of the pro-fibrotic mediators, IGF-1 and fibronectin, may exist. 
Combined with the results above, it appears that LPS stimulation favours a pro-inflammatory 
phenotype, but does not necessarily suppress a wound healing phenotype.  AMφ display a high degree 
of flexibility and are able to respond to two divergent signals simultaneously by forming hybrid 
phenotypes. This is best illustrated by AMφ primed with IL-13 and then stimulated with LPS, where 
transcript levels of the pro-inflammatory cytokine TNF-α (Figure 3.15), the pro-fibrotic mediator IGF-1 
(Figure 3.16), and protein levels of the ECM component fibronectin (Figure 3.16) were all elevated. Such 
hybrid phenotypes may be more relevant to the disease phenotype observed in fibrotic lungs, where 
levels of both IL-13580 and PRR-stimulating alarmins630–632,651,654 are elevated. 
3.7 Future directions 
As aforementioned in section 3.6.1, there are several experimental limitations to the studies above that 
requires to be amended, including repeats of preliminary experiments, investigation of the gene 
transcript and protein levels of both M1- and M2-associated mediators in IFN-Υ or IL-4-primed BMMφ to 
ascertain that distinct subsets, rather than hybrid macrophages are generated, and flow or mass 
cytometry to evaluate the efficiency of macrophage priming in generating distinct subsets. With respect 
to IL-12 protein level analysis, the IL-12 p40 (total) MSD measured all oligomers containing IL-12 p40, 
including IL-12 p40 monomer, IL-12 p40 homodimer, IL-12 p70 (p40 + p35) and IL-23 (p40 + p19). 
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Further studies measuring the specific oligomeric forms of IL-12p40 will have to be carried out to resolve 
this. 
Future experiments can be carried out to further explore macrophage heterogeneity. These current 
studies reflect only a certain time point following cytokine/ growth factor/ hypoxia priming and LPS 
stimulation. Different genes/ proteins may be released at different time points following AMφ 
activation. For example, acute LPS stimulation induces a M1 associated pro-inflammatory response, but 
chronic LPS stimulation promotes the increased expression of M2-like associated mediators, including IL-
10, TGF-β and Arg-1 in peritoneal macrophages346. Kinetic studies for the aforementioned proteins of 
interest will therefore have to be carried out for AMφ induced by various priming and/or stimulatory 
mediators. The changes in gene transcript or protein levels of these mediators produced by ex vivo 
generated AMφ subsets will then be compared to those that are generated in the BLM-induced model 
of pulmonary fibrosis in vivo. A huge body of work will be involved in assessing a wide range of 
mediators over multiple time points. Therefore, a more efficient screening method in the form of 
microarrays could be used to allow the simultaneous assessment of the transcript levels of a large 
number of pre-selected genes. The quantity and quality of RNA required for microarray analyses is also 
pivotal for its result. As there are small numbers of AMφ that can be isolated per mouse, AMφ pooled 
from different BLM-challenged mice will have to be assessed. Alternatively, mRNA from AMφ can be 
pre-amplified prior to gene transcript analyses using commercially available kits (Life Technologies). 
These microarray analyses will provide a useful reference for future studies of lung macrophage subsets 
in pulmonary diseases. The use of microarrays will be discussed in greater detail in the general 
discussion (section ϲ͘ϰ.1). 
In these studies, LPS was chosen as the stimulatory signal for TLR4 on AMφ as it is able to induce 
pronounced inflammation, which allows a greater window of opportunity to study the changes in 
expression of pro-inflammatory mediators in response to cytokine priming. In addition to microbial 
derived proteins alarmins would also relevant ligands for PRRs. Alarmins may simultaneously activate a 
number of PRRs that produces a different cytokine profile as compared to LPS. For example, HMGB1 
activates both TLR2 and TLR4, and is able to act as a molecular chaperone to the ligands of TLR2, TLR4 
and TLR9. TLR4 and TLR9 ligation induces a predominantly TH1 response, and the latter also promotes 
the production of type 1 IFNs. TLR2 is also able to induce a mixed TH1 and TH2 response. It would 
therefore be interesting to carry out further ex vivo studies to evaluate the effects of various alarmins 
on differentially primed AMφ subsets to better understand macrophage polarization in tissue injury. 
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Pulmonary macrophages exposed in the lung environment are subject to a multitude of signals that may 
alter their gene transcript and protein levels, as observed in the change in the studies above. Since the 
lung environment is ever changing, long-lived pulmonary macrophages would likely have to display 
plasticity and adapt to these alterations in environmental signals. In other words, AMφ that are 
polarised towards a certain direction can be reversed and polarised towards an opposite direction (e.g. 
M1 → M2 or vice versa). In order to test for the plasticity of AMφ, experiments can be carried out to 
reverse AMφ that are polarised either ex vivo (by cytokine priming) or in vivo (in TH1-or TH2 driven 
disease models, e.g. endotoxin-induced lung inflammation or helminth infection respectively). 
3.8 Conclusion 
Collectively, these results demonstrate that terminally differentiated AMφ freshly isolated from the lung 
can alter their mRNA and protein levels in response to various external signals, including cytokines, 
growth factors and hypoxia. There are a high number of signals contributing to the diversity of 
macrophage function, including the synergistic or antagonistic effects of different cytokines and related 
signals on their differential expression. For example, IL-10 promotes IL-4 induced M2 phenotype in 
BMMφ, and increased the gene expression of Arg-1, Retn1α and MRC1784. In addition, LPS stimulation 
can antagonise Arg-1 expression in IL-13 induced AMφ (Figure 3.16) but increase PDGF-β gene 
expression by TGF-β induced AMφ (Figure 3.8). It is highly likely that multiple priming and stimulatory 
signals will exist within the lung environment, such that AMφ phenotype will not be strictly M1-like or 
M2-like in vivo, but will exhibit characteristics of both polarities. Also the response in the lungs will be 
dynamic and therefore AMφ phenotypes have the capacity to alter as pulmonary inflammation and 
fibrosis develop.  This suggests that AMφ participating in various pulmonary diseases should not simply 
be defined as being M1-like or M2-like, but rather characterised as a separate phenotype ex vivo. The 
phenotype of AMφ in BLM-induced pulmonary fibrosis will be explored in the next chapter (chapter 4). 
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Chapter 4 
Alveolar macrophage heterogeneity in Bleomycin-induced pulmonary 
fibrosis 
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Chapter 4| AMφ heterogeneity in BLM-induced pulmonary fibrosis 
4.1 Introduction 
4.1.1 Macrophage subsets in IPF 
In the previous chapter, it was demonstrated that terminally differentiated AMφ were able to respond 
to external conditions and alter their phenotypes to generate distinct macrophage subsets. These 
macrophage subsets potentially could play a role in IPF. 
Macrophage subset-associated markers have been identified in IPF: M1-like pro-inflammatory FRβ-
positive macrophages are present in patients with this disease565,566; M2-associated markers, including 
galactin (Gal)3, CCL18, chitinase 3 like 3 (Chi3l3), CD163, insulin like growth factor (IGF)-1, and platelet 
derived growth factor (PDGF) are also reported to be elevated in AMφ 568–572,575,785,786. In addition, there 
is an increase in the M2-inducing cytokine IL-13 in IPF patients compared to controls, and AMɸ isolated 
from these patients produced more IL-13 than that detected in control lungs580. M2 markers, including 
Arg-1, found in inflammatory zone (FIZZ)1 and MRC1 have also been found to be elevated in murine 
models of pulmonary fibrosis576–579,787.  
Distinct macrophage subsets are reported to play different roles in the pathology of IPF. In a BLM-
induced pulmonary fibrosis mouse model, M2 and/or M2-like macrophages contribute to fibrosis and 
tissue remodelling175. Depletion of lung macrophages using liposomal chrondrate or DTR during the 
progressive fibrotic phase abolished collagen deposition and fibrosis. This was accompanied by a decline 
in M2-associated markers, including Arg-1 or Chi3l3 but not the M1-associated marker NOS2 in the 
lung175. M2 or M2-like macrophages are associated with wound healing and if this process is 
dysregulated, as could occur in IPF, the overexpression of a number of pro-fibrotic mediators may drive 
pulmonary fibrosis (Table 4.1). 
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In contrast M1 macrophages have a less well established role in pulmonary fibrosis. They have a pro-
inflammatory phenotype, and are therefore likely to contribute to acute lung injury in BLM-induced 
pulmonary fibrosis (Table 4.2), although further studies are required to confirm this. However, depletion 
of lung macrophages during the inflammatory phase had no effect on early stage or peak fibrosis175. This 
suggests that either macrophages in the inflammatory phase are not essential, or that inflammation 
itself is non-essential for the development of fibrosis.
Mediator Function 
Arg-1 
Conversion of arginine to orthinine, the precursor of proline required for collagen 
synthesis581,582  
FIZZ1 
Differentiation and survival of myofibroblasts, increase in ECM production in 
fibroblasts577,583  
IGF-1 Fibroblast proliferation and transformation into myofibroblasts120 
PDGF Fibroblast proliferation and transformation into myofibroblasts120 
Fibronectin Major component of the fibrotic clot; scaffold for fibroblast migration520 
Table 4.1 M2-associated proteins and their potential pro-fibrotic functions. Arg-1, Arginase-1; ECM, 
extracellular matrix; FIZZ1, Found in inflammatory one 1, IGF-1, insulin like growth factor-1; PDGF, platelet 
derived growth factor.  
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4.1.2 Multiple oropharyngeal dose of BLM-induced pulmonary fibrosis 
Despite published reports of increased expression of distinct macrophage subset-associated mediators 
at various stages of pulmonary fibrosis, it should be noted that macrophages found in vivo are unlikely 
to fall into separate in vitro defined subsets, but rather form a gradient of phenotypes, for as discussed 
above there will be a variety of diverse signals within the lungs that may influence macrophage gene and 
protein expression.  
In the following studies, a comprehensive analysis of macrophage heterogeneity was carried out in a 
BLM-induced pulmonary fibrosis mouse model using a novel repeated oropharyngeal dosing regimen, 
developed by Dr. Elizabeth Jarman at Novartis Institute of Biomedical Research (NIBR), Horsham. Three 
doses of BLM at lower concentrations (0.13 IU) were applied at 72 hour intervals, rather than a single 
dose at a higher concentration, as commonly described in the literature, via an oropharyngeal route. An 
oropharyngeal delivery route was chosen to mimic direct aggravation of environmental irritants to the 
lung, and multiple doses were applied to mimic the persistent irritation that is thought to give rise to 
pulmonary fibrosis. This model has the advantage over single dose regimens previously used in the 
 Mediator Function 
TNF-α Pro-inflammatory cytokine contributing to tissue injury; potential anti-fibrotic role in 
inhibiting collagen synthesis in myofibroblasts313,367,739 
IL-1β Pro-inflammatory cytokine contributing to tissue injury; also induces the production of 
pro-fibrotic mediators TGF-β1 and PDGF376,567,739 
IL-6 Pro-inflammatory cytokine contributing to tissue injury739 
IL-12 Pro-inflammatory cytokine contributing to tissue injury; facilitates IL-17A dependent 
pulmonary fibrosis124,739 
ROS Tissue injury739 
NO Tissue injury739 
Table 4.2 M1-associated proteins and their potential role in Acute Lung Injury (ALI). IL, Interleukin; NO, 
nitric oxide; PDGF, platelet derived growth factor; ROS, reactive oxygen species; TGF-β, transforming 
growth factor-β; TNF-α, tumour necrosis factor-α.  
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literature where no such repeated irritation was induced175. There is also reduced mortality in mice 
presumably due to better tolerance to lower concentration of BLM applied at each dose.  
Figure 4.1 Diagram illustrating time course of pathogenesis in multiple oropharyngeal dose BLM-induced 
pulmonary fibrosis. Mice were dosed via an oropharyngeal route at 72 hour intervals at days -7, -4 and -1. Mice 
were culled at days 7, 14 and 21 for analysis at the late inflammatory, active fibrotic and established fibrotic 
phases respectively. o.p., oropharyngeal; U, international units. 
BLM-induced pulmonary fibrosis consists of three phases, including inflammation-induced ALI, active 
fibrosis and established fibrosis595,620. For the current model of multiple oropharyngeal dose of BLM 
induced pulmonary fibrosis, ALI occurs within the first week after the last dose of drug delivery, 
characterized by an intense inflammation and oedema with an elevation of cytokines (e.g. TNF-α and IL-
1β). By the second week (approximately day 14), the expression of the pro-fibrotic mediator TGF-β is 
upregulated as well. By the second to third week post-challenge, there is development of patchy 
isolated collagen deposits representative of fibrosis, with conspicuous deposition of ECM components, 
such as fibronectin and collagen (Figure 4.1). In-house data also revealed that BLM-challenged mice had 
a decline in lung function, including total lung capacity (TLC) and tissue elastance as measured by 
Flexivent®, and a decline in oxygen saturation of arterial blood as determined by pulse oximetry (data 
not shown). 
4.1.3 Investigation of the potential role of foamy macrophages in Hermansky Pudlak Syndrome 
(HPS)1 mice 
Foamy macrophages are macrophages that have accumulated cholesterol crystals within their 
lysosomes, either through excessive uptake of modified LDL, or by defective cholesterol efflux. 
Accumulation of cholesterol crystals have been reported to modify macrophage gene and protein 
expression and bias it towards a pro-inflammatory phenotype, potentially via the activation of the 
NLRP3 inflammasome. However, one study has found that oxidised LDL (oxLDL) induced a M2-like 
phenotype in vitro, and the author speculated that whether or not a M1- or M2- profile was induced 
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was dependent on the level of oxidation (or modification of LDL). Increased number and size of 
lysosomes due to the accumulation of cholesterol crystals may also lead to enhanced fragility of 
lysosomes leading to more severe lung abnormalities including lung cell apoptosis that may generate 
persistent irritation that leads to pulmonary fibrosis. Foamy macrophages are found to accumulate in 
IPF patients, and may contribute to pathology through the release of pro-inflammatory and/or pro-
fibrotic mediators. It would therefore be interesting to investigate the role of foamy macrophages in 
pulmonary fibrosis. Foamy macrophages have been reported to accumulate in the lung tissue of BLM-
induced pulmonary fibrosis, and it is possible to enrich for foamy macrophages by FACS sorting of 
macrophages that are larger in size and have greater autofluoresence (as a result of increased 
cholesterol accumulation). However, FACS sorting is technically challenging and may be disruptive to 
cells, and therefore a simpler, less intrusive alternative method was explored. Rather than attempting to 
enrich for foamy macrophages isolated from BLM-challenged mice by FACS sorting ex vivo, it was 
thought that enrichment in vivo, where there is increased intrinsic accumulation of foamy macrophages 
within the lung, in the HPSPF mouse models, can provide a simpler method reveal the phenotype of 
these cells. 
As aforementioned in the general introduction, HPS is a collection of autosomal recessive genetic 
disorders that is characterized by abnormal biogenesis, trafficking and/or function of LROs found in 
specialized secretory cells, such as AECs and/or AMφ690–692. HPS-1, HPS-2 and HPS-4 patients have been 
associated with the development of interstitial pulmonary fibrosis (HPSPF) that resembles IPF in terms 
of disease progression1,693 and its UIP histopathology1. However, HPSPF is characterized by giant lamellar 
body formation in AEC2, resulting in AEC2 swelling702,703. An accumulation of foamy macrophages has 
also been observed in the lungs of HPSPF patients788, and may arise as a result of accumulation of ceroid 
deposition due to lysosomal defects. Defective lysosome related organelle (LRO) trafficking and 
biogenesis have been suggested to promote pulmonary fibrosis in several ways. Increased number and 
size of lysosomes may lead to enhanced fragility of lysosomes leading to more severe lung abnormalities 
including lung cell apoptosis that may generate persistent irritation that leads to pulmonary fibrosis. 
Accumulation of lysosomes may also lead to ligation of cytosolic NLRP3 inflammasome and result in 
AMφ activation and subsequent release of pro-inflammatory mediators. Reduced secretion of lysosome 
contents, such as pulmonary surfactant from AEC2s, may also disrupt normal lung physiology692. 
Pulmonary surfactants are important lubricants that prevent alveolar collapse; indeed mutations in 
surfactant folding and secretion, including surfactants A57 and C12,49,58–62, are responsible for the onset of 
certain subsets of familial pulmonary fibrosis. 
Chapter 4 | AMφ heterogeneity in BLM-induced pulmonary fibrosis 
 
165 
 
Three HPS mouse models have mainly been used to study HPSPF, including HPS1/ ep mice carrying a 
homozygous recessive mutation in the HPS1 gene, HPS2/ pe mice carrying a homozygous recessive 
mutation in the HPS2 gene, and HPS1/HPS2 mice with homozygous recessive mutations in both HPS1 
and HPS2 genes. 
HPS1 and HPS2 mice have been shown to have structural abnormalities in the alveolar compartments 
that are similar to those observed in humans with HPS, including foamy AMφ and enlarged AEC2 
containing irregular dense inclusions789. HPS1 and HPS2 mice also have basal inflammatory dysregulation 
and constitutive AMφ activation that parallels the abnormalities observed in HPS patients695,709. Silica 
challenged HPS1 mice also develop a persistent accumulation of AMφ and increased collagen fibres in 
alveolar tissue790. HPS1 and HPS2 mice have an increased susceptibility to BLM-induced pulmonary 
fibrosis with an increase in collagen deposition and elevated levels of TGF-β and IL-12/23 p40 in the 
lungs and secreted by AMφ as compared to saline controls696. However, unchallenged HPS1 and HPS2 
mice do not spontaneously develop histologically significant pulmonary fibrosis by 1 year of age, but 
instead exhibit progressive airspace enlargement697. It is unclear for the cause for increased 
susceptibility to BLM-induced pulmonary fibrosis in HPS1 and HPS2 mice, although it is speculated to be 
due to defective lyososomal transport in pulmonary cells as is the case for HPSPF patients as mentioned 
above. HPS1 and HPS2 mice do not spontaneously develop pulmonary fibrosis, possibly due to some 
degree of redundancy in gene function between mouse HPS genes, although this remains to be tested. 
HPS1/HPS2 mice carrying double homozygous recessive mutation in both HPS1 and HPS2 have impaired 
lamellar body secretion from AEC2791 and their lung hydroxyproline content is significantly increased 
compared to controls717. These mice spontaneously develop pulmonary fibrosis after 3 months of age, 
patchy and subpleural at first, which then progresses to established fibrosis by the age of 9 months with 
cellular infiltration, collagen accumulation and increased hydroxyproline content within the lung719. 
HPS1/HPS2 mice has been proposed as a model of spontaneous onset pulmonary fibrosis that may be 
used to increase our understanding of mechanisms underlying disease pathogenesis in familial 
interstitial pulmonary fibrosis linked to mutations in surfactant proteins, as well as in IPF.  
The role of foamy AMφ in pulmonary fibrosis is unclear, although it was thought that they may 
contribute to pathology through the release of a number of pro-inflammatory and pro-fibrotic 
mediators. Initially it was planned to use HPS1/HPS2 double homozygous recessive mice as a model of 
HPSPF in which to study foamy AMφ in terms of cholesterol accumulation, and changes in mRNA and 
protein levels of various pro-inflammatory and pro-fibrotic mediators in association with pulmonary 
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fibrosis. Breeding pairs of HPS1 and HPS2 mice backcrossed to a C57BL/6 background were purchased 
from the Jackson laboratory (Maine, USA) and the resulting colonies were maintained at Novartis 
Institute of Biomedical Research (Horsham, UK). These two strains of mice were then bred together in 
an attempt to generate the HPS1/HPS2 double mutant mouse. Several breeding attempts have 
generated a few mice with albino coat colour and hypopigmented eyes matching the phenotype of the 
HPS1/HPS2 double mutant. However, these did not survive infancy (2-3 weeks old).  
As HPS1/HPS2 mice could not be generated after several attempts, an alternative plan to study the 
effects of foamy AMφ on interstitial pulmonary fibrosis was devised. To this end, AMφ isolated from 
BLM-challenged HPS1 mice was to be compared to that from WT controls. As mentioned above, HPS1 
mice do not spontaneously develop histologically significant pulmonary fibrosis697, but have an 
increased susceptibility to BLM-induced pulmonary fibrosis696. This may be caused by the increased 
accumulation of foamy macrophages and/or AEC2 that results from the defective intracellular organelle 
trafficking in pulmonary cells696 as a consequence of the HPS1 mutation. These foam cells may promote 
pulmonary fibrosis through the increased release of pro-inflammatory and/or pro-fibrotic mediators. 
Indeed, foamy macrophages that are constitutively activated are found to accumulate in naïve HPS1 
mice789. The comparison of total AMφ isolated from BLM-challenged HPS1 mice, where there is thought 
to be increased foamy AMφ accumulation, as compared to that from WT controls, where less foamy 
AMφ are present, should therefore provide clues on the phenotype of foamy AMφ.  
4.2 Hypothesis 
The hypothesis to be tested here is that AMφ are able to adapt to the changing lung environment in vivo 
following persistent lung irritation by altering their phenotype and thereby contribute to pulmonary 
fibrosis. The reported accumulation of foamy macrophages in HPS1 mice695, potentially as a result of 
defective lysosomal trafficking, may lead to the observed increased susceptibility to BLM-induced 
pulmonary fibrosis (day 7)696. 
4.3 Aims 
The first part of this chapter aims to assess the phenotype of AMφ isolated from WT C57BL/6 mice at 
various stages of BLM-induced pulmonary fibrosis, including the late inflammatory phase (day 7), the early 
fibrotic phase (day 14) and the established fibrotic phase (day 21). AMφ will be characterised based on 
gene transcript and secreted protein levels of mediators that are associated with inflammation and 
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pulmonary fibrosis and surface protein expression of M1- or M2-like surface proteins. The first part of 
chapter 4 aims to: 
1. Characterise AMφ isolated from BLM-challenged mice or saline controls at days 7, 14 and 21 based 
on their mRNA levels of the M1-associated gene NOS2, or the M2-associated gene Arg1. 
2. Characterise AMφ isolated from BLM-challenged mice or saline controls at days 7, 14 and 21 based 
on their surface protein expression levels of M1-associated markers (MHC-IImid/hi MRC1-) and M2-
associated markers (MHC-II-/lo MRC1-/+). 
3. Characterise AMφ isolated from BLM-challenged mice or saline controls at days 7, 14 and 21 based 
on the protein levels of M1-associated mediators, including IL-1β and IL-12 p40 (total), or M2-
associated mediator, fibronectin, in culture supernatant. The protein levels of other mediators, 
including TNF-α, IL-6, IL-10, CCL2, CCL3, CCL4, CCL5, CCL20, and CXCL1, were also assessed in AMφ 
culture supernatant. 
4. Evaluate the pro-fibrotic role of AMφ isolated from BLM-challenged mice at days 7, 14 and 21, as 
compared to saline controls, in inducing increased Col1α1 mRNA levels in mouse pulmonary 
fibroblasts ex vivo. 
This is the first time macrophage heterogeneity is investigated in a novel repeated oropharyngeal dosing 
regimen of BLM induced pulmonary fibrosis, and the results may provide further information on the 
biology of the macrophages involved in the disease pathophysiology.  
The second part of this chapter aims to compare the phenotype of AMφ isolated from HPS1 mice with 
WT C57BL/6 mice at various stages of BLM-induced pulmonary fibrosis, including the late inflammatory 
phase (day 7), the early fibrotic phase (day 14) and the established fibrotic phase (day 21). HPS1 mice 
are reported to have an increased susceptibility to BLM-induced pulmonary fibrosis that may be caused 
by their intrinsic accumulation of foamy macrophages. Comparison of total AMφ from BLM-challenged 
HPS1 mice, where there is likely to be a higher proportion of foamy AMφ, with WT C57BL/6 controls, 
may provide clues to the phenotype and contributions of these cells to pathology. Comparisons 
between naïve HPS1 mice and WT C57BL/6 controls were first made to identify constitutive differences 
between the two mouse strains, which is followed by the comparison of differences in susceptibility to 
BLM-induced pulmonary fibrosis. More specifically, part 2 of chapter 4 aims to: 
1. Examine and detect for lung inflammation and fibrosis by histology and gene expression analysis in 
naïve HPS1 mice backcrossed to a C57BL/6 background to validate observations from previous 
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reports695,709 and establish whether or not HPS1 mice spontaneously develop pulmonary fibrosis. 
Differential cell count and the number of foamy macrophages in BAL will also be quantified as will 
the basal expression of various pro-inflammatory and pro-fibrotic mediators in HPS1 and WT 
C57BL/6 control mice. 
2. Evaluate the tolerance of HPS1 mice to BLM challenge with respect to percentage weight loss, and
also susceptibility to BLM-induced pulmonary fibrosis by histological analysis of lung inflammation
and fibrosis, and the gene expression profiles of inflammatory and fibrotic mediators within the lung
at days 7, 14 and 21.
3. Investigate the potential contribution of foamy AMφ to increased susceptibility to BLM-induced
pulmonary fibrosis in HPS1 mice will be investigated. The number of foamy AMφ in saline and BLM-
challenged HPS1 and WT C57BL/6 control mice and their protein expression of the pro-inflammatory
mediator IL-12 p40 (total) and the ECM component fibronectin will be determined.
4.4 Methods 
4.4.1 Multiple oropharyngeal dose protocol for BLM-induced pulmonary fibrosis 
BLM-induced pulmonary fibrosis in mice were carried out as described in section 2.2.Ϯ. In brief, WT 
C57BL/6 male mice or male or female HPS1 mice were challenged three times by oropharyngeal 
instillations of 50μl of 0.13U BLM sulfate (Kyowa Nippon, Kayakin Co Ltd.) or saline controls at 72 hour 
intervals on Days -7, -4 and -1. Mice were culled on days 7, 14 and 21 post-challenge, which include time 
points in the ALI phase, early fibrotic phase and the progressive fibrotic stage respectively (Figure 2.1). 
4.4.2 Histology 
Preparation of histological slides and staining procedures for H&E, PSR and CD68 stains are described in 
section 2.2.3. 
4.4.3 AMφ enrichment and culture 
AMφ were isolated from BAL of BLM-challenged mice or saline controls at days 7, 14 and 21 following 
two PBS washes in mice, and enriched by plastic adherence to tissue culture plates, the details of which 
are described in detail in sections 2.2.4, 2.2.5 and 2.2.6. 1 x 105 AMφ that were enriched by plastic 
adherence per well of a 48-well plate were further cultured in macrophage complete media for 4 or 24 
hours for mRNA and protein level analysis respectively.   
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4.4.4 AMφ mRNA and protein level determination 
Total RNA extraction, reverse transcription, and qRT-PCR for gene expression anal ysis were carried out 
as described at sections 2.2.11, 2.2.12 and 2.2.13 respectively. Measurements of proteins of interest in 
culture supernatant was measured as mentioned in sections 2.2.14 (fibronectin enzyme linked 
immunosorbent assay (ELISA) and 2.2.15 [Meso-Scale Discovery (MSD)]. 
4.4.3 Flow cytometry 
3 x 105 cells/ml of BAL cells were separated into 3 tubes (i.e. 1 x 105 cells/tube), one for positive staining 
for surface proteins of interest (CD11c, MHC-II and MRC1), one for unstained negative control, and one 
for isotype control of nonspecific antibody binding. For each tube, cells were resuspended at 1x105 cells 
per 100 Pl Fluorescence Activated Cell Sorting (FACS) analysis buffer (DPBS + 0.1% FCS), 1% of Fc Receptor 
(FcR) block (Miltenyi Biotech) and 5% mouse serum per 100Pl reaction. FcR block was added to prevent 
non-specific binding of the Fc (constant) region of detection antibodies/ isotype controls to cell surface 
FcR that may generate a false positive signal. Mouse serum was added to prevent non-specific binding of 
the variable region of detection antibodies/ isotype controls.  
For the tube stained for proteins of interest, cells were incubated with FACS analysis buffer, 0.25 μg/100 
μl CD11c-APC, 0.25 μg/100 μl MHC-II-FITC and 0.5 μg/100 μl MRC1-PerCP/Cy5.5 for 30 minutes in the dark 
at 4oC. For the isotype control tube, cells were incubated with 0.25 μg/100 μl Armenian hamster IgG-APC, 
0.25 μg/100 μl Rat IgG2b-FITC and 0.5 μg/100 μl Rat IgG2a-PerCP/Cy5.5 for 30 minutes in the dark at 4oC. 
For unstained negative control, cells were incubated in FACS analysis buffer only for 30 minutes in the 
dark at 4oC. 
BAL cells were then washed in 2 ml DPBS and centrifuged at 500 g for 10 minutes at 4oC. The supernatant 
was then discarded and BAL cells were fixed and permeabilised with 300 μl BD Cytofix/CytopermTM (BD 
Biosciences) for 20 minutes in the dark at 4oC. BAL cells were then washed with 2 ml BD Perm/WashTM 
(BD Biosciences). Cells were then resuspended in 500 μl 1 x Cell Fix (BD Biosciences) (diluted 1:10 from 
10x stock solution), and kept in the dark at 4oC until further analysis. 
Anti-Rat/ anti-Hamster IgK compensation kit (BD Biosciences) was used on the day of flow cytometric 
analysis to compensate for fluorophore spectral overlap in multi-colour staining. The set consists of two 
populations of microparticles, including the BD CompBeads Anti-Rat/Hamster Ig, κ particles (positive 
control), which bind any rat or hamster κ light chain-bearing immunoglobulin, and the BD CompBeads 
Negative Control (FBS) Particles (negative control), which has no binding capacity. When mixed together 
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with a flurochrome-conjugated rat or hamster antibody, the BD-CompBeads provide distinct positive 
and negative (background fluorescence)-stained populations that can be used to set compensation 
levels manually. Anti-Rat/ anti-Hamster IgK compensation kit (BD Biosciences) was prepared according 
to manufacturer’s instructions. In brief, 60 μl of BD CompBeads Anti-Rat/Hamster Ig, κ particles and 60 
μl of BD CompBeads Negative Control (FBS) particles were added to 100 μl FACS buffer (+0.1 % FBS), and 
20 μl of pre-diluted antibody stock (where final concentration in 220 μl is equivalent to that used in 
experiments) was subsequently added. This process was carried out separately for every different type 
of fluorophore that was used in multicolour experiments. The BD CompBeads Anti-Rat/Hamster Ig, κ 
particles/ BD CompBeads Negative Control (FBS) particles/ antibody mixture was then incubated in the 
dark at 4oC for 30 minutes. The mixture was then washed with 2 ml FACS buffer and centrifuged at 500 g 
for 10 minutes. The supernatant containing unbound antibodies was discarded, and the pellet 
containing Compbeads was resuspended in 500 μl FACS buffer.  
FACS data was read by FACS CANTO II (BD Biosciences). Prior to recording data for samples, 
compensation for spectral overlap was determined from the pre-stained BD CompBeads Anti-
Rat/Hamster Ig, κ particles/ BD CompBeads Negative Control (FBS) particles using the compensation 
setup on the FACS CANTO II software (BD Biosciences). FACS data was analyzed by Flowjo (Tree Star Inc). 
AMφ were defined as SSChi FSChi CD11c+, and the expression of the protein of interest was gated with 
respect to their respective isotype controls. Data was presented as median fluorescence intensity (MFI) 
and % positive with respect to isotype controls. 
4.4.4 Statistical analyses 
All statistical analysis was carried out using GraphPad Prism 6.0 software (GraphPad 
software, CA, USA). Normal distribution was evaluated by visual inspection of data due to insufficient 
numbers for normality tests. 
For the studies evaluating AMφ phenotype in C57BL/6 mice only, two-way ANOVA was used to compare 
time-course curves followed by Sidak’s multiple comparison test to determine the significance. P values 
of less than 0.05 were deemed statistically significant with *** p < 0.001, ** p <0.01 and * p < 0.05. 
Error bars represent standard deviation (SD) as indicated in the figure legends. 
For the studies comparing HPS1 mice with WT C57BL/6 mice, when comparing two groups unpaired 
two-tailed t-tests (followed by Welch’s correction test for non-equal standard deviations) and Mann-
Whitney tests were used for parametric and non-parametric datasets, respectively.  
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4.5 Results 
4.5.1 AMφ heterogeneity in BLM-induced pulmonary fibrosis in WT C57BL/6 mice 
4.5.1.1 Histological analysis of BLM-induced pulmonary fibrosis in C57BL/6 mice 
Haematoxylin and eosin (H&E) were used to evaluate the cellular influx into the lungs following 
challenge with BLM. Picrosirius Red (PSR) staining which detects collagen deposition was employed 
as an indicator of fibrotic pathology and tissue remodelling. Intracellular staining with CD68 was 
carried out to measure the influx of macrophages into the lung following exposure to BLM in order 
to validate their presence during fibrosis.  
4.5.1.1.1 H&E staining 
H&E staining showed that there was a cellular influx within the lung post-BLM challenge, with cells 
accumulating from day 7 during the late inflammatory phase, and the cellular infiltration was 
sustained through the early and late fibrotic phase at days 14 and 21. The loss of alveolar 
architecture in the interstitium of the BLM-challenged lung can also be observed (Figure 4.2). There 
was a loss of the regular mesh like alveoli structure and the infiltration of a large number of cells. It 
was also noted that there is spatial heterogeneity in cellular infiltration across the entire lung slice 
used for histology (data not shown), in which areas of normal tissue were often found adjacent to 
affected tissue. This may reflect the nature of BLM-induced injury, in which only regions within the 
lung that comes into direct contact with BLM is affected. 
4.5.1.1.2 PSR staining 
PSR staining revealed an increase in collagen deposition in BLM-challenged lungs. Collagen 
deposition was observed from day 7 post challenge, and was greatest at around day 14 and 
sustained until at least day 21 occurring within the interstitium and around the small airways (Figure 
4.3). 
4.5.1.1.3 CD68+ Staining for Macrophages 
CD68 is an intracellular glycoprotein that binds low density lipoproteins, which are found exclusively 
in monocytes and macrophages792. CD68 staining indicated that there was an influx of macrophages 
within the lungs in BLM-challenged mice (Figure 4.4). Positive pixel count of CD68+ cells showed that 
macrophage numbers were increased from day 7 by around 15-fold (p<0.001), and remained 
elevated by 15-fold at day 14 (p<0.005), and 10-fold to until at least day 21 (p<0.05) (Figure 4.5). 
There is great variation in CD68+ cell number at day 21 of BLM-challenged mice (Figure 4.5), 
suggesting that these cells are not essential at the established fibrotic phase. 
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Together these results demonstrate that BLM induces pulmonary fibrosis in mice characterised by 
the deposition of collagen within the lung. This was accompanied by a cellular influx from at least 
the late inflammatory phase (day 7) until the late fibrotic phase (day 21) and CD68+ macrophages 
constitute a component of the infiltrate.  
Figure 4.2 Haematoxylin and Eosin (H&E) staining of lung from either saline or bleomycin (BLM)-
challenged C57BL/6 mice. 8-10 week old male mice were challenged via an oropharyngeal route 
three times at 72 hour intervals with either saline, or 0.13 International Units (IU) BLM, and were 
harvested at days 7, 14 and 21 after the last dose. Paraffin-embedded sections of the left lung were 
stained for cellular influx using the H&E stain; n=5 for saline or n=4 for BLM-challenged mice from a 
single representative study. 
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Figure 4.3 Picrosirius Red (PSR) staining of lung from either saline or BLM-challenged C57BL/6 mice. 
8-10 week old male mice were challenged three times via an oropharyngeal route at 72 hour
intervals with either saline, or 0.13 IU BLM, and were harvested at days 7, 14 and 21 after the last
dose. Paraffin-embedded sections of the left lung were stained for collagen using PSR stain; n=5 for
saline or n=4 for BLM-challenged mice from a single representative study.
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Figure 4.4 CD68+ staining of lung from either saline or BLM-challenged C57BL/6 mice. 8-10 week old 
male mice were challenged via an oropharyngeal route three times at 72 hour intervals with either 
saline, or 0.13 IU BLM, and were harvested at days 7, 14 and 21 after the last dose. Paraffin-
embedded sections of the left lung were stained for CD68+ cells; n=5 for saline or n=4 for BLM-
challenged mice from a single representative study from a single representative study. 
Figure 4.5 Positive Pixel Count of CD68+ cells in lung of either saline or BLM-challenged C57BL/6 mice. 
8-10 week old male mice were challenged three times via an oropharyngeal route at 72 hour intervals
with either saline, or 0.13 IU BLM, and were harvested at days 7, 14 and 21 after the last dose. n=5 for 
saline or n=4 for BLM-challenged mice from a single representative study. Two way ANOVA with Tukey 
post-test was carried out for days 7 and 14 and data was represented as mean ± SD; for day 21, data
appeared non-parametric and non-parametric student t-test was carried out for saline vs. BLM foam
cell count; data was represented as mean ± interquartile range. *: p<0.05, ***: p<0.005, ****:
p<0.001. BLM, Bleomycin.
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4.5.1.2 BAL differential cell count 
In order to analyse cellular composition within the alveolar space during BLM-induced pulmonary 
fibrosis, differential cell counts were carried out on BAL. The results revealed an influx of 
macrophages in the alveolar space, with numbers increasing by about 8-fold (p<0.005) at day 7, and 
they remained elevated (~ 3-fold) at day 14 (p<0.01) and day 21 (~3-fold; p<0.05). Granulocyte levels 
in BAL were not significantly increased from day 7 onwards, indicating that this time point may 
represent the end of the inflammatory phase or a shift in the cellular components of the 
inflammatory response. There is also some lymphocytic influx at day 7 (p<0.005), but this had mostly 
subsided by day 14 (Figure 4.6). 
4.5.1.3 BAL foam cell count 
Foam cells are lipid-laden cells generated through the excessive phagocytosis of cholesterol via its 
carrier modified Low Density Lipoprotein (LDL), or the defective efflux of cholesterol. Foamy 
macrophages generated in vitro793 or isolated in vivo from atherosclerosis patients794 have been 
reported to have a pro-inflammatory phenotype, although one in vitro study reported a pro-fibrotic 
phenotype714.  
Foamy macrophages have been found to accumulate in BALF of IPF patients715 and HPS patients with 
interstitial pulmonary fibrosis709. The cause of the formation of the foam cells is unknown in these 
patients, although a candidate for this is defective cholesterol efflux of macrophages. 
Apolipoprotein-AI (Apo-AI) is a major component of high density lipoprotein (HDL) that facilitates 
cholesterol efflux from cells. In one report, Apo-AI is reported to be downregulated in BALF of IPF 
patients, and this is inversely correlated with the number of foamy macrophages. Treatment of BLM-
challenged mice with dosage of Apo-AI via an intranasal route reduced collagen deposition and 
inflammatory cell accumulation715. Foamy macrophages may play a role in pulmonary fibrosis 
through promoting tissue injury and/or fibrosis.  
Oil Red O (ORO) is a lysochrome (fat-soluble) diazo dye that stains for neutral triglycerides and lipids, 
and can be used to stain for cholesterol crystals that are characteristic of foam cells. Application of 
Oil Red O (ORO) lipid staining showed that there is an accumulation of lipid-laden foam cells, with an 
increase from below 2% of cells in BALF in the saline controls to an average of around 8% at day 7 
(p<0.005), 8% at day 14 (p<0.01) and a non-significant trend suggesting an increase of 4.4% at day 21 
(Figures 4.7 & 4.8). 
Collectively these results demonstrate that there is an accumulation of AMφ, including foamy 
macrophages, during BLM-induced pulmonary fibrosis, which may suggest a role for these cells in 
lung pathology that leads to fibrosis.
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Figure 4.8 Foam cell count in BAL of saline or BLM-challenged C57BL/6 mice. 8-10 week old male mice were 
 challenged via an oropharyngeal route three times at 72 hour intervals with either saline, or 0.13 IU BLM, 
and were culled at days 7, 14 and 21 after the last dose. BAL was collected by 2 x 0.5 ml DPBS washes of the 
lung; 100 μl aliquot was prepared for foam cell count by cytospin followed by ORO stain. Differential cell 
count was carried out by counting at least 300 stained cells across 3 different fields. Results are from 2 
studies, n=6 for saline or n=6 for BLM-challenged mice from a single representative study. Two way ANOVA 
 with Sidak post-test was carried out; ****: p<0.001. BLM, Bleomycin; NS, Not Significant. 
4.5.1.4 'ĞŶĞĂŶĚƉŚĞŶŽƚǇƉŝĐĐŚĂŶŐĞƐŝŶDʔĨŽůůŽǁŝŶŐ>DĐŚĂůůĞŶŐĞ
It was previously shown that AMφ isolated from naïve mice can be induced by selective conditions of 
cytokine priming into distinct subsets in vitro (section 3.ϱ͘ϭ͘ϯ), indicating that these terminally 
differentiated tissue macrophages display plasticity and are able to respond to their immediate 
environment by altering their phenotype. 
In the current chapter, it is validated that BLM induces pulmonary fibrosis in mice;ƐĞĐƚŝŽŶϰ͘ϱ͘ϭ͘ϭͿ, and 
AMφ were observed to accumulate in the lung (section 4.ϱ.ϭ͘Ϯ). The next set of experiments were 
designed to investigate whether or not these AMφ from a disease model altered their phenotype to 
adapt to the change in pulmonary environment. It has been proposed that M1 macrophages play a 
more important role in inflammation-induced tissue injury, whereas M2 or M2-like macrophages have 
a greater role in active fibrosis278. In the following studies, AMφ were isolated from saline or BLM-
challenged mice at various time points and analysed ex vivo for their gene, protein and surface protein 
expression of several key macrophage subset-associated markers.  
The mRNA levels of the M2-associated mediator Arg-1 was increased in BLM-challenged mice. Arg-1 
mRNA levels was significantly elevated from day 7 (51.3-fold; p<0.005); this trend appeared to 
sustain until at least day 21, although this was non-significant from day 14 (Figure 4.9). The mRNA 
levels of the M1-associated marker NOS2 was marginally enhanced at day 7 but this increase was 
not significant and was undetectable from day 14 onwards (Figure 4.9). A trend suggesting reduction 
of the gene transcript levels ŽĨƚŚĞd'&ͲɴͬŚǇƉŽǆŝĂͲĂƐƐŽĐŝĂƚĞĚPAI-1 was observed in AMφ isolated
from BLM challenged mice as compared to saline controls (Figure 4.10). 
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dŚĞƐĞƌĞƐƵůƚƐǁĞƌĞƐƵƌƉƌŝƐŝŶŐĂƐŝŶĐƌĞĂƐĞĚW/ͲϭůĞǀĞůƐŝŶAMφ have been associated with TGF-β or
hypoxia induction in the previous chapter (section 3.ϱ͘ϭ.3.1), two signals that have been reported to 
be prominent in the fibrotic environment118,261. Perhaps a negative feedback loop exists in which 
PAI-1 in AMφ is downregulated followed prolonged induction.  
Figure 4.10 mRNA level analysis of PAI-1 in AMφ isolated from C57BL/6 mice at various stages of BLM-
induced pulmonary fibrosis. 8-10 week old male mice were challenged via an oropharyngeal route three 
times at 72 hour intervals with either saline, or 0.13 IU BLM, and were culled at days 7, 14 and 21 after the 
last dose. 1x105 AMφ were seeded per well of 48-well culture plates for 90 minutes, and plastic adherence 
enriched AMφ were then analysed for change in mRNA levels of macrophage subset associated genes. The 
mRNA levels of PAI-1 were determined by qRT-PCR. Each sample was run in triplicates in qRT-PCR and the 
average was used to calculate the mean of sample repeats. Data is represented as mean ± SD; n=3 from 
three separate studies. Two way ANOVA with Sidak post-test was carried out. BLM, Bleomycin; ND, Not 
Detected; NS, Not significant. 
Figure 4.9 mRNA level analysis of macrophage subset-associated markers in AMφ isolated from C57BL/6 
mice at various stages of BLM-induced pulmonary fibrosis. 8-10 week old male mice were challenged via an 
oropharyngeal route three times at 72 hour intervals with either saline, or 0.13 IU BLM, and were culled at 
days 7, 14 and 21 after the last dose. 1x105 AMφ were seeded per well of 48-well culture plates for 90 
minutes, and plastic adherence enriched AMφ were then analysed for change in mRNA levels of 
macrophage subset associated genes. The mRNA levels of NOS2 and Arg-1 were determined by qRT-PCR. 
Each sample was run in triplicates in qRT-PCR and the average was used to calculate the mean of sample 
repeats. Data is represented as mean ± SD; n=5 (day 7), n=3 (days 14 and 21) for saline or n=7 (NOS2), n=9 
(Arg-1) (day 7), n=7 (day 14), n=7 (day 21) for BLM-challenged mice from three separate studies. Two way 
ANOVA with Sidak post-test was carried out; ***: p<0.005. BLM, Bleomycin; ND, Not Detected; NS, Not 
significant. 
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No increase in the levels of the M1-associated protein IL-1β was detectable in BLM-challenged mice 
beyond the late inflammatory phase at day 7 as compared to saline controls. On the other hand, the 
expression of another M1-associated protein IL-12 p40 (total), including free IL-12 p40, IL-12 p40 
homodimers, or IL-12 p40 heterodimers (IL-12 p70 or IL-23) was elevated from day 7 onwards, from 
below 200 pg/ml in saline controls to ~ 600 pg/ml on day 7, ~800 pg/ml on day 14 and persists to 
~1000 pg/ml at day 21 in BLM-challenged mice (p<0.01). However, the bioactive IL-12 p70 was 
undetectable (data not shown), indicating that IL-12 p40 (or IL-23), rather than IL-12 p70 participates 
in pulmonary fibrosis. Fibronectin, which is associated with a M2-phenotype, was increased by 6-fold 
during BLM-induced pulmonary fibrosis, from day 7 (p<0.01) through day 14 (p<0.005) to day 21 
(p<0.01) (Figure 4.11).
Figure 4.11 Protein level analysis of macrophage-associated markers in AMφ isolated from C57BL/6 mice at 
various stages of BLM-induced pulmonary fibrosis. 8-10 week old male mice were challenged via an 
oropharyngeal route three times at 72 hour intervals with either saline, or 0.13 IU BLM, and were culled at 
days 7, 14 and 21 after the last dose. 1x105 AMφ were seeded per well of 48-well culture plates for 90 
minutes, and plastic adherence enriched AMφ were then further cultured for 24 hours in fresh media. 
Isolated AMφ were then analysed for change in levels of macrophage subset associated proteins. The 
protein levels of IL-1β and IL-12 p40 (total), and fibronectin, were determined by ELISA and MSD 
respectively. Each sample was run in duplicates in MSD/ELISA and the average was used to calculate the 
mean of sample repeats. Data is represented as mean ± SD; IL-1β (saline): n=6 (day 7), n=7 (days 14 and 21), 
IL-1β (BLM): n=9 (days 7, 14 and 21); IL-12 p40 (total) (saline): n=6 (day 7), n=7 (days 14 and 21), IL-12 p40 
(total) (BLM): n=8 (days 7 and 14), n=7 (day 21), fibronectin (saline): n=3 (days 7 and 21), n=5 (day 14), 
fibronectin (BLM): n=4 (day 7), n=6 (days 14 and 21) from two separate studies. Two way ANOVA with Sidak 
post-test was carried out; **: p< 0.01, ***: p<0.005, ****: p<0.001. BD, Below Detection; BLM, Bleomycin; 
NS, Not significant. IL-12 p40 (total) incudes free IL-12 p40, IL-12 p40 homodimers and IL-12 p40 
heterodimers (IL-12 p70 and IL-23). Standard curves for ELISA/MSD of these proteins of interest can be 
found in Appendix 4. 
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These results also demonstrate that AMφ are capable of altering their phenotype to adapt to the 
immediate environment in BLM challenged mice, and have different gene and protein expression at 
different stages of pulmonary fibrosis. The AMφ phenotypes do not necessarily fall within a 
predefined subset that has been characterised in vitro, but rather express a mixture of M1- and M2-
associated mediators when analysed ex vivo. These results suggested that there was either the 
presence of two independent macrophage subset populations, or a hybrid population expressing 
mediators of both subsets. 
At the late inflammatory phase (day 7), AMφ displayed a trend suggesting increase of the M1-
associated markers, including NOS2 (Figure 4.9) and IL-1β (Figure 4.11). It was also observed that 
AMφ had a significant increase in another M1-associated mediator IL-12 p40 (total) (Figure 4.11), 
and also the M2-associated products Arg-1 (Figure 4.9) and fibronectin (Figure 4.11). Flow cytometry 
analysis of M1- or M2-associated surface protein expression has revealed two separate populations, 
including a MHC-IIhi MRC1- and a MHC-II-/lo MRC1- population (Figures 4.12 and 4.13) that may 
contribute to the mixture of M1- and M2-associated phenotypes. 
The M1-associated mediator IL-12 p40 (total), and also the M2-associated mediator fibronectin both 
persist throughout the early and established fibrotic phases (days 14 and 21) (Figure 4.11); analysis 
of the changes in mRNA levels of the M2-associated mediator Arg-1 also revealed a trend suggesting 
its increase in the fibrotic phases (Figure 4.9). However, flow cytometric analysis of M1- or M2-
associated surface protein levels has revealed one predominant population, MHC-II-/lo MRC1-/lo
(Figures 4.12 and 4.13), suggesting that a hybrid macrophage population may participate in active 
fibrosis. These results may reflect the presence of a complex variety of signals within the lung 
environment that may influence AMφ phenotype during pulmonary fibrosis, such that they cannot 
be neatly classified into pre-defined subsets that have been characterised in vitro. 
4.5.1.5 Other phenotypic changes in AMφ isolated from BLM-challenged mice  
Having identified that there is a shift in AMφ phenotype from M1-like to M2-like from the late 
inflammatory phase to the fibrotic phases, the next set of experiments were designed to investigate 
whether or not this phenotypic reprogramming was associated with changes in other macrophage 
derived proteins that have been reported to play a role in pulmonary fibrosis. AMφ were isolated 
from saline or BLM-challenged mice at days 7, 14 and 21, cultured in media ex vivo for 24 hours, and 
the culture supernatant was measured for protein levels of pulmonary fibrosis-associated mediators, 
including IL-6408,436, CCL2 (MCP-1)438,752–755, CCL3 (MIP-1α)435–437,439, CCL4 (MIP-1β)435,436, CCL5 
(RANTES)461, CXCL2 (MIP-2)381,756, CCL20 (MIP-3α), and mMMP-913,106,108,112,692,755,795–797. Surprisingly, 
CCL3, CCL4, CCL20 and mMMP-9 levels were all below detectable level in both saline and BLM 
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challenged mice. There was a small increase in CCL5 in AMφ BLM challenged mice at day7, but this 
change in expression disappeared by day 14. There was also a trend indicating an elevation in IL-6 
levels and CCL2 that mirrored that of CCL5, but significance was not reached possibly as the increase 
in production was limited. No enhancement was observed for CXCL2 (Figure 4.14). This lack of 
significance in the increase in pro-inflammatory mediators associated with IPF may reflect the 
decline of inflammation by the late inflammatory phase when expression was first measured. 
Alternatively BLM-induced pulmonary fibrosis may have different characteristics to IPF.as compared 
to saline controls. 
Figure 4.14. Protein level analysis of pro-inflammatory mediators in AMφ isolated from C57BL/6 mice at 
various stages of BLM-induced pulmonary fibrosis. 8-10 week old male mice were challenged via an 
oropharyngeal route three times at 72 hour intervals with either saline, or 0.13 IU bleomycin, and were 
culled at days 7, 14 and 21 after the last dose. 1x105 AMφ were seeded per well of 48-well culture plates 
for 90 minutes, and plastic adherence enriched AMφ were then further cultured for 24 hours in fresh 
media. Isolated AMφ were then analysed for changes in levels of pro-inflammatory proteins. The protein 
levels of IL-6, CCL2, CCL5 and CXCL2 were determined by MSD. Each sample was run in duplicates in MSD/
ELISA and the average was used to calculate the mean of sample repeats. Data is represented as mean ± 
SD; n=6 (saline), n=7 (BLM) from two separate studies. Two way ANOVA with Sidak post-test was carried 
out; *: p<0.05, **: p< 0.01, ***: p<0.005, ****: p<0.001. BD, Below Detection; BLM, Bleomycin; NS, Not 
significant. Standard curves for ELISA/MSD of these proteins of interest can be found in Appendix 6. 
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In conclusion, the results reported here demonstrate that this novel multi-dose oropharyngeal 
challenge of BLM induces pulmonary fibrosis in mice, as observed by excessive collagen deposition 
and influx of inflammatory cells. There is an accumulation of CD68+ lung macrophages, which 
included a population of foamy AMφ present in the BAL. An influx of lymphocytes was also observed 
in BAL. The macrophage infiltrate may contribute to pulmonary fibrosis by differentiating into 
distinct functional phenotypes. M1-like macrophages accumulate during the late inflammatory 
phase (day 7), and may be a key pathogenic component of the acute response that causes lung 
injury. However their numbers subside by the early fibrotic phase (day 14), and are accompanied by 
reduced biosynthesis of pro-inflammatory mediators. A M1/M2-like hybrid phenotype was identified 
from the late inflammatory phase (day 7) until at least the established fibrotic phase (day 21).  This 
may be an active cellular component that drives fibrosis through the direct release of the ECM 
component fibronectin and potentially other pro-fibrotic mediators, and also macrophage 
recruitment through the release of IL-12 p40 (total).   
4.5.1.6 Co-culture of Mouse Pulmonary Fibroblasts (MPF) with supernatant from AMφ isolated from 
saline or BLM-challenged mice 
In the above studies it was observed that the phenotype of AMφ was influenced by its surroundings 
following BLM challenge, and resulted in the increased expression of many pro-inflammatory or pro-
fibrotic mediators. These mediators may influence the phenotype of other cells downstream to 
further facilitate fibrosis. In the following preliminary studies, the influence of AMφ activation on the 
phenotype of MPFs, one of the major contributors to ECM deposition in pulmonary fibrosis, was 
investigated. Supernatants were collected from AMφ isolated from BLM-challenged mice or saline 
controls, and then co-cultured with MPF. The change in MPF gene expression of collagen 1 α 1 
(Col1α1), a major ECM component found in lung fibrosis was then analysed.  
The results indicate that the co-culture of supernatants from AMφ from BLM-challenged mice, but 
not saline controls, promoted Col1α1 gene expression in MPF in the late inflammatory phase (day 7) 
to early fibrotic phase (day 14). However the increase in expression of Col1α1 that was observed 
early on in the response returned to basal levels by the late fibrotic phase (day 21) (Figure 4.15). 
These results suggest that in addition to directly increasing the expression of the ECM component 
fibronectin, AMφ may also promote fibrosis indirectly by activating pulmonary fibroblasts through 
the release of various pro-fibrotic mediators. Further studies will have to be carried out to confirm 
the identity of these mediators. 
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Figure 4.15 Secreted proteins produced by AMΦ isolated from BLM-challenged C57BL/6 mice promote a pro-fibrotic 
response in mouse pulmonary fibroblasts (MPF). 8-10 week old male mice were challenged via an oropharyngeal route, 
with either saline or 0.13 U BLM, for 3 times at 72 hour intervals. Mice were culled at 7, 14 and 21 days after the last 
dose. 1x105 AMΦ were seeded per well of 48-well culture plates for 90 minutes, and then further cultured in fresh 
media for 24 hours; AMΦ culture supernatant was collected and then co-cultured with 1x105 MPF per well of a 48-well 
plate from naïve mice for 24 hours. MPF were then harvested and analysed for Col1α1 mRNA levels. Secreted protein by 
AMΦ isolated from BLM-challenged mice promotes a pro-fibrotic response, as indicated by the increase in Col1α1 mRNA 
levels in MPF co-cultured with AMΦ supernatant from BLM-challenged mice as compared to saline controls. Data are 
represented as mean ± SD; n=3 from two separate studies. Two way ANOVA with Sidak post-test was carried out; ***: 
p<0.005, ****: p<0.001. NS: Not Significant. 
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4.5.2 Comparison between HPS1 mice and WT C57BL/6 mice 
Foamy macrophages were reported to accumulate in IPF and HPSPF patients, and this was also 
observed in my own studies of BLM-induced pulmonary fibrosis. Foamy macrophages arise from 
increased modified LDL uptake by scavenger receptors on macrophages, or defective cholesterol 
efflux from macrophages. It was proposed that foamy macrophages may contribute to pulmonary 
fibrosis through increased release of pro-inflammatory and/or pro-fibrotic mediators. 
As aforementioned in the introduction, HPS1 mice have defects in lysosomal transport that may 
result in the excessive accumulation of foamy macrophages, which may contribute to their reported 
increased susceptibility to BLM-induced pulmonary fibrosis696. By comparing BLM-induced 
pulmonary fibrosis in HPS1 mice that are more likely than not to have an increased accumulation of 
foamy macrophages (versus non foamy counterparts) as compared to WT C57BL/6 controls, the 
potential phenotype of foamy macrophages can be evaluated. 
4.5.2.1 Comparison between naïve HPS1 mice and WT C57BL/6 mice 
The phenotypes of naïve HPS1 mice and WT C57BL/6 controls were first evaluated to identify any 
baseline differences that may exist between the two strains. Several parameters were assessed: 
first, the generation of HPS1 mice was confirmed by visual inspection of mice appearance, and also 
outsourced genotyping [Transnetyx (Tennessee, United States)]. Second, spontaneous inflammation 
and/or fibrosis in HPS mice were evaluated by histological analyses of cellular infiltration and 
collagen accumulation, and mRNA level analyses of the pro-inflammatory mediator IL-6, and the pro-
fibrotic mediators Col1α1 and fibronectin. Third, the constitutive activation state of AMφ was 
assessed by measuring for the pro-inflammatory mediators TNF-α and CXCL1, and the pro-fibrotic 
mediator fibronectin, in the culture supernatant. 
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4.5.2.1.1 Differences in phenotype between HPS1 and WT C57BL/6 mice 
The breeding pair of HPS1 mice were purchased from Jackson Laboratory (Maine) and the colony 
was bred and maintained in-house. HPS1 mice were genotyped by Transnetyx (Tennessee, United 
States). As published HPS1 mice have hypopigmented ears and tails compared to their wild type 
counterparts (Figure 4.16), and often referred to as ‘pale ear’. This phenotypic difference may result 
from defective intracellular trafficking in melanosomes found in the ears and tail of HPS1 mice. 
Figure 4.16 Differences in phenotype between wild type (WT) C57BL/6 and Hermansky Pudlak Syndrome 1 
(HPS1) mice. The breeding pair of HPS1 mice were purchased from The Jackson Laboratory (Maine) and the 
colony was bred and maintained in-house. HPS1 mice generated were genotyped by Transnetyx (Tennessee, 
United States). 
WT C57BL/6 HPS1 
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4.5.2.1.2 Histological analysis of the lungs of naïve HPS1 and WT mice 
Histological analysis of the lung showed that there was no constitutive cell accumulation or fibrosis 
in the lungs of HPS1 mice, as indicated by H&E (Figure 4.17) and PSR staining (Figure 4.18) 
respectively. 
Figure 4.17 Haematoxylin and Eosin (H&E) staining of lung sections in WT C57BL/6 and HPS1 mutant mice. 
8-14 week HPS1 mice and WT C57BL/6 controls were culled. Bronchoalveolar Lavage (BAL) was performed
for the isolation of alveolar macrophages (AMΦ). Lungs were then inflated with Optimal Cutting
Temperature (OCT) and snap frozen in liquid nitrogen; 10μm sections were cut for histology analysis. The
remainder of the frozen lung was crushed for mRNA level analysis. Representative images are shown. WT
C57BL/6, n=3; HPS1, n=4 from one study.
WT C57BL/6 HPS1 
Figure 4.18 Picrosirius Red (PSR) staining of lung sections in WT C57BL/6 and HPS1 mutant mice. 8-14 week 
HPS1 mice and WT C57BL/6 controls were culled. BAL was performed for the isolation of AMφ. Lungs were 
then inflated with OCT and snap frozen in liquid nitrogen; 10μm sections were cut for histology analysis. The 
remainder of the frozen lung was crushed for mRNA level analysis. Representative images are shown. WT 
C57BL/6, n=3; HPS1, n=4 from one study. 
WT C57BL/6 HPS1 
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Figure 4.19 The mRNA level analysis of the pro-inflammatory mediators in lung tissue from HPS1 mice and 
WT C57BL/6 controls. 8-14 week HPS1 mice and WT C57BL/6 controls were culled; BAL was performed for 
the isolation of AMφ. Lungs were then inflated with OCT and snap frozen in liquid nitrogen; 10μm sections 
were cut for histology analysis. The remainder of the frozen lung was crushed for mRNA level analysis. The 
mRNA of the pro-inflammatory mediators IL-6 and TNF-α were determined by qRT-PCR. Data are from one 
pilot study, and each sample was run in triplicates and the average was presented as relative % to the 
housekeeping gene HPRT-1. Data is represented as mean ± SD; WT, n=4; HPS1, n=4. Student t-test was 
carried out; NS: Not significant. 
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4.5.2.1.3 Analysis of mRNA levels in lung tissue from HPS1 and WT mice 
The analysis of mRNA levels in the lungs following BAL washing (i.e. in the absence of AMФ) revealed 
the presence of a non-significant trend towards increased expression of the pro-inflammatory 
cytokines IL-6 and TNF-α in the lungs of HPS1 mice aged 8-14 weeks (Figure 4.19). There is a high 
level of variation in the mRNA levels of IL-6 and TNF-α in the lungs of HPS1 mice, potentially because 
there is variation in the degree of functional lysosomal transport caused by the HPS1 mutation 
between individual mice. HPS1 mice with less functional lysosomal transport may have greater 
intrinsic lung injury that is caused by defective surfactant proteins by AEC2, or cholesterol 
accumulation in foamy AMφ, which results in increased inflammation. 
This is concurrent with the lack of cellular infiltration as identified in H&E staining of histological 
analysis (section 4.ϱ.2.1.Ϯ). The increased pro-inflammatory mediator transcript levels may be found 
in activated AECs in response to intrinsic lung injury. Further repeats and protein level analysis of 
these mediators will have to be carried out to assess whether or not constitutive inflammation is 
prevalent in HPS1 mice. There have been no previous reports of constitutive inflammation in young 
HPS1 mice, although histological analysis has revealed that CD45+ inflammatory cell infiltrates 
accumulate in aged HPS1 mice (>1.5 years old)718. 
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There was a trend suggesting a reduction of fibronectin in HPS1 mice, although this was not 
significant (Figure 4.20). There appeared to be a large increase in Col1α1 mRNA levels in one of the 
HPS1 mice compared to controls. As with the spread of mRNA levels of pro-inflammatory mediators 
observed above, it is possible that different levels of defective lysosomal transport, as a result of 
HPS1 mutation, may lead to various degrees of tissue injury, thereby inducing different amounts of 
Col1α1 gene expression. Further repeats assessing gene transcript levels and assays evaluating 
protein levels will have to be carried out to confirm this. 
Figure 4.20 The mRNA levels of ECM components in lung tissue from HPS1 mice and WT C57BL/6 controls. 8-
14 week HPS1 mice and WT C57BL/6 controls were culled; BAL was performed for the isolation of AMφ. 
Lungs were then inflated with OCT and snap frozen in liquid nitrogen; 10μm sections were cut for histology 
analysis. The remainder of the frozen lung was crushed for mRNA level analysis. The mRNA levels of the 
ECM components collagen 1 α 1 (Col1α1) and fibronectin were determined by qRT-PCR. Data are from one 
pilot study, and each sample was run in triplicates and the average was presented as relative % to the 
housekeeping gene HPRT-1. Non-parametric Mann-Whitney post-test was carried out for Col1α1 data, and 
presented as median ± interquartile range. Parametric student t-test was carried out for Fibronectin data, 
and is represented as mean ± SD. WT C57BL/6 control, n=4; HPS1, n=4 from one study. NS: Not significant. 
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4.5.2.1.4 Differential cell count of BAL cells from HPS1 and WT mice 
Differential cell count by Wright-Giemsa staining showed that there was no difference in cellular 
composition in BALF isolated from HPS1 mice compared to C57BL/6 controls. In both cases AMφ was 
the predominant BAL cell population (>95%), with few lymphocytes or granulocytes observed (Figure 
4.21). 
 
 
 
Figure 4.21 Differential cell count of BAL cells isolated from HPS1 mice and WT C57BL/6 controls. 8-14 week 
HPS1 mice and WT C57BL/6 controls were culled; BAL was performed by 2 x 1 ml DPBS washes. 100 μl of 
BAL was aliquoted and BAL cells were centrifuged onto microscopic slides and stained with Wright-Giemsa 
stain for differential cell count. Differential cell count was carried out by counting 300 cells from at least 3 
fields per sample. Data is presented as number of cells/mouse [i.e. no. of cells counted x 20 (2 ml/ 100 μl)] 
and is represented as mean ± SD; WT, n=4; HPS1, n=4 from one pilot study.  One way ANOVA with Tukey 
post-test was carried out; NS: Not significant. 
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4.5.2.1.5 Naïve HPS1 mice do not have altered numbers of foam cells in their lungs compared to WT 
C57BL/6 mice 
As foamy macrophages have been reported to accumulate in the lungs of HPSPF patients, it was 
investigated whether or not such accumulation also occurred in HPS1 mice. However, as shown by 
the lack of ORO staining of the AMφ there were no foamy macrophages detected in either HPS1 
mice or WT C57BL/6 controls (Figure 4.22). 
 
 
 
4.5.2.1.6 Measurement of IL-12 p40 (total) and fibronectin protein levels in AMφ isolated from naïve 
HPS1 and WT C57BL/6 mice 
AMφ isolated from naïve HPS1 or WT C57BL/6 mice were then analyzed for constitutive protein 
expression of pro-inflammatory mediators and fibronectin. In contrast to a previous report where 
AMφ isolated from HPS1 were described as constitutively activated, there appeared to be no such 
activation of AMφ from naïve HPS1 mice here, as observed by unaltered levels of TNF-α and CXCL1 
in HPS1 mice as compared to WT C57BL/6 controls (Figure 4.23). Levels of IL-1β were also 
investigated, but they were below detection limit in both mouse strains (data not shown). There was 
also no increased levels of fibronectin in HPS1 mice compared to WT C57BL/6 controls (Figure 4.24). 
Overall these results suggest that AMФ do not contribute towards increased inflammation and 
fibrosis in naïve HPS1 mice.
Figure 4.22 Oil Red O (ORO) staining of BAL cells isolated from naïve HPS1 mice or WT C57BL/6 controls. 8-
14 week HPS1 mice and WT C57BL/6 controls were culled. 1 x 105 AMφ were seeded per well of a 48-well 
tissue culture plate for 90 minutes. AMφ enriched by plastic adherence were then further cultured in fresh 
media for 24 hours. ORO stained cells were determined by counting 300 cells from at least 3 fields per 
sample. Representative images are shown; n=4 (WT C57BL/6) and n=3 (HPS1) from one study. 
WT C57BL/6 HPS1 
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Figure 4.23 Protein level analyses of pro-inflammatory mediators in AMφ from HPS1 mice and WT C57BL/6 
controls. 8-14 week HPS1 mice and WT C57BL/6 controls were culled; BAL was performed for the isolation 
of AMφ by 2 x 1 ml DPBS washes. 1 x 105 AMΦ was seeded per well of a 48-well tissue culture plate and 
isolated from other BAL cells by plastic adherence for 90 minutes. Culture media was then changed and 
AMφ were further cultured for 24 hours. Culture supernatant then was collected and subject to TNF-α and 
CXCL1 protein level analysis. Protein levels of the pro-inflammatory mediators TNF-α and CXCL1 were 
determined by MSD. WT, n=3; HPS1, n=3 from one pilot study and evaluation per samples were carried out 
in duplicates. Parametric student t-test was carried out for TNF-α data, and is represented as mean ± SD. 
Non-parametric Mann-Whitney post-test was carried out for CXCL1 data, and presented as median ± 
interquartile range. NS: Not significant. Standard curves for MSD of TNF-α and CXCL1 are shown in appendix 
7. 
Figure 4.24 Protein level analysis of Fibronectin in AMφ from HPS1 mice and WT C57BL/6 controls. 8-14 
week HPS1 mice and WT C57BL/6 controls were culled; BAL was performed for the isolation of AMφ by 2 x 1 
ml DPBS washes. 1 x 105 AMΦ was seeded per well of a 48-well tissue culture plate and isolated from other 
BAL cells by plastic adherence for 90 minutes. Culture media was then changed and AMφ were further 
cultured for 24 hours. Culture supernatant then was collected and subject to fibronectin protein level 
analysis. WT, n=4; HPS1, n=4 from one pilot study and evaluation per samples were carried out in 
duplicates. Protein level of fibronectin was determined by ELISA. Data is represented as median ± 
interquartile range. Non-parametric Mann-Whitney test was carried out; NS: Not significant. Standard 
curves for ELISA of Fibronectin is shown in appendix 7. 
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4.ϱ.2.2 Comparison of BLM-induced pulmonary fibrosis between HPS1 mice and WT C57BL/6 mice 
Having identified that there were no differences in basal levels of inflammation, collagen 
accumulation and fibrosis, foamy macrophage accumulation and macrophage activation between 
naïve HPS1 mice and WT C57BL/6 controls, next it was assessed whether or not HPS1 mice had an 
increased susceptibility to BLM-induced pulmonary fibrosis as reported before, and if an increased 
accumulation of foamy macrophages was observable when compared to WT controls. 
4.ϱ.2.2.1 Comparison of weight change between HPS1 mice and WT C57BL/6 controls following
BLM-challenge 
Having established that there was no lung inflammation or fibrosis in naïve HPS1 mice as compared 
to WT C57BL/6 controls, next it was investigated whether or not HPS1 mice have increased 
susceptibility to BLM-induced pulmonary fibrosis challenge696.  
Although Young and colleagues696 have investigated the susceptibility of HPS1 mice to BLM-induced 
pulmonary fibrosis, this study differs in two key aspects. First, in contrast to previous work HPS1 and 
WT C57BL/6 mice received multiple doses of BLM, namely three times via an oropharyngeal route 
rather than a single intratracheal dose. This protocol allows better tolerance of the mice to BLM 
challenge, and mimics more appropriately the persistent irritation encountered during pulmonary 
fibrosis. Secondly, the effects of BLM challenge on HPS1 and WT C57BL/6 mice were also studied 
beyond the late inflammatory phase at day 7 (as previously reported Young LR, 2007696) until day 21 
(established fibrotic phase).  
Increased susceptibility to BLM-induced pulmonary fibrosis is associated with reduced tolerance to 
BLM challenge that is marked with elevated weight loss in mice. It was observed that mice that are 
less tolerant of BLM are more poorly and have a reduced appetite, resulting in a greater weight loss. 
Tolerance of mice to BLM challenge was initially determined by percentage weight loss. The results 
demonstrated that there was a significant increase in % weight loss in BLM-challenged HPS1 mice 
compared to WT C57BL/6 controls, from a loss of 0.978% in WT C57BL/6 controls to 7.36% in HPS1 
mice at day 8 (7.53-fold; p<0.01), and from a weight gain of 2.31% in WT C57BL/6 mice to a weight 
loss of 9.45% in HPS1 mice at day 11 (5.09-fold; p<0.05), around the late inflammatory phase. 
However, there was no significant weight change between saline challenged HPS1 and WT C57BL/6 
mice beyond day 11 (Figure 4.25). As significant weight loss occurred at days 8 and 11 of the late 
inflammatory phase but not later in the fibrotic phase, this would suggest that reduced tolerance to 
BLM challenge in HPS1 mice may be due to enhanced inflammation rather than increased pulmonary 
fibrosis. 
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Figure 4.25 Weight change in HPS1 and WT C57BL/6 control mice after BLM or saline challenge. 8-14 week 
old HPS1 and WT C57BL/6 mice were challenged via an oropharyngeal route, with either saline or 0.13 U 
BLM, for 3 times at 72 hour intervals at days -7, -4 and -1. Mice were culled at 7, 14 and 21 days after the 
last dose. Mice were weighed daily from the first day of oropharyngeal challenge. The average weight of 
 each group per time point is reported, and data is represented as mean ± SD. Saline-challenged WT C57BL/6 
mice (day-7, day-4, day-1, day 2, and day 5, n=12; day 8 and day 11, n=8; day 14, day 17 and day 20, n=4), 
 BLM-challenged WT C57BL/6 mice (day-7, day-4, day-1, day 2, and day 5, n=12; day 8, day 11 and day 14, 
n=8; day 17 and day 20, n=4), saline-challenged HPS1 mice (day-7, day-4, day-1, day 2, and day 5, n=12; day 
8 and day 11, n=8; day 14, n=6; day 17 and day 20, n=4), BLM-challenged HPS1 mice (day-7, day-4, day-1, 
n=11; day 2, and day 5, n=10; day 8, n=7; day 11, n=6; day 14, n=4; day 17 and day 20, n=2). Two way 
 ANOVA with Sidak post-test was carried out; NS: Not significant, *: p<0.05, **: p< 0.01, ***: p<0.005, ****: 
p<0.001.
4.ϱ.2.2.2 Histological analysis of lung tissue from saline or BLM-challenged HPS1 and WT C57BL/6
mice 
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4.ϱ.2.2.3 Analysis of mRNA levels of lung tissue from saline or BLM-challenged HPS1 mice or WT
C57BL/6 mice 
Having confirmed that BLM challenge induces both cellular infiltration in HPS1 mice as well as WT 
C57BL/6 mice, active inflammation and fibrosis was then evaluated by mRNA level analysis. In the 
following studies, lung tissues were first washed with DPBS (BAL), and AMφ in BAL was isolated by 
plastic adherence on tissue culture plates for later studies. Lavaged lung tissue that is depleted of 
AMφ is then subject to mRNA level analysis, and it is therefore presumed that any changes in mRNA 
levels to the lung observed in these studies are independent of AMФ. The role of AMФ was 
investigated separately (section ϰ͘ϰ͘Ϯ.2.6). IL-6 was chosen as this pro-inflammatory cytokine has an 
established role in pulmonary fibrosis. IL-6 is elevated in the lungs of mice with experimental 
pulmonary fibrosis407, and also in BALF of IPF patients88. Genetic or pharmacological ablation of IL-6 
attenuated pulmonary fibrosis in BLM challenged mice407. IL-6 may play a role in pulmonary fibrosis 
by inducing the conversion of lung fibroblasts into myofibroblasts403, and thereby promote collagen 
synthesis. Results showed that on day 7 post-BLM challenge, there was a significant increase of 9.31-
fold (p<0.05) in IL-6 gene transcript levels in the lungs of BLM-challenged HPS1 mice, and a non-
significant trend towards an increase of 2.96-fold (p>0.05) in BLM-challenged WT C57BL/6 mice 
compared to their respective saline controls (Figure 4.28). IL-6 gene transcript levels returned to 
basal levels by day 14 in both BLM-challenged HPS1 and WT C57BL/6 mice. This potential early 
increase in the inflammatory response in HPS1 mice may contribute to their reduced tolerance and 
increased weight loss following exposure to BLM (Figure 4.25).  
As regards to the fibrotic response it was noted that there was an increase in the mRNA levels of the 
ECM component Col1α1 in both WT C57BL/6 mice and HPS1 mice upon BLM challenge as compared 
to saline controls. Col1α1 gene transcript levels in WT C57BL/6 mice were increased by 3.34-fold at 
day 7 (p<0.05) and 2.89-fold at day 14 (p<0.01), but returned to basal levels at day 21 post BLM 
challenge. A rise in Col1α1 gene transcript levels in HPS1 mice by 3-fold was also observed at day7 
(p<0.05), but this returned to basal levels at day 14 post BLM challenge, suggesting a decreased 
duration of active fibrosis (Figure 4.29). However, there is no difference in the amount of increase 
between the two strains of mice at day 7 post BLM challenge (Figure 4.29).  This difference in gene 
transcript levels was reflected in histology analysis using PSR staining, where reduced fibrosis was 
observed in BLM-challenged HPS1 mice as compared to WT C57BL/6 controls (Figure 4.27). 
A similar trend was observed for another ECM component fibronectin (Figure 4.30). Fibronectin 
mRNA levels in WT C57BL/6 mice were elevated by 5.27-fold at day 7 (p<0.05) and 4.32-fold at day 
14 (p<0.005), but returned to basal levels at day 21 post BLM challenge. There was a trend 
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suggesting increase in mRNA levels of fibronectin in HPS1 mice by 3.73-fold at day7, but this was no 
longer observed by day 14 post BLM challenge. This suggests that enhancement of ECM gene 
transcript levels in response to BLM challenge is short-lived in HPS1 mice as compared to WT 
C57BL/6 controls. Such increase in ECM levels also does not appear to affect long-lasting 
accumulation, as less collagen deposition was observed across the whole lung in HPS1 mice as 
compared to WT C57BL/6 controls, observed from PSR staining (data not shown). 
Collectively these results reveal a trend in elevated levels of inflammation but not fibrosis within the 
lungs of HPS1 mice compared to WT C57BL/6 controls. In contrast, there may be less ECM deposition 
within the lungs of HPS1 mice, as revealed by a shorter duration of increased transcript levels of the 
key pro-fibrotic mediators Col1α1 and fibronectin within the lungs of HPS1 mice, and also a lesser 
extent of PSR staining observed. These suggests that reduced tolerance in HPS1 mice to BLM 
challenge compared to WT C57BL/6 controls is not caused by an increased susceptibility to BLM-
induced pulmonary fibrosis but perhaps an increased pro-inflammatory response. 
4.ϱ.2.2.4 Differential cell count of BAL cells from saline and BLM challenged HPS1 and WT C57BL/6
mice 
The results showed that the inflammatory response in the BLM challenged HPS1 mice and WT 
C57BL/6 controls were comparable. However, there was a difference in the kinetics of active fibrosis, 
in that increase of gene transcript levels of ECM components in HPS1 mice returned to basal level at 
an earlier time point than that observed in the WT C57BL/6 counterparts. In the next set of 
experiments I then investigated whether or not the influx of immune cells into the lungs varied 
between the two mouse strains after BLM challenge. The differential cell count was carried out by 
Wright-Giemsa staining of BAL cells. AMφ are identified by their larger size (10-20 μm), round shape, 
with a large central nucleus and clear vacuolated cytoplasm. Lymphocytes are smaller in size (8-
10μm) with a large central nucleus and little cytoplasm. Granulocytes are also small in size (8-10 μm) 
but are polynucleated and are characterised by their cytoplasmic granules. 
As the results indicate, there was an influx of AMφ upon BLM challenge in both HPS1 and WT 
C57BL/6 mice at day 7 post-challenge. The number of AMφ present significantly increased from 2.53 
x 104 to 15.0 x 104 in WT C57BL/6 mice following BLM challenge (5.92-fold; p<0.05), and there was a 
trend suggesting an escalation in the number of AMφ, from 6.56 x 104 to 18.0 x 104, in the HPS1 mice 
(2.74-fold). However, this returned to basal levels by day 14 post-challenge in both mouse strains 
(Figure 4.31). Furthermore, there is no apparent difference in the number of AMφ infiltrating the 
lungs of BLM-challenged HPS1 or WT C57BL/6 mice (Figure 4.31). 
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An influx of lymphocytes was noted in WT C57BL/6 mice in response to BLM challenge, increasing 
from 0.0361 x 104 to 3.53 x 104 at day 7 (96.5-fold; p<0.01), and 0.0915 x 104 to 1.97 x 104 at day 14 
(21.5-fold; p<0.01) after challenge. This enhancement returned to basal levels at day 21 (Figure 
4.32). In contrast no lymphocytic infiltration was observed in HPS1 mice post BLM-challenge (Figure 
4.32). 
There was a trend suggesting an increased accumulation of granulocytes in BLM challenged WT 
C57BL/6 mice at day 7, from undetectable levels to 1.95 x 103 cells; however by day 14 post 
challenge this had returned to baseline levels, whereas in the HPS1 mice there was no indication of a 
granulocyte infiltration into the lungs (Figure 4.33). This granulocytic infiltration was observed to be 
that of neutrophils based on the polynucleated horseshoe-shaped nucleus observed. 
These results indicate that there is a disparity both in the number and type of immune cells that 
infiltrate in the lungs of WT C57BL/6 and HPS1 mice upon BLM challenge. This difference may 
contribute to the altered patterns of gene transcript levels of inflammatory and pro-fibrotic 
mediators observed within the lungs of BLM challenged HPS1 and WT C57BL/6 mice (Section 
4.ϱ.2.2.3).
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4.ϱ2.2.5 The presence of foamy AMφ in saline and BLM-challenged HPS1 and WT C57BL/6 mice 
Foamy AMφ accumulation has been observed in IPF715 and HPSPF patients788, and can adopt either a 
pro-inflammatory709 or a pro-fibrotic M2-like phenotype714, which may contribute to pulmonary 
fibrosis through tissue injury and excess ECM deposition respectively. Although no constitutive 
accumulation of foamy AMφ was observed for HPS1 mice, there may be a predisposition for these 
cells to accumulate following BLM challenge when compared to the WT C57BL/6 controls.  
ORO staining of lipid droplets demonstrated that there were no foamy AMφ detectable in either 
HPS1 or C57BL/6 mice when challenged with saline. In contrast there was a marked accumulation of 
these cells in both strains of mice after exposure to BLM (Figure 4.34). However no difference in 
foamy AMφ numbers was observed between HPS1 or WT C57BL/6 control mice (Figure 4.35). The 
lack of a detectable increase in the accumulation of foamy AMφ in HPS1 mice compared to the WT 
C57BL/6 controls suggests that these cells may not play a role in the reduced tolerance to BLM-
challenge observed in HPS1 mice. 
4.ϱ.2.2.6 Measurement of IL-12 p40 (total) and fibronectin protein in AMφ isolated from saline 
and BLM challenged HPS1 and WT C57BL/6 mice 
AMφ from saline and BLM challenged HPS1 and WT C57BL/6 control mice were then analysed to 
investigate if there was differential expression of pro-inflammatory or pro-fibrotic mediators that 
might in part help to explain the reduced tolerance of HPS1 mice to BLM. 
The results indicated that there was a trend suggesting the IL-12 p40 (total) protein levels in AMφ 
from HPS1 mice and WT C57BL/6 controls was amplified following BLM challenge. Analysis of IL-12 
p40 (total) in WT C57BL/6 mice following BLM challenge revealed a non-significant trend suggesting 
increased levels from 10.4 pg/ml to 554 pg/ml at day 7 (53.4-fold), and this was significantly elevated 
from 15.0 pg/ml to 390 pg/ml at day 14 (30-fold; p<0.005). IL-12 p40 (total) production in HPS1 mice 
post BLM-challenge was significantly enhanced from 92.7 pg/ml to 1,040 pg/ml at day 7 (11.2-fold), 
and had a non-significant trend of escalation from 2.95 pg/ml to 209 pg/ml at day 14 (70.8-fold). IL-
12 p40 (total) levels in both strains returned to basal levels by day 21. Despite increased levels of IL-
12 p40 (total) in HPS1 derived AMφ, both at the baseline and following BLM-challenge, there was no 
significant difference in IL-12 p40 (total) levels between HPS1 mice and WT C57BL/6 controls (Figure 
4.36). 
Fibronectin production increased significantly from day 7 to day 14 post BLM challenge in both HPS1 
and WT C57BL/6 control mice. The levels of fibronectin underwent a significant increase in the WT 
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C57BL/6 mice post BLM challenge, from undetectable levels to 42.8 ng/ml at day 7 (p<0.01), and 
from 3.13 ng/ml to 131 ng/ml at day 14 (42-fold; p<0.005). In the HPS1 mice, fibronectin levels were 
similarly amplified at significant levels from 13.3 ng/ml to 106 ng/ml at day 7 (7.96-fold; p<0.001), 
and from 11.7 ng/ml to 135 ng/ml at day 14 (11.6-fold; p<0.005). There was a trend suggesting 
enhanced protein levels of fibronectin at day 21 post BLM-challenge in both strains, from 10.5 ng/ml 
to 121 ng/ml in WT C57BL/6 mice (11.6-fold), and from 11.6 ng/ml to 93.5 ng/ml (8.04-fold) in HPS1 
mice (Figure 4.37). Together these results revealed an increased pro-fibrotic response by AMφ 
isolated from BLM-challenged HPS1 mice at day 7, which was matched by WT C57BL/6 controls by 
day 14 through to day 21. This may suggest that the fibrotic response was induced earlier in HPS 1 
mice than their WT C57BL/6 counterparts. 
Collectively these observations suggest that HPS1 mice may have slightly different kinetics in the 
development of pulmonary fibrosis in response to BLM compared to WT C57BL/6 mice. Gene 
transcript levels analysis of the lung have suggested increased inflammation at day 7, but shortened 
duration of active fibrosis in HPS1 mice. The latter observation corresponded with the overall less 
PSR staining of collagen observed across whole lung slices of BLM-challenged HPS1 mice compared 
to WT C57BL/6 controls that suggests reduced established fibrosis. Protein level analysis of AMφ 
supernatants has revealed an exaggerated pro-fibrotic response in AMφ from HPS1 mice at day 7 
that was matched by WT C57BL/6 controls at day 14. From these results it can be proposed that 
AMφ in HPS1 mice have an earlier and accelerated pro-fibrotic response. Further experiments will 
have to be carried out at earlier time points to validate these hypotheses.
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Figure 4.35 Count of ORO stained foamy AMφ in HPS1 mice or WT C57BL/6 controls following saline or BLM 
challenge. 8-14 week old HPS1 and WT C57BL/6 mice were challenged via an oropharyngeal route, with 
either saline or 0.13 U BLM, for 3 times at 72 hour intervals. Mice were culled at 7, 14 and 21 days after the 
last dose. AMΦ was isolated from BAL by plastic adherence to culture plates for 90 minutes and further 
cultured for 24 hours. ORO stained foamy macrophages were quantified by counting at least 300 cells from 
3 separate fields. Representative images are shown; WT C57BL/6 (Saline) (days 7, 14 and 21), n=4; WT 
C57BL/6 (BLM) (days 7, 14 and 21), n=4; HPS1 (Saline) (days 7, 14 and 21), n=4; HPS1 (BLM) (days 7, and 14), 
n=3; HPS (BLM) (day 21), n=2 from one study. Two way ANOVA with Sidak post-test was carried out; NS: Not 
significant. 
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4.ϲ Discussion 
In the first part of chapter 4, the phenotype of AMφ isolated at various stages of BLM-induced 
pulmonary fibrosis, using a novel repeated oropharyngeal dosing regimen, was investigated in the 
results reported here. Histology analyses confirmed collagen accumulation and infiltration of CD68+ 
pulmonary macrophages. Assessment of the different immune cell types in BAL also demonstrated 
that there was an accumulation of AMφ. Using macrophage subset associated mediators that have 
been predefined in vitro in Chapter 1, it was revealed that AMφ of different phenotypes 
accumulated at various stages of BLM-induced pulmonary fibrosis.  
These studies for the first time study the kinetics of the changes in mRNA and protein levels of AMφ 
in BLM-induced pulmonary fibrosis, and demonstrate that AMφ have the capacity to alter their 
phenotype in response to signals in vivo, as well as in vitro which is reported in Chapter 1. These 
phenotypic changes involved the increased levels of pro-inflammatory and pro-fibrotic mediators 
that may contribute to the pathophysiology of pulmonary fibrosis. It was also demonstrated that in a 
paracrine culture, supernatant from AMφ isolated from BLM challenged mice were able to stimulate 
an increase in Col1α1 gene transcript levels in MPF, indicating that AMφ may promote pulmonary 
fibrosis by the activation of MPF. 
In the second part of chapter 4, the potential role of foamy macrophages in BLM-induced pulmonary 
fibrosis was investigated. For these studies, HPS1 mice that have been reported to have an 
accumulation of foam cells, including foamy macrophages and AEC2, as a result of defective 
lysosomal trafficking, were used. The increased number of foamy macrophages in HPS1 mice should 
give clues about their role when compared to WT C57BL/6 mice where such cells are less populated. 
HPS1 mice represent an experimental model of HPS1 patients, of whom often develop pulmonary 
fibrosis (HPSPF) that resembles IPF in terms of disease progression1,693 and its UIP histopathology1. 
HPS1 mice do not spontaneously develop pulmonary fibrosis in contrast to HPS1 patients, but 
display increased susceptibility to BLM-induced pulmonary fibrosis at day 7 post challenge696. It is 
possible that this increased susceptibility may be promoted by elevated foamy macrophages 
accumulation through elevated pro-inflammatory and pro-fibrotic mediator release. 
The phenotype of naïve HPS1 mice was first compared to that of the WT C57BL/6 control. It was 
observed in accordance with literature these had hypopigmented ears, paws and tails but not coat 
(Figure 4.16). HPS1 mice did not have intrinsic cellular infiltration (Figure 4.17) or collagen 
accumulation (Figure 4.18), although there was a non-significant trend suggesting increase in pro-
inflammatory (TNF-α, and IL-6) (Figure 4.19), and reduction of the ECM component fibronectin 
(Figure 4.20). HPS1 mice did not have different numbers of AMφ, lymphocytes and granulocytes as 
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compared to WT C57BL/6 controls (Figure 4.21), nor increased number of foamy AMφ (Figure 4.22), 
and AMφ had no increased levels of pro-inflammatory (TNF-α, CXCL1) (Figure 4.23) and pro-fibrotic 
(fibronectin) mediators (Figure 4.24). 
HPS1 mice were than challenged with BLM using the multiple oropharyngeal dosing method, and 
subsequent pathology (e.g. cellular infiltration, collagen accumulation, mRNA levels of pro-
inflammatory and pro-fibrotic mediators) in BLM-induced pulmonary fibrosis was observed for the 
first time, beyond day 7 of the late inflammatory phase, into days 14 and 21 of the active and 
established fibrotic phases. The number of foamy macrophages was also measured by ORO staining 
to evaluate their potential increased accumulation in HPS1 mice as compared to WT C57BL/6 
controls. The protein levels of pro-inflammatory and/or pro-fibrotic mediators released by these 
AMφ were also assessed to determine whether or not they were involved in the reported increased 
susceptibility to BLM-induced pulmonary fibrosis696. 
HPS1 mice showed reduced tolerance to BLM challenge as observed by increased weight loss as 
compared to WT C57BL/6 controls (Figure 4.25), which was in accordance to the literature696. 
However, increased weight loss occurred during the late inflammatory phase (days 8-11); this was 
also not accompanied by increased collagen transcript levels (Figure 4.29) and accumulation (Figure 
4.27) within the lungs, suggesting that reduced BLM tolerance was due to increased inflammation 
but not increased susceptibility to BLM-induced pulmonary fibrosis. Indeed there was a trend 
suggesting increase in IL-6 in the lungs to support this hypothesis (Figure 4.28). There was no 
difference in AMφ (Figure 4.31) or granulocyte (Figure 4.33) infiltration, although there was a lack of 
accumulation of lymphocytes (Figure 4.32). There was no difference in the number of foamy AMφ 
(Figure 4.34 and 4.35), suggesting that accumulation of cholesterol crystals in AMφ is not 
prerequisite of reduced tolerance in HPS1 mice. There were increased protein levels of IL-12 p40 
(total) (Figure 4.36) and fibronectin (Figure 4.37) in HPS1 mice as compared to WT C57BL/6 controls 
at day 7 that returns to basal levels by day 14. Increased IL-12 p40 levels may lead to the reduced 
BLM tolerance in HPS1 mice observed in the late inflammatory phase at day 7. 
In the following sections. AMφ heterogeneity in BLM-challenged pulmonary fibrosis in WT C57BL/6 
mice will first be evaluated in section 4.ϲ.1. The comparisons between naïve, saline or BLM-
challenged mice HPS1 mice and WT C57BL/6 mice, for the investigation of the role of foamy 
macrophages in pulmonary fibrosis, will be deliberated in section 4.ϲ.2. 
4.ϲ.1 AMφ heterogeneity in BLM-induced pulmonary fibrosis in WT C57BL/6 mice 
In this section, AMφ heterogeneity in BLM-induced pulmonary fibrosis in WT C57BL/6 mice will be 
evaluated. This section begins with experimental limitations and their potential implications, 
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followed by discussion of the characterisation of AMφ at different stages of BLM-induced pulmonary 
fibrosis, and their role in inducing collagen expression in mouse lung fibroblasts ex vivo, and finally 
the future directions of these studies will be deliberated. 
4.ϲ.1.1 Experimental limitations 
Several experimental limitations have been identified in these studies. First, there was no 
quantification for cellular infiltration and collagen accumulation for histology analyses. While drastic 
differences in these parameters could be observed visually between saline and BLM-challenged 
mice, further positive pixel count of the H&E and PSR stained slides will have to be carried out to 
quantify the extent of these alterations. 
Second, in the flow cytometry analyses, multiple stained AMφ were gated with respect to the MFI of 
their isotype controls, rather than using a fluorescence minus one (FMO) regime. Isotype controls 
are antibodies of the same isotype of that of the primary antibody but without the specificity to the 
target protein, and may serve as negative controls for non-specific antibody binding. However, 
isotype controls may have different activities to the primary antibody (since they are different 
antibodies) and therefore are not the best candidates for identifying staining boundaries. Instead 
FMO controls, which consists of all primary antibodies but the one that is being controlled, is widely 
accepted as gating controls. Gating strategies employed in these studies may therefore be misplaced 
and further FMO controls will have to be established to properly set up gates for analysis. 
Third, there was no test for normal distribution in these studies due to limited number of samples 
available. The Kolmogorov-Smirnov test requires 5 or more values, the Shapiro-Wilk test requires 7 
or more values, and the D'Agostino test requires 8 or more values, whereas n<5 in some studies. 
Results were therefore classified as parametric or non-parametric based on visual inspection on the 
spread of data, which may be unreliable. Further repeats will have to be carried out to increase 
sample size for normal distribution testing and the validation of the statistical testing used. 
In light of these caveats however, drastic changes were still observed in AMφ mRNA and protein 
levels in BLM-challenged mice with respect to saline controls. These results will be further discussed 
in the following sections (section 4.ϲ.1.2 – 4.ϲ.1.6); future directions to further these studies will be 
deliberated in section 4.ϲ.1.7. 
Despite these shortfalls in experimental design, observations from the current studies may provide a 
useful indication of changes in mRNA and protein levels of AMφ in saline versus BLM-challenged 
mice at the late inflammatory (day 7), early fibrotic (day 14) and late fibrotic (day 21) phases, which 
will be discussed further in the sections below. However,it is acknowledged here that further 
Chapter 4 | AMφ heterogeneity in BLM-induced pulmonary fibrosis 
217 
experiments employing the controls mentioned above will have to be carried out for a more 
definitive comparison. 
4.ϲ.1.2 A novel repeated oropharyngeal dosage of BLM-induced pulmonary inflammation and fibrosis 
A novel repeated oropharyngeal dose protocol for BLM-induced pulmonary fibrosis in mice recently 
developed by Dr. Elizabeth Jarman (Novartis, Horsham) was used in these studies. Histological 
analyses of cellular infiltration and collagen accumulation were carried out in order to validate this 
model. H&E staining showed that there was a large cellular influx into the lungs that is coupled with 
an apparent destruction of the alveoli and emphysema (Figure 4.2). These cell infiltrates included 
CD68+ macrophages (Figures 4.4 and 4.5), indicating that these cells may contribute to the 
pathology. PSR staining also revealed a gradual increase in collagen accumulation, a hallmark of the 
onset of fibrosis (Figure 4.3). This temporal heterogeneity of collagen deposition is indicative that 
pulmonary fibrosis is a progressive disease that is caused by increased production and/or reduced 
removal of ECM components. Spatial heterogeneity was also observed across the whole lung slice in 
both H&E and PSR staining where areas of cellular infiltration/fibrosis were immediately adjacent to 
unaffected areas. This finding suggests a localised rather than a general response to BLM-induced 
injury to the lung tissue. Differential cell counts in BAL revealed that AMφ were increased following 
BLM-challenge between the late inflammatory phase (day 7) to the late fibrotic phase (day 21), 
suggesting a role for these cells in the initiation and progression of pulmonary fibrosis (Figure 4.6). 
Lymphocytes were also increased on day 7, indicating a role for these cells in the initiation of 
pulmonary fibrosis (Figure 4.6). However there was no evidence of elevated numbers of 
granulocytes (Figure 4.6), which reflect the lungs of IPF patients in that the progression of fibrosis is 
granulocyte-independent.  
4.ϲ.1.3 M1-like AMφ accumulated in the alveolar space at day 7, whereas M1/M2-like hybrid AMφ were 
found from days 7 to 21 of BLM-induced pulmonary fibrosis 
The phenotype of AMφ within the fibrotic lung was assessed to study macrophage heterogeneity in 
a disease model. These studies are the first of its kind to investigate the change in AMφ phenotype 
at different stages of BLM-induced pulmonary fibrosis. Flow cytometric analyses revealed that there 
were two populations expressing M1-like (MHCIIhi MRC1-) and M2-like (MHCII-/lo MRC1-/lo) surface 
proteins at day 7, but by day 14 and then day 21 only the latter group (MHCII-/lo MRC1-/lo) remained 
(Figure 4.12 and 4.13). The mRNA and protein level analyses of select macrophage subset associated 
mediators have largely supported this observation, with a trend suggesting an increase in the M1-
associated mediators NOS2 (Figure 4.9) and IL-1β (Figure 4.11) at day 7, and an elevation of the M2-
associated mediators Arg-1 (Figure 4.9) and fibronectin (Figure 4.11) between days 7 to 21. 
Conversely it was observed that the M1-associated mediator IL-12 p40 (total), including monomeric 
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and/or homodimeric IL-12 p40, heterodimeric IL-12 p70 (p40 + p35) and/or IL-23 (p40 + p19) (Figure 
4.11), was also elevated at day 7 and persisted until at least day 21. It is therefore possible that a 
M1-/M2-like hybrid population of AMφ may contribute to the release of IL-12 p40 (total) from at 
least day 14 to day 21 when M1-like AMφ were absent. 
IL-12 p40 (total) was increased in the supernatants of AMφ from BLM-challenged mice from days 7 
to 21 (Figure 4.11). Follow-up studies have shown that despite the increased levels of IL-12 p40 
(total), levels of the bioactive IL-12 p70 were undetectable (data not shown). This suggests that the 
increase of IL-12 p40 (total) is not contributed by the elevation of IL-12 p70, but of IL-12 p40 
monomers, homodimers and/ or IL-23. IL-12 p40 may play a role in macrophage recruitment, as was 
observed in a mouse model of silica-induced pulmonary fibrosis123. Alternatively IL-12 p40 may 
combine with the p19 subunit to form IL-23 to promote pulmonary fibrosis. IL-23 p19 can play a 
significant role in BLM-induced pulmonary fibrosis. IL-23 may promote the differentiation of IL-17 
producing TH17 cells385–387, and IL-17A can mediate BLM124,384 or IL-1β induced pulmonary fibrosis124. 
Further studies will have to be carried out to establish whether IL-12 p40 and/ or IL-23 is responsible 
for the progression of pulmonary fibrosis. The potential role of IL-12 p40 monomers/ homodimers in 
monocyte recruitment and the pathology of pulmonary fibrosis can be evaluated by administration 
into the lungs of BLM-challenged mice and assessing the change in collagen accumulation and 
pulmonary fibrosis. The potential role of IL-23 can be determined by measuring its protein levels in 
the supernatants of AMφ, BAL and lung of BLM-challenged mice. The effect of lung-specific 
instillation of IL-23, or retrospectively removal of IL-23 by specific antibodies, to BLM-induced 
pulmonary fibrosis can also be analysed to determine its role in pathology.   
This is the first time that a hybrid phenotype, rather than a strictly M2-like phenotype, has been 
reported to play a role in pulmonary fibrosis. The hybrid macrophage may be generated by diverse 
signals promoting dysregulated wound healing (e.g. IL-4, IL-13, TGF-β, and IL-10) and persistent 
irritation (e.g. IFN-Υ, and TNF-α) within the fibrotic lung, which induces a M2-like and M1-like 
phenotype respectively. However prolonged TLR stimulation can induce tolerance in peritoneal 
macrophages leading to diminished M1-like responses and elevated M2-like responses346. The 
accumulation of oxidised phosphatidylcholine (oxPc) can also induce a M2-like phenotype and a 
foamy appearance in human and mice AMφ798. Indeed, ORO staining revealed an accumulation of 
foam cells in BAL (Figures 4.7 and 4.8). These results therefore suggest the presence of a M1-like 
phenotype during the late inflammatory phase (day 7) that is gradually replaced by a M1-/M2-like 
hybrid phenotype (days 7 to 21) as pathology progress. 
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4.ϲ.1͘ϰ W/ͲϭŐĞŶĞƚƌĂŶƐĐƌŝƉƚůĞǀĞůƐǁĞƌĞĚĞĐƌĞĂƐĞĚŝŶ>DͲĐŚĂůůĞŶŐĞĚŵŝĐĞ
In Chapter 3, PAI-1 transcript levels were found to be increased i n AMφ following TGF-β or hypoxia 
induction (Chapter 3, section 3.ϱ.ϭ.3.1), and it is well documented that these two signals are 
increased in the fibrotic lung. PAI-1 was also reported to be elevated in the lung tissue of fibrotic 
lungs and essential for BLM-induced pulmonary  fibrosis264. It was therefore surprising that a trend 
gene suggesting decreased transcript levels of PAI-1 was observed in AMφ isolated from BLM-
challenged mice compared to saline controls (Figure 4.10). It is unclear why this was the case, 
although several potential reasons can be considered. First, there may be a difference in pathology 
mechanism between the repeated lower doses regimens used in these studies versus the single 
higher doses regimens applied in the literature. Perhaps multiple lower doses allow AMφ to 
tolerate or even overcompensate for BLM-induced PAI-1 gene expression. dŚŝƐŵĂǇĐĂůůŝŶƚŽ
ƋƵĞƐƚŝŽŶƚŚĞƌĞƉƌĞƐĞŶƚĂƚŝǀĞŶĞƐƐŽĨƚŚĞŵƵůƚŝƉůĞĚŽƐĞ>DͲŝŶĚƵĐĞĚƉƵůŵŽŶĂƌǇĨŝďƌŽƐŝƐŵŽƵƐĞ
ŵŽĚĞůƚŽ/W&͕ǁŝƚŚƉĂƌƚŝĐƵůĂƌƌĞƐƉĞĐƚƚŽŚǇƉŽǆŝĂͲƌĞůĂƚĞĚƐƚƵĚŝĞƐ͕ĂŶĚĨƵƌƚŚĞƌĞǆƉĞƌŝŵĞŶƚƐ͕ĂƐ
ĚŝƐĐƵƐƐĞĚďĞůŽǁ͕ǁŝůůŚĂǀĞƚŽďĞĐĂƌƌŝĞĚŽƵƚƚŽĞǀĂůƵĂƚĞƚŚŝƐ͘Second, PAI-1 gene transcript levels by
disease-relevant AMφ may be masked by that of bystander AMφ due to spatial heterogeneity of 
fibrosis (neighbouring regions of normal and fibrotic tissue) within the lung. Third, there may be 
increased degradation of PAI-1 mRNA in AMφ within the fibrotic lung. Indeed, PAI-1 mRNA are 
regulated at a post-transcriptional level by a variety of mediators, including phorbol myristate 
acetate (PMA), insulin, IGF-1, and cyclic nucleotide analogues799–802. It may therefore be more 
informative to investigate PAI-ϭlevels at a protein levels for a more accurate analysis of their levels
in pathology. Further studies could be carried out by in situ hybridisation or immunohistochemistry 
to determine the cellular localisation of PAI-1 RNA or protein respectively, and the location within 
the lung where such cells are present. 
4.ϲ.1.5 AMφ have increased CCL5 and ŝŶĐƌĞĂƐĞĚƚƌĞŶĚƐ of IL-6 and CCL2 protein levels at day 7  
Levels of macrophage-associated proteins associated with pulmonary fibrosis have been assessed 
in the supernatants of AMφ isolated from different stages of BLM exposed and control mice ex vivo 
(Figure 4.14). The results revealed that CCL3, CCL4, CCL20 and MMP-9 were undetectable, while 
CCL5 was significantly increased at day 7, and a trend suggesting an increase in IL-6 and CCL2 levels 
in AMφ from BLM-challenged mice was observed. The protein levels of CXCL2 remained 
unchanged. It was revealed that AMφ do not produce detectable levels of CCL20 and mMMP-9 
(Chapter ϯ, Section ϯ͘ϱ͘ϭ.3.3). Preliminary studies have shown that hypoxia induced CCL3, CCL4 and 
CXCL2 production in AMφ (Chapter ϯ, Section ϯ͘ϱ͘ϭ͘3.3). The failure to generate measurable levels 
of CCL3, CCL4, and the unchanged amounts of CXCL2 suggests that the hypoxia induced AMφ 
phenotype was not prevalent in BLM-induced pulmonary fibrosis, a feature that was mirrored by 
the lack of PAI-1 gene transcript increase (Figure 4.10). This calls into question whether or not 
hypoxia-inducible mediators involved in pathology are directly translatable from mouse model to  
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ŚƵŵĂŶƉĂƚŝĞŶƚƐ͘dŚĞrole of hypoxia in this current model of BLM-induced pulmonary fibrosis has
to be further evaluated by measuring the protein levels of the hypoxia induced transcription factors 
HIF-1α and HIF-2α within cells.dŚĞƌĞƉƌĞƐĞŶƚĂƚŝǀĞŶĞƐƐŽĨƚŚŝƐŵŽĚĞůŝŶƚŚĞƐƚƵĚǇŽĨƉƵůŵŽŶĂƌǇ
ĨŝďƌŽƐŝƐͲĂƐƐŽĐŝĂƚĞĚŚǇƉŽǆŝĂǁŝůůĂůƐŽŚĂǀĞƚŽďĞĞǀĂůƵĂƚĞĚƵƐŝŶŐďǇŵĞĂƐƵƌĞŵĞŶƚŽĨƉƌŽƚĞŝŶůĞǀĞůƐŽĨ
ŚǇƉŽǆŝĂͲĂƐƐŽĐŝĂƚĞĚƉƌŽƚĞŝŶƐ;Ğ͘Ő͘W/ͲϭͿ͘
The role of CCL5 in pulmonary fibrosis has not been extensively investigated, although it is a 
chemoattractant for mast cells803. It is known that mast cells accumulate in pulmonary fibrosis804, 
and clinically correlations between mast cells and fibrosis have been observed187. Mast cells may 
drive fibrosis through the stimulation of fibroblasts resident in the lung194. Antagonism of CCL5 also 
protected from liver fibrosis, possibly through the modulation of monocyte subpopulations805,806. 
The role of AMφ-derived CCL5 in the recruitment of mast cells can be assessed by chemoattractant 
assays ex vivo. Its contribution to BLM-induced pulmonary fibrosis can be evaluated by genetic or 
pharmacological inhibition, or retrospectively by lung-specific CCL5 overexpression studies, with 
the corresponding changes in fibrosis represented by collagen and mast cell accumulation. 
The roles of CCL2 and IL-6 in pulmonary fibrosis are well established. Monocytes and fibrocytes are 
attracted into the airways following lung injury by CCL2594,807, and it can also stimulate fibroblast 
collagen production via upregulation of TGF-β expression808. IL-6 participates in airway remodelling 
in asthma401, and induces differentiation of fibroblasts into myofibroblasts402. It was therefore 
unexpected that these two essential AMφ-derived pro-fibrotic mediators were only weakly 
increased in BLM-challenged mice. Perhaps these mediators are only increased in pro-fibrotic AMφ 
that exerts its effects locally in a paracrine manner. Immunohistochemical investigations of these 
mediators would allow the identification of their location within the fibrotic lung.  
4.ϲ.1.6 Supernatants of AMφ isolated from BLM-challenged mice promoted collagen gene transcript 
levels in MPFs  
Supernatants from AMφ isolated from BLM-challenged mice, but not saline controls, increased 
Col1α1 gene transcript levels in MPFs (Figure 4.1ϱ). These novel results demonstrate that AMφ 
derived from BLM-induced pulmonary fibrosis have a pro-fibrotic role ex vivo in a paracrine 
manner. While it has not been determined here which mediator(s) is/are responsible for such 
induction, potential candidates include IGF-1809, TGF-β810, and PDGF811,812.  Further genetic ablation 
or pharmacological inhibition studies will have to be carried out to determine the key mediator(s) 
responsible for this process. 
4.ϲ.1.7 Future directions 
4.ϲ.1.7.1 Spatial heterogeneity of BLM-induced pulmonary fibrosis 
In these studies, AMφ from the whole lung were analysed. Since the AMφ from BLM-challenged 
mice in this study are a mixture of macrophages from both fibrotic areas and unaffected areas the 
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functional phenotype and plasticity of the disease associated cells may be underrepresented. Future 
studies using laser capture microdissection (LCM) can isolate diseased areas from the fibrotic lung 
and allow for a more representative comparison. Alternatively, single lung dosing of mice can be 
carried out, where a high dose of BLM is applied intratracheally. The high dose of BLM can induce 
more homogenous fibrosis in the challenged lung, whereas the unchallenged lung can maintain 
survival of the mice and serve as the direct negative control for BLM challenge. 
4.ϲ.1.7.2 AMφ heterogeneity in BLM-induced pulmonary fibrosis 
A particular difficulty in studying disease-associated AMφ mRNA and protein levels ex vivo is to 
separate the heterogeneous subpopulations, such that the same functional subset, rather than a 
pooled sample of different subsets are analysed. As demonstrated above, macrophage subsets pre-
defined in vitro, namely M1-like and M2-like macrophages may be insufficient to fully represent the 
complexity of macrophage genotype in vivo. However, these may serve as a good starting point of 
which to pre-sort AMφ for further analyses. The transcriptome and proteome of AMφ in pulmonary 
fibrosis can be analysed by DNA microarray and next generation sequencing (NGS), or protein 
microarrays.  
4.ϲ.1.7.3 IL-12 p40 (total) MSD measures different forms of IL-12 p40 oligomers 
As mentioned above IL-12 p40 (total) measures different forms of IL-12 p40m including monomeric 
and homodimeric IL-12 p40, and also heterodimeric IL-12 p70 (p40 + p35) and IL-23 (p40 + p19). IL-
12 p40 (total) was found to be increased in AMφ of BLM-challenged mice, although the exact 
oligomer form it is increased in is unknown. As different IL-12p40 isoforms have different functions, 
it is important to determine the specific isoform that is increased to determine its function. 
4.ϲ.1.8 Summary 
Collectively it is shown in these studies that AMφ display heterogeneity during the fibrotic process to 
release a variety of pro-inflammatory and pro-fibrotic mediators at various stages of BLM-induced 
pulmonary fibrosis. AMφ-derived pro-fibrotic mediators can directly increase collagen transcript 
levels in MPF in a paracrine manner, and AMφ therefore has the capacity to promote fibrosis. 
4.ϲ.2 The comparison of HPS1 mice and WT C57BL/6 controls in BLM-induced pulmonary 
fibrosis 
In this section, the susceptibility of HPS1 mice to BLM-induced pulmonary fibrosis was assessed. 
HPS1 mice were used here as they represent an experimental model of HPS1 patients. HPS1 
patients often develop pulmonary fibrosis (HPSPF) that resembles IPF in terms of disease 
progression1,693 and its UIP histopathology1. HPSPF patients also have increased numbers of foamy 
macrophages, potentially due to defective cholesterol efflux in these cells788. 
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hŶůŝŬĞƚŚĞŝƌŚƵŵĂŶĐŽƵŶƚĞƌƉĂƌƚƐ͕HPS1 mice do not spontaneously develop pulmonary fibrosis, but
display increased susceptibility to BLM-induced pulmonary fibrosis at day 7 post challenge696. As 
foamy macrophages accumulate in IPF patients and also in the lungs of mice with BLM-induced 
pulmonary fibrosis (Figure 4.7 and 4.8), and foamy macrophages have been described to have a pro-
inflammatory and pro-fibrotic phenotype, it is possible that these cells may contribute to pulmonary 
fibrosis through promoting tissue injury and fibrosis. The increased susceptibility of HPS1 mice to 
BLM-induced pulmonary fibrosis may therefore be resulting from the increased accumulation of 
these foamy AMφ. The susceptibility of HPS1 mice to a novel multiple oropharyngeal BLM-induced 
pulmonary fibrosis, and the phenotype of AMφ were investigated in the above studies. 
In the studies here the phenotype of naïve HPS1 mice was first reaffirmed. It was observed in 
accordance with literature these had hypopigmented ears, paws and tails but not coat (Figure 4.16). 
HPS1 mice did not have intrinsic cellular infiltration (Figure 4.17) or collagen accumulation (Figure 
4.18), although there was a non-significant trend suggesting increase in pro-inflammatory (TNF-α 
and IL-6) (Figure 4.19), and reduction in pro-fibrotic (Col1α1 and fibronectin) (Figure ϰ͘ϮϬͿ 
mediators. HPS1 mice did not have different numbers of AMφ, lymphocytes and granulocytes as 
compared to WT C57BL/6 controls (&igure 4.21), nor increased number of foamy AMφ (Figure 4.22), 
and AMφ had no increased levels of pro-inflammatory (TNF-α, CXCL1) (Figure 4.23) and pro-fibrotic 
(fibronectin) mediators (Figure 4.24). 
HPS1 mice showed reduced tolerance to BLM challenge as observed by increased weight loss as 
compared to WT C57BL/6 controls (Figure 4.25), which was in accordance to the literature696. 
However, increased weight loss occurred during the late inflammatory phase (days 8-11); this was 
also not accompanied by increased collagen transcript levels (Figure 4.29) and accumulation (Figure 
4.27) within the lungs, suggesting that reduced BLM tolerance was due to increased inflammation 
but not increased susceptibility to BLM-induced pulmonary fibrosis. Indeed there was a trend 
suggesting increase in IL-6 in the lungs to support this hypothesis (Figure 4.28). There was no 
difference in AMφ (Figure 4.31) or granulocyte (Figure 4.33) infiltration, although there was a lack of 
accumulation of lymphocytes (Figure 4.32). There was no difference in the number of foamy AMφ 
(Figure 4.34 and 4.35), suggesting that accumulation of cholesterol crystals in AMφ is not 
prerequisite of reduced tolerance in HPS1 mice. There were increased protein levels of IL-12 p40 
(total) (Figure 4.36) and fibronectin (Figure 4.37) in HPS1 mice as compared to WT C57BL/6 controls 
at day 7 that returns to basal levels by day 14. Increased IL-12 p40 levels may lead to the reduced 
BLM tolerance in HPS1 mice observed in the late inflammatory phase at day 7. 
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In the following sections, the limitations of the HPS1 mice versus WT C57BL/6 control studies and 
their potential implications will first be assessed in section 4.ϲ.2.1. The experimental results will
then be discussed in sections 4.ϲ.2.2 – 4.ϲ.2.5, and the future directions will be evaluated in section
4.ϲ.2.6.
4.ϲ.2.1 Experimental limitations 
The primary experimental limitations in the comparison studies between HPS1 and WT C57BL/6 
mice, in both the experiments with naïve mice and also BLM-induced pulmonary fibrosis, were that 
due to time constraints, only one study was carried out to a limited sample size. The data from HPS1 
mice with respect to pro-inflammatory and pro-fibrotic mediators and also cellular infiltration was 
very diverse, perhaps because the increased levels of these parameters are secondary to tissue 
injury resulting from defective lysosomal transport. In other words, there may be other factors aside 
from HPS1 mutation associated defective lysosomal transport that may contribute to lung injury in 
HPS1 mice. A greater number of mice is therefore required to test for significance, and the number 
of mice needed can be determined using online power calculators. This will be discussed further in 
the discussion of results later. 
Similar to the BLM-induced pulmonary fibrosis in WT C57BL/6 mice only studies (section 4.ϲ.1),
histological analyses for cellular infiltration (H&E staining) and collagen accumulation (PSR staining) 
have been described qualitatively but not measured quantitatively. Further positive pixel counts of 
the histological slides will be required to assess the level of staining. 
In the following sections, experimental results from the comparison of HPS1 mice with WT C57BL/6 
controls in unchallenged (naïve), or saline or BLM-challenged conditions are discussed with respect 
to the limitations mentioned above (sections 4.ϲ.2.2 to 4.ϲ.2.5). Section 4.ϲ.2.6 explores future
directions to the HPS1 studies, and section 4.ϲ.2.7 concludes the findings of section 4.ϲ.2.
4.ϲ.2.2 HPS1 mice have hypopigmentation in their ears, paws and tails 
In initial studies, the phenotype of HPS1 mice was assessed with respect to appearance and 
histological findings to validate findings from others, and to establish a baseline reference for further 
studies in BLM-induced pulmonary fibrosis. HPS1 mice that have been generated in-house had 
hypopigmented ears, paws, and tail but normal (black) coat colour compared to WT C57BL/6 
controls (Figure 4.16), which was in accordance to the literature. Melanocytes only reside in follicles 
on the adult mouse back skin, whereas melanocytes are found in interfollicular epidermis and 
dermis as well as follicles of tail and skin813. Hypopigmentation may be caused by faulty intracellular 
trafficking in melanocytes as a result of defective HPS1 protein. Hypopigmentation in the ears and 
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tails but not coat colour can be explained by differential regulation of different types of melanocytes 
found at these sites814.  
4.ϲ.2.3 HPS1 mice do not spontaneously develop pulmonary fibrosis 
Observations from histological slides revealed that in accordance with previous literature there 
appeared to be no alterations in alveolar architecture, cellular infiltration (Figure 4.17) and excess 
collagen accumulation (Figure 4.18) in naïve HPS1 mice compared to WT C57BL/6 controls. 
Differential cell count also confirmed that there was no difference in cellular composition within the 
alveolar space between naïve HPS1 mice and WT C57BL/6 controls (Figures 4.21). This was in line 
with a previous report in that HPS1 mice, unlike their human counterparts, do not spontaneously 
develop pulmonary fibrosis696. These results suggest that naïve HPS1 mice have neither intrinsic 
inflammation nor pulmonary fibrosis. However, as these observations have been made qualitatively, 
further measurements involving positive pixel count of hematoxylin- or PSR-stained lungs will have 
to be carried out to quantify cellular infiltration and collagen accumulation respectively. 
Having verified from histological analyses that HPS1 mice do not have increased cellular infiltration 
nor fibrosis, novel studies were carried out here to evaluate whether or not HPS1 lungs had low level 
underlying active inflammation and/or fibrosis that may be amplified rapidly in response to an insult 
(e.g. BLM-challenge). Gene transcript analyses showed a trend suggesting increase in inflammation 
(IL-6 and TNF-α) (Figure 4.23), but a trend suggesting reduction for fibronectin production (Figure 
4.24). It is possible that IL-6 and TNF-α transcripts may be increased as a response to mild tissue 
injury resulting from defective release by AECs of homeostatic proteins, such as pulmonary 
surfactants and mucin695. It may also be possible that HPS1 mice are more susceptible to infection by 
airborne pathogens due to lysosomal defects, although this has not been reported. The increased 
gene transcripts may be contributed by resident AEC2s. IL-6 is an inducer of Col1α1 and fibronectin 
expression via promoting TGF-β expression; it was therefore surprising that a non-significant trend 
suggesting reduced levels of these ECM components were observed in HPS1 mice. Perhaps other low 
level of pro-inflammatory mediators present, such as TNF-α, is present to inhibit Col1α1 gene 
expression367. The enhanced inflammation in response to BLM challenge, rather than any pro-fibrotic 
response, are more likely to be associated with the weight loss observed. AMφ did not appear to 
contribute to neither inflammation (Figure 4.23) nor fibrosis (Figure 4.24) in naïve HPS1 mice. 
Further repeats will have to be carried out to test the significance of these observations. 
4.ϲ.2.4 Reduced tolerance to BLM challenge is not correlated with more severe pulmonary fibrosis in 
HPS1 mice 
Following the characterisation of naïve HPS1 mice, their susceptibility to BLM-induced pulmonary 
fibrosis was assessed. In these studies the novel multiple low dose oropharyngeal protocol was used 
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to challenge HPS1 mice and WT C57BL/6 controls with BLM. In addition to mimicking repeated 
challenge to the lung by a persistent irritant, lower dosage per challenge allows better BLM 
tolerance in mice. This has enabled for the first time evaluation of BLM-induced pulmonary fibrosis 
in HPS1 mice beyond the late inflammatory phase (day 7) reported by Young et al.696 into the active 
(day 14) and established fibrotic phases (day 21). Percentage weight loss was used in these studies 
as a crude indicator for tolerance to BLM challenge, as mice that are more poorly generally lose 
more body weight. BLM challenge of mice induced a more severe weight loss in HPS1 mice 
compared to WT controls between days 8 to 11, indicating that HPS1 mice had reduced BLM 
tolerance (Figure 4.25). A previous study has attributed reduced BLM tolerance of HPS1 mice to 
elevated BLM-induced pulmonary fibrosis696. However, PSR staining revealed that there was 
decreased collagen accumulation (and established fibrosis) in HPS1 mice (Figure 4.27). This is in line 
with gene transcript levels of Col1α1, and also fibronectin, observed in BLM challenged HPS1 mice, 
which had a reduced duration of increased levels (day 7 increase only in HPS1 mice, versus day 7 and 
14 increase in WT C57BL/6 control), thereby signifying shorter active fibrosis (Figures 4.29 and 4,30). 
IL-6 transcript levels in BLM challenged HPS1 mice followed a similar trend, suggesting a shorter 
duration of inflammation as well (Figure 4.28). However, there was a trend suggesting increase in 
the elevation of IL-6 levels in BLM challenged HPS1 mice compared to WT C57BL/6 controls at day 7 
(Figure 4.28). Collectively, it may appear that in contrast to the previous study by Young et al.696, 
reduced tolerance in HPS1 mice is not due to increased susceptibility to BLM-induced pulmonary 
fibrosis, but rather as a result of increased inflammation. Further investigation into the change in 
levels of other pro-inflammatory mediators with proposed roles in pulmonary fibrosis, such as IL-1β 
and IL-12 p40, have to be carried out to test whether or not increased inflammation does occur in 
HPS1 mice. The role of inflammation can then be examined by assessing whether or not 
preventative or therapeutic anti-inflammatory treatment can improve BLM tolerance in HPS1 mice. 
Alternatively, there may be a difference in kinetics in BLM-induced pulmonary fibrosis between HPS1 
mice and WT C57BL/6 controls. HPS1 mice may have an initial burst in collagen production shortly 
after BLM challenge, which may then be rapidly degraded and resolved. Indeed, protein level 
analyses revealed that there was a trend suggesting an increase of IL-12 p40 (total) (Figure 4.36), 
and also elevated fibronectin (Figure 4.37) levels in AMφ from BLM-challenged HPS1 mice compared 
to WT C57BL/6 controls at day 7 that were matched in both strains by day 14. It may be possible that 
increased macrophage recruitment by IL-12 p40123, and elevated fibroblast migration by 
fibronectin520,521, may occur earlier in HPS1 mice and contribute to reduced BLM tolerance. 
Resolution of wound repair requires the coordinated elimination of the persistent irritant, 
reparation of the alveolar epithelium and endothelium, and clearance of apoptotic and necrotic cells 
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and excessive ECM components. There have been few studies that have investigated potential 
mediators involved in resolution of pulmonary fibrosis. One such mediator that has been identified is 
Mfge 8, which decreases severity in BLM-induced pulmonary fibrosis by binding and targeting 
collagen for cellular uptake through its discoidin domains815. It would be interesting to assess the 
levels of Mfge8 to determine whether or not there was indeed an increased resolution of pulmonary 
fibrosis in BLM-challenged HPS1 mice.  
The difference in dosing regimen may also affect development of pulmonary fibrosis in mice. The 
single high dose regimen used by Young et al 696 may have incurred a more severe initial tissue injury 
that resulted in an exaggerated fibrotic response. On the other hand, the repeated low dose regimen 
used in my studies may have allowed for better tolerance of mice to BLM-induced tissue injury, 
which resulted in a milder fibrotic response, thereby masking the differences in pulmonary fibrosis 
between the two strains of mice. Further assessment of the gene transcript and protein levels of 
other pro-inflammatory mediators with known roles in pulmonary fibrosis, including IL-12 p40 and 
TNF-α, will have to be carried out to determine whether or not increased inflammation was indeed 
present in HPS1 mice. Earlier time points will have to be assessed for the expression of various pro-
inflammatory and pro-fibrotic mediators in repeated BLM dosing regimen to evaluate the potential 
difference in kinetics in pulmonary fibrosis between the two strains. 
It is also possible that other systemic immune effects may contribute to such reduced BLM 
tolerance, although this is unlikely as BLM activity has been reported to be restricted to the lung 
only670,671. Future studies will have to be carried out to evaluate the potential participation of other 
organs in the increased susceptibility of HPS1 to BLM-challenge, for example the kidneys, that 
function to remove BLM from the body.  
4.ϲ.2.5 There is decreased lymphocytic infiltration in BLM-challenged HPS1 mice as compared to WT 
controls 
There was an increase in the number of AMφ (Figure 4.31) and foamy AMφ (Figure 4.34 and 4.35) in 
both strains of mice following BLM-challenge compared to saline controls, suggesting that AMφ and 
foamy AMφ may participate in the pathology of pulmonary fibrosis, and the consequent stress may 
in turn lead to the weight loss observed in both mouse strains (Figure 4.25). However, there was no 
difference in the number of AMφ (Figure 4.31) and foamy AMφ (Figure 4.34 and 4.35) observed 
between BLM-challenged HPS1 mice and WT controls, suggesting that these cell populations are less 
likely to contribute to the increased weight loss in HPS1 mice. An absence in lymphocytic infiltration 
into the alveolar space was observed in BLM-challenged HPS1 mice as compared to WT C57BL/6 
controls (Figure 4.32), although the role of lymphocytes in pulmonary fibrosis is unclear (Section 
1.1.4.5). Further studies will have to be carried out to determine the role of various lymphocytes in 
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pulmonary fibrosis. For example, DTR can be used to deplete specific subpopulations of T and B 
lymphocytes in DTR transgenic mice, including all T lymphocytes (CD3), T helper cells (CD4), cytotoxic 
T lymphocytes (CD8) or B lymphocytes (BLyS), and the corresponding effects on BLM-induced 
pulmonary fibrosis analysed. Lymphocytes from BLM-challenged WT C57BL/6 controls can also be 
isolated and introduced into BLM-challenged HPS1 mice and their effects on pulmonary fibrosis 
assessed. 
4.ϲ.2.6 Future directions 
4.ϲ.2.6.1 Evaluation of the root cause(s) for reduced BLM tolerance in HPS1 mice 
There is evidence suggesting a difference in kinetics for the pathology of BLM-induced pulmonary 
fibrosis between HPS1 mice and WT C57BL/6 controls prior to and at day 7; further studies at earlier 
time points may be helpful in distinguishing differences between HPS1 and WT C57BL/6 mice 
regarding their response to BLM and the development of lung damage. The levels of inflammatory 
cell infiltration, collagen accumulation, and also protein levels of pro- and anti-fibrotic mediators will 
be assessed. The role of AMφ with regards to inflammation and fibrosis can also be analysed. 
Alternatively it may be possible that reduced tolerance to BLM is not caused by more severe 
pulmonary fibrosis. Further analysis of a potential systemic effect to BLM, or reduced BLM removal 
by other organs, such as the kidney, in HPS1 mice is required to evaluate whether or not non-
pulmonary effects are involved in increased pathology to oropharyngeal BLM-challenge.  
4.ϲ.2.6.2 Evaluation of pulmonary fibrosis in HPS1/HPS2 double mutant mice 
HPS1 and HPS2 patients develop interstitial pulmonary fibrosis that resembles IPF in terms of 
disease progression1,693, and its UIP histopathology1. This phenomenon is observed in HPS1/HPS2 
double homozygous recessive mice, which spontaneously develop interstitial pulmonary fibrosis at 
nine months to one year of age. It would be of interest to evaluate the events leading up to and 
during naturally occurring pulmonary fibrosis in mice, which would improve our understanding of 
the initiation and progression of this devastating disease. There are several parameters to be 
measured: the levels of pro-inflammatory, pro-fibrotic, tissue remodelling mediators and also 
alarmins within the lung and BALF that can be assessed at a genetic level by microarrays or at a 
protein level by multiplex assays; cellular infiltration and collagen accumulation can be assessed by 
histological analyses; AEC2 hyperplasticity can be evaluated by measurement of development genes 
that play a role in dysregulated wound healing (e.g. Shh). 
Spontaneous pulmonary fibrosis in HPS1/HPS2 mice that results from effective intracellular 
trafficking is thought to result either directly or indirectly with AMφ activation as mentioned 
(section ϰ͘ϭ͘ϯ).
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measuring apoptotic markers, including PTEN and active caspase 3. AMφ may also contribute to the 
resolution of fibrosis through the efferocytosis of apoptotic cells and phagocytosis of cellular debris 
and/or irritants, thereby removing the source of inflammation. The phagocytic rate of AMφ can be 
measured by phagocytosis assays to measure their uptake of apoptotic cells, pathogens and/or 
latex beads. 
4.ϲ.2.7 Summary  
Collectively these results suggest that naïve HPS1 mice do not spontaneously develop pulmonary 
inflammation or fibrosis, but have reduced tolerance to BLM challenge. This reduced BLM tolerance 
however does not appear to be correlated with more severe pulmonary fibrosis as mentioned in a 
previous study696. This may represent a difference in kinetics of BLM-induced pulmonary fibrosis in 
HPS1 mice whereby inflammation, fibrosis and resolution is accelerated compared to that in WT 
C57BL/6 controls. It is interesting to learn what constitutes to hastened resolution of fibrosis in 
HPS1 mice. Alternatively, this may indicate non-pulmonary effects of BLM that may affect tolerance 
to this drug. Further studies assessing the cause of reduced BLM tolerance in HPS1 mice will 
improve our understanding of the other side effects of BLM, which may be manipulated to improve 
survival in mouse models of BLM-induced pulmonary fibrosis, and also human patients undergoing 
BLM chemotherapy. Further assessment of spontaneous pulmonary fibrosis in HPS1/HPS2 mice may 
provide clues to the natural (not artificially generated) course of induction and progression of 
pulmonary fibrosis in mice. 
4.ϲ.3 Conclusion 
Together these results show that AMφ display heterogeneity in BLM-induced pulmonary fibrosis. 
M1-like AMφ accumulate in the late inflammatory phase (day 7), whereas M2-like AMφ accumulate 
from the early to the late fibrotic phases (days 14 to 21). During BLM-induced pulmonary fibrosis, 
AMφ secrete mediators that are able to increase Col1α1 mRNA transcripts in pulmonary fibroblasts. 
Foamy macrophages were also found to accumulate in the alveolar space of BLM-challenged mice. 
The role of foamy macrophages in pulmonary fibrosis was evaluated in BLM-challenged HPS1 mice 
due to their alleged elevated number of foamy macrophages, their increased susceptibility to BLM-
induced pulmonary fibrosis, and the similarities in pathologies between HPS1 and IPF patients (e.g. 
UIP histological pattern). However, in the studies here HPS1 mice had reduced tolerance to BLM-
challenge that was independent of pulmonary fibrosis, and there was an absence of an increased 
foamy macrophage accumulation with respect to WT C57BL/6 controls. This suggests that HPS1 
mice are not good models for the study of foamy macrophages. Further experiments involving the 
isolation of foamy macrophages directly by flow cytometry, or perhaps the depletion of foamy 
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macrophages by inducing cholesterol efflux using high density lipoproteins (e.g. Apo-AI) can reveal 
the potential role of these cells. 
230 
Chapter 5 
The role of pathogen recognition receptors on alveolar macrophages 
in bleomycin-induced pulmonary fibrosis 
Chapter 5 | The role of PRRs on AMφ in BLM-induced pulmonary fibrosis 
231 
Chapter 5| The role of PRRs on AMφ in BLM-induced pulmonary 
fibrosis 
5.1 Introduction 
PRRs are expressed on a number of cells of the innate and adaptive immune system, including AMφ, 
and also resident structural cells, such as AECs. PRRs detect exogenous pathogens or endogenous 
alarmins and trigger immune responses. PRRs also play a critical role in pulmonary fibrosis through 
the recognition of alarmins released by necrotic cells following tissue injury628,630–632,816,817, including 
HA fragments628,630–632,816,817, HMGB1651, and uric acid231. This may result in further tissue injury 
induced by chronic inflammation, leading to subsequent dysregulated wound healing. PRRs are also 
thought to exacerbate pulmonary fibrosis in IPF patients following viral infection19. A variety of PRRs 
are increased on all types of BAL cells in IPF patients, including TLR2595, TLR3596, TLR7, TLR9595,596 and 
NLRP3231,666. The importance of these receptors in pulmonary fibrosis has been highlighted in various 
mouse studies (section 1.2.4); however, none of these studies have directly addressed the role of 
PRRs on AMφ. 
AMφ express a range of such PRRs capable of recognizing endogenous alarmins or exogenous 
irritants that can induce chronic inflammation and potential fibrosis within the lung. TLR2 are 
extracellular PRRs found on the cell surface of macrophages and recognize LMW (<500kDa) HA 
fragments, which are alarmins that accumulate during tissue injury in IPF patients and within the 
BLM mouse model of pulmonary fibrosis630–632. TLR2 stimulation by HA fragments promotes the 
upregulation of pro-inflammatory mediator genes in MH-S cells (a mouse AMφ-derived cell line) 
including the chemokines CCL3/MIP-1α, CCL4/ MIP-1β, CXCL2/MIP-2 and the cytokine TNF-D628. 
These chemokines actively recruit pro-inflammatory cells487,818,819 and promote inflammation-
induced tissue injury. BLM also appears to be a TLR2 ligand, and promotes the production of pro-
inflammatory mediators in a human monocytic cell line817. HMGB1 is an alarmin that is upregulated 
in macrophages and injured epithelial cells during acute exacerbation of IPF651, and is important in 
BLM-induced pulmonary fibrosis654. HMGB1 can induce a pro-inflammatory response directly 
through TLRs 2, and 4607–610, or indirectly amplify TLR2 and TLR9 responses in peritoneal 
macrophages by acting as a molecular chaperone for their respective ligands611,653,820. 
TLR9 are intracellular PRRs found on endosomal surfaces that recognise extracellular histones as 
alarmins and promote a pro-inflammatory response. In a model of hepatic ischemic/ reperfusion 
(I/R) injury in rat liver, there was an increase of extracellular histones. Injection of exogenous 
histones exacerbates I/R injury in wild type (WT) mice, but this exacerbation was absent in TLR9-/- or 
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MYD88657. TLR7 are also intracellular PRRs that are found on endosomal membranes. TLRs 7 and 9 
may be involved in the acute viral exacerbation of pulmonary fibrosis through their anti-viral 
responses (See Section 1.2.ϰ). 
The NLRP3 inflammasome are intracellular PRRs that are found in the cytoplasm of macrophages 
and promotes a pro-inflammatory response in LPS-primed AMφ challenged by silica, which is known 
to cause interstitial lung disease, resulting in an increase of IL-1β secretion. The NLRP3 
inflammasome can also induce a pro-inflammatory response in LPS-primed peritoneal macrophages 
from WT mice challenged by silica or asbestosis, but this is abolished in NLRP3-/-, Caspase 1 -/- and 
ASC-/- (components of the NLRP3 inflammasome) mice665. The NLRP3 inflammasome can be 
stimulated by other endogenous alarmins, including extracellular ATP667, amyloid-β821, ROS822 and 
monosodium urate (MSU) crystals823.  
5.2 Hypothesis 
AMφ express a number of PRRs and therefore can be stimulated by a variety of exogenous 
pathogens or endogenous alarmins to induce pro-inflammatory responses. It was proposed that 
alarmins are present at elevated levels in pulmonary fibrosis due to passive release by necrotic cells, 
or active release by immune cells and further promote tissue injury. In this chapter experiments are 
designed to test the hypothesis that PRR expression on AMφ is increased and when ligated may 
drive a more pronounced pro-inflammatory response. This outcome may as a consequence generate 
more extensive tissue injury.  
5.3 Aims 
The aim of the following studies are to: 
1. Assess the mRNA and protein levels of several PRRs that have been reported to be
upregulated in BALF of IPF patients595,596, including TLR2, TLR7, TLR9 and NLRP3, in BLM-
challenged mice as compared to saline controls. The gene transcript and protein levels of
TLR4, a PRR that shares many common ligands with TLR2, including HA fragments and
HMGB1, was also assessed.
2. Evaluate the changes of protein level of several pre-selected mediators that are associated
with pulmonary fibrosis following challenge of AMφ with respective ligands to their elevated
PRRs. This may help identify the possible role of these PRRs in pulmonary fibrosis.
The potential value of the results described in this section is that they may identify key PRRs on AMφ 
that have increased expression in pulmonary fibrosis and this information may add to our 
understanding of their role in chronic inflammation that results in tissue remodelling in the lung. 
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5.4 Methods 
5.4.1 Multiple oropharyngeal dose protocol for BLM-induced pulmonary fibrosis 
BLM-induced pulmonary fibrosis in mice were carried out as described in section 2.2.Ϯ. In brief, WT 
C57BL/6 male mice or male or female HPS1 mice were challenged three times by oropharyngeal 
instillations of 50μl of 0.13U BLM sulfate (Kyowa Nippon, Kayakin Co Ltd.) or saline controls at 72 
hour intervals on Days -7, -4 and -1. Mice were culled on days 7, 14 and 21 post-challenge, which 
include time points in the ALI phase, early fibrotic phase and the progressive fibrotic stage 
respectively (Figure 2.1). 
5.4.2 Flow cytometry 
3 x 105 cells/ml of BAL cells were separated into 3 tubes (i.e. 1 x 105 cells/tube), one for positive 
staining for proteins of interest (surface: CD11c, TLR2, and TLR4; intracellular: TLR7, TLR9, 
NLRP3), one for unstained negative control, and one for isotype control of nonspecific antibody 
binding. For each tube, cells were resuspended at 1x105 cells per 100 Pl Fluorescence Activated Cell 
Sorting (FACS) analysis buffer (DPBS + 0.1% FCS), 1% of Fc Receptor (FcR) block (Miltenyi Biotech) 
and 5% mouse serum per 100Pl reaction. FcR block was added to prevent non-specific binding of 
the Fc (constant) region of detection antibodies/ isotype controls to cell surface FcR that may 
generate a false positive signal. Mouse serum was added to prevent non-specific binding of 
the variable region of detection antibodies/ isotype controls.  
In the preliminary study, cells for staining of proteins of interest were incubated with FACS analysis 
buffer, 2 μg/ml CD11c-APC, 2 μg/ml TLR2-eFluor 660®, 2 μg/ml TLR4-APC for 30 minutes in the dark 
at 4oC. For the staining for isotype control, cells were incubated with 2 μg/ml Armenian hamster IgG-
APC, 2 μg/ml Rat IgG2b-eFluor®, or 2 μg/ml Rat IgG2a-APC for 30 minutes in the dark at 4oC. For 
unstained controls, cells were incubated in FACS analysis buffer only for 30 minutes in the dark at 
4oC. 
BAL cells were then washed in 2 ml DPBS and centrifuged at 500 g for 10 minutes at 4oC. The 
supernatant was then discarded and BAL cells were fixed and permeabilised with 300 μl BD Cytofix/
CytopermTM (BD Biosciences) for 20 minutes in the dark at 4oC. BAL cells were then washed with 2 
ml BD Perm/WashTM (BD Biosciences). Cells were then resuspended in 500 μl 1 x Cell Fix (BD 
Biosciences) (diluted 1:10 from 10x stock solution), and kept in the dark at 4oC until further analysis. 
For intracellular staining, permeabilised BAL cells were stained with primary (2 μg/ml TLR7-rabbit or 
2 μg/ml TLR9-Biotin) or directly conjugated antibodies (10 μl/106 cells NLRP3-APC) for 30 minutes in 
the dark at 4oC, and then washed with 2 ml BD Perm/WashTM (BD Biosciences). For isotype controls, 
cells were incubated with primary (2 μg/ml rabbit control IgG or 2 μg/ml RatIgG2A-Biotin) or directly 
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conjugated antibodies (10 μl/106 cells Rat IgG2A-APC) for 30 minutes in the dark at 4oC This step was 
repeated for staining with secondary antibodies (2 μg/ml mouse anti-rabbit or Streptavidin-APC 
respectively for TLR7 or TLR9, or their respective isotype control staining). Stained cells were then 
resuspended in 500 μl 1 x Cell Fix (BD Biosciences), and kept at 4oC until further analysis. The staining 
procedures for AMφ are summarised in table 5.1 below. 
Surface Intracellular 
TLR2 TLR4 TLR7 TLR9 NLRP3 
No 
Stain N/A N/A N/A N/A N/A N/A 
Stained 
1o Anti-Mouse CD11c PE 
Anti-Mouse 
CD282 
(TLR2) 
eFluor® 660 
Mouse 
TLR4-APC 
MAb (Clone 
267518), 
Rat IgG2A 
Rabbit Anti-
TLR7 
antibody 
Rat Anti-
Mouse 
CD289 
(TLR9) 
Biotin 
Monoclonal 
Anti-mouse 
NLRP3-APC 
2o N/A N/A N/A 
Goat 
polyclonal 
Secondary 
Antibody to 
Rabbit IgG - 
Fc (DyLight® 
650) 
Streptavidin 
APC N/A 
Isotype 
control 
1o
Armenian 
Hamster IgG 
Isotype 
Control PE 
Rat IgG2b 
Isotype 
Control 
eFluor® 660 
Rat IgG2A-
APC Isotype 
Control, Rat 
IgG2A 
Rabbit 
Control IgG 
Rat IgG2A 
control 
Biotin 
Rat IgG2A-
APC Isotype 
Control, Rat 
IgG2A 
2o N/A N/A N/A 
Goat 
polyclonal 
Secondary 
Antibody to 
Rabbit IgG - 
Fc (DyLight® 
650) 
Streptavidin 
APC N/ A 
Table 5.1 Summary of antibodies used for staining BAL cells in preliminary flow cytometry study. 
In the follow-up study, AMφ were stained for the cell surface proteins CD11c, TLR2, MHC-II and 
MRC1 with directly conjugated antibodies, including 2 μg/ml anti-mouse CD11c-APC/Cy7, 2 μg/ml 
anti-mouse TLR2 eFlour660®, 2 μg/ml MHC-II-FITC and 2 μg/ml MRC1-PerCP/Cy5.5. For the isotype 
control, cells were incubated with 2 μg/ml Armenian hamster IgG-APC, 2 μg/ml Rat IgG2b Isotype 
Control eFluor® 660, 2 μg/ml Rat IgG2b-FITC and 2 μg/ml Rat IgG2a-PerCP/Cy5.5 in the same cell 
surface staining protocol mentioned above. Unstained controls were also prepared by the 
incubation of AMφ in FACS analysis buffer in the absence of antibodies as with the aforementioned 
protocols. 
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Anti-Rat/ anti-Hamster IgK compensation kit (BD Biosciences) was used on the day of flow 
cytometric analysis to compensate for fluorophore spectral overlap in multi-colour staining. The set 
consists of two populations of microparticles, including the BD CompBeads Anti-Rat/Hamster Ig, κ 
particles (positive control), which bind any rat or hamster κ light chain-bearing immunoglobulin, and 
the BD CompBeads Negative Control (FBS) Particles (negative control), which has no binding 
capacity. When mixed together with a flurochrome-conjugated rat or hamster antibody, the BD-
CompBeads provide distinct positive and negative (background fluorescence)-stained populations 
that can be used to set compensation levels manually. Anti-Rat/ anti-Hamster IgK compensation kit 
(BD Biosciences) was prepared according to manufacturer’s instructions. In brief, 60 μl of BD 
CompBeads Anti-Rat/Hamster Ig, κ particles and 60 μl of BD CompBeads Negative Control (FBS) 
particles were added to 100 μl FACS buffer (+0.1 % FBS), and 20 μl of pre-diluted antibody stock 
(where final concentration in 220 μl is equivalent to that used in experiments) was subsequently 
added. This process was carried out separately for every different type of fluorophore that was used 
in multicolour experiments. The BD CompBeads Anti-Rat/Hamster Ig, κ particles/ BD CompBeads 
Negative Control (FBS) particles/ antibody mixture was then incubated in the dark at 4oC for 30 
minutes. The mixture was then washed with 2 ml FACS buffer and centrifuged at 500 g for 10 
minutes. The supernatant containing unbound antibodies was discarded, and the pellet containing 
Compbeads was resuspended in 500 μl FACS buffer.  
FACS data was read by FACS CANTO II (BD Biosciences). Prior to recording data for samples, 
compensation for spectral overlap was determined from the pre-stained BD CompBeads Anti-
Rat/Hamster Ig, κ particles/ BD CompBeads Negative Control (FBS) particles using the compensation 
setup on the FACS CANTO II software (BD Biosciences). FACS data was analyzed by Flowjo (Tree Star 
Inc). AMφ were defined as SSChi FSChi CD11c+, and the expression of the protein of interest was 
gated with respect to their respective isotype controls. Data was presented as median fluorescence 
intensity (MFI) and % positive with respect to isotype controls. 
5.4.3 AMφ enrichment and culture 
AMφ were isolated from BAL of BLM-challenged mice or saline controls at days 7, 14 and 21 
following two PBS washes in mice, and enriched by plastic adherence to tissue culture plates, the 
details of which are described in detail in sections 2.2.4, 2.2.5 and 2.2.6. 1 x 105 AMφ per well in a 
48-well plate that were enriched by plastic adherence for 90 minutes were further cultured in fresh
macrophage complete media for 4 hours for mRNA level analysis of various PRRs. Total RNA 
extraction, reverse transcription, and qRT-PCR for mRNA level analysis were carried out as described 
at sections 2.2.11, 2.2.12 and 2.2.13 respectively. 
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5.4.4 TLR2 and 9 stimulation of AMφ isolated from saline or BLM-challenged mice 
1 x 105 AMφ per well in a 6-well plate were enriched by plastic adherence for 90 minutes as 
mentioned above (section 5.4.3). AMφ were then stimulated with 10 ng/ml of TLR2 ligand, 
Pam2CSK4 (P2C) (Invivogen), 10ng/ml of TLR9 ligand, CpG-ODN (A) (Invivogen), or 10 ng/ml CpG-
ODN (A) control (Invivogen) in fresh culture media for 24 hours. Measurements of proteins of 
interest in culture supernatant was measured as mentioned in sections 2.2.14 (fibronectin enzyme 
linked immunosorbent assay (ELISA) and 2.2.15 [Meso-Scale Discovery (MSD)]. 
5.4.5 Statistical analyses 
All statistical analysis was carried out using GraphPad Prism 6.0 software (GraphPad software, CA, 
USA). Normality distribution was tested by visual inspection of data as there are insufficient 
samples for normality testing. Two-way ANOVA was used to compare time-course curves followed 
by Sidak’s multiple comparison test to determine the significance. P values of less than 0.05 were 
deemed statistically significant with *** p < 0.001, ** p <0.01 and * p < 0.05. Error bars represent 
standard deviation (SD) as indicated in the figure legends. 
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5.5 Results 
5.5.1 The mRNA and protein level analyses of PRRs on AMφ isolated from saline or BLM-
challenged mice 
In the following investigation, the mRNA and protein levels of the selective PRRs on AMφ from BLM-
challenged mice or saline controls was investigated. This analysis was designed to test the 
hypothesis that exposure to BLM might activate AMφ via PRRs and that this may contribute to the 
pathology that occurs in pulmonary fibrosis. Stimulation of cells via their PRRs lead to the release of 
pro-inflammatory mediators (e.g. TNF-α), which may in turn upregulate PRR mRNA levels in a 
positive feedback loop1,2. For example, macrophages stimulated by peptidoglycan or LPS, which are 
TLR2 and TLR4 ligands respectively, have increased mRNA levels of TLR2 in a NFKB –dependent 
manner1. Stimulation of P815 cells (mastocytoma cell line) with IL-12 increases TLR2 mRNA levels in 
a PI3K-dependent manner2. It is possible that TLRs that are increased in levels as a result of such 
inflammation have a greater response to their respective ligands in vivo and therefore have a larger 
contribution to pathology in pulmonary fibrosis. 
The mRNA level analysis revealed that TLR9 was significantly increased by 3-fold (p<0.01) at day 7 
after the last dose of BLM. Although there was a trend indicating a 2-fold increase in the mRNA 
levels of TLR9 in AMφ from BLM-challenged at days 14 and 21 compared to the saline controls it was 
not significant (Figure 5.2). This suggests that TLR9 mediated activation of AMφ may play a more 
important role in inflammation than fibrosis. In contrast to TLR9 mRNA levels no increases in TLRs 2, 
4 and 7, and NLRP3 specific transcripts was detected (Figure 5.1). 
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Figure 5.1 Selected Pathogen Recognition Receptor (PRR) mRNA levels in alveolar macrophages (AMφ) from 
bleomycin (BLM)-challenged mice compared to saline controls. 8-10 week old male mice were challenged 
via an oropharyngeal route three times at 72 hour intervals with either saline, or 0.13 International Units 
(IU) BLM, and were culled at days 7, 14 and 21 respectively. 1x105 AMφ were seeded per well of a 48-well
tissue culture plate and enriched by plastic adherence for 90 minutes. Isolated AMφ were further cultured 
in fresh macrophage complete media for 4 hours. PRR mRNA levels in AMφ was determined by qRT-PCR. 
Each sample was run in triplicates and the average was used to determine mean of sample repeats. Data is 
represented as mean ± SD; n=3 from two separate studies. Two way ANOVA with Sidak post-test was 
carried out. BD, Below Detection; BLM, Bleomycin; NS, Not significant. 
Figure 5.2 TLR9 mRNA levels in AMφ from BLM-challenged mice compared to saline controls. 8-10 week old
male mice were challenged via an oropharyngeal route three times at 72 hour intervals with either saline, or 
0.13 IU BLM, and were culled at days 7, 14 and 21 respectively. 1x105 AMφ were seeded per well of a 48-
well tissue culture plate and enriched by plastic adherence for 90 minutes. Isolated AMφ were further
cultured in fresh macrophage complete media for 4 hours. TLR9 mRNA levels in AMφ was determined by 
qRT-PCR. Each sample was run in triplicates and the average was used to determine mean of sample
repeats. Data is represented as mean ± SD; saline (day 7), n=5; saline (day 14), n=3; saline (day 21), n=3; 
BLM (day 7), n=9; BLM (day 14), n=7; BLM (day 21), n=5  from two separate studies. Two way ANOVA with 
Sidak post-test was carried out; **: p< 0.0. BD, Below Detection; BLM, Bleomycin; NS, Not significant. 
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TLR2 and TLR4 are expressed on the cell surface and binds to bacterial peptidoglycans and LPS 
respectively. TLR7 and TLR9 are intracellular and found on endosomal surfaces, and binds to viral 
RNA and CpG-DNA respectively. The NLRP3 inflammasome is also intracellular and found in the 
cytoplasm, and is activated by binding to endogenous alarmins (e.g. ROS, uric acid). Preliminary flow 
cytometric analysis was performed in order to evaluate the surface protein levels of extracellular 
TLRs 2 and 4, and intracellular protein levels of intracellular TLRs 7 and 9, and the NLRP3 
inflammasome, to investigate if their level was modulated following exposure to BLM.  
The results showed that TLR2 was constitutively expressed on the surface of all AMφ; however, 
there was an increase in this baseline level as determined by MFI on the AMφ at days 7, 14 and 21 
post BLM challenge. Thus it appears that cell surface protein levels of TLR2, which is present on AMφ 
in control mice is enhanced following challenge with BLM (Figure 5.3).   
In order to validate this result for TLR2 surface protein levels a repeat experiment was performed in 
which a 2.3-fold increase in MFI (from 1500 to 3500; p<0.001) on AMφ from the BLM-challenged 
mice was also observed compared to saline controls (p<0.001) (Figures 5.4 and 5.5). The increase in 
surface protein but not transcript levels observed for TLR2 may be due to post-transcriptional or 
post-translational regulation; a possibility is the mobilisation of internal stores of preformed TLR2 
onto the cell surface upon appropriate stimuli. MicroRNAs (miRNA) may also inhibit the translation 
of TLR2 gene transcript under normal conditions by targeting it for degradation, but this process may 
be inhibited under fibrotic conditions. It is unclear whether or not the increasing surface protein 
levels of TLR2 in AMφ where they are already highly expressed would matter physiologically. The 
potential increased response to TLR2 stimulation in AMφ owing to increased TLR2 surface protein 
levels was evaluated in section 5.ϱ.2͘Ϯ. The ƉŚǇƐŝŽůŽŐŝĐĂůrole of the increased surface protein levels
of TLR2 in AMφ of mice in promoting BLM-induced pulmonary fibrosis can also be tested by 
inhibiting TLR2 using concentration gradient of pharmacological inhibitors or neutralising antibodies. 
Flow cytometric analysis also revealed an increase in the number of AMφ expressing TLR9 from 4% 
to 25% upon BLM challenge at day 7, but this elevation returned to saline control levels by day 14. 
These results are concurrent with the mRNA level data, and suggest that TLR9 mediated signalling 
may play a more important role in the inflammatory response initiated by BLM. It was observed that 
AMφ showed a biphasic increase in the intracellular protein levels of NLRP3: there was an increase 
from 22% to 67% of AMφ expressing NLRP3 at day 7 upon BLM challenge, and from 36% to 59% at 
day 21. This suggests that NLRP3 may play a role in the initiation of pulmonary fibrosis through 
inflammation induced tissue injury, and maintenance of established fibrosis, but has no role in active 
fibrosis. No increased surface protein level for TLR4 or intracellular protein level for TLR7 was 
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observed in BLM-challenged mice compared to saline controls (Figure 5.3). It was observed that the 
median fluorescence intensity (MFI) for the AMφ stained with TLR7-specific antibodies is lower than 
that of the corresponding isotype control at days 7 and 21. This indicates that there was more 
binding for isotype controls than TLR7-specific antibodies. The large amount of non-specific binding 
by the isotype control may be due to rabbit polyclonal antibodies versus a monoclonal antibody 
being used. Perhaps a monoclonal antibody would provide greater specificity in binding in the 
future. 
The median fluorescence intensity (MFI) for isotype controls for the intracellular proteins, including 
TLR7, TLR9 and NLRP3 were high despite the usage of FcR to eliminate non-specific binding on the 
cell surface. This is presumably because isotype controls are optimised towards cell surface proteins. 
Isotype controls may therefore not behave as expected intracellularly than that on the cell surface 
because of inherent difference in amino acid composition to different amount of fluorophore 
conjugated to the isotype control versus the experimental antibody. 
Collectively these data suggest that TLRs2 and 9 are increased in AMφ during BLM-induced 
pulmonary fibrosis, and therefore may play a role in pathological response resulting in fibrosis within 
the lung.
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Figure 5.3 PRR protein levels in AMφ from BLM-challenged mice compared to saline controls. 8-10 week old 
C57BL/6 male mice were challenged via an oropharyngeal route three times at 72 hour intervals with either 
saline, or 0.13 IU BLM, and were culled at days 7, 14 and 21 after the last dose. BAL cells were then 
harvested and stained with cluster of differentiation (CD)11c-PE (2 μg/ml), and toll like receptor (TLR)2-
eFluor660® (2μg/ml), TLR4-APC (2μg/ml) at the cell surface, or intracellular staining for TLR7-Rabbit 
(2μg/ml) + mouse anti-rabbit-APC (2μg/ml), TLR9-Biotin (2μg/ml) + Streptavidin-APC (2μg/ml), or NLRP3-
APC (10μl/106 cells) antibodies. AMΦ were identified as Side Scatter (SSC)hi Forward Scatter (FSC)hi CD11c+ 
and autofluorescent in the FL1 channel, and analysed for changes in protein levels of TLR2, TLR4, TLR7, TLR9 
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5.5.2 The effect of TLR stimulation on AMφ phenotypes 
5.5.2.1 TLR stimulation of AMφ from naïve mice 
Having identified that TLR2 surface protein level and TLR9 mRNA level were elevated in AMφ 
following BLM challenge the potential role of these TLRs in pulmonary fibrosis was then investigated. 
To this end, AMφ from naïve mice were challenged with media in the control group, P2C (a synthetic 
diacetylated lipoprotein that acts as a TLR2 ligand), CpG-ODN (A) (a TLR9 ligand), or non-CpG ODN 
(GpC-ODN) [a non-TLR9 specific control for CpG-ODN (A)]. The production of several mediators with 
reported roles in pulmonary fibrosis, including IL-1β, TNF-α368,438,739, CXCL1438,755,826, IL-10592,594,827,828, 
and IL-12 p40 (total)125,739 were then analysed. 
From the results it was observed that TLR2 stimulation of AMφ significantly increased the production 
of the pro-inflammatory mediators. IL-1β levels were elevated by about 4-fold from 7 pg/ml to 27 
pg/ml (p<0.01), similarly protein levels of TNF-α was increased by about 7-fold from 2,400 pg/ml to 
18,000 pg/ml (p<0.005). CXCL1 was amplified by 12-fold from 840 pg/ml to 10,000 pg/ml (p<0.001). 
Production of IL-10 was also escalated by around 8-fold from 33 pg/ml to 260 pg/ml (p<0.05), possibly 
as part of a negative feedback loop activated to limit inflammation (Figure 5.6). Activation via TLR9 
significantly increased the production of IL-12 p40 (total) by 3.7-fold from 469 pg/ml to 1,740 pg/ml 
(p<0.01). However, it had little effect on the protein levels of other pro-inflammatory mediators 
investigated (Figure 5.6). Therefore, TLR9 stimulation of AMφ may trigger a predominantly pro-
inflammatory response indirectly through the induction of a TH1 response.  
Collectively these data demonstrate that activation of AMφ via different TLRs trigger different 
mediator profiles which could potentially drive pulmonary fibrosis through either interacting or 
independent mechanisms. For example, IL-12 p40 can promote IL-1β induced fibrosis in mice via the 
IL-17A pathway125 or recruit macrophages in silica-induced pulmonary fibrosis124. On the other hand, 
long term lung-specific overexpression of IL-10 in mice induced pulmonary fibrosis through fibrocyte 
recruitment and M2-like macrophage activation through a CCR2/CCL2 axis594. 
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Figure 5.6 Protein level analysis of pro-inflammatory mediator biosynthesis in AMφ from naïve mice 
following TLR2 or TLR9 stimulation. 1x105 AMΦ were seeded per well of a 48-well tissue culture plates for 
90 minutes, and then stimulated with macrophage complete media, 10 ng/ml Pam૛CSK4 (P2C), 3μM CpG-
ODN (A) (CpG) or 3μM CpG-ODN (A) Control (Ctrl) in fresh macrophage complete media for 24 hours. IL-1β, 
TNF-α, CXCL1, IL-10 and IL-12 p40 (total) was determined by Meso Scale Discovery (MSD) of culture 
supernatants. Each sample was run in duplicate in MSD determination of protein levels, and the average 
was used to calculate sample repeat mean. Data are represented as mean ± SD; n=3 from three separate 
studies. One way ANOVA with Tukey post-test was carried out; *: p<0.05, **: p< 0.01, ***: p<0.005, ****: 
p<0.001. BD, Below Detection; ND, Not Detected. IL-12 p40 (total) incudes free IL-12 p40, IL-12 p40 
homodimers and IL-12 p40 heterodimers (IL-12 p70 and IL-23). Standard curves for the MSD of the above 
proteins are found in appendix 9. 
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5.5.2.2 TLR stimulation of AMφ from saline or BLM-challenged mice 
Having identified that different TLR stimulation induces a different mediator response in naïve mice, 
it was next investigated whether or not the increased surface protein levels of TLRs 2 and 
intracellular protein levels of TLR9 observed in AMφ isolated from BLM-challenged mice result in an 
enhanced response to the corresponding ligands and produce increased amounts of associated 
mediators.  
In order to investigate these issues AMφ isolated at different stages of BLM-induced pulmonary 
fibrosis in mice or saline controls were stimulated with TLRs 2 or 9 ligands and assessed for their 
responsiveness by their production of the pro-inflammatory mediators investigated in the previous 
section (section 5.ϱ.2.1), including IL-1β, TNF-α, CXCL1, IL-10 and IL-12 p40 (total). The key 
comparison here is the fold change in pro-inflammatory mediator levels in AMφ culture 
supernatant, between BLM-challenged mice and the corresponding saline control, following TLR2 or 
TLR9 stimulation. It was presumed that an increased response to TLR ligands would induce a greater 
fold change in protein levels of pro-inflammatory mediators in AMφ. The panel of mediators was 
extended to assess the effect of TLRs 2 or 9 stimulation on pro-fibrotic mediators, such as 
fibronectin, and other mediators that have been reported to be involved in pulmonary fibrosis, 
including IL-6409,437, CCL2/MCP-1439,752–755, CCL3/MIP-1α436–438,440, CCL4/MIP-1β436,437, CCL5/RANTES462, 
and also CCL20/MIP-3α. 
AMφ from BLM-challenged mice have an increased response to TLR2 mediated signalling, and the 
levels of a number of pro-inflammatory mediators induced following P2C stimulation were increased 
as compared to their saline controls (Table 5.1). IL-1β levels in the culture supernatant of P2C-
stimulated AMφ from BLM-challenged mice as compared to their corresponding saline controls 
were significantly increased by 8.6-fold at day 7 (p<0.001), 5.87-fold at day 14 (p<0.001), and 322.5-
fold at day 21 (p<0.05) (Figure 5.7). 
A significant enhancement in TNF-α protein levels in P2C-stimulated AMφ from BLM- versus saline 
challenge mice by 2.90-fold (p<0.01) was detected at day 21, but no such amplification was 
observed at days 7 and 14 (Figure 5.8).  
P2C stimulation induced increase in the protein levels of CXCL1 were also significantly elevated in 
AMφ from BLM-challenged mice as compared to saline controls by 2.53-fold at day 7 (p<0.001), 
1.51-fold at day 14 (p<0.005) and 3.09-fold (p<0.001) at day 21 (Figure 5.9).  
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Similarly levels of IL-10 following P2C stimulation was significantly increased in AMφ from BLM-
challenged mice as compared to saline controls by 24.8-fold at day 7 (p<0.001), 10.3-fold at day 14 
(p<0.01) and 23.3-fold (p<0.001) at day 21 (Figure 5.10). 
There was also a significant difference in IL-12 p40 (total) production between P2C-stimulated AMφ 
from saline or BLM-challenged mice by 5.00-fold at day 7 (p<0.001); 4.00-fold at day 14 (p<0.005) 
and 7-fold at day 21 (p<0.01) (Figure 5.11). However, this increase in IL-12 p40 (total) production 
may be due to direct effects of BLM as opposed to TLR2 stimulation, as P2C has little effect on IL-12 
p40 (total) production (Figure 5.6). Alternatively in contrast to the saline controls BLM exposure 
might increase the sensitivity of AMφ to TLR2 ligation ex vivo. However as noted above there was an 
increased response to TLR2 stimulation in saline controls at day 14 by around 2- to 3-fold as 
compared to its counterparts at other time points, although the reason for this is unclear. TLR2 
stimulation had no effect on the production of the M2-associated protein fibronectin in both saline 
controls and BLM-challenged mice (Figure 5.12). 
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There is a significant enhancement of IL-6 protein levels by 11.6-fold at day 7 (p<0.01), 9.61-fold at 
day 14 (p<0.01) and 27.5-fold (p<0.01) at day 21 in P2C stimulated BLM-challenged mice as 
compared to saline controls (Figure 5.13).  
As regards to CCL2 protein levels, there was a non-significant trend indicating an elevated response 
by 3.95-fold (p>0.05) at day 7 (Figure 5.14) between P2C stimulated AMφ from BLM-challenged mice 
as compared to the corresponding saline control. However, there was a significant increase in CCL2 
production by 2.06-fold at day 14 (p<0.05) and 5.23-fold at day 21 (p<0.001) in P2C stimulated AMφ 
from BLM- versus saline-challenged mice (Figure 5.14). 
A significant rise in CCL4 protein levels, in P2C stimulated AMφ from BLM-challenged mice as 
compared to saline controls, by 2.30-fold was observed at day 7 (p<0.05), and 3.39-fold (p<0.001) at 
day 21 (Figure 5.16). There is also a non-significant trend suggesting an enhancement of CCL4 levels, 
by 1.73-fold (p>0.05), at day 14 (Figure 5.16).  
The levels of CCL5 in the culture supernatant of P2C-stimulated AMφ isolated from BLM-challenged 
mice as compared to the saline controls increased significantly from by 6.09-fold; p<0.01 at day 7, 
4.28-fold at day 14 (p<0.001), and 4.43-fold at day 21 (p<0.001) (Figure 5.17). 
It was also noted that CCL20 protein was significantly increased by 4.24-fold at day 7 (p<0.05), but 
the levels were below the limit of detection at days 14 and 21(Figure 5.18). These increases in the 
response to TLR2 stimulation with P2C corresponds to increased TLR2 surface protein levels in these 
cells observed from flow cytometric analysis (Figure 5.4 and 5.5). 
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TLR9 stimulation with CpG-ODN (A) induced only a minimal change in pro-inflammatory mediators 
and also fibronectin levels in the saline controls, but this was increased in BLM-challenged animals 
(Table 5.2). It was observed that IL-1β levels were significantly increased from 2.14 pg/ml to 17.7 
pg/ml at day 7 (8.28-fold; p<0.005), and from 1.76 pg/ml to 14.8 pg/ml at day 14 (8.42-fold; p<0.001) 
(Figure 5.19) in CpG-ODN (A) stimulated AMφ from saline controls as compared to BLM-challenged 
mice. There was also a trend suggesting an escalation in IL-1β from 1.24 pg/ml to 104 pg/ml at day 
21 (83.8-fold; p>0.05). TNF-α levels were also significantly elevated from 111 pg/ml to 421 pg/ml at 
day 7 (3.80-fold; p<0.05) (Figure 5.20). In the fibrotic phases, a trend suggesting a small rise in TNF-α 
protein was revealed, namely an increase from 187 pg/ml to 594 pg/ml at day 14 (3.18-fold; p>0.05) 
and 167 pg/ml to 1,170 pg/ml at day 21(6.99-fold; p>0.05) (Figure 5.20). Similarly, there was a 
significant amplification of CXCL1 protein levels from 322 pg/ml to 2,670 pg/ml at day 7 (8.29-fold; 
p<0.001), 545 pg/ml to 3,180 pg/ml at day 14 (5.84-fold; p<0.001) and 288 pg/ml to 3,960 pg/ml at 
day 21 (13.8-fold; p<0.001) (Figure 5.21). Moreover, IL-10 was detected rising significantly from 6.68 
pg/ml to 112 pg/ml at day 7 (16.8-fold; p<0.001), 7.66 pg/ml to 179 pg/ml at day 14 (23.3-fold; 
p<0.05) and 6.61 pg/ml to 90 pg/ml (13.7-fold; p<0.05) (Figure 5.22). The increased response to CpG 
stimulation in AMφ was concurrent with a significant elevation in TLR9 mRNA levels observed at day 
7, and also is consistent with the trend suggesting increase in TLR9 mRNA levels in the fibrotic 
phases at days 14 and 21 (Figure 5.2). There was no such increase in protein levels of TLR9 in the 
fibrotic phases (days 14 and 21) as observed by flow cytometry (Figure 5.3). This may result from the 
fact that TLR9 is weakly expressed in AMφ, and the increased levels of TLR9 in the fibrotic phases 
may be too small to be accurately detected by flow cytometry.  
There was also a significant increase in IL-12 p40 (total) production between P2C-stimulated AMφ 
from saline or BLM-challenged mice, rising from 477 pg/ml to 4870 pg/ml at day 7 (10-fold; 
p<0.001); 200 pg/ml to 5,780 pg/ml at day 14 (29-fold; p<0.05) and 764 pg/ml to 8.080 pg/ml at day 
21 (11-fold; p<0.05); however, this increase may be in part be due to BLM-challenge of mice rather 
than TLR9 stimulation per se (Figure 5.23).  
CpG-ODN (A) stimulation led to a decrease of fibronectin protein levels in AMφ isolated from BLM-
challenged mice. However, this reduction was also observed for AMφ challenged with the non-CpG 
control (Figure 5.24). This suggests that oligonucleotides in general, rather than CpG-ODN (A), 
suppressed fibronectin protein level in a non-TLR9 specific manner. Although guanine-
phosphorothiorate-cytosine (GpC)-ODN, the negative control used for these studies, has been 
demonstrated to be non-stimulatory ligands of TLR923, little is known about the other properties of 
this ligand. However, it may be possible that GpC-ODN may bind to other PRRs that recognize nucleic 
acids to trigger an immune response. For example, GpC-ODN was reported to have 
Chapter 5 | The role of PRRs on AMφ in BLM-induced pulmonary fibrosis 
263 
immunosuppressive activities on plasmacytoid DCs (pDC) in a TLR7 manner24. GpC-ODN may act on 
AMφ via such nucleic acid binding PRRs to suppress fibronectin protein level. 
Collectively these results demonstrate that the increased surface protein level of TLR 2 and elevated 
mRNA level of 9 in AMφ from BLM-challenged mice compared to saline controls, is correlated with 
an increased pro-inflammatory response to their respective ligands. This suggests that the elevated 
levels of TLRs in AMφ of BLM-challenged mice are functional and may result in an increased AMφ 
response to endogenous alarmins, such as HMGB1, that are also ligands to TLR2 or TLRs 2 and 9 
respectively. Alternatively stimulation of TLRs does not appear to modulate the levels of the ECM 
component fibronectin. 
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5.5.3 HMGB1 levels in BALF from saline or BLM challenged mice 
From the above studies, it was demonstrated that AMφ isolated from BLM challenged mice have 
increased surface protein and mRNA levels of TLRs 2 and 9 respectively, which corresponded to the 
enhanced pro-inflammatory responses they displayed to their respective ligands when stimulated ex 
vivo. It was next investigated whether or not any naturally occurring ligands to these TLRs 
accumulated in vivo in the BLM disease model. One such ligand is the alarmin HMGB1, a 
nucleoprotein that is passively released by necrotic cells647, or actively released by activated 
macrophages648–652. HMGB1 can stimulate TLRs 2, and 4607–610, and also act as a molecular chaperone 
for TLR 2, 4, and 9 ligands, escorting them to their respective receptors to amplify the pro-
inflammatory response611,653,820. HMGB1 also appears to be important in pulmonary fibrosis: HMGB1 
protein levels are elevated in macrophages and injured epithelial cells in IPF patients with acute 
exacerbations651. An increase in HMGB1 levels was also detected in the BALF of mice challenged with 
a single BLM dose, and clearance of HMGB1 with therapeutic antibodies attenuated the 
pathophysiological responses654.  
In the following study, whether or not there was an accumulation of HMGB1 in BALF was assessed in 
mice challenged with the novel repeat BLM dosing regimen or saline controls. The results reveal that 
HMGB1 levels were elevated in BALF from BLM challenged mice as compared to saline controls, 
escalating from 116 ng/ml to 257 ng/ml at day 7 (2.22-fold; p<0.01), and from 112 ng/ml to 237 
ng/ml at day 14 (2.11-fold; p<0.01). HMGB1 levels also appeared to be marginally increased, albeit 
at non-significant levels, from 122 ng/ml to 152 ng/ml (1.23; p>0.05) at day 21 (Figure 5.25). These 
results suggest that there are changes in the levels of a select alarmin in mice following the onset of 
fibrosis and reinforce the importance of PRR signalling in the pathophysiology of pulmonary fibrosis. 
 Figure 5.2ϱŶĂůǇƐŝƐŽĨ,D'ϭƉƌŽƚĞŝŶůĞǀĞůƐŝŶ>&ŝƐŽůĂƚĞĚĨƌŽŵ>DͲĐŚĂůůĞŶŐĞĚŵŝĐĞĐŽŵƉĂƌĞĚƚŽƐĂůŝŶĞ
ĐŽŶƚƌŽůƐ͘ϴͲϭϬǁĞĞŬŽůĚŵĂůĞϱϳ>ͬϲŵŝĐĞǁĞƌĞĐŚĂůůĞŶŐĞĚǀŝĂĂŶŽƌŽƉŚĂƌǇŶŐĞĂůƌŽƵƚĞƚŚƌĞĞƚŝŵĞƐĂƚϳϮ
ŚŽƵƌŝŶƚĞƌǀĂůƐǁŝƚŚĞŝƚŚĞƌƐĂůŝŶĞ͕ŽƌϬ͘ϭϯ/h>D͕ĂŶĚǁĞƌĞĐƵůůĞĚĂƚĚĂǇƐϳ͕ϭϰĂŶĚϮϭĂĨƚĞƌƚŚĞůĂƐƚĚŽƐĞ͘
>&ǁĂƐĐŽůůĞĐƚĞĚďǇϮǆϬ͘ϱŵůW^ǁĂƐŚĞƐŽĨƚŚĞŵŽƵƐĞůƵŶŐƐ͘ĂƚĂŝƐƌĞƉƌĞƐĞŶƚĞĚĂƐŵĞĂŶц^͖Ŷсϱ
;ƐĂůŝŶĞĚĂǇƐϳ͕ϭϰĂŶĚϮϭͿ͖Ŷсϲ;>DĚĂǇƐϳ͕ϭϰĂŶĚϮϭͿĨƌŽŵƚǁŽƐĞƉĂƌĂƚĞƐƚƵĚŝĞƐ͘ĂĐŚƐĂŵƉůĞǁĂƐƌƵŶĂƐ
ĚƵƉůŝĐĂƚĞƐĨŽƌƚŚĞĚĞƚĞƌŵŝŶĂƚŝŽŶŽĨƉƌŽƚĞŝŶůĞǀĞůƐďǇ>/^͕ĂŶĚƚŚĞĂǀĞƌĂŐĞǁĂƐƚĂŬĞŶƚŽĐĂůĐƵůĂƚĞƚŚĞ
ŵĞĂŶŽĨƚŚĞƐĂŵƉůĞƌĞƉĞĂƚƐ͘dǁŽǁĂǇEKsǁŝƚŚ^ŝĚĂŬƉŽƐƚͲƚĞƐƚǁĂƐĐĂƌƌŝĞĚŽƵƚ͖ΎΎ͗ƉфϬ͘Ϭϭ͘͕ĞůŽǁ
ĞƚĞĐƚŝŽŶ͖>D͕ůĞŽŵǇĐŝŶ͖E^͕EŽƚƐŝŐŶŝĨŝĐĂŶƚ͘
Chapter 5 | The role of PRRs on AMφ in BLM-induced pulmonary fibrosis 
272 
5.6 Discussion 
The mRNA levels and flow cytometric analyses of various PRRs from AMφ at different stages of BLM-
induced pulmonary fibrosis and their functional outcomes were determined in this chapter. The 
mRNA level analysis revealed that TLR9 gene transcripts were increased, whereas from flow 
cytometry it was noted that TLR2 surface protein expression was elevated in AMφ isolated from 
BLM challenged mice. An amplified response was observed when AMφ from BLM-challenged mice 
were stimulated with TLRs 2 or 9 ligands. There were also increased levels of the alarmin HMGB1, 
which is a ligand for TLRs 2, 4 and 9, in the BAL of BLM-challenged mice. 
In the following section, experimental limitations and their implications to analyses will first be 
discussed in section 5.ϲ.1. Experimental results will be discussed in sections 5.ϲ.2-5.ϲ.4, and this will 
be followed by future directions of the studies in section 5.ϳ and conclusions to the chapter at 
section 5.ϴ. 
5.6.1 Experimental limitations 
There are several experimental limitations to these studies. Preliminary studies were carried out for 
the flow cytometry analyses of increased surface expression of TLRs 2 and 4, or enhanced 
intracellular section for TLRs 7, 9 or NLRP3. Further repeats will have to be carried out validate the 
observations made. 
There were high MFI for isotype controls for intracellular staining in flow cytometry studies. It was 
later discovered that isotype controls were optimised for extracellular use, and may have different 
binding activities when exposed to an intracellular environment. It may therefore be more suitable 
to employ a negative control in the form of FMO, where all antibodies but the one to be controlled is 
present. 
The majority of these studies BLM-challenged mice were compared to their respective saline 
controls, whereas data of constitutive expression from naïve mice was absent. Whereas it was 
assumed that saline challenge does not elicit any responses within the lung, mRNA and protein 
levels of AMφ-derived mediators of interest from naïve controls should still be evaluated to 
determine their basal expression. 
As discussed before IL-12 p40 (total) measures different forms of IL-12 p40 and was found to be 
increased in TLR2 and TLR9 stimulated AMφ isolated from BLM-challenged mice, although the exact 
oligomer form it is increased in is unknown. As different IL-12p40 isoforms have different functions, 
it is important to determine the specific isoform that is increased to determine its function, and 
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further protein analyses of specific IL-12 isoforms will have to be carried out. In light of these 
experimental limitations, results are discussed in the sections below (section 5.62 - 5.64). 
5.6.2 TLR2 surface protein and TLR9 gene transcript levels are increased in BLM-challenged 
mice 
The mRNA and protein levels of various PRRs on AMφ, including TLRs 2, 4, 7 and 9, and NLRP3, were 
determined by qRT-PCR and flow cytometry respectively. This is the first time that the mRNA and 
protein levels of various PRRs is systematically assessed on AMφ specifically and over a time course, 
rather than collectively over the whole lung at a single time point in BLM-challenged mice. This may 
thus allow the determination of the potential participation of various PRRs on AMφ phenotype at 
different stages of pulmonary fibrosis. Results have indicated a role for TLRs 2 and 9 in the pathology 
of pulmonary fibrosis. There was increased TLR2 surface protein (Figures 5.3 and 5.4) but not in 
mRNA levels (Figure 5.1).  As regards TLR9 mRNA levels (Figure 5.2) they were significantly elevated 
during the inflammatory phase (day 7), and had a non-significant trend suggesting elevation at the 
active (day 14) and established fibrotic phases (day 21) in BLM-challenged mice compared to saline 
controls, but flow cytometry indicated no change in intracellular expression was observed between 
the two groups. These results may represent errors in gating owing from the use of isotype control 
that are optimised for extracellular use (see section 5.ϲ.1), although it is also likely that protein 
expression is not increased. 
The increase in TLR2 surface protein levels but not mRNA levels suggest that it is regulated at the 
post-transcriptional and/or post-translational level, which may reflect its function in the lung 
microenvironment. TLR2 is constitutively highly expressed and participates in tissue homeostasis in 
addition to innate immunity to extracellular bacteria. For example, TLRs 2 and 4 have an anti-
apoptotic role on AECs through the recognition of HMW HA816. This PRR may also recognize airway 
microbiota to influence the nature of the host immune response to ‘invader pathogens’ and thereby 
maintain pulmonary homeostasis831,832. For example, Staphylococcus aureus (S. aureus), the most 
common commensal bacteria found in the human upper respiratory tract833 negatively regulates 
influenza-mediated ALI in a TLR2-dependent manner834. Under normal conditions, these airway 
microbiota may also continuously enter the alveoli upon breathing834.  
A potential post-translational regulatory mechanism is the transmigration of TLR2 from the 
endoplasmic reticulum (ER) where it is synthesized onto the cell surface. ER-intrabodies are 
artificially generated intracellular antibodies (intrabodies) consisting of an N-terminal ligand-binding 
domain that is fused to a C-terminal ER-retention domain. ER-intrabodies are therefore expressed 
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and retained within the ER, and can act to inhibit protein surface expression and/or secretion. 
Adenoviral gene transfer allowed overexpression of anti-TLR2 ER-intrabodies (αT2ib) in human 
embryonic kidney (HEK) 293 cells, RAW264.7 (a murine monocyte cell line), and BMMφ, which 
abolished TLR2 surface expression and attenuated TLR2-dependent cell activation to Pam3CSK4 (a 
synthetic triacetylated lipoprotein)835, thereby indicating the importance of TLR2 surface expression 
to the responsiveness to extracellular PAMPs. To my knowledge there have been no reports on 
naturally occurring regulation of TLR2 activity through alteration of its surface expression. However, 
the decreased surface expression of another TLR, TLR4 plays a significant role in dampening of the 
inflammatory response following LPS tolerance836. Further studies will have to be carried out to 
determine the role of TLR2 surface expression in BLM-induced pulmonary fibrosis by blocking their 
transmigration to the cell surface, which can be achieved by the overexpression of αT2ib through 
adenoviral gene transfer in vivo systematically. The specific role of TLR2 surface expression on 
hematopoietic cells in pathology can also be determined through the assessment of changes in BLM-
induced pulmonary fibrosis in adoptive transfer experiments of bone marrow overexpressing αT2ib 
into non-transfected mice, or vice versa, as compared with non-transfected and transfected 
controls.  
The increase in TLR9 mRNA levels suggest that it is regulated at a transcriptional level, which may 
also reflect on its functionality. TLR9 is responsible for the recognition of CpG-ODN in intracellular 
viruses, but does not appear to display this homeostatic role. They may therefore be found to be 
weakly expressed on AMφ at basal levels in mice837 and humans838 and only induced during viral 
infection. Preliminary intracellular flow cytometry study of TLR9 revealed a small increase at day 7 in 
BLM-challenged mice that returned to basal levels at days 14 and 21. The lack of intracellular TLR9 
protein expression may be due to the use of isotype controls optimised for extracellular studies as 
negative controls, although it may be possible that TLR9 protein expression is unchanged at days 14 
and 21 owing to post-transcriptional inhibition. Further studies of TLR9 using FMO as negative 
control will have to be carried out to evaluate its protein expression in BLM-challenged mice versus 
saline controls. 
5.6.3 AMφ from BLM-challenged mice have increased response to TLR2 and TLR9 ligands 
Stimulation of AMφ from naïve mice with P2C and CpG-ODN (A), the ligands of TLR2 and TLR9 
respectively, have revealed different protein expression profiles. TLR9 stimulation induced a strong 
increase in the levels of the pro-inflammatory cytokine IL-12 p40 (total), whereas TLR2 stimulation 
resulted in a moderate increase in both pro-inflammatory (IL-1β, TNF-α, and CXCL1) and anti-
inflammatory (IL-10) mediator levels (Figure 5.6). These results indicate that TLRs not only recognize 
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specific ligands, but are also capable of generating distinct expression profiles that may bring about a 
certain degree of specificity to the pulmonary innate immune system. This is similar to previous 
observations made in pDCs839–841. Stimulation of AMφ from BLM-challenged mice with P2C or CpG-
ODN (A) revealed an amplified response to TLR2 and TLR9 respectively, with an increased production 
of pro- and anti-inflammatory mediators in both cases, but had no effect on fibronectin levels 
(Tables 5.1 and 5.2; Figures 5.7 to 5.24). However, TLR2-stimulated AMφ displayed a more robust 
increase in TNF-α (Figure 5.8) and CXCL1 (Figure 5.9) protein levels, whereas TLR9-stimulated AMφ 
had a stronger increase in IL-12 p40 (total) levels (Figure 5.23). This suggests that stimulation of AMφ 
via different TLRs may contribute to pulmonary fibrosis slightly differently. TNF-α facilitates IL-1β 
mediated increase in pro-inflammatory (e.g. CXCL1, CXCL2) and pro-fibrotic mediators (e.g. TGF-β, 
PDGF) that may contribute to tissue injury and fibrosis respectively376,377. The chemokine CXCL1 is 
the mouse analogue of human CXCL8, and may play a role in angiogenesis842. As highlighted before 
IL-12 p40 (total) measures monomeric and homodimeric IL-12 p40, and also heterodimeric IL-12 p70 
(p40 + p35) and IL-23 (p40 + p19) and each of these may play a role in pulmonary fibrosis. IL-12 p40 
is chemotactic for macrophages in vitro and in vivo383,384, and was proposed to promote silica-
induced pulmonary fibrosis through the macrophage recruitment124. IL-12 p40 facilitates IL-17A 
mediated BLM- and IL-1E-induced pulmonary fibrosis125. IL-23 may promote the differentiation of IL-
17 producing TH17 cells386–388, and IL-17A can mediate BLM125,385 or IL-1β induced pulmonary 
fibrosis125. On the other hand, IL-12 p70 protects from BLM-induced pulmonary fibrosis382, 
potentially through the induction of IFN-Υ382, thereby shifting the cytokine balance away from a pro-
fibrotic TH2 response. It is likely that TLR stimulation promotes the increased expression of IL-12 p40 
in the form of the bioactive IL-12 p70839. It has been reported that TLR2 promotes, whereas TLR9 
protects from BLM-induced pulmonary fibrosis in mice, which may be attributed to the different 
levels of IL-12 p70 generated in differentially stimulated AMφ. Further protein expression analyses 
of these different forms of IL-12 oligomers will have to be carried out to confirm this hypothesis.  
The stimulation of AMφ from BLM-challenged mice with P2C also increased the expression of other 
mediators with reported roles in IPF, namely IL-6, CCL2, CCL4, and CCL5 (Figure 5.13 to 5.17), which 
reinforces the potential role for TLR2 in pulmonary fibrosis. Further experiments will have to be 
carried out to assess the expression of these proteins following TLR9 stimulation. Together these 
studies suggest multiple potential roles for AMφ activation by TLR stimulation in pulmonary fibrosis. 
These suggestions have to be verified by various studies, including chemoattraction, angiogenesis 
and/or fibroblast activation studies, of hematopoietic cells, endothelial cells and/or fibroblasts 
respectively, which are co-cultured with supernatant from AMφ isolated from BLM-challenged mice 
and stimulated by either TLR2 or TLR9 ligands ex vivo. 
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5.6.4 The alarmin HMGB1 is increased in BALF of BLM-challenged mice 
There were increased levels of HMGB1 detected in BALF of BLM-challenged mice compared to saline 
controls (Figure 5.25). HMGB1 is an alarmin647 that plays an important role in pulmonary fibrosis in 
IPF patients651 and BLM-challenged mice654. HMGB1 may promote an inflammatory response directly 
through binding to TLRs 2 or 4607–610, or indirectly by chaperoning ligands of TLRs 2, 4 and 9 to their 
respective receptors611,653,820. Further immunofluorescence studies of lung histological sections and 
also coimmunoprecipitation studies from BLM-challenged mice can be carried out to evaluate 
binding of HMGB1 to various TLRs in pulmonary fibrosis. Other alarmins, such as LMW HA 
fragments, extracellular histones and HSP70 may also be present in BLM-induced lung injury and 
fibrosis. The contributions of these alarmins to pulmonary fibrosis can be evaluated by measuring 
their levels in BALF and lung from BLM-challenged mice. Alarmin-specific antibodies can then be 
administered into the lung at various stages of pathology to remove these alarmins, and the changes 
to collagen accumulation and fibrosis assessed.  
Given that endogenous alarmins are present in BALF at elevated levels, and there was also an 
increase in TLRs 2 and 9 expressions that correlated with amplified responses to their corresponding 
ligands in AMφ ex vivo, it was perhaps therefore surprising that there was little intrinsic increase of 
pro-inflammatory mediators observed in AMφ from BLM-challenged mice. There may be several 
non-exclusive reasons for this outcome. First, immunosuppressive mediators, including IL-10126,587,843 
and TGF-β are prevalent within the fibrotic lung and may dampen AMφ response to TLR stimulation. 
Second, there may be tolerance of TLRs347 to persistent alarmins in vivo. However, these reasons are 
unlikely as the results above have revealed that TLRs, including TLRs 2 and 9 at least, commence a 
functional response to commercially available ligands. Another reason may be that alarmins found in 
vivo may have a weaker pro-inflammatory capacity compared to commercially available TLR ligands 
in vitro. To better evaluate tissue injury induced AMφ activation, AMφ from naïve mice can be 
stimulated by various alarmins ex vivo and their expression profile of various pro-inflammatory and 
pro-fibrotic mediators can be characterised. The responsiveness of AMφ from BLM-challenged mice 
to these alarmins can then be assessed ex vivo. It may also be possible that alarmins act on AMφ in a 
paracrine manner, such that only AMφ in the vicinity of tissue injury is affected. In these studies, 
AMφ were isolated from across the whole lung from BLM-challenged mice, which was spatially 
heterogeneous and included both fibrotic and normal regions. It is likely that the protein expression 
of activated disease-state AMφ in fibrotic areas is masked by those from non-fibrotic areas. The 
distribution of alarmins in binding to various cells can be evaluated by immunohistochemistry. 
Protein expression of disease-state AMφ can be more specifically characterised by isolating them 
specifically by LCM from fibrotic areas.  
Chapter 5 | The role of PRRs on AMφ in BLM-induced pulmonary fibrosis 
277 
5.7 Future directions 
Although it was observed that TLR2 surface expression and TLR9 gene transcript expression were 
increased in AMφ of BLM-challenged mice, which corresponded to an increased response to their 
respective ligands, whether or not these responses translated into a pro- or anti-fibrotic response is 
unclear. To further evaluate the specific role of TLRs of AMφ in pulmonary fibrosis, the effects on 
BLM-induced pulmonary fibrosis, following adoptive transfer of AMφ from TLR2-/- or TLR9-/- mice into 
WT C57BL/6 mice that are depleted of AMφ (by liposomal chondrate), can be evaluated with respect 
to cellular infiltration, collagen accumulation and pro-fibrotic mediator levels. It is also possible to 
inhibit TLR2 and/or TLR9 of AMφ in BLM-challenged mice or saline controls in vivo through the 
application of pharmacological inhibitors and/or neutralising antibodies. The role of TLR2 and/or 
TLR9 can be determined through the comparison of the phenotype of AMφ isolated from TLR 
inhibited mice versus uninhibited controls. The effect of various alarmins that are found in the 
fibrotic lung, such as LMW HA fragments and HMGB1, on AMφ phenotype with respect to their 
protein expression of pro-inflammatory and pro-fibrotic mediators, and also their subsequent effects 
on fibroblast collagen expression, monocyte chemotaxis and or EMT can be assessed in co-culture 
studies. 
5.8 Conclusion 
Collectively these studies have for the first time identified TLRs 2 and 9 as the potential contributing 
PRRs on AMφ to BLM-induced pulmonary fibrosis, and demonstrated a corresponding increase in 
functional activity of AMφ in response to the ligands. These TLRs may contribute to pathology 
through the binding of endogenous alarmins, such as HMGB1, and release of a number of pro-
inflammatory mediators. The protective role of TLR9 stimulation in BLM-induced pulmonary fibrosis 
may be in part brought about by the TH1 –inducing cytokine IL-12 p70 that suppresses the pro-
fibrotic TH2 response. 
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Chapter 6| General Discussion 
In the following chapter, I will first review the key findings regarding the heterogeneity of AMφ in 
vitro and in vivo discovered in this thesis in section 6.1, the results of which will be summarised into 
a model of AMφ activation in section 6.2. I will then discuss the various experimental limitations to 
these studies and follow-up studies in section 6.ϯ. Future work to further advance the current 
findings will be discussed in section 6.4, and the thesis will be concluded in section 6.5.  
6.1 Significance of finding and key results 
AMφ have a known role in IPF through the release of various pro-inflammatory and pro-fibrotic 
mediators. Differential expression of these mediators may be accomplished by different macrophage 
subsets, which have been predetermined by selecting the in vitro culture conditions for BMMφ and 
MDM. Recent studies in IPF patients and rodent models of pulmonary fibrosis have reported the 
accumulation of M2-associated markers in BAL and lung, and M2 macrophages were therefore 
suggested to play a role in pathology. However, several caveats have put these findings into 
question. 
The translatability of macrophage subset-associated markers from artificially generated BMMφ in 
vitro into terminally differentiated AMφ in vivo is unclear. Whilst BMMφ may provide a useful model 
for the study of macrophage behaviour, they are artificially generated through the culture of bone 
marrow cells with M-CSF in mice, or GM-CSF in humans. These may not truly represent terminally 
differentiated AMφ that reside within the alveolar space, which are constantly exposed to a variety 
of homeostatic signals, exogenous pathogens, and also endogenous surfactants and growth factors 
within the lung. AMφ may therefore have different phenotypes to BMMφ such that markers 
identified within the two populations are not directly interchangeable. For example, CD11b is a well 
characterised macrophage marker that is identified in BMMφ and found in most tissue 
macrophages, but this is absent in AMφ and CD11c, a common dendritic cell marker, is found 
instead. The use of BMMφ subset markers for AMφ has not been limited to studies of pulmonary 
fibrosis, but also asthma, COPD278, and lung cancer. There is thus a need to validate macrophage 
subset markers identified from BMMφ in AMφ. 
Previous studies of AMφ heterogeneity in pulmonary fibrosis have assessed either M1- or M2-
associated markers. However, in an in vivo environment a multitude of inducing signals, including 
cytokines, growth factors, microbes, hypoxia and alarmins are present. Different signals may have 
accumulative effects on influencing AMφ phenotypes. For example, in vitro studies have revealed 
that IFN-Υ may amplify the pro-inflammatory phenotype induced by LPS stimulation738. IL-4 priming 
overnight prior to the addition of LPS amplifies the inflammatory response, whereas simultaneous 
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addition of IL-4 with LPS suppresses it844. IL-10 is also reported to amplify IL-4 induced M2 
phenotype845. Therefore in an in vivo environment, AMφ are unlikely to fall neatly into the category 
of a particular M1 or M2 subset, but rather display hybrid phenotypes. A simultaneous assessment 
of M1 and M2-associated markers on AMφ is therefore required to better characterise its 
phenotype. Another caveat of previous studies is that the phenotypes of AMφ were in general only 
characterised at a single time point in pulmonary fibrosis. As pulmonary fibrosis is a progressive 
disease that displays temporal heterogeneity, the changes of AMφ phenotype at different stages of 
pathology may be neglected. In pulmonary fibrosis, M1 macrophages were hypothesised to 
participate in initial inflammation induced tissue injury, whereas M2 and M2-like macrophages were 
involved in dysregulated wound healing and fibrosis. An analysis of AMφ phenotype over a time 
course is therefore required to assess the kinetics of AMφ contribution to the different stages of 
pathology. 
In addition to these potential limitations in the analysis of AMφ phenotypes in pulmonary fibrosis, 
the contribution of PRRs in selecting/modifying AMφ phenotypes in the pathology has not been 
addressed. Several TLRs, including TLRs 2, 3, 7, 8 and 9 are increased in the BAL cells of IPF patients. 
Rodent models of pulmonary fibrosis have also identified pathogenic roles for TLR2 and the NLRP3 
inflammasome, whereas TLR9 in contrary to its human orthologue was reported to be protective in 
mice. These PRRs may promote a pro-inflammatory response and alter AMφ phenotypes that are 
induced by cytokine priming. As extensive tissue injury occurs in pulmonary fibrosis, a large amount 
of alarmins are likely to be present and capable of modifying AMφ phenotypes through ligation to 
their respective PRRs. The expression and functional activity of various PRRs on AMφ specifically is 
therefore of interest to fully appreciate the activation of these cells. 
HPS is a collection of autosomal recessive genetic disorders that is characterized by abnormal 
biogenesis and/or function of LROs found in specialised secretory cells, including melanosomes, 
platelets, epithelial cells and macrophages690–692. HPS1 is a genetic disease prevalent in Northwest 
Puerto Ricans, and is commonly associated with interstitial pulmonary fibrosis, termed HPSPF, that 
resembles IPF in histopathology and progression. Foamy macrophages are often found in HPS1 
patients with or without HPSPF, although their role in pathology is unclear. HPS1 mice provide in 
part a disease model of HPS1 patients, although unlike their human counterparts these do not 
spontaneously develop pulmonary fibrosis. Nevertheless HPS1 mice were reported to have 
increased susceptibility to BLM-induced pulmonary fibrosis at the late inflammatory phase (day 7)696. 
The effect of BLM-induced pulmonary fibrosis in HPS1 mice has however not been assessed at later 
time points in this study where fibrosis is more prominent696. It was therefore interesting to evaluate 
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the severity of BLM-induced pulmonary fibrosis at the active (day 14) and established (day 21) 
fibrotic phases.  
The first significant finding was that terminally-differentiated AMφ displayed plasticity in vitro, and 
are able to respond to priming signals, including IFN-Υ and IL-13. IFN-Υ induced a ‘M1-like’ 
phenotype that is pro-inflammatory, whereas IL-13 promoted a ‘M2-like’ phenotype that is pro-
wound healing. Preliminary experiments also revealed that AMφ promoted a wound-healing 
phenotype in response to TGF-β and hypoxia.  LPS stimulation either augmented or suppressed 
priming induced AMφ phenotypes. These results revealed for the first time the plasticity of 
terminally differentiated AMφ in vitro, and validated the use of several subset-associated markers 
for future studies of AMφ heterogeneity in vivo. 
The second significant finding was that different AMφ subsets accumulated at various stages of BLM-
induced pulmonary fibrosis. M1-like AMφ were found at the late inflammatory phase (day 7), 
whereas a M1/ M2-like hybrids were present from day 7 to the established fibrotic phase (day 21). 
These results demonstrate here for the first time that AMφ are able to alter their phenotype during 
the progression in pulmonary fibrosis and potentially contribute to different aspects of disease. It is 
shown here as well that AMφ do not necessarily fall into a M1-like or M2-like phenotype ex vivo, but 
rather have a mixed phenotype that is in between these two polarization extremities.  
The third significant finding is that TLRs 2 and 9 were elevated, at the surface protein and gene 
transcript level respectively, in AMφ in BLM-induced pulmonary fibrosis, and this corresponded with 
an increased response to their ligands, P2C and CpG-ODN (A) respectively. The alarmin HMGB 1, 
which exerts its effects through the ligation of TLRs 2 and 4, or acting as a molecular chaperone to 
ligands of TLRs 2, 4 and 9 to their respective receptors, was also elevated in the BAL of BLM-
challenged mice. These results implicate a role for TLRs 2 and 9 in influencing AMφ phenotype in 
BLM-induced pulmonary fibrosis.  
The fourth major finding is that HPS1 mice appear to have reduced tolerance to BLM challenge 
between days 8 to 11, but this does not appear to be correlated with more severe pulmonary 
fibrosis. These results suggest that the susceptibility of HPS1 mice to BLM-induced pulmonary 
fibrosis requires reviewing, and broaden future studies to explore other mechanisms that may 
contribute to reduced tolerance to this chemotherapeutic agent. 
6.2 Model of AMφ activation in pulmonary fibrosis 
From the above studies, it was revealed that AMφ are able to respond to priming and/or stimuli to 
alter their mRNA and protein levels. Under normal conditions AMφ are constantly stimulated by 
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exogenous pathogens, but homeostasis is maintained by endogenous anti-inflammatory mediators 
(e.g. TGF-β) secreted by AECs.  
During initial tissue injury, inflammatory cells are recruited via pro-inflammatory chemokines 
released from tissue resident AEC and AMφ that are activated by alarmins via their TLRs in an 
attempt to clear cellular debris and the source of irritation. Fibroblasts and fibrocytes should also be 
recruited during acute inflammation to aid in ECM deposition and wound closure. 
In the case of IPF, tissue injury is thought to be prolonged, similar to that observed in silicosis/ 
asbestosis. Under these circumstances acute inflammation may become chronic in an IL-6 
dependent manner, which promotes the accumulation of long-lived macrophages and lymphocytes 
in place of short-lived granulocytes. This is particularly important to protect from further tissue 
damage as neutrophils produce large quantities of ROS and RNS that may lead to further tissue 
damage. The lung environment may switch from predominantly pro-inflammatory into an 
exaggerated wound-healing response, in a frustrated attempt to repair the injured tissue. There are 
several potential causes for such a switch in environment, perhaps due to anti-inflammatory 
mediators (e.g. TGF-B, IL-10) that are released as a negative feedback to the pro-inflammatory 
response, dampening of the pro-inflammatory response through prolonged TLR activation and also 
anti-inflammatory mediator engagement, and in the case of APCs, efferocytosis of apoptotic cells.  
The gene and protein expression of pulmonary macrophages may adapt to the aforementioned 
environmental cues to generate different subsets that are specialised in different functions. In acute 
inflammation, AMφ are more likely than not to be activated via PRR stimulation by alarmins released 
during tissue injury, and inflammation is further amplified through AMφ activation by pro-
inflammatory mediators. Indeed in Chapter 4, it was observed that AMφ isolated from day 7 of BLM-
induced pulmonary fibrosis had a M1-like phenotype. In normal wound healing however, AMφ may 
adopt a wound-healing M2-like phenotype following priming by anti-inflammatory mediators (e.g. 
TGF-β). On the other hand in chronic inflammation/ fibrosis, a M1/M2-like hybrid may result from 
simultaneous PRR stimulation by persistent tissue injury and the presence of excessive pro-wound 
healing/ pro-fibrotic mediators. These M1/M2 hybrid macrophages may further contribute to the 
non-resolving cycle of chronic inflammation and fibrosis through the simultaneous release of pro-
inflammatory and pro-fibrotic mediators. 
6.3 Experimental limitations  
As aforementioned in the previous chapters, there are several limitations with respect to 
experimental repeats, sample numbers, statistical analyses, and controls. Due to the wide 
preliminary scope of PhD project, there are several studies in this thesis, including in vitro mRNA 
and/or protein level analysis studies of IFN-Υ or IL-13-primed BMMφ and TGF-β and hypoxia-primed 
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AMφ in Chapter 3, and also evaluation of levels of TLR4, TLR7, TLR9 and NLRP3 on AMφ in Chapter 5. 
There are also insufficient sample numbers for the evaluation of naïve, saline or BLM-challenged 
HPS1 mice in Chapter 4, the experiments of which have to be repeated to confirm the results 
observed.  
Due to the lack of sample numbers, normality testing was based on visual inspection of data rather 
than statistical testing [e.g. Kolmogorov-Smirnov test (n=5), Shapiro-Wilk test (n=7), and D’Agostino 
test (n=8)]. This is a crude way of the assessment of normality and further repeats will have to be 
carried out to confirm parametric/ non-parametric distribution to determine the most appropriate 
statistical testing to be used. 
For the limitations to experimental controls, there is a lack of baseline controls from naïve mice in 
the studies of AMφ heterogeneity in vivo in BLM-induced WT C57BL/6 and HPS1 mice (Chapter 4), 
and also the studies of the role of PRR expressed on AMφ in BLM-induced pulmonary fibrosis 
(Chapter 5). It was assumed in the previous experiments that saline was inert and therefore saline 
controls would behave in a similar fashion as naïve mice. However, this assumption needs to be 
reaffirmed to determine constitutive expression of various proteins of interest by AMφ in 
unchallenged mice. 
For flow cytometry studies, there was also a lack of fluorescence minus one (FMO) controls, which 
are cells stained with all antibodies against the proteins of interest but the one that is being 
controlled. Instead isotype controls was used for gating for positively stained cells. As 
aforementioned, isotype controls may serve as good negative controls against non-specific antibody 
binding, but ultimately they have different specificity to the actual protein of interest-specific 
antibodies under use, and therefore are not the best candidates for negative control against cells 
unstained for that particular protein of interest. While spectral shift was very pronounced for MHC-II 
in IFN-Υ-primed AMφ in chapter 3, and also TLR2 for AMφ from BLM-challenged mice in chapter 5, 
flow cytometry results in chapters 3, 4 and 5 will therefore have to be repeated using FMO for a 
more accurate measurement of the changes in the respective protein levels. 
For histology staining, results were analysed qualitatively but no quantification assessment was 
carried out. While drastic changes with respect to cellular infiltration and collagen accumulation was 
observed for H&E and PSR staining respectively between saline and BLM-challenged WT C57BL/6 
mice, further assessment may be required to detect subtle differences in these parameters between 
BLM-challenged WT C57BL/6 and HPS1 mice (Chapter 4). 
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For the assessment of the protein levels of IL-12 family members, IL-12 p40 (total) MSD that 
measures various IL-12 p40 containing isoforms was used. These include the pro-inflammatory IL-12 
p70, IL-23, and also the anti-inflammatory IL-12 p40 monomer/ dimers. Further measurements of 
the protein levels of these isoforms have to be carried out to determine the role of IL-12 p40 in 
pulmonary fibrosis.  
For the study between HPS1 and WT C57BL/6 mice, HPS1 mice of mixed gender was used due to lack 
of mouse numbers. Further experiments using WT C57BL/6 and HPS1 mice of matching gender will 
have to be carried out to eliminate any potential inherent gender related differences. 
Finally, the current experiments are limited to the late inflammatory phase (day 7), early fibrotic 
phase (day 14) and late fibrotic phase (day 21) in WT C57BL/6 mice. It may be of interest to evaluate 
later time points to investigate potential spontaneous resolution of fibrosis in BLM-challenged WT 
C57BL/6 mice, or perhaps assess earlier time points in BLM-challenged HPS1 mice to evaluate the 
reasons behind their reduced BLM tolerance during BLM-induced inflammation (Chapter 4). 
6.4 Future work 
6.4.1 Analysis of AMφ transcriptome and proteome ex vivo 
Current studies analysing the role of AMφ in pulmonary fibrosis have focused on evaluating the 
expression of genes with known roles in pathology, using qRT-PCR in AMφ. Whilst these studies have 
pushed forward our understanding in their contributions to pulmonary fibrosis, the process involved 
are low throughput. I therefore propose the use of high throughput sequencing in the analysis of 
AMφ genotype using microarray and/or next generation sequencing (NGS) studies. 
In a recent study, the transcriptome was evaluated in the lungs of BLM-challenged mice and 
compared to that in patients using two separate IPF gene expression datasets available in Gene 
Expression Omnibus (GEO): GSE2052846 and GSE10667847. GSE2052 assayed lung tissue from IPF 
patients, and also non-IPF controls. GSE10667 sampled lung tissue from IPF patients with slow 
progression, acute exacerbations and also non-IPF patients. It was observed from these studies that 
gene sets from BLM-challenged mice that were upregulated in the active (day 14) and the 
established fibrotic phases (days 21-35), were also upregulated in IPF patients compared to non-IPF 
controls. Analysis of leading edge genes (genes that contribute most to the enrichment of BLM 
signatures in the clinical fibrosis expression profiles) show an upregulation of many cell cycle-related 
genes [cell division cycle proteins (CDC), cyclin-dependent kinases (CDKs)], fibrosis related pathways 
(PDGF-, integrin-, and syndecan-mediated signalling) gene sets, and other pro-fibrotic mediators 
(MMPs, collagen, TGF-β). It would be interesting to evaluate the specific contributions of AMφ to 
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these processes in a large scale through microarray analysis and subsequent comparison to the 
aforementioned gene expression datasets. 
6.4.2 Phenotype comparison of macrophages in pulmonary fibrosis with Tumour Associated 
Macrophages (TAM) 
In the current literature macrophage heterogeneity in pulmonary fibrosis have been widely 
described as M1-like and M2-like. However, due to the wide range of signals within the lung, 
pulmonary macrophages are more likely than not to fall within the spectrum of these two opposing 
phenotypes, and the actual repertoire of macrophage phenotypes in vivo may be much broader than 
M1-like versus M2-like. It is therefore more appropriate to assign macrophage subsets based on 
their functional phenotype in vivo, rather than an artificially generated one predetermined in vitro. 
To this end, functional phenotypes identified in TAMs may serve as a useful guidance for such 
characterisation in AMφ in pulmonary fibrosis.  
TAM stimulate tumour cell migration, invasion, intravastation, and also the angiogenic response 
required for tumour growth and metastasis848–850. Various subpopulations of TAM with different 
functions have been identified and characterised into different subpopulations based on in vitro 
characterised or ex vivo determined functional subsets, although it is unclear whether or not these 
are distinct or overlapping entities (Table ϲ.1). Events such as tissue invasion and neoangiogenesis 
occurs in pulmonary fibrosis as well as tumourigenesis. The information obtained from TAMs may 
therefore be useful to further define functional subsets of macrophages in these similar events at 
different stages of pulmonary fibrosis. 
Macrophage subpopulation Markers 
M1-like macrophages (Tumoricidal) IL-12+, MHCIIhi, TNF-α+, CD80/86+, ROS, RNS851,852 
M2-like macrophages (Tumorigenic) Arginase+, EGF+, VEGF+, FGF+ 851,852
Invasive macrophages WNT+, EGF+, VEGF+, CSFR1+853–856 
Angiogenic macrophages VEGF+, Tie2+, TNF-α+, IL-1β+, CXCL8+, PDGF+, FGF+848,857,858 
Metastasis-associated macrophages VEGFR1+, VEGF+, CXCR4-, CCR2+, Tie2-, intergrin α4859,860 
Table 6.1 Subpopulations of macrophages in cancer biology. Arg-2, Arginase-2; CCL, CC-chemokine Ligand; 
CCR, CC-chemokine receptor; CD, cluster of differentiation; CXCL, CXC-chemokine ligand; CXCR, CXC-
chemokine receptor; EGF, Epidermal Growth Factor; IL, Interleukin; PDGF, platelet derived growth factor; 
PGE2, prostaglandin E2; Tie2, receptor Tyrosine kinase with Ig-like and EGF-like domains; TNF-α, Tumour 
Necrosis Factor-α; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor. 
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6.4.3 Interstitial macrophages (IMφ) in pulmonary fibrosis 
The lung is occupied by two populations of pulmonary macrophages, including AMφ residing in the 
alveolar space, and interstitial macrophages (IMφ) occupying the lung interstitium. Given that these 
two populations of macrophages behave differently (described further below), I propose the analysis 
of IMφ heterogeneity in rodent models of pulmonary fibrosis. 
Current studies of the role of macrophages, including those in this thesis, have largely relied on 
AMφ, presumably due to the ease of isolation of these cells. Whereas AMφ can be easily isolated 
through washings of the lung with DPBS, the isolation of IMφ involves homogenisation of the lung, 
followed by separation from other lung populations through fluorescence or magnetic activated cell 
sorting (FACS or MACS respectively). While AMφ are undoubtedly key players in the pathogenesis of 
pulmonary fibrosis, IMφ may possess a more central role as they are located within the interstitium 
where fibrosis occurs.  
IMφ and AMφ possess different phenotypes and play different roles within the lung.  AMφ are long-
lived tissue resident cells that act as the first line of defence against invading pathogens, with a 
turnover rate of around 40% per year273,274. AMφ are constantly exposed to a hyperoxic environment 
and are in intimate contact with both air- and blood-borne materials, and function as a primary 
defence of the lung against inhaled particulate matter, microorganisms and environmental toxins861–
863. These cells express great capacity in providing non-specific innate immunity, and express greater
functional activity to inflammation and anti-microbial defence, including increased chemotaxis, 
phagocytosis, cytotoxicity and release of reactive oxygen and nitrogen intermediates, Prostaglandin 
E (PGE), TNF-α and Interferon (IFN)864. Mouse studies has shown that although AMφ are capable of 
transporting antigens to the lymph nodes865, they are poor APCs866–868.  
IMφ act as the intermediate between the innate and adaptive response, and are shorter lived than 
AMφ, with a turnover rate of 21 days176,274. IMφ have pronounced immunoregulatory activity, and 
express greater quantities of the C3 Receptor and intracellular adhesion molecule 1, and more active 
in secreting IL-1 and IL-6, and exhibit greater MHCII along with stronger antigen-presenting 
capacity275,869–881. Moreover, IMφ, but not AMφ, produce high levels of Interleukin (IL)-10 and 
therefore inhibit dendritic cell migration882. 
As mentioned in the general introduction, IL-1β, IL-6 (section 1.2.3.1) and IL-10 (section 1.2.3.2.3) 
are important mediators in the fibrotic response. IL-1β promotes tissue injury375 and the expression 
of angiogenic mediators (CXCL1, CXCL2, and CXCL8)376 and pro-fibrotic mediators (TGF-β and PDGF) 
375. IL-6 may promote collagen expression398–400 and also fibroblast differentiation into
myofibroblasts402. IL-10 may protect from further tissue injury through its anti-inflammatory 
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properties in suppressing TNF-α and ROS production in macrophages588, but promote fibrosis 
through fibrocyte recruitment and M2-like macrophage activation via a (CCR2)/ CCL2 axis594. 
It is therefore of interest to evaluate the specific contributions of IMφ in interstitial pulmonary 
fibrosis. IMφ can be isolated by FACS or MACS of lung homogenates by positively selecting their 
specific cell surface markers, such as CD11c and MHC-II (appendices 12 and 13) following the 
removal of AMφ by BAL. A broad comparison of AMφ versus IMφ in BLM-induced pulmonary fibrosis 
can be compared. On the other hand, it is also possible to isolate and assess the specific genotype 
and phenotype of different IMφ subpopulations using ĨůŽǁĐǇƚŽŵĞƚƌǇ. Assessment of the role of 
IMφ in BLM-induced pulmonary fibrosis will help us further understand the different roles of these 
cells in pathology. 
6.4.4 Isolation of diseased from non-diseased tissues in pulmonary fibrosis 
A particular difficulty for studying AMφ transcriptome ex vivo is to separate the heterogeneous 
subpopulations, such that the same functional subset, rather than a pooled sample of different 
subsets are analysed. As demonstrated in Chapter 2, macrophage subsets pre-defined in vitro, 
namely M1-like and M2-like macrophages, may be insufficient to fully represent the complexity of 
macrophage genotype in vivo. However, these may serve as a good starting point of which to pre-
sort AMφ for further analyses. A particular caveat of isolation of macrophage subsets is that there 
are insufficient numbers for kinetic microarray analysis. On the other hand, emerging technologies 
for single cell/ low quantity RNA analysis may be able to bypass the use of markers altogether. Cells 
of interest may be isolated from different histopathological regions using LCM (appendix 14), and 
their specific role can be assessed. There are at present several types of single cell/ low quantity RNA 
analysis technologies, including singe cell RNA-seq, NanoString n Counter system, and microfluidic 
platform by Fluidigm for single-cell gene expression analyses. Target genes identified in animal 
models can then be translated and validated in human tissue using qRT-PCR. Protein analysis by 
mass cytometry also allows the simultaneous assessment of a large panel of proteins expressed 
within a single cell, which would improve our distinction of different subpopulations of cells within a 
sample.  
ϲ͘ϰ͘ϱ/ŶǀĞƐƚŝŐĂƚŝŽŶŽĨƌĞƐŽůƵƚŝŽŶŝŶ>DͲŝŶĚƵĐĞĚƉƵůŵŽŶĂƌǇĨŝďƌŽƐŝƐ
Current studies of BLM-induced pulmonary fibrosis have focused on the assessment of the initiation 
and progression of pathology. BLM-induced pulmonary fibrosis by a single intratracheal dose has 
been reported to resolve over time175. There was a decrease in the gene expression of pro-
inflammatory and pro-fibrotic mediators, a reduced cellular infiltration, hydroxyproline (collagen 
precursor) content883, and collagen accumulation, with minimal disruption to alveolar 
architecture349, suggesting that chronic inflammation, fibrosis and tissue remodelling are 
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spontaneously reversible. However, the resolution pulmonary fibrosis in mice have not been 
extensively investigated, primarily because this phenomenon is not observed in IPF patients1,202,242. 
Nevertheless, study of the resolution phase may be useful to better understand the criterion for 
reversing pathology, and perhaps identify target genes or proteins that can be manipulated to 
promote this anti-fibrotic activity. 
Chronic inflammation arises from non-resolving acute inflammation that is caused by the presence 
of a persistent irritant, and is related to dysregulated wound healing that progresses into tissue 
fibrosis. It is unclear how this process may be spontaneously inhibited in models of resolving fibrosis, 
although it is possible that the source of irritation is simply cleared by mononuclear phagocytes. For 
example, removal of the injury stimulus has been shown to improve liver fibrosis in alcoholic liver 
disease884, viral hepatitis885–887, biliary obstruction888 and autoimmune hepatitis889. In a CCl4-induced 
model of liver fibrosis, rats that are challenged for 4 to 8 weeks develop fibrosis but undergo 
spontaneous resolution347,890,891, whereas when the injury is continued for a longer time (>12 weeks), 
cirrhosis (advance fibrosis) develops and in the absence of ongoing injury there is only partial 
reversal with remodelling890. Similarly as aforementioned in local administration models of BLM-
induced pulmonary fibrosis, resolution was observed in single intratracheal but not multiple 
repetitive endotracheal dose models. The number of apoptotic cells, levels of alarmins and also 
efferocytotic activity of macrophages can be assessed to determine clearance of inducers of chronic 
inflammation, and their correlation with reversal of chronic inflammation can also be evaluated.  
The progressive nature of fibrosis in IPF patients is largely accredited to the long-lived 
myofibroblasts that are resistant to apoptosis and the failure of macrophages to resolve the 
aberrant wound healing/ fibrotic response. Fibrosis may be attenuated through the inhibition of 
fibroblast proliferation and activation and/or active removal of collagen secreting cells85,892,893. 
Indeed in BLM-induced pulmonary fibrosis, there is decreased levels of G0/G1 switch gene 2 (G0s2) 
transcripts during the resolution phase. G0s2 belongs to the family of peroxisome proliferator-
activated receptors (PPARs) that promotes the reduction of fibroblast proliferation and its 
differentiation into myofibroblasts894. In CCl4-induced liver fibrosis, apoptosis of the hepatic stellate 
cell, the primary collagen-secreting cell in the liver, was observed during the resolution phase347. The 
proliferation and apoptotic rate of myofibroblasts in BLM-induced pulmonary fibrosis should be 
evaluated to confirm these hypotheses. The signalling pathways associated with myofibroblast 
survival and resistance to apoptosis can also be targeted to evaluate their importance in the 
progression of fibrosis. 
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There are a number of mediators that may be involved in the reversal of tissue fibrosis, in particular 
those that play a role in ECM turnover such as MMPs. It has been described earlier that MMPs (e.g. 
MMP-9, MMP-12) play a pro-fibrotic role, in aberrant tissue remodelling and also activation of pro-
fibrotic precursors (e.g. latent TGF-β) in pulmonary fibrosis. However, other MMPs may also play a 
role in resolution through the degradation of excess ECM deposits. The levels of MMPs have not 
been extensively evaluated at the resolution phase, and it would be useful to identify candidates 
that lead to successful reversal of pulmonary fibrosis. Other mediators may include anti-fibrotic 
proteins, collagen uptake proteins (e.g. mfge8), and also the phagocytotic activity of macrophages of 
degraded ECM components. 
There is much debate on the degree of reversibility of tissue fibrosis, which may depend on the 
maturity of the scar tissue: it has been observed that sufficiently advanced fibrosis becomes 
irreversible. There are several unique features of advance fibrosis that may contribute to their 
resistance to resolution: the paucity of cellular infiltration within the scar tissue, and greater cross-
linking of ECM components. Inflammatory cellular influx is required to resolve fibrosis353, possibly by 
their release of ECM degrading enzymes (e.g. MMPs)891 and phagocytosis of ECM components. For 
example, macrophages are reported to play a role in the resolution of pulmonary fibrosis. Depletion 
of macrophages in CD11b-DTR mice at the onset of fibrosis resolution could retard ECM degradation 
and the loss of HSCs in a CCl4-induced model of liver fibrosis348. Depletion of AMφ using liposomal 
clodronate from days 42-46 slows ECM degradation and reversal of fibrosis when assessed at day 56 
in BLM-induced pulmonary fibrosis175. The genotype and phenotype of these resolution phase 
macrophages should be characterised ex vivo to help better understand their role in the reversal of 
fibrosis. ECM cross-linking may stiffen the matrix and result in the concealment of epitopes 
important for integrin-mediated regeneration and stabilisation of the physical properties of the 
matrix895. For example, the copper-dependent enzyme lysyl oxidase(LOX)-like 2 (LOXL2) facilitates 
the cross-linking of collagen and elastin896. LOXL2 is increased in levels in IPF patients and also 
human hepatitis C-associated liver fibrosis896. Treatment of single intratracheal dose BLM-challenged 
mice with copper chelator tetrathiomolybdate reduced LOX (LOX, LOXL1 and LOXL2), collagen-1, 
MMP (MMPs2 and 8) and TIMP1 protein expression and regressed fibrosis897. Inhibition of LOXL2 
with an anti-LOXL2 monoclonal antibody prevented fibrosis and α-SMA+ myofibroblast accumulation 
in CCl4-induced liver fibrosis896. Prevention and treatment with an anti-LOX2 monoclonal antibody 
also reduced collagen cross-linking, accumulation, and myofibroblast accumulation in a single 
intratracheal BLM dose model of pulmonary fibrosis in mice896. The importance of ECM cross-linking 
in driving pulmonary fibrosis can be determined by comparing that in fibrotic lesions of resolvable 
(i.e. single dose) versus unresolvable (i.e. multiple dose) models of BLM-induced pulmonary fibrosis. 
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6.5 Future directions 
In conclusion, to tackle the role of AMφ in IPF it is essential to learn more about AMφ heterogeneity 
in those isolated directly from human patients. To increase our understanding of the role of AMφ in 
interstitial lung diseases it will be necessary to conduct more ex vivo studies to assess macrophage 
functional response, such as efferocytosis of labelled apoptotic cells, response to other alarmins, and 
how this correlates with the gene expression and phenotype in vivo in a range of animal models that 
addresses different responses. For example, BLM-induced pulmonary fibrosis directly induces AEC 
injury and apoptosis, and the subsequent activation of macrophages by alarmins and apoptotic AECs 
is critical to the fibrotic response. Asbestos and silica fibres directly activate macrophages – their 
large size and resistance to removal results in ‘frustrated phagocytosis’ by macrophages triggers a 
pro-inflammatory response by NLRP3 activation666, leading to peripheral damage to AECs that in turn 
undergo apoptosis to further activate macrophages through their release of alarmins. It would 
therefore be interesting to dissect some of the downstream signalling pathways involved, as means 
to target these responses.  
In addition to the role of AMφ, there are several other problems surrounding IPF that needs to be 
addressed. The mechanism for the initiation of IPF is still not fully understood. As aforementioned in 
the general introduction there are two prevailing hypothesis, including the inflammation-driven 
model (section 1.1.4.2) and the AEC injury driven model (section 1.1.4.3). However, whether or not 
these two pathways are interdependent or independent is unknown. In other words, pulmonary 
fibrosis may be initiated by AEC injury and/or chronic inflammation in separate processes, or AEC 
injury may lead to chronic inflammation that initiates pulmonary fibrosis (or vice versa). It is also 
unclear what constitutes the transition from initial tissue injury and dysregulated wound healing to 
active fibrosis. It was aforementioned that IL-6 induced shift in immune cell recruitment, from 
granulocytes to monocytes and lymphocytes90, which may play a role in the switch from acute to 
chronic inflammation and promote the expression of wound-healing/ pro-fibrotic mediators within 
the lung. It would be interesting to assess whether or not other mechanisms are at play to facilitate 
this transition. To this end, the HPS1/HPS2 mice may be of use to investigate these processes, as 
naturally occurring mutations in these mice lead to spontaneous development of pulmonary fibrosis 
9 months719. It would be interesting to study the kinetics with respect to various pro-inflammatory, 
pro-fibrotic and tissue remodelling mediators, and also alarmin levels in the BAL and lung tissue.  
The reversibility of pulmonary fibrosis is also unclear, and may be dependent on the ability of 
collagen-secreting myofibroblasts to apotose, the amount of cross-linking in ECM components and 
clearance of excessive ECM components, the persistent irritant, alarmins and apoptotic cells (section 
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ϲ͘ϰ͘5). The criterion for resolution may be investigated through comparing resolvable models of 
pulmonary fibrosis with unresolvable ones (e.g. single vs. multiple oropharyngeal dose of BLM). 
More recently, it was discovered that epigenetics may also play a role in IPF pathology. For example, 
effective histone acetylation is responsible for the repression of two anti-fibrotic genes, 
cyclooxygenase-2898 and CXCL10/IFN-γ induced protein 10 (IP-10)899. Different levels of DNA 
methylation of 3 CpG islands in the promoter of α-SMA in fibroblasts, myofibroblasts, and AEC2 
were shown to correlate with α-SMA gene expression in these cells900. Silencing with pharmacologic 
inhibitors or siRNA, or overexpression of DNA methyltransferase increased or reduced α-SMA 
expression, but both affected TGF-β1-induced myofibroblast differentiation900. A number of gene 
expression profiles have also identified the change in levels of miRNA with roles in fibroproliferation, 
EMT and TGF-β signalling, including the downregulation of let-7d and miR-29, and upregulation of 
miR-155 and miR-21, in IPF patients compared to controls901–905. Evaluation of the epigenomic profile 
may provide novel therapeutics for the treatment for this devastating disease.  
This thesis therefore ends with the proposal that a combination of murine models and studies in 
human patients will provide a thorough evaluation of the role of AMφ and also the course of 
pathology in this devastating disease, which may provide novel therapeutic implications in the 
future.
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Appendix 1 – Standard curve for MSD analyses of fibrosis-associated mediators in 
differentially primed AMφ from naïve mice (Figure 3.10) 
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Appendix 2 – Standard curve for ELISA/MSD analyses of macrophage subset-associated 
mediators in differentially primed AMφ from naïve mice (Figure 3.12, 3.14 and 3.16) 
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Appendix 3- Flow cytometry for differentially primed AMФ (Figures 3.13-3.14) 
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Appendix 4 – Standard curve for ELISA/MSD analyses of macrophage subset-associated 
mediators in AMφ from saline or BLM-challenged mice (Figure 4.11) 
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Appendix 5 – Flow cytometry analysis of MRC1 and MHC-II in CD11c+ FSChi SSChi AMφ 
(Figure 4.11) 
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Appendix 6 – Standard curve for MSD analyses of fibrosis-associated mediators in 
differentially primed AMφ from saline or BLM-challenged mice (Figure 4.14) 
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Appendix 7 – Standard curve for MSD analyses of TNF-α and CXCL1, and ELISA analysis 
of fibronectin from WT C57BL/6 or HPS1 mice (Figure 4.23 and 4.24) 
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Appendix 8 - Standard curve for MSD analyses of IL-12 p40 and fibronectin from WT 
C57BL/6 or HPS1 mice (Figure 4.36 and 4.37) 
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Appendix 9 – Standard curve for MSD analyses of IL-1β, TNF-α, CXCL1, IL-10, IL-12 p40 
(total) and ELISA analysis of fibronectin from saline or BLM-challenged (Figure 5.6 – 
5.14; Figures 5.21 – 5.26) 
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Appendix 10 – Standard curve for MSD analyses of IL-6, CCL2, CCL3, CCL4, CCL5 and 
CCL20 from saline or BLM-challenged WT C57BL/6 mice (Figure 5.15 – 5.20) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IL-6 CCL2 (MCP-1) 
CCL3 (MIP-1α) CCL4 (MIP-2) 
CCL5 (RANTES) CCL20 (MIP-3α) 
Chapter 8 | Appendices 
 
372 
 
Saline
Isotype Control
Unstained Control
Appendix 11 – Flow cytometry data for TLR2 stained AMФ isolated from saline or BLM-
challenged mice (Figure 5.4) 
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